Clustering	O 0
of	O 0
missense	O 0
mutations	O 0
in	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
gene	O 0
in	O 0
a	O 0
sporadic	B-Disease 0
T	I-Disease 0
-	I-Disease 0
cell	I-Disease 0
leukaemia	I-Disease 0
.	O 0

Ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
is	O 0
a	O 0
recessive	B-Disease 0
multi	I-Disease 0
-	I-Disease 0
system	I-Disease 0
disorder	I-Disease 0
caused	O 0
by	O 0
mutations	O 0
in	O 0
the	O 0
ATM	O 0
gene	O 0
at	O 0
11q22	O 0
-	O 0
q23	O 0
(	O 0
ref	O 0
.	O 0
3	O 0
)	O 0
.	O 0

The	O 0
risk	O 0
of	O 0
cancer	B-Disease 0
,	O 0
especially	O 0
lymphoid	B-Disease 0
neoplasias	I-Disease 0
,	O 0
is	O 0
substantially	O 0
elevated	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
and	O 0
has	O 0
long	O 0
been	O 0
associated	O 0
with	O 0
chromosomal	O 0
instability	O 0
.	O 0

By	O 0
analysing	O 0
tumour	B-Disease 0
DNA	O 0
from	O 0
patients	O 0
with	O 0
sporadic	B-Disease 0
T	I-Disease 0
-	I-Disease 0
cell	I-Disease 0
prolymphocytic	I-Disease 0
leukaemia	I-Disease 0
(	O 0
T	B-Disease 0
-	I-Disease 0
PLL	I-Disease 0
)	O 0
,	O 0
a	O 0
rare	O 0
clonal	B-Disease 0
malignancy	I-Disease 0
with	O 0
similarities	O 0
to	O 0
a	O 0
mature	B-Disease 0
T	I-Disease 0
-	I-Disease 0
cell	I-Disease 0
leukaemia	I-Disease 0
seen	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
,	O 0
we	O 0
demonstrate	O 0
a	O 0
high	O 0
frequency	O 0
of	O 0
ATM	O 0
mutations	O 0
in	O 0
T	B-Disease 0
-	I-Disease 0
PLL	I-Disease 0
.	O 0

In	O 0
marked	O 0
contrast	O 0
to	O 0
the	O 0
ATM	O 0
mutation	O 0
pattern	O 0
in	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
,	O 0
the	O 0
most	O 0
frequent	O 0
nucleotide	O 0
changes	O 0
in	O 0
this	O 0
leukaemia	B-Disease 0
were	O 0
missense	O 0
mutations	O 0
.	O 0

These	O 0
clustered	O 0
in	O 0
the	O 0
region	O 0
corresponding	O 0
to	O 0
the	O 0
kinase	O 0
domain	O 0
,	O 0
which	O 0
is	O 0
highly	O 0
conserved	O 0
in	O 0
ATM	O 0
-	O 0
related	O 0
proteins	O 0
in	O 0
mouse	O 0
,	O 0
yeast	O 0
and	O 0
Drosophila	O 0
.	O 0

The	O 0
resulting	O 0
amino	O 0
-	O 0
acid	O 0
substitutions	O 0
are	O 0
predicted	O 0
to	O 0
interfere	O 0
with	O 0
ATP	O 0
binding	O 0
or	O 0
substrate	O 0
recognition	O 0
.	O 0

Two	O 0
of	O 0
seventeen	O 0
mutated	O 0
T	B-Disease 0
-	I-Disease 0
PLL	I-Disease 0
samples	O 0
had	O 0
a	O 0
previously	O 0
reported	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
allele	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
no	O 0
mutations	O 0
were	O 0
detected	O 0
in	O 0
the	O 0
p53	O 0
gene	O 0
,	O 0
suggesting	O 0
that	O 0
this	O 0
tumour	B-Disease 0
suppressor	O 0
is	O 0
not	O 0
frequently	O 0
altered	O 0
in	O 0
this	O 0
leukaemia	B-Disease 0
.	O 0

Occasional	O 0
missense	O 0
mutations	O 0
in	O 0
ATM	O 0
were	O 0
also	O 0
found	O 0
in	O 0
tumour	B-Disease 0
DNA	O 0
from	O 0
patients	O 0
with	O 0
B	B-Disease 0
-	I-Disease 0
cell	I-Disease 0
non	I-Disease 0
-	I-Disease 0
Hodgkins	I-Disease 0
lymphomas	I-Disease 0
(	O 0
B	B-Disease 0
-	I-Disease 0
NHL	I-Disease 0
)	O 0
and	O 0
a	O 0
B	B-Disease 0
-	I-Disease 0
NHL	I-Disease 0
cell	O 0
line	O 0
.	O 0

The	O 0
evidence	O 0
of	O 0
a	O 0
significant	O 0
proportion	O 0
of	O 0
loss	O 0
-	O 0
of	O 0
-	O 0
function	O 0
mutations	O 0
and	O 0
a	O 0
complete	O 0
absence	O 0
of	O 0
the	O 0
normal	O 0
copy	O 0
of	O 0
ATM	O 0
in	O 0
the	O 0
majority	O 0
of	O 0
mutated	O 0
tumours	B-Disease 0
establishes	O 0
somatic	O 0
inactivation	O 0
of	O 0
this	O 0
gene	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
sporadic	B-Disease 0
T	I-Disease 0
-	I-Disease 0
PLL	I-Disease 0
and	O 0
suggests	O 0
that	O 0
ATM	O 0
acts	O 0
as	O 0
a	O 0
tumour	B-Disease 0
suppressor	O 0
.	O 0

As	O 0
constitutional	O 0
DNA	O 0
was	O 0
not	O 0
available	O 0
,	O 0
a	O 0
putative	O 0
hereditary	O 0
predisposition	O 0
to	O 0
T	B-Disease 0
-	I-Disease 0
PLL	I-Disease 0
will	O 0
require	O 0
further	O 0
investigation	O 0
.	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
protein	O 0
kinase	O 0
is	O 0
involved	O 0
in	O 0
the	O 0
modulation	O 0
of	O 0
the	O 0
Ca2	O 0
+	O 0
homeostasis	O 0
in	O 0
skeletal	O 0
muscle	O 0
cells	O 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
,	O 0
the	O 0
most	O 0
prevalent	O 0
muscular	B-Disease 0
disorder	I-Disease 0
in	O 0
adults	O 0
,	O 0
is	O 0
caused	O 0
by	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
-	O 0
repeat	O 0
expansion	O 0
in	O 0
a	O 0
gene	O 0
encoding	O 0
a	O 0
protein	O 0
kinase	O 0
(	O 0
DM	B-Disease 0
protein	O 0
kinase	O 0
;	O 0
DMPK	O 0
)	O 0
and	O 0
involves	O 0
changes	O 0
in	O 0
cytoarchitecture	O 0
and	O 0
ion	O 0
homeostasis	O 0
.	O 0

To	O 0
obtain	O 0
clues	O 0
to	O 0
the	O 0
normal	O 0
biological	O 0
role	O 0
of	O 0
DMPK	O 0
in	O 0
cellular	O 0
ion	O 0
homeostasis	O 0
,	O 0
we	O 0
have	O 0
compared	O 0
the	O 0
resting	O 0
[	O 0
Ca2	O 0
+	O 0
]	O 0
i	O 0
,	O 0
the	O 0
amplitude	O 0
and	O 0
shape	O 0
of	O 0
depolarization	O 0
-	O 0
induced	O 0
Ca2	O 0
+	O 0
transients	O 0
,	O 0
and	O 0
the	O 0
content	O 0
of	O 0
ATP	O 0
-	O 0
driven	O 0
ion	O 0
pumps	O 0
in	O 0
cultured	O 0
skeletal	O 0
muscle	O 0
cells	O 0
of	O 0
wild	O 0
-	O 0
type	O 0
and	O 0
DMPK	O 0
[	O 0
-	O 0
/	O 0
-	O 0
]	O 0
knockout	O 0
mice	O 0
.	O 0

In	O 0
vitro	O 0
-	O 0
differentiated	O 0
DMPK	O 0
[	O 0
-	O 0
/	O 0
-	O 0
]	O 0
myotubes	O 0
exhibit	O 0
a	O 0
higher	O 0
resting	O 0
[	O 0
Ca2	O 0
+	O 0
]	O 0
i	O 0
than	O 0
do	O 0
wild	O 0
-	O 0
type	O 0
myotubes	O 0
because	O 0
of	O 0
an	O 0
altered	O 0
open	O 0
probability	O 0
of	O 0
voltage	O 0
-	O 0
dependent	O 0
l	O 0
-	O 0
type	O 0
Ca2	O 0
+	O 0
and	O 0
Na	O 0
+	O 0
channels	O 0
.	O 0

The	O 0
mutant	O 0
myotubes	O 0
exhibit	O 0
smaller	O 0
and	O 0
slower	O 0
Ca2	O 0
+	O 0
responses	O 0
upon	O 0
triggering	O 0
by	O 0
acetylcholine	O 0
or	O 0
high	O 0
external	O 0
K	O 0
+	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
we	O 0
observed	O 0
that	O 0
these	O 0
Ca2	O 0
+	O 0
transients	O 0
partially	O 0
result	O 0
from	O 0
an	O 0
influx	O 0
of	O 0
extracellular	O 0
Ca2	O 0
+	O 0
through	O 0
the	O 0
l	O 0
-	O 0
type	O 0
Ca2	O 0
+	O 0
channel	O 0
.	O 0

Neither	O 0
the	O 0
content	O 0
nor	O 0
the	O 0
activity	O 0
of	O 0
Na	O 0
+	O 0
/	O 0
K	O 0
+	O 0
ATPase	O 0
and	O 0
sarcoplasmic	O 0
reticulum	O 0
Ca2	O 0
+	O 0
-	O 0
ATPase	O 0
are	O 0
affected	O 0
by	O 0
DMPK	O 0
absence	O 0
.	O 0

In	O 0
conclusion	O 0
,	O 0
our	O 0
data	O 0
suggest	O 0
that	O 0
DMPK	O 0
is	O 0
involved	O 0
in	O 0
modulating	O 0
the	O 0
initial	O 0
events	O 0
of	O 0
excitation	O 0
-	O 0
contraction	O 0
coupling	O 0
in	O 0
skeletal	O 0
muscle	O 0
.	O 0
.	O 0

Constitutional	O 0
RB1	O 0
-	O 0
gene	O 0
mutations	O 0
in	O 0
patients	O 0
with	O 0
isolated	O 0
unilateral	B-Disease 0
retinoblastoma	I-Disease 0
.	O 0

In	O 0
most	O 0
patients	O 0
with	O 0
isolated	O 0
unilateral	B-Disease 0
retinoblastoma	I-Disease 0
,	O 0
tumor	B-Disease 0
development	O 0
is	O 0
initiated	O 0
by	O 0
somatic	O 0
inactivation	O 0
of	O 0
both	O 0
alleles	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
.	O 0

However	O 0
,	O 0
some	O 0
of	O 0
these	O 0
patients	O 0
can	O 0
transmit	O 0
retinoblastoma	B-Disease 0
predisposition	O 0
to	O 0
their	O 0
offspring	O 0
.	O 0

To	O 0
determine	O 0
the	O 0
frequency	O 0
and	O 0
nature	O 0
of	O 0
constitutional	O 0
RB1	O 0
-	O 0
gene	O 0
mutations	O 0
in	O 0
patients	O 0
with	O 0
isolated	O 0
unilateral	B-Disease 0
retinoblastoma	I-Disease 0
,	O 0
we	O 0
analyzed	O 0
DNA	O 0
from	O 0
peripheral	O 0
blood	O 0
and	O 0
from	O 0
tumor	B-Disease 0
tissue	O 0
.	O 0

The	O 0
analysis	O 0
of	O 0
tumors	B-Disease 0
from	O 0
54	O 0
(	O 0
71	O 0
%	O 0
)	O 0
of	O 0
76	O 0
informative	O 0
patients	O 0
showed	O 0
loss	O 0
of	O 0
constitutional	O 0
heterozygosity	O 0
(	O 0
LOH	O 0
)	O 0
at	O 0
intragenic	O 0
loci	O 0
.	O 0

Three	O 0
of	O 0
13	O 0
uninformative	O 0
patients	O 0
had	O 0
constitutional	O 0
deletions	O 0
.	O 0

For	O 0
39	O 0
randomly	O 0
selected	O 0
tumors	B-Disease 0
,	O 0
SSCP	O 0
,	O 0
hetero	O 0
-	O 0
duplex	O 0
analysis	O 0
,	O 0
sequencing	O 0
,	O 0
and	O 0
Southern	O 0
blot	O 0
analysis	O 0
were	O 0
used	O 0
to	O 0
identify	O 0
mutations	O 0
.	O 0

Mutations	O 0
were	O 0
detected	O 0
in	O 0
21	O 0
(	O 0
91	O 0
%	O 0
)	O 0
of	O 0
23	O 0
tumors	B-Disease 0
with	O 0
LOH	O 0
.	O 0

In	O 0
6	O 0
(	O 0
38	O 0
%	O 0
)	O 0
of	O 0
16	O 0
tumors	B-Disease 0
without	O 0
LOH	O 0
,	O 0
one	O 0
mutation	O 0
was	O 0
detected	O 0
,	O 0
and	O 0
in	O 0
9	O 0
(	O 0
56	O 0
%	O 0
)	O 0
of	O 0
the	O 0
tumors	B-Disease 0
without	O 0
LOH	O 0
,	O 0
both	O 0
mutations	O 0
were	O 0
found	O 0
.	O 0

Thus	O 0
,	O 0
a	O 0
total	O 0
of	O 0
45	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
tumors	B-Disease 0
of	O 0
36	O 0
patients	O 0
.	O 0

Thirty	O 0
-	O 0
nine	O 0
of	O 0
the	O 0
mutations	O 0
-	O 0
including	O 0
34	O 0
small	O 0
mutations	O 0
,	O 0
2	O 0
large	O 0
structural	O 0
alterations	O 0
,	O 0
and	O 0
hypermethylation	O 0
in	O 0
3	O 0
tumors	O 0
-	O 0
were	O 0
not	O 0
detected	O 0
in	O 0
the	O 0
corresponding	O 0
peripheral	O 0
blood	O 0
DNA	O 0
.	O 0

In	O 0
6	O 0
(	O 0
17	O 0
%	O 0
)	O 0
of	O 0
the	O 0
36	O 0
patients	O 0
,	O 0
a	O 0
mutation	O 0
was	O 0
detected	O 0
in	O 0
constitutional	O 0
DNA	O 0
,	O 0
and	O 0
1	O 0
of	O 0
these	O 0
mutations	O 0
is	O 0
known	O 0
to	O 0
be	O 0
associated	O 0
with	O 0
reduced	O 0
expressivity	O 0
.	O 0

The	O 0
presence	O 0
of	O 0
a	O 0
constitutional	O 0
mutation	O 0
was	O 0
not	O 0
associated	O 0
with	O 0
an	O 0
early	O 0
age	O 0
at	O 0
treatment	O 0
.	O 0

In	O 0
1	O 0
patient	O 0
,	O 0
somatic	O 0
mosaicism	O 0
was	O 0
demonstrated	O 0
by	O 0
molecular	O 0
analysis	O 0
of	O 0
DNA	O 0
and	O 0
RNA	O 0
from	O 0
peripheral	O 0
blood	O 0
.	O 0

In	O 0
2	O 0
patients	O 0
without	O 0
a	O 0
detectable	O 0
mutation	O 0
in	O 0
peripheral	O 0
blood	O 0
,	O 0
mosaicism	O 0
was	O 0
suggested	O 0
because	O 0
1	O 0
of	O 0
the	O 0
patients	O 0
showed	O 0
multifocal	O 0
tumors	B-Disease 0
and	O 0
the	O 0
other	O 0
later	O 0
developed	O 0
bilateral	B-Disease 0
retinoblastoma	I-Disease 0
.	O 0

In	O 0
conclusion	O 0
,	O 0
our	O 0
results	O 0
emphasize	O 0
that	O 0
the	O 0
manifestation	O 0
and	O 0
transmissibility	O 0
of	O 0
retinoblastoma	B-Disease 0
depend	O 0
on	O 0
the	O 0
nature	O 0
of	O 0
the	O 0
first	O 0
mutation	O 0
,	O 0
its	O 0
time	O 0
in	O 0
development	O 0
,	O 0
and	O 0
the	O 0
number	O 0
and	O 0
types	O 0
of	O 0
cells	O 0
that	O 0
are	O 0
affected	O 0
.	O 0
.	O 0

Hereditary	B-Disease 0
deficiency	I-Disease 0
of	I-Disease 0
the	I-Disease 0
fifth	I-Disease 0
component	I-Disease 0
of	I-Disease 0
complement	I-Disease 0
in	O 0
man	O 0
.	O 0

I	O 0
.	O 0

Clinical	O 0
,	O 0
immunochemical	O 0
,	O 0
and	O 0
family	O 0
studies	O 0
.	O 0

The	O 0
first	O 0
recognized	O 0
human	O 0
kindred	O 0
with	O 0
hereditary	B-Disease 0
deficiency	I-Disease 0
of	I-Disease 0
the	I-Disease 0
fifth	I-Disease 0
component	I-Disease 0
of	I-Disease 0
complement	I-Disease 0
(	O 0
C5	O 0
)	O 0
is	O 0
described	O 0
.	O 0

The	O 0
proband	O 0
,	O 0
a	O 0
20	O 0
-	O 0
year	O 0
-	O 0
old	O 0
black	O 0
female	O 0
with	O 0
systemic	B-Disease 0
lupus	I-Disease 0
erythematosus	I-Disease 0
since	O 0
age	O 0
11	O 0
,	O 0
lacked	O 0
serum	O 0
hemolytic	O 0
complement	O 0
activity	O 0
,	O 0
even	O 0
during	O 0
remission	O 0
.	O 0

C5	O 0
was	O 0
undetectable	O 0
in	O 0
her	O 0
serum	O 0
by	O 0
both	O 0
immunodiffusion	O 0
and	O 0
hemolytic	O 0
assays	O 0
.	O 0

Other	O 0
complement	O 0
components	O 0
were	O 0
normal	O 0
during	O 0
remission	O 0
of	O 0
lupus	O 0
,	O 0
but	O 0
C1	O 0
,	O 0
C4	O 0
,	O 0
C2	O 0
,	O 0
and	O 0
C3	O 0
levels	O 0
fell	O 0
during	O 0
exacerbations	O 0
.	O 0

A	O 0
younger	O 0
half	O 0
-	O 0
sister	O 0
,	O 0
who	O 0
had	O 0
no	O 0
underlying	O 0
disease	O 0
,	O 0
was	O 0
also	O 0
found	O 0
to	O 0
lack	O 0
immunochemically	O 0
detectable	O 0
C5	O 0
.	O 0

By	O 0
hemolytic	O 0
assay	O 0
,	O 0
she	O 0
exhibited	O 0
1	O 0
-	O 0
2	O 0
%	O 0
of	O 0
the	O 0
normal	O 0
serum	O 0
C5	O 0
level	O 0
and	O 0
normal	O 0
concentrations	O 0
of	O 0
other	O 0
complement	O 0
components	O 0
.	O 0

C5	O 0
levels	O 0
of	O 0
other	O 0
family	O 0
members	O 0
were	O 0
either	O 0
normal	O 0
or	O 0
approximately	O 0
half	O 0
-	O 0
normal	O 0
,	O 0
consistent	O 0
with	O 0
autosomal	O 0
codominant	O 0
inheritance	O 0
of	O 0
the	O 0
gene	O 0
determining	O 0
C5	B-Disease 0
deficiency	I-Disease 0
.	O 0

Normal	O 0
hemolytic	O 0
titers	O 0
were	O 0
restored	O 0
to	O 0
both	O 0
homozygous	O 0
C5	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
(	O 0
C5D	B-Disease 0
)	O 0
sera	O 0
by	O 0
addition	O 0
of	O 0
highly	O 0
purified	O 0
human	O 0
C5	O 0
.	O 0

In	O 0
specific	O 0
C5	O 0
titrations	O 0
,	O 0
however	O 0
,	O 0
it	O 0
was	O 0
noted	O 0
that	O 0
when	O 0
limited	O 0
amounts	O 0
of	O 0
C5	O 0
were	O 0
assayed	O 0
in	O 0
the	O 0
presence	O 0
of	O 0
low	O 0
dilutions	O 0
of	O 0
either	O 0
C5D	B-Disease 0
serum	O 0
,	O 0
curving	O 0
rather	O 0
than	O 0
linear	O 0
dose	O 0
-	O 0
response	O 0
plots	O 0
were	O 0
consistently	O 0
obtained	O 0
,	O 0
suggesting	O 0
some	O 0
inhibitory	O 0
effect	O 0
.	O 0

Further	O 0
studies	O 0
suggested	O 0
that	O 0
low	O 0
dilutions	O 0
of	O 0
C5D	B-Disease 0
serum	O 0
contain	O 0
a	O 0
factor	O 0
(	O 0
or	O 0
factors	O 0
)	O 0
interfering	O 0
at	O 0
some	O 0
step	O 0
in	O 0
the	O 0
hemolytic	O 0
assay	O 0
of	O 0
C5	O 0
,	O 0
rather	O 0
than	O 0
a	O 0
true	O 0
C5	O 0
inhibitor	O 0
or	O 0
inactivator	O 0
.	O 0

Of	O 0
clinical	O 0
interest	O 0
are	O 0
(	O 0
a	O 0
)	O 0
the	O 0
documentation	O 0
of	O 0
membranous	O 0
glomerulonephritis	B-Disease 0
,	O 0
vasculitis	B-Disease 0
,	O 0
and	O 0
arthritis	B-Disease 0
in	O 0
an	O 0
individual	O 0
lacking	O 0
C5	O 0
(	O 0
and	O 0
its	O 0
biologic	O 0
functions	O 0
)	O 0
,	O 0
and	O 0
(	O 0
b	O 0
)	O 0
a	O 0
remarkable	O 0
propensity	O 0
to	O 0
bacterial	B-Disease 0
infections	I-Disease 0
in	O 0
the	O 0
proband	O 0
,	O 0
even	O 0
during	O 0
periods	O 0
of	O 0
low	O 0
-	O 0
dose	O 0
or	O 0
alternate	O 0
-	O 0
day	O 0
corticosteroid	O 0
therapy	O 0
.	O 0

Other	O 0
observations	O 0
indicate	O 0
that	O 0
the	O 0
C5D	B-Disease 0
state	O 0
is	O 0
compatible	O 0
with	O 0
normal	O 0
coagulation	O 0
function	O 0
and	O 0
the	O 0
capacity	O 0
to	O 0
mount	O 0
a	O 0
neutrophilic	O 0
leukocytosis	O 0
during	O 0
pyogenic	B-Disease 0
infection	I-Disease 0
.	O 0
.	O 0

Susceptibility	O 0
to	O 0
ankylosing	B-Disease 0
spondylitis	I-Disease 0
in	O 0
twins	O 0
:	O 0
the	O 0
role	O 0
of	O 0
genes	O 0
,	O 0
HLA	O 0
,	O 0
and	O 0
the	O 0
environment	O 0
.	O 0

OBJECTIVE	O 0
To	O 0
determine	O 0
the	O 0
relative	O 0
effects	O 0
of	O 0
genetic	O 0
and	O 0
environmental	O 0
factors	O 0
in	O 0
susceptibility	O 0
to	O 0
ankylosing	B-Disease 0
spondylitis	I-Disease 0
(	O 0
AS	B-Disease 0
)	O 0
.	O 0

METHODS	O 0
Twins	O 0
with	O 0
AS	B-Disease 0
were	O 0
identified	O 0
from	O 0
the	O 0
Royal	O 0
National	O 0
Hospital	O 0
for	O 0
Rheumatic	B-Disease 0
Diseases	I-Disease 0
database	O 0
.	O 0

Clinical	O 0
and	O 0
radiographic	O 0
examinations	O 0
were	O 0
performed	O 0
to	O 0
establish	O 0
diagnoses	O 0
,	O 0
and	O 0
disease	O 0
severity	O 0
was	O 0
assessed	O 0
using	O 0
a	O 0
combination	O 0
of	O 0
validated	O 0
scoring	O 0
systems	O 0
.	O 0

HLA	O 0
typing	O 0
for	O 0
HLA	O 0
-	O 0
B27	O 0
,	O 0
HLA	O 0
-	O 0
B60	O 0
,	O 0
and	O 0
HLA	O 0
-	O 0
DR1	O 0
was	O 0
performed	O 0
by	O 0
polymerase	O 0
chain	O 0
reaction	O 0
with	O 0
sequence	O 0
-	O 0
specific	O 0
primers	O 0
,	O 0
and	O 0
zygosity	O 0
was	O 0
assessed	O 0
using	O 0
microsatellite	O 0
markers	O 0
.	O 0

Genetic	O 0
and	O 0
environmental	O 0
variance	O 0
components	O 0
were	O 0
assessed	O 0
with	O 0
the	O 0
program	O 0
Mx	O 0
,	O 0
using	O 0
data	O 0
from	O 0
this	O 0
and	O 0
previous	O 0
studies	O 0
of	O 0
twins	O 0
with	O 0
AS	B-Disease 0
.	O 0

RESULTS	O 0
Six	O 0
of	O 0
8	O 0
monozygotic	O 0
(	O 0
MZ	O 0
)	O 0
twin	O 0
pairs	O 0
were	O 0
disease	O 0
concordant	O 0
,	O 0
compared	O 0
with	O 0
4	O 0
of	O 0
15	O 0
B27	O 0
-	O 0
positive	O 0
dizygotic	O 0
(	O 0
DZ	O 0
)	O 0
twin	O 0
pairs	O 0
(	O 0
27	O 0
%	O 0
)	O 0
and	O 0
4	O 0
of	O 0
32	O 0
DZ	O 0
twin	O 0
pairs	O 0
overall	O 0
(	O 0
12	O 0
.	O 0
5	O 0
%	O 0
)	O 0
.	O 0

Nonsignificant	O 0
increases	O 0
in	O 0
similarity	O 0
with	O 0
regard	O 0
to	O 0
age	O 0
at	O 0
disease	O 0
onset	O 0
and	O 0
all	O 0
of	O 0
the	O 0
disease	O 0
severity	O 0
scores	O 0
assessed	O 0
were	O 0
noted	O 0
in	O 0
disease	O 0
-	O 0
concordant	O 0
MZ	O 0
twins	O 0
compared	O 0
with	O 0
concordant	O 0
DZ	O 0
twins	O 0
.	O 0

HLA	O 0
-	O 0
B27	O 0
and	O 0
B60	O 0
were	O 0
associated	O 0
with	O 0
the	O 0
disease	O 0
in	O 0
probands	O 0
,	O 0
and	O 0
the	O 0
rate	O 0
of	O 0
disease	O 0
concordance	O 0
was	O 0
significantly	O 0
increased	O 0
among	O 0
DZ	O 0
twin	O 0
pairs	O 0
in	O 0
which	O 0
the	O 0
co	O 0
-	O 0
twin	O 0
was	O 0
positive	O 0
for	O 0
both	O 0
B27	O 0
and	O 0
DR1	O 0
.	O 0

Additive	O 0
genetic	O 0
effects	O 0
were	O 0
estimated	O 0
to	O 0
contribute	O 0
97	O 0
%	O 0
of	O 0
the	O 0
population	O 0
variance	O 0
.	O 0

CONCLUSION	O 0
Susceptibility	O 0
to	O 0
AS	B-Disease 0
is	O 0
largely	O 0
genetically	O 0
determined	O 0
,	O 0
and	O 0
the	O 0
environmental	O 0
trigger	O 0
for	O 0
the	O 0
disease	O 0
is	O 0
probably	O 0
ubiquitous	O 0
.	O 0

HLA	O 0
-	O 0
B27	O 0
accounts	O 0
for	O 0
a	O 0
minority	O 0
of	O 0
the	O 0
overall	O 0
genetic	O 0
susceptibility	O 0
to	O 0
AS	B-Disease 0
.	O 0

Cell	O 0
cycle	O 0
-	O 0
dependent	O 0
colocalization	O 0
of	O 0
BARD1	O 0
and	O 0
BRCA1	O 0
proteins	O 0
in	O 0
discrete	O 0
nuclear	O 0
domains	O 0
.	O 0

Germ	O 0
-	O 0
line	O 0
mutations	O 0
of	O 0
the	O 0
BRCA1	O 0
gene	O 0
predispose	O 0
women	O 0
to	O 0
early	O 0
-	O 0
onset	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
by	O 0
compromising	O 0
the	O 0
genes	O 0
presumptive	O 0
function	O 0
as	O 0
a	O 0
tumor	B-Disease 0
suppressor	O 0
.	O 0

Although	O 0
the	O 0
biochemical	O 0
properties	O 0
of	O 0
BRCA1	O 0
polypeptides	O 0
are	O 0
not	O 0
understood	O 0
,	O 0
their	O 0
expression	O 0
pattern	O 0
and	O 0
subcellular	O 0
localization	O 0
suggest	O 0
a	O 0
role	O 0
in	O 0
cell	O 0
-	O 0
cycle	O 0
regulation	O 0
.	O 0

When	O 0
resting	O 0
cells	O 0
are	O 0
induced	O 0
to	O 0
proliferate	O 0
,	O 0
the	O 0
steady	O 0
-	O 0
state	O 0
levels	O 0
of	O 0
BRCA1	O 0
increase	O 0
in	O 0
late	O 0
G1	O 0
and	O 0
reach	O 0
a	O 0
maximum	O 0
during	O 0
S	O 0
phase	O 0
.	O 0

Moreover	O 0
,	O 0
in	O 0
S	O 0
phase	O 0
cells	O 0
,	O 0
BRCA1	O 0
polypeptides	O 0
are	O 0
hyperphosphorylated	O 0
and	O 0
accumulate	O 0
into	O 0
discrete	O 0
subnuclear	O 0
foci	O 0
termed	O 0
"	O 0
BRCA1	O 0
nuclear	O 0
dots	O 0
.	O 0

"	O 0
BRCA1	O 0
associates	O 0
in	O 0
vivo	O 0
with	O 0
a	O 0
structurally	O 0
related	O 0
protein	O 0
termed	O 0
BARD1	O 0
.	O 0

Here	O 0
we	O 0
show	O 0
that	O 0
the	O 0
steady	O 0
-	O 0
state	O 0
levels	O 0
of	O 0
BARD1	O 0
,	O 0
unlike	O 0
those	O 0
of	O 0
BRCA1	O 0
,	O 0
remain	O 0
relatively	O 0
constant	O 0
during	O 0
cell	O 0
cycle	O 0
progression	O 0
.	O 0

However	O 0
,	O 0
immunostaining	O 0
revealed	O 0
that	O 0
BARD1	O 0
resides	O 0
within	O 0
BRCA1	O 0
nuclear	O 0
dots	O 0
during	O 0
S	O 0
phase	O 0
of	O 0
the	O 0
cell	O 0
cycle	O 0
,	O 0
but	O 0
not	O 0
during	O 0
the	O 0
G1	O 0
phase	O 0
.	O 0

Nevertheless	O 0
,	O 0
BARD1	O 0
polypeptides	O 0
are	O 0
found	O 0
exclusively	O 0
in	O 0
the	O 0
nuclear	O 0
fractions	O 0
of	O 0
both	O 0
G1	O 0
-	O 0
and	O 0
S	O 0
-	O 0
phase	O 0
cells	O 0
.	O 0

Therefore	O 0
,	O 0
progression	O 0
to	O 0
S	O 0
phase	O 0
is	O 0
accompanied	O 0
by	O 0
the	O 0
aggregation	O 0
of	O 0
nuclear	O 0
BARD1	O 0
polypeptides	O 0
into	O 0
BRCA1	O 0
nuclear	O 0
dots	O 0
.	O 0

This	O 0
cell	O 0
cycle	O 0
-	O 0
dependent	O 0
colocalization	O 0
of	O 0
BARD1	O 0
and	O 0
BRCA1	O 0
indicates	O 0
a	O 0
role	O 0
for	O 0
BARD1	O 0
in	O 0
BRCA1	O 0
-	O 0
mediated	O 0
tumor	B-Disease 0
suppression	O 0
.	O 0

Ethnic	O 0
differences	O 0
in	O 0
the	O 0
HFE	O 0
codon	O 0
282	O 0
(	O 0
Cys	O 0
/	O 0
Tyr	O 0
)	O 0
polymorphism	O 0
.	O 0

Recent	O 0
studies	O 0
have	O 0
shown	O 0
that	O 0
hereditary	B-Disease 0
hemochromatosis	I-Disease 0
(	O 0
HH	B-Disease 0
)	O 0
is	O 0
likely	O 0
to	O 0
be	O 0
caused	O 0
by	O 0
homozygosity	O 0
for	O 0
a	O 0
Cys282Tyr	O 0
mutation	O 0
in	O 0
the	O 0
HFE	O 0
gene	O 0
located	O 0
4	O 0
.	O 0

5	O 0
Mb	O 0
telomeric	O 0
to	O 0
HLA	O 0
-	O 0
A	O 0
.	O 0

Population	O 0
studies	O 0
of	O 0
this	O 0
polymorphism	O 0
are	O 0
facilitated	O 0
by	O 0
the	O 0
fact	O 0
that	O 0
the	O 0
Cys282Tyr	O 0
mutation	O 0
creates	O 0
a	O 0
Rsal	O 0
restriction	O 0
site	O 0
.	O 0

We	O 0
have	O 0
studied	O 0
the	O 0
codon	O 0
282	O 0
(	O 0
Cys	O 0
/	O 0
Tyr	O 0
)	O 0
polymorphism	O 0
in	O 0
different	O 0
ethnic	O 0
groups	O 0
.	O 0

In	O 0
agreement	O 0
with	O 0
previous	O 0
observations	O 0
the	O 0
Tyr	O 0
allele	O 0
appeared	O 0
to	O 0
be	O 0
rare	O 0
or	O 0
absent	O 0
in	O 0
Asiatic	O 0
(	O 0
Indian	O 0
,	O 0
Chinese	O 0
)	O 0
populations	O 0
.	O 0

The	O 0
highest	O 0
allele	O 0
frequency	O 0
(	O 0
7	O 0
.	O 0
5	O 0
%	O 0
)	O 0
was	O 0
found	O 0
in	O 0
Swedes	O 0
.	O 0

Saamis	O 0
(	O 0
2	O 0
%	O 0
)	O 0
and	O 0
Mordvinians	O 0
(	O 0
1	O 0
.	O 0
8	O 0
%	O 0
)	O 0
had	O 0
significantly	O 0
lower	O 0
frequencies	O 0
of	O 0
the	O 0
Tyr	O 0
allele	O 0
.	O 0

Comparisons	O 0
with	O 0
allele	O 0
frequencies	O 0
based	O 0
on	O 0
prevalence	O 0
estimates	O 0
of	O 0
HH	B-Disease 0
showed	O 0
some	O 0
disagreements	O 0
with	O 0
the	O 0
RFLP	O 0
data	O 0
,	O 0
particularly	O 0
in	O 0
Finns	O 0
.	O 0

The	O 0
newly	O 0
described	O 0
HFE	O 0
marker	O 0
provides	O 0
a	O 0
new	O 0
approach	O 0
to	O 0
the	O 0
screening	O 0
of	O 0
HH	B-Disease 0
as	O 0
well	O 0
as	O 0
studies	O 0
of	O 0
the	O 0
relationship	O 0
between	O 0
the	O 0
HFE	O 0
Tyr	O 0
allele	O 0
and	O 0
different	O 0
disorders	O 0
including	O 0
cancer	B-Disease 0

Autosomal	B-Disease 0
dominant	I-Disease 0
neurohypophyseal	I-Disease 0
diabetes	I-Disease 0
insipidus	I-Disease 0
associated	O 0
with	O 0
a	O 0
missense	O 0
mutation	O 0
encoding	O 0
Gly23	O 0
-	O 0
-	O 0
>	O 0
Val	O 0
in	O 0
neurophysin	O 0
II	O 0
.	O 0

Autosomal	B-Disease 0
dominant	I-Disease 0
neurohypophyseal	I-Disease 0
diabetes	I-Disease 0
insipidus	I-Disease 0
(	O 0
ADNDI	B-Disease 0
)	O 0
is	O 0
an	O 0
inherited	B-Disease 0
disease	I-Disease 0
caused	O 0
by	O 0
progressive	O 0
degeneration	O 0
of	O 0
the	O 0
magnocellular	O 0
neurons	O 0
of	O 0
the	O 0
hypothalamus	O 0
leading	O 0
to	O 0
decreased	O 0
ability	O 0
to	O 0
produce	O 0
the	O 0
hormone	O 0
arginine	O 0
vasopressin	O 0
(	O 0
AVP	O 0
)	O 0
.	O 0

Affected	O 0
individuals	O 0
are	O 0
not	O 0
symptomatic	O 0
at	O 0
birth	O 0
,	O 0
but	O 0
usually	O 0
develop	O 0
diabetes	B-Disease 0
insipidus	I-Disease 0
at	O 0
1	O 0
-	O 0
6	O 0
yr	O 0
of	O 0
age	O 0
.	O 0

The	O 0
genetic	O 0
locus	O 0
of	O 0
the	O 0
disease	O 0
is	O 0
the	O 0
AVP	O 0
-	O 0
neurophysin	O 0
II	O 0
(	O 0
NPII	O 0
)	O 0
gene	O 0
,	O 0
and	O 0
mutations	O 0
that	O 0
cause	O 0
ADNDI	B-Disease 0
have	O 0
been	O 0
found	O 0
in	O 0
both	O 0
the	O 0
signal	O 0
peptide	O 0
of	O 0
the	O 0
prepro	O 0
-	O 0
AVP	O 0
-	O 0
NPII	O 0
precursor	O 0
and	O 0
within	O 0
NPII	O 0
itself	O 0
.	O 0

An	O 0
affected	O 0
girl	O 0
who	O 0
presented	O 0
at	O 0
9	O 0
months	O 0
of	O 0
age	O 0
and	O 0
her	O 0
similarly	O 0
affected	O 0
younger	O 0
brother	O 0
and	O 0
father	O 0
were	O 0
all	O 0
found	O 0
to	O 0
have	O 0
a	O 0
novel	O 0
missense	O 0
mutation	O 0
(	O 0
G1758	O 0
-	O 0
-	O 0
>	O 0
T	O 0
)	O 0
encoding	O 0
the	O 0
amino	O 0
acid	O 0
substitution	O 0
Gly23	O 0
-	O 0
-	O 0
>	O 0
Val	O 0
within	O 0
NPII	O 0
.	O 0

The	O 0
mutation	O 0
was	O 0
confirmed	O 0
by	O 0
restriction	O 0
endonuclease	O 0
analysis	O 0
.	O 0

A	O 0
T1	O 0
-	O 0
weighted	O 0
magnetic	O 0
resonance	O 0
imaging	O 0
of	O 0
the	O 0
fathers	O 0
pituitary	O 0
gland	O 0
demonstrates	O 0
an	O 0
attenuated	O 0
posterior	O 0
pituitary	O 0
bright	O 0
spot	O 0
.	O 0

This	O 0
mutation	O 0
may	O 0
be	O 0
valuable	O 0
for	O 0
developing	O 0
models	O 0
of	O 0
dominantly	B-Disease 0
inherited	I-Disease 0
neurodegeneration	I-Disease 0
,	O 0
as	O 0
the	O 0
early	O 0
age	O 0
of	O 0
onset	O 0
of	O 0
symptoms	O 0
suggests	O 0
that	O 0
this	O 0
mutation	O 0
may	O 0
be	O 0
particularly	O 0
deleterious	O 0
to	O 0
the	O 0
magnocellular	O 0
neuron	O 0
.	O 0
.	O 0

Frequent	O 0
inactivation	O 0
of	O 0
PTEN	O 0
/	O 0
MMAC1	O 0
in	O 0
primary	O 0
prostate	B-Disease 0
cancer	I-Disease 0
.	O 0

Sporadic	B-Disease 0
prostate	I-Disease 0
carcinoma	I-Disease 0
is	O 0
the	O 0
most	O 0
common	O 0
male	B-Disease 0
cancer	I-Disease 0
in	O 0
the	O 0
Western	O 0
world	O 0
,	O 0
yet	O 0
many	O 0
of	O 0
the	O 0
major	O 0
genetic	O 0
events	O 0
involved	O 0
in	O 0
the	O 0
progression	O 0
of	O 0
this	O 0
often	O 0
fatal	O 0
cancer	B-Disease 0
remain	O 0
to	O 0
be	O 0
elucidated	O 0
.	O 0

Numerous	O 0
cytogenetic	O 0
and	O 0
allelotype	O 0
studies	O 0
have	O 0
reported	O 0
frequent	O 0
loss	O 0
of	O 0
heterozygosity	O 0
on	O 0
chromosomal	O 0
arm	O 0
10q	O 0
in	O 0
sporadic	B-Disease 0
prostate	I-Disease 0
cancer	I-Disease 0
.	O 0

Deletion	O 0
mapping	O 0
studies	O 0
have	O 0
unambiguously	O 0
identified	O 0
a	O 0
region	O 0
of	O 0
chromosome	O 0
10q23	O 0
to	O 0
be	O 0
the	O 0
minimal	O 0
area	O 0
of	O 0
loss	O 0
.	O 0

A	O 0
new	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
,	O 0
PTEN	O 0
/	O 0
MMAC1	O 0
,	O 0
was	O 0
isolated	O 0
recently	O 0
at	O 0
this	O 0
region	O 0
of	O 0
chromosome	O 0
10q23	O 0
and	O 0
found	O 0
to	O 0
be	O 0
inactivated	O 0
by	O 0
mutation	O 0
in	O 0
three	O 0
prostate	B-Disease 0
cancer	I-Disease 0
cell	O 0
lines	O 0
.	O 0

We	O 0
screened	O 0
80	O 0
prostate	B-Disease 0
tumors	I-Disease 0
by	O 0
microsatellite	O 0
analysis	O 0
and	O 0
found	O 0
chromosome	O 0
10q23	O 0
to	O 0
be	O 0
deleted	O 0
in	O 0
23	O 0
cases	O 0
.	O 0

We	O 0
then	O 0
proceeded	O 0
with	O 0
sequence	O 0
analysis	O 0
of	O 0
the	O 0
entire	O 0
PTEN	O 0
/	O 0
MMAC1	O 0
coding	O 0
region	O 0
and	O 0
tested	O 0
for	O 0
homozygous	O 0
deletion	O 0
with	O 0
new	O 0
intragenic	O 0
markers	O 0
in	O 0
these	O 0
23	O 0
cases	O 0
with	O 0
10q23	O 0
loss	O 0
of	O 0
heterozygosity	O 0
.	O 0

The	O 0
identification	O 0
of	O 0
the	O 0
second	O 0
mutational	O 0
event	O 0
in	O 0
10	O 0
(	O 0
43	O 0
%	O 0
)	O 0
tumors	B-Disease 0
establishes	O 0
PTEN	O 0
/	O 0
MMAC1	O 0
as	O 0
a	O 0
main	O 0
inactivation	O 0
target	O 0
of	O 0
10q	O 0
loss	O 0
in	O 0
sporadic	B-Disease 0
prostate	I-Disease 0
cancer	I-Disease 0
.	O 0
.	O 0

Risk	O 0
reversals	O 0
in	O 0
predictive	O 0
testing	O 0
for	O 0
Huntington	B-Disease 0
disease	I-Disease 0
.	O 0

The	O 0
first	O 0
predictive	O 0
testing	O 0
for	O 0
Huntington	B-Disease 0
disease	I-Disease 0
(	O 0
HD	B-Disease 0
)	O 0
was	O 0
based	O 0
on	O 0
analysis	O 0
of	O 0
linked	O 0
polymorphic	O 0
DNA	O 0
markers	O 0
to	O 0
estimate	O 0
the	O 0
likelihood	O 0
of	O 0
inheriting	O 0
the	O 0
mutation	O 0
for	O 0
HD	B-Disease 0
.	O 0

Limits	O 0
to	O 0
accuracy	O 0
included	O 0
recombination	O 0
between	O 0
the	O 0
DNA	O 0
markers	O 0
and	O 0
the	O 0
mutation	O 0
,	O 0
pedigree	O 0
structure	O 0
,	O 0
and	O 0
whether	O 0
DNA	O 0
samples	O 0
were	O 0
available	O 0
from	O 0
family	O 0
members	O 0
.	O 0

With	O 0
direct	O 0
tests	O 0
for	O 0
the	O 0
HD	B-Disease 0
mutation	O 0
,	O 0
we	O 0
have	O 0
assessed	O 0
the	O 0
accuracy	O 0
of	O 0
results	O 0
obtained	O 0
by	O 0
linkage	O 0
approaches	O 0
when	O 0
requested	O 0
to	O 0
do	O 0
so	O 0
by	O 0
the	O 0
test	O 0
individuals	O 0
.	O 0

For	O 0
six	O 0
such	O 0
individuals	O 0
,	O 0
there	O 0
was	O 0
significant	O 0
disparity	O 0
between	O 0
the	O 0
tests	O 0
.	O 0

Three	O 0
went	O 0
from	O 0
a	O 0
decreased	O 0
risk	O 0
to	O 0
an	O 0
increased	O 0
risk	O 0
,	O 0
while	O 0
in	O 0
another	O 0
three	O 0
the	O 0
risk	O 0
was	O 0
decreased	O 0
.	O 0

Knowledge	O 0
of	O 0
the	O 0
potential	O 0
reasons	O 0
for	O 0
these	O 0
changes	O 0
in	O 0
results	O 0
and	O 0
impact	O 0
of	O 0
these	O 0
risk	O 0
reversals	O 0
on	O 0
both	O 0
patients	O 0
and	O 0
the	O 0
counseling	O 0
team	O 0
can	O 0
assist	O 0
in	O 0
the	O 0
development	O 0
of	O 0
strategies	O 0
for	O 0
the	O 0
prevention	O 0
and	O 0
,	O 0
where	O 0
necessary	O 0
,	O 0
management	O 0
of	O 0
a	O 0
risk	O 0
reversal	O 0
in	O 0
any	O 0
predictive	O 0
testing	O 0
program	O 0
.	O 0
.	O 0

A	O 0
novel	O 0
common	O 0
missense	O 0
mutation	O 0
G301C	O 0
in	O 0
the	O 0
N	O 0
-	O 0
acetylgalactosamine	O 0
-	O 0
6	O 0
-	O 0
sulfate	O 0
sulfatase	O 0
gene	O 0
in	O 0
mucopolysaccharidosis	B-Disease 0
IVA	I-Disease 0
.	O 0

Mucopolysaccharidosis	B-Disease 0
IVA	I-Disease 0
(	O 0
MPS	B-Disease 0
IVA	I-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
lysosomal	I-Disease 0
storage	I-Disease 0
disorder	I-Disease 0
caused	O 0
by	O 0
a	O 0
genetic	B-Disease 0
defect	I-Disease 0
in	O 0
N	O 0
-	O 0
acetylgalactosamine	O 0
-	O 0
6	O 0
-	O 0
sulfate	O 0
sulfatase	O 0
(	O 0
GALNS	O 0
)	O 0
.	O 0

In	O 0
previous	O 0
studies	O 0
,	O 0
we	O 0
have	O 0
found	O 0
two	O 0
common	O 0
mutations	O 0
in	O 0
Caucasians	O 0
and	O 0
Japanese	O 0
,	O 0
respectively	O 0
.	O 0

To	O 0
characterize	O 0
the	O 0
mutational	O 0
spectrum	O 0
in	O 0
various	O 0
ethnic	O 0
groups	O 0
,	O 0
mutations	O 0
in	O 0
the	O 0
GALNS	O 0
gene	O 0
in	O 0
Colombian	O 0
MPS	B-Disease 0
IVA	I-Disease 0
patients	O 0
were	O 0
investigated	O 0
,	O 0
and	O 0
genetic	O 0
backgrounds	O 0
were	O 0
extensively	O 0
analyzed	O 0
to	O 0
identify	O 0
racial	O 0
origin	O 0
,	O 0
based	O 0
on	O 0
mitochondrial	O 0
DNA	O 0
(	O 0
mtDNA	O 0
)	O 0
lineages	O 0
.	O 0

Three	O 0
novel	O 0
missense	O 0
mutations	O 0
never	O 0
identified	O 0
previously	O 0
in	O 0
other	O 0
populations	O 0
and	O 0
found	O 0
in	O 0
16	O 0
out	O 0
of	O 0
19	O 0
Colombian	O 0
MPS	B-Disease 0
IVA	I-Disease 0
unrelated	O 0
alleles	O 0
account	O 0
for	O 0
84	O 0
.	O 0

2	O 0
%	O 0
of	O 0
the	O 0
alleles	O 0
in	O 0
this	O 0
study	O 0
.	O 0

The	O 0
G301C	O 0
and	O 0
S162F	O 0
mutations	O 0
account	O 0
for	O 0
68	O 0
.	O 0

4	O 0
%	O 0
and	O 0
10	O 0
.	O 0

5	O 0
%	O 0
of	O 0
mutations	O 0
,	O 0
respectively	O 0
,	O 0
whereas	O 0
the	O 0
remaining	O 0
F69V	O 0
is	O 0
limited	O 0
to	O 0
a	O 0
single	O 0
allele	O 0
.	O 0

The	O 0
skewed	O 0
prevalence	O 0
of	O 0
G301C	O 0
in	O 0
only	O 0
Colombian	O 0
patients	O 0
and	O 0
haplotype	O 0
analysis	O 0
by	O 0
restriction	O 0
fragment	O 0
length	O 0
polymorphisms	O 0
in	O 0
the	O 0
GALNS	O 0
gene	O 0
suggest	O 0
that	O 0
G301C	O 0
originated	O 0
from	O 0
a	O 0
common	O 0
ancestor	O 0
.	O 0

Investigation	O 0
of	O 0
the	O 0
genetic	O 0
background	O 0
by	O 0
means	O 0
of	O 0
mtDNA	O 0
lineages	O 0
indicate	O 0
that	O 0
all	O 0
our	O 0
patients	O 0
are	O 0
probably	O 0
of	O 0
native	O 0
American	O 0
descent	O 0

Low	O 0
frequency	O 0
of	O 0
BRCA1	O 0
germline	O 0
mutations	O 0
in	O 0
45	O 0
German	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
.	O 0

In	O 0
this	O 0
study	O 0
we	O 0
investigated	O 0
45	O 0
German	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
for	O 0
germline	O 0
mutations	O 0
in	O 0
the	O 0
BRCA1	O 0
gene	O 0
.	O 0

We	O 0
identified	O 0
four	O 0
germline	O 0
mutations	O 0
in	O 0
three	O 0
breast	B-Disease 0
cancer	I-Disease 0
families	O 0
and	O 0
in	O 0
one	O 0
breast	B-Disease 0
-	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
family	O 0
.	O 0
among	O 0
these	O 0
were	O 0
one	O 0
frameshift	O 0
mutation	O 0
,	O 0
one	O 0
nonsense	O 0
mutation	O 0
,	O 0
one	O 0
novel	O 0
splice	O 0
site	O 0
mutation	O 0
,	O 0
and	O 0
one	O 0
missense	O 0
mutation	O 0
.	O 0

The	O 0
missense	O 0
mutation	O 0
was	O 0
also	O 0
found	O 0
in	O 0
2	O 0
.	O 0

8	O 0
%	O 0
of	O 0
the	O 0
general	O 0
population	O 0
,	O 0
suggesting	O 0
that	O 0
it	O 0
is	O 0
not	O 0
disease	O 0
associated	O 0
.	O 0

The	O 0
average	O 0
age	O 0
of	O 0
disease	O 0
onset	O 0
in	O 0
those	O 0
families	O 0
harbouring	O 0
causative	O 0
mutations	O 0
was	O 0
between	O 0
32	O 0
.	O 0

3	O 0
and	O 0
37	O 0
.	O 0

4	O 0
years	O 0
,	O 0
whereas	O 0
the	O 0
family	O 0
harbouring	O 0
the	O 0
missense	O 0
mutation	O 0
had	O 0
an	O 0
average	O 0
age	O 0
of	O 0
onset	O 0
of	O 0
51	O 0
.	O 0

2	O 0
years	O 0
.	O 0

These	O 0
findings	O 0
show	O 0
that	O 0
BRCA1	O 0
is	O 0
implicated	O 0
in	O 0
a	O 0
small	O 0
fraction	O 0
of	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
suggesting	O 0
the	O 0
involvement	O 0
of	O 0
another	O 0
susceptibility	O 0
gene	O 0
(	O 0
s	O 0
)	O 0

Paternal	O 0
transmission	O 0
of	O 0
congenital	B-Disease 0
myotonic	I-Disease 0
dystrophy	I-Disease 0
.	O 0

We	O 0
report	O 0
a	O 0
rare	O 0
case	O 0
of	O 0
paternally	O 0
transmitted	O 0
congenital	B-Disease 0
myotonic	I-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
.	O 0

The	O 0
proband	O 0
is	O 0
a	O 0
23	O 0
year	O 0
old	O 0
,	O 0
mentally	B-Disease 0
retarded	I-Disease 0
male	O 0
who	O 0
suffers	O 0
severe	O 0
muscular	B-Disease 0
weakness	I-Disease 0
.	O 0

He	O 0
presented	O 0
with	O 0
respiratory	O 0
and	O 0
feeding	O 0
difficulties	O 0
at	O 0
birth	O 0
.	O 0

His	O 0
two	O 0
sibs	O 0
suffer	O 0
from	O 0
childhood	O 0
onset	O 0
DM	B-Disease 0
.	O 0

Their	O 0
late	O 0
father	O 0
had	O 0
the	O 0
adult	O 0
type	O 0
of	O 0
DM	B-Disease 0
,	O 0
with	O 0
onset	O 0
around	O 0
30	O 0
years	O 0
.	O 0

Only	O 0
six	O 0
other	O 0
cases	O 0
of	O 0
paternal	O 0
transmission	O 0
of	O 0
congenital	B-Disease 0
DM	I-Disease 0
have	O 0
been	O 0
reported	O 0
recently	O 0
.	O 0

We	O 0
review	O 0
the	O 0
sex	O 0
related	O 0
effects	O 0
on	O 0
transmission	O 0
of	O 0
congenital	B-Disease 0
DM	I-Disease 0
.	O 0

Decreased	O 0
fertility	O 0
of	O 0
males	O 0
with	O 0
adult	O 0
onset	O 0
DM	B-Disease 0
and	O 0
contraction	O 0
of	O 0
the	O 0
repeat	O 0
upon	O 0
male	O 0
transmission	O 0
contribute	O 0
to	O 0
the	O 0
almost	O 0
absent	O 0
occurrence	O 0
of	O 0
paternal	O 0
transmission	O 0
of	O 0
congenital	B-Disease 0
DM	I-Disease 0
.	O 0

Also	O 0
the	O 0
fathers	O 0
of	O 0
the	O 0
reported	O 0
congenitally	O 0
affected	O 0
children	O 0
showed	O 0
,	O 0
on	O 0
average	O 0
,	O 0
shorter	O 0
CTG	O 0
repeat	O 0
lengths	O 0
and	O 0
hence	O 0
less	O 0
severe	O 0
clinical	O 0
symptoms	O 0
than	O 0
the	O 0
mothers	O 0
of	O 0
children	O 0
with	O 0
congenital	B-Disease 0
DM	I-Disease 0
.	O 0

We	O 0
conclude	O 0
that	O 0
paternal	O 0
transmission	O 0
of	O 0
congenital	B-Disease 0
DM	I-Disease 0
is	O 0
rare	O 0
and	O 0
preferentially	O 0
occurs	O 0
with	O 0
onset	O 0
of	O 0
DM	B-Disease 0
past	O 0
30	O 0
years	O 0
in	O 0
the	O 0
father	O 0
.	O 0
.	O 0

The	O 0
RB1	O 0
gene	O 0
mutation	O 0
in	O 0
a	O 0
child	O 0
with	O 0
ectopic	B-Disease 0
intracranial	I-Disease 0
retinoblastoma	I-Disease 0
.	O 0

The	O 0
RB1	O 0
gene	O 0
mutation	O 0
was	O 0
investigated	O 0
in	O 0
a	O 0
child	O 0
with	O 0
ectopic	B-Disease 0
intracranial	I-Disease 0
retinoblastoma	I-Disease 0
using	O 0
DNA	O 0
obtained	O 0
from	O 0
both	O 0
the	O 0
pineal	B-Disease 0
and	I-Disease 0
retinal	I-Disease 0
tumours	I-Disease 0
of	O 0
the	O 0
patient	O 0
.	O 0

A	O 0
nonsense	O 0
mutation	O 0
in	O 0
exon	O 0
17	O 0
(	O 0
codon	O 0
556	O 0
)	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
was	O 0
found	O 0
to	O 0
be	O 0
present	O 0
homozygously	O 0
in	O 0
both	O 0
the	O 0
retinal	B-Disease 0
and	I-Disease 0
the	I-Disease 0
pineal	I-Disease 0
tumours	I-Disease 0
.	O 0

The	O 0
same	O 0
mutation	O 0
was	O 0
present	O 0
heterozygously	O 0
in	O 0
the	O 0
DNA	O 0
from	O 0
the	O 0
constitutional	O 0
cells	O 0
of	O 0
the	O 0
patient	O 0
,	O 0
proving	O 0
it	O 0
to	O 0
be	O 0
of	O 0
germline	O 0
origin	O 0
.	O 0

The	O 0
initial	O 0
mutation	O 0
was	O 0
shown	O 0
to	O 0
have	O 0
occurred	O 0
in	O 0
the	O 0
paternally	O 0
derived	O 0
RB1	O 0
allele	O 0
.	O 0

The	O 0
mutation	O 0
is	O 0
in	O 0
an	O 0
area	O 0
of	O 0
the	O 0
gene	O 0
that	O 0
encodes	O 0
the	O 0
protein	O 0
-	O 0
binding	O 0
region	O 0
known	O 0
as	O 0
the	O 0
pocket	O 0
region	O 0
and	O 0
has	O 0
been	O 0
detected	O 0
in	O 0
other	O 0
cases	O 0
of	O 0
retinoblastoma	B-Disease 0
.	O 0
.	O 0

Low	O 0
levels	O 0
of	O 0
beta	O 0
hexosaminidase	O 0
A	O 0
in	O 0
healthy	O 0
individuals	O 0
with	O 0
apparent	O 0
deficiency	O 0
of	O 0
this	O 0
enzyme	O 0
.	O 0

Appreciable	O 0
beta	O 0
hexosaminidase	O 0
A	O 0
(	O 0
hex	O 0
A	O 0
)	O 0
activity	O 0
has	O 0
been	O 0
detected	O 0
in	O 0
cultured	O 0
skin	O 0
fibroblasts	O 0
and	O 0
melanoma	B-Disease 0
tissue	O 0
from	O 0
healthy	O 0
individuals	O 0
previously	O 0
reported	O 0
as	O 0
having	O 0
deficiency	B-Disease 0
of	I-Disease 0
hex	I-Disease 0
A	I-Disease 0
activity	O 0
indistinguishable	O 0
from	O 0
that	O 0
of	O 0
patients	O 0
with	O 0
Tay	B-Disease 0
-	I-Disease 0
Sachs	I-Disease 0
disease	I-Disease 0
(	O 0
TSD	B-Disease 0
)	O 0
.	O 0

Identification	O 0
and	O 0
quantitation	O 0
of	O 0
hex	O 0
A	O 0
,	O 0
amounting	O 0
to	O 0
3	O 0
.	O 0

5	O 0
%	O 0
-	O 0
6	O 0
.	O 0

9	O 0
%	O 0
of	O 0
total	O 0
beta	O 0
hexosaminidase	O 0
activity	O 0
,	O 0
has	O 0
been	O 0
obtained	O 0
by	O 0
cellulose	O 0
acetate	O 0
gel	O 0
electrophoresis	O 0
,	O 0
DEAE	O 0
-	O 0
cellulose	O 0
ion	O 0
-	O 0
exchange	O 0
chromatography	O 0
,	O 0
radial	O 0
immunodiffusion	O 0
,	O 0
and	O 0
radioimmunoassay	O 0
.	O 0

Previous	O 0
family	O 0
studies	O 0
suggested	O 0
that	O 0
these	O 0
individuals	O 0
may	O 0
be	O 0
compound	O 0
heterozygotes	O 0
for	O 0
the	O 0
common	O 0
mutant	O 0
TSD	B-Disease 0
gene	O 0
and	O 0
a	O 0
rare	O 0
(	O 0
allelic	O 0
)	O 0
mutant	O 0
gene	O 0
.	O 0

Thus	O 0
,	O 0
the	O 0
postulated	O 0
rate	O 0
mutant	O 0
gene	O 0
appears	O 0
to	O 0
code	O 0
for	O 0
the	O 0
expression	O 0
of	O 0
low	O 0
amounts	O 0
of	O 0
hex	O 0
A	O 0
.	O 0

Heterozygotes	O 0
for	O 0
the	O 0
rare	O 0
mutant	O 0
may	O 0
be	O 0
indistinguishable	O 0
from	O 0
heterozygotes	O 0
for	O 0
the	O 0
common	O 0
TSD	B-Disease 0
mutant	O 0
.	O 0

However	O 0
,	O 0
direct	O 0
visualization	O 0
and	O 0
quantitation	O 0
of	O 0
hex	O 0
A	O 0
by	O 0
the	O 0
methods	O 0
described	O 0
may	O 0
prevent	O 0
false	O 0
-	O 0
positive	O 0
prenatal	O 0
diagnosis	O 0
of	O 0
TSD	B-Disease 0
in	O 0
fetuses	O 0
having	O 0
the	O 0
incomplete	O 0
hex	B-Disease 0
A	I-Disease 0
deficiency	I-Disease 0
of	O 0
the	O 0
type	O 0
described	O 0
in	O 0
the	O 0
four	O 0
healthy	O 0
individuals	O 0

The	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
Smad4	O 0
/	O 0
Dpc4	O 0
is	O 0
required	O 0
for	O 0
gastrulation	O 0
and	O 0
later	O 0
for	O 0
anterior	O 0
development	O 0
of	O 0
the	O 0
mouse	O 0
embryo	O 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
SMAD4	O 0
/	O 0
DPC4	O 0
tumor	B-Disease 0
suppressor	O 0
gene	O 0
,	O 0
a	O 0
key	O 0
signal	O 0
transducer	O 0
in	O 0
most	O 0
TGFbeta	O 0
-	O 0
related	O 0
pathways	O 0
,	O 0
are	O 0
involved	O 0
in	O 0
50	O 0
%	O 0
of	O 0
pancreatic	B-Disease 0
cancers	I-Disease 0
.	O 0

Homozygous	O 0
Smad4	O 0
mutant	O 0
mice	O 0
die	O 0
before	O 0
day	O 0
7	O 0
.	O 0

5	O 0
of	O 0
embryogenesis	O 0
.	O 0

Mutant	O 0
embryos	O 0
have	O 0
reduced	O 0
size	O 0
,	O 0
fail	O 0
to	O 0
gastrulate	O 0
or	O 0
express	O 0
a	O 0
mesodermal	O 0
marker	O 0
,	O 0
and	O 0
show	O 0
abnormal	O 0
visceral	O 0
endoderm	O 0
development	O 0
.	O 0

Growth	B-Disease 0
retardation	I-Disease 0
of	O 0
the	O 0
Smad4	O 0
-	O 0
deficient	O 0
embryos	O 0
results	O 0
from	O 0
reduced	O 0
cell	O 0
proliferation	O 0
rather	O 0
than	O 0
increased	O 0
apoptosis	O 0
.	O 0

Aggregation	O 0
of	O 0
mutant	O 0
Smad4	O 0
ES	O 0
cells	O 0
with	O 0
wild	O 0
-	O 0
type	O 0
tetraploid	O 0
morulae	O 0
rescues	O 0
the	O 0
gastrulation	B-Disease 0
defect	I-Disease 0
.	O 0

These	O 0
results	O 0
indicate	O 0
that	O 0
Smad4	O 0
is	O 0
initially	O 0
required	O 0
for	O 0
the	O 0
differentiation	O 0
of	O 0
the	O 0
visceral	O 0
endoderm	O 0
and	O 0
that	O 0
the	O 0
gastrulation	B-Disease 0
defect	I-Disease 0
in	O 0
the	O 0
epiblast	O 0
is	O 0
secondary	O 0
and	O 0
non	O 0
-	O 0
cell	O 0
autonomous	O 0
.	O 0

Rescued	O 0
embryos	O 0
show	O 0
severe	O 0
anterior	O 0
truncations	O 0
,	O 0
indicating	O 0
a	O 0
second	O 0
important	O 0
role	O 0
for	O 0
Smad4	O 0
in	O 0
anterior	O 0
patterning	O 0
during	O 0
embryogenesis	O 0
.	O 0

Prevalence	O 0
of	O 0
p16	O 0
and	O 0
CDK4	O 0
germline	O 0
mutations	O 0
in	O 0
48	O 0
melanoma	B-Disease 0
-	O 0
prone	O 0
families	O 0
in	O 0
France	O 0
.	O 0

The	O 0
French	O 0
Familial	B-Disease 0
Melanoma	I-Disease 0
Study	O 0
Group	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
the	O 0
p16	O 0
and	O 0
CDK4	O 0
genes	O 0
have	O 0
been	O 0
reported	O 0
in	O 0
a	O 0
subset	O 0
of	O 0
melanoma	B-Disease 0
pedigrees	O 0
,	O 0
but	O 0
their	O 0
prevalence	O 0
is	O 0
not	O 0
well	O 0
known	O 0
.	O 0

We	O 0
searched	O 0
for	O 0
such	O 0
germline	O 0
mutations	O 0
in	O 0
48	O 0
French	O 0
melanoma	B-Disease 0
-	O 0
prone	O 0
families	O 0
selected	O 0
according	O 0
to	O 0
two	O 0
major	O 0
criteria	O 0
families	O 0
with	O 0
at	O 0
least	O 0
three	O 0
affected	O 0
members	O 0
(	O 0
n	O 0
=	O 0
20	O 0
)	O 0
or	O 0
families	O 0
with	O 0
two	O 0
affected	O 0
members	O 0
,	O 0
one	O 0
of	O 0
them	O 0
affected	O 0
before	O 0
the	O 0
age	O 0
of	O 0
50	O 0
(	O 0
n	O 0
=	O 0
28	O 0
)	O 0
,	O 0
and	O 0
one	O 0
additional	O 0
minor	O 0
criterion	O 0
.	O 0

Sixteen	O 0
different	O 0
p16	O 0
germline	O 0
mutations	O 0
were	O 0
found	O 0
in	O 0
21	O 0
families	O 0
,	O 0
while	O 0
one	O 0
germline	O 0
mutation	O 0
,	O 0
Arg24His	O 0
,	O 0
was	O 0
detected	O 0
in	O 0
the	O 0
CDK4	O 0
gene	O 0
.	O 0

The	O 0
frequency	O 0
of	O 0
p16	O 0
gene	O 0
mutation	O 0
in	O 0
our	O 0
sample	O 0
(	O 0
44	O 0
%	O 0
)	O 0
is	O 0
among	O 0
the	O 0
highest	O 0
rates	O 0
yet	O 0
reported	O 0
and	O 0
the	O 0
CDK4	O 0
mutation	O 0
is	O 0
the	O 0
second	O 0
mutation	O 0
detected	O 0
in	O 0
this	O 0
gene	O 0
worldwide	O 0
.	O 0

In	O 0
summary	O 0
,	O 0
our	O 0
results	O 0
show	O 0
frequent	O 0
involvement	O 0
of	O 0
the	O 0
p16	O 0
gene	O 0
in	O 0
familial	B-Disease 0
melanoma	I-Disease 0
and	O 0
confirm	O 0
the	O 0
role	O 0
of	O 0
the	O 0
CDK4	O 0
gene	O 0
as	O 0
a	O 0
melanoma	B-Disease 0
-	O 0
predisposing	O 0
gene	O 0
.	O 0
.	O 0

Progression	O 0
of	O 0
somatic	O 0
CTG	O 0
repeat	O 0
length	O 0
heterogeneity	O 0
in	O 0
the	O 0
blood	O 0
cells	O 0
of	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
patients	O 0
.	O 0

The	O 0
genetic	O 0
basis	O 0
of	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
the	O 0
expansion	O 0
of	O 0
an	O 0
unstable	O 0
CTG	O 0
repeat	O 0
in	O 0
the	O 0
34	O 0
UTR	O 0
of	O 0
the	O 0
DM	B-Disease 0
protein	O 0
kinase	O 0
gene	O 0
on	O 0
chromosome	O 0
19	O 0
.	O 0

One	O 0
of	O 0
the	O 0
principal	O 0
features	O 0
of	O 0
the	O 0
DM	B-Disease 0
mutation	O 0
is	O 0
an	O 0
extraordinarily	O 0
high	O 0
level	O 0
of	O 0
somatic	O 0
mosaicism	O 0
,	O 0
due	O 0
to	O 0
an	O 0
extremely	O 0
high	O 0
degree	O 0
of	O 0
somatic	O 0
instability	O 0
both	O 0
within	O 0
and	O 0
between	O 0
different	O 0
tissues	O 0
.	O 0

This	O 0
instability	O 0
appears	O 0
to	O 0
be	O 0
biased	O 0
towards	O 0
further	O 0
expansion	O 0
and	O 0
continuous	O 0
throughout	O 0
the	O 0
life	O 0
of	O 0
an	O 0
individual	O 0
,	O 0
features	O 0
that	O 0
could	O 0
be	O 0
associated	O 0
with	O 0
the	O 0
progressive	O 0
nature	O 0
of	O 0
the	O 0
disease	O 0
.	O 0

Although	O 0
increasing	O 0
measured	O 0
allele	O 0
size	O 0
between	O 0
patients	O 0
clearly	O 0
correlates	O 0
with	O 0
an	O 0
increased	O 0
severity	O 0
of	O 0
symptoms	O 0
and	O 0
an	O 0
earlier	O 0
age	O 0
of	O 0
onset	O 0
,	O 0
this	O 0
correlation	O 0
is	O 0
not	O 0
precise	O 0
and	O 0
measured	O 0
allele	O 0
length	O 0
cannot	O 0
be	O 0
used	O 0
as	O 0
an	O 0
accurate	O 0
predictor	O 0
of	O 0
age	O 0
of	O 0
onset	O 0
.	O 0

In	O 0
order	O 0
to	O 0
further	O 0
characterize	O 0
the	O 0
dynamics	O 0
of	O 0
DM	B-Disease 0
CTG	O 0
repeat	O 0
somatic	O 0
instability	O 0
,	O 0
we	O 0
have	O 0
studied	O 0
repeat	O 0
length	O 0
changes	O 0
over	O 0
time	O 0
in	O 0
111	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
patients	O 0
with	O 0
varying	O 0
clinical	O 0
severity	O 0
and	O 0
CTG	O 0
repeat	O 0
size	O 0
over	O 0
time	O 0
intervals	O 0
of	O 0
1	O 0
-	O 0
7	O 0
years	O 0
.	O 0

We	O 0
have	O 0
found	O 0
a	O 0
direct	O 0
progression	O 0
of	O 0
the	O 0
size	O 0
heterogeneity	O 0
over	O 0
time	O 0
related	O 0
to	O 0
initial	O 0
CTG	O 0
repeat	O 0
size	O 0
and	O 0
the	O 0
time	O 0
interval	O 0
and	O 0
always	O 0
biased	O 0
towards	O 0
further	O 0
expansion	O 0
.	O 0

Attempts	O 0
to	O 0
mathematically	O 0
model	O 0
the	O 0
dynamics	O 0
have	O 0
proved	O 0
only	O 0
partially	O 0
successful	O 0
suggesting	O 0
that	O 0
individual	O 0
specific	O 0
genetic	O 0
and	O 0
/	O 0
or	O 0
environmental	O 0
factors	O 0
also	O 0
play	O 0
a	O 0
role	O 0
in	O 0
somatic	O 0
mosaicism	O 0
.	O 0
.	O 0

Aspartylglucosaminuria	B-Disease 0
among	O 0
Palestinian	O 0
Arabs	O 0
.	O 0

Aspartylglucosaminuria	B-Disease 0
(	O 0
AGU	B-Disease 0
)	O 0
is	O 0
a	O 0
rare	O 0
disorder	B-Disease 0
of	I-Disease 0
glycoprotein	I-Disease 0
metabolism	I-Disease 0
caused	O 0
by	O 0
the	O 0
deficiency	B-Disease 0
of	I-Disease 0
the	I-Disease 0
lysosomal	I-Disease 0
enzyme	I-Disease 0
aspartylglucosaminidase	I-Disease 0
(	O 0
AGA	O 0
)	O 0
.	O 0

AGU	B-Disease 0
is	O 0
inherited	O 0
as	O 0
an	O 0
autosomal	O 0
recessive	O 0
trait	O 0
and	O 0
occurs	O 0
with	O 0
a	O 0
high	O 0
frequency	O 0
in	O 0
Finland	O 0
because	O 0
of	O 0
a	O 0
founder	O 0
effect	O 0
.	O 0

While	O 0
very	O 0
few	O 0
patients	O 0
with	O 0
AGU	B-Disease 0
have	O 0
been	O 0
reported	O 0
from	O 0
non	O 0
-	O 0
Finnish	O 0
origin	O 0
,	O 0
we	O 0
diagnosed	O 0
the	O 0
disorder	O 0
in	O 0
8	O 0
patients	O 0
originating	O 0
from	O 0
3	O 0
unrelated	O 0
families	O 0
,	O 0
all	O 0
Palestinian	O 0
Arabs	O 0
from	O 0
the	O 0
region	O 0
of	O 0
Jerusalem	O 0
.	O 0

The	O 0
clinical	O 0
diagnosis	O 0
of	O 0
AGU	B-Disease 0
is	O 0
often	O 0
difficult	O 0
,	O 0
in	O 0
particular	O 0
early	O 0
in	O 0
the	O 0
course	O 0
of	O 0
the	O 0
disease	O 0
,	O 0
and	O 0
most	O 0
of	O 0
the	O 0
patients	O 0
are	O 0
diagnosed	O 0
after	O 0
the	O 0
age	O 0
of	O 0
5	O 0
years	O 0
.	O 0

However	O 0
,	O 0
since	O 0
these	O 0
patients	O 0
excrete	O 0
early	O 0
large	O 0
amounts	O 0
of	O 0
aspartylglucosamine	O 0
in	O 0
urine	O 0
,	O 0
biochemical	O 0
screening	O 0
is	O 0
easy	O 0
by	O 0
urine	O 0
chromatography	O 0
.	O 0
.	O 0

Detection	O 0
of	O 0
heterozygous	O 0
carriers	O 0
of	O 0
the	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
ATM	O 0
)	O 0
gene	O 0
by	O 0
G2	O 0
phase	O 0
chromosomal	O 0
radiosensitivity	O 0
of	O 0
peripheral	O 0
blood	O 0
lymphocytes	O 0
.	O 0

In	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
patients	O 0
,	O 0
mutations	O 0
in	O 0
a	O 0
single	O 0
gene	O 0
,	O 0
ATM	O 0
,	O 0
result	O 0
in	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
syndrome	I-Disease 0
that	O 0
embraces	O 0
a	O 0
variety	O 0
of	O 0
clinical	O 0
features	O 0
and	O 0
manifests	O 0
extreme	O 0
radiosensitivity	O 0
and	O 0
a	O 0
strong	O 0
pre	O 0
-	O 0
disposition	O 0
to	O 0
malignancy	B-Disease 0
.	O 0

Heterozygotes	O 0
for	O 0
the	O 0
ATM	O 0
gene	O 0
have	O 0
no	O 0
clinical	O 0
expression	O 0
of	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
but	O 0
may	O 0
be	O 0
cancer	B-Disease 0
prone	O 0
with	O 0
a	O 0
moderate	O 0
increase	O 0
in	O 0
in	O 0
vitro	O 0
radiosensitivity	O 0
.	O 0

We	O 0
performed	O 0
a	O 0
blind	O 0
chromosomal	O 0
analysis	O 0
on	O 0
G2	O 0
-	O 0
phase	O 0
lymphocytes	O 0
from	O 0
7	O 0
unrelated	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
,	O 0
13	O 0
obligate	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
heterozygotes	O 0
(	O 0
parents	O 0
of	O 0
the	O 0
patients	O 0
)	O 0
,	O 0
and	O 0
14	O 0
normal	O 0
controls	O 0
following	O 0
X	O 0
-	O 0
irradiation	O 0
with	O 0
1	O 0
Gy	O 0
in	O 0
order	O 0
to	O 0
evaluate	O 0
this	O 0
cytogenetic	O 0
method	O 0
as	O 0
a	O 0
tool	O 0
for	O 0
detection	O 0
of	O 0
ATM	O 0
carriers	O 0
.	O 0

Both	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
homozygotes	O 0
and	O 0
heterozygotes	O 0
showed	O 0
significantly	O 0
increased	O 0
levels	O 0
of	O 0
radiation	O 0
-	O 0
induced	O 0
chromatid	O 0
damage	O 0
relative	O 0
to	O 0
that	O 0
of	O 0
normal	O 0
controls	O 0
.	O 0

These	O 0
results	O 0
show	O 0
that	O 0
the	O 0
G2	O 0
-	O 0
phase	O 0
chromosomal	O 0
radiosensitivity	O 0
assay	O 0
can	O 0
be	O 0
used	O 0
for	O 0
the	O 0
detection	O 0
of	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
heterozygotes	O 0
.	O 0

In	O 0
combination	O 0
with	O 0
molecular	O 0
genetic	O 0
analyses	O 0
,	O 0
this	O 0
test	O 0
may	O 0
be	O 0
of	O 0
value	O 0
in	O 0
studies	O 0
of	O 0
familial	B-Disease 0
and	I-Disease 0
sporadic	I-Disease 0
cancers	I-Disease 0
aimed	O 0
at	O 0
determination	O 0
of	O 0
the	O 0
potential	O 0
involvement	O 0
of	O 0
ATM	O 0
mutations	O 0
in	O 0
tumor	B-Disease 0
risk	O 0
or	O 0
development	O 0
.	O 0
.	O 0

Ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
:	O 0
identification	O 0
and	O 0
detection	O 0
of	O 0
founder	O 0
-	O 0
effect	O 0
mutations	O 0
in	O 0
the	O 0
ATM	O 0
gene	O 0
in	O 0
ethnic	O 0
populations	O 0
.	O 0

To	O 0
facilitate	O 0
the	O 0
evaluation	O 0
of	O 0
ATM	O 0
heterozygotes	O 0
for	O 0
susceptibility	O 0
to	O 0
other	O 0
diseases	O 0
,	O 0
such	O 0
as	O 0
breast	B-Disease 0
cancer	I-Disease 0
,	O 0
we	O 0
have	O 0
attempted	O 0
to	O 0
define	O 0
the	O 0
most	O 0
common	O 0
mutations	O 0
and	O 0
their	O 0
frequencies	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
homozygotes	O 0
from	O 0
10	O 0
ethnic	O 0
populations	O 0
.	O 0

Both	O 0
genomic	O 0
mutations	O 0
and	O 0
their	O 0
effects	O 0
on	O 0
cDNA	O 0
were	O 0
characterized	O 0
.	O 0

Protein	O 0
-	O 0
truncation	O 0
testing	O 0
of	O 0
the	O 0
entire	O 0
ATM	O 0
cDNA	O 0
detected	O 0
92	O 0
(	O 0
66	O 0
%	O 0
)	O 0
truncating	O 0
mutations	O 0
in	O 0
140	O 0
mutant	O 0
alleles	O 0
screened	O 0
.	O 0

The	O 0
haplotyping	O 0
of	O 0
patients	O 0
with	O 0
identical	O 0
mutations	O 0
indicates	O 0
that	O 0
almost	O 0
all	O 0
of	O 0
these	O 0
represent	O 0
common	O 0
ancestry	O 0
and	O 0
that	O 0
very	O 0
few	O 0
spontaneously	O 0
recurring	O 0
ATM	O 0
mutations	O 0
exist	O 0
.	O 0

Assays	O 0
requiring	O 0
minimal	O 0
amounts	O 0
of	O 0
genomic	O 0
DNA	O 0
were	O 0
designed	O 0
to	O 0
allow	O 0
rapid	O 0
screening	O 0
for	O 0
common	O 0
ethnic	O 0
mutations	O 0
.	O 0

These	O 0
rapid	O 0
assays	O 0
detected	O 0
mutations	O 0
in	O 0
76	O 0
%	O 0
of	O 0
Costa	O 0
Rican	O 0
patients	O 0
(	O 0
3	O 0
)	O 0
,	O 0
50	O 0
%	O 0
of	O 0
Norwegian	O 0
patients	O 0
(	O 0
1	O 0
)	O 0
,	O 0
25	O 0
%	O 0
of	O 0
Polish	O 0
patients	O 0
(	O 0
4	O 0
)	O 0
,	O 0
and	O 0
14	O 0
%	O 0
of	O 0
Italian	O 0
patients	O 0
(	O 0
1	O 0
)	O 0
,	O 0
as	O 0
well	O 0
as	O 0
in	O 0
patients	O 0
of	O 0
Amish	O 0
/	O 0
Mennonite	O 0
and	O 0
Irish	O 0
English	O 0
backgrounds	O 0
.	O 0

Additional	O 0
mutations	O 0
were	O 0
observed	O 0
in	O 0
Japanese	O 0
,	O 0
Utah	O 0
Mormon	O 0
,	O 0
and	O 0
African	O 0
American	O 0
patients	O 0
.	O 0

These	O 0
assays	O 0
should	O 0
facilitate	O 0
screening	O 0
for	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
heterozygotes	O 0
in	O 0
the	O 0
populations	O 0
studied	O 0
.	O 0
.	O 0

The	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
tumor	I-Disease 0
suppressor	O 0
gene	O 0
is	O 0
required	O 0
for	O 0
cell	O 0
cycle	O 0
exit	O 0
upon	O 0
serum	O 0
withdrawal	O 0
.	O 0

The	O 0
inactivation	O 0
of	O 0
the	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
(	I-Disease 0
VHL	I-Disease 0
)	I-Disease 0
tumor	I-Disease 0
suppressor	O 0
gene	O 0
predisposes	O 0
affected	O 0
individuals	O 0
to	O 0
the	O 0
human	O 0
VHL	B-Disease 0
cancer	I-Disease 0
syndrome	I-Disease 0
and	O 0
is	O 0
associated	O 0
with	O 0
sporadic	B-Disease 0
renal	I-Disease 0
cell	I-Disease 0
carcinomas	I-Disease 0
(	O 0
RCC	B-Disease 0
)	O 0
and	O 0
brain	B-Disease 0
hemangioblastomas	I-Disease 0
.	O 0

VHL	O 0
-	O 0
negative	O 0
786	O 0
-	O 0
0	O 0
RCC	B-Disease 0
cells	O 0
are	O 0
tumorigenic	O 0
in	O 0
nude	O 0
mice	O 0
which	O 0
is	O 0
suppressed	O 0
by	O 0
the	O 0
reintroduction	O 0
of	O 0
VHL	B-Disease 0
.	O 0

Remarkably	O 0
,	O 0
this	O 0
occurs	O 0
without	O 0
affecting	O 0
the	O 0
growth	O 0
rate	O 0
and	O 0
cell	O 0
cycle	O 0
profile	O 0
of	O 0
these	O 0
cells	O 0
in	O 0
culture	O 0
.	O 0

The	O 0
786	O 0
-	O 0
0	O 0
cell	O 0
line	O 0
,	O 0
like	O 0
many	O 0
cancer	B-Disease 0
cells	O 0
,	O 0
fails	O 0
to	O 0
exit	O 0
the	O 0
cell	O 0
cycle	O 0
upon	O 0
serum	O 0
withdrawal	O 0
.	O 0

Here	O 0
,	O 0
it	O 0
is	O 0
shown	O 0
that	O 0
reintroduction	O 0
of	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
VHL	B-Disease 0
gene	O 0
restores	O 0
the	O 0
ability	O 0
of	O 0
VHL	O 0
-	O 0
negative	O 0
RCC	B-Disease 0
cancer	I-Disease 0
cells	O 0
to	O 0
exit	O 0
the	O 0
cell	O 0
cycle	O 0
and	O 0
enter	O 0
G0	O 0
/	O 0
quiescence	O 0
in	O 0
low	O 0
serum	O 0
.	O 0

Both	O 0
VHL	O 0
-	O 0
positive	O 0
and	O 0
VHL	O 0
-	O 0
negative	O 0
RCC	B-Disease 0
cells	O 0
exit	O 0
the	O 0
cell	O 0
cycle	O 0
by	O 0
contact	O 0
inhibition	O 0
.	O 0

The	O 0
cyclin	O 0
-	O 0
dependent	O 0
kinase	O 0
inhibitor	O 0
,	O 0
p27	O 0
,	O 0
accumulates	O 0
upon	O 0
serum	O 0
withdrawal	O 0
,	O 0
only	O 0
in	O 0
the	O 0
presence	O 0
of	O 0
VHL	B-Disease 0
,	O 0
as	O 0
a	O 0
result	O 0
of	O 0
the	O 0
stabilization	O 0
of	O 0
the	O 0
protein	O 0
.	O 0

We	O 0
propose	O 0
that	O 0
the	O 0
loss	O 0
of	O 0
wild	O 0
-	O 0
type	O 0
VHL	B-Disease 0
gene	O 0
results	O 0
in	O 0
a	O 0
specific	O 0
cellular	O 0
defect	O 0
in	O 0
serum	O 0
-	O 0
dependent	O 0
growth	O 0
control	O 0
,	O 0
which	O 0
may	O 0
initiate	O 0
tumor	B-Disease 0
formation	O 0
.	O 0

This	O 0
is	O 0
corrected	O 0
by	O 0
the	O 0
reintroduction	O 0
of	O 0
wild	O 0
-	O 0
type	O 0
VHL	B-Disease 0
,	O 0
implicating	O 0
VHL	B-Disease 0
as	O 0
the	O 0
first	O 0
tumor	B-Disease 0
suppressor	O 0
involved	O 0
in	O 0
the	O 0
regulation	O 0
of	O 0
cell	O 0
cycle	O 0
exit	O 0
,	O 0
which	O 0
is	O 0
consistent	O 0
with	O 0
its	O 0
gatekeeper	O 0
function	O 0
in	O 0
the	O 0
kidney	O 0
.	O 0
.	O 0

Piebaldism	B-Disease 0
with	O 0
deafness	B-Disease 0
:	O 0
molecular	O 0
evidence	O 0
for	O 0
an	O 0
expanded	O 0
syndrome	O 0
.	O 0

In	O 0
a	O 0
South	O 0
African	O 0
girl	O 0
of	O 0
Xhosa	O 0
stock	O 0
with	O 0
severe	O 0
piebaldism	B-Disease 0
and	O 0
profound	O 0
congenital	O 0
sensorineural	B-Disease 0
deafness	I-Disease 0
we	O 0
identified	O 0
a	O 0
novel	O 0
missense	O 0
substitution	O 0
at	O 0
a	O 0
highly	O 0
conserved	O 0
residue	O 0
in	O 0
the	O 0
intracellular	O 0
kinase	O 0
domain	O 0
of	O 0
the	O 0
KIT	O 0
proto	O 0
-	O 0
oncogene	O 0
,	O 0
R796G	O 0
.	O 0

Though	O 0
auditory	B-Disease 0
anomalies	I-Disease 0
have	O 0
been	O 0
observed	O 0
in	O 0
mice	O 0
with	O 0
dominant	O 0
white	O 0
spotting	O 0
(	O 0
W	O 0
)	O 0
due	O 0
to	O 0
KIT	O 0
mutations	O 0
,	O 0
deafness	B-Disease 0
is	O 0
not	O 0
typical	O 0
in	O 0
human	O 0
piebaldism	B-Disease 0
.	O 0

Thus	O 0
,	O 0
the	O 0
occurrence	O 0
of	O 0
sensorineural	B-Disease 0
deafness	I-Disease 0
in	O 0
this	O 0
patient	O 0
extends	O 0
considerably	O 0
the	O 0
phenotypic	O 0
range	O 0
of	O 0
piebaldism	B-Disease 0
due	O 0
to	O 0
KIT	O 0
gene	O 0
mutation	O 0
in	O 0
humans	O 0
and	O 0
tightens	O 0
the	O 0
clinical	O 0
similarity	O 0
between	O 0
piebaldism	B-Disease 0
and	O 0
the	O 0
various	O 0
forms	O 0
of	O 0
Waardenburg	B-Disease 0
syndrome	I-Disease 0
.	O 0
.	O 0

Cycloheximide	O 0
facilitates	O 0
the	O 0
identification	O 0
of	O 0
aberrant	O 0
transcripts	O 0
resulting	O 0
from	O 0
a	O 0
novel	O 0
splice	O 0
-	O 0
site	O 0
mutation	O 0
in	O 0
COL17A1	O 0
in	O 0
a	O 0
patient	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
.	O 0

Patients	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
often	O 0
show	O 0
decreased	O 0
expression	O 0
of	O 0
type	O 0
XVII	O 0
collagen	O 0
,	O 0
a	O 0
transmembrane	O 0
hemidesmosomal	O 0
protein	O 0
encoded	O 0
by	O 0
COL17A1	O 0
.	O 0

This	O 0
report	O 0
documents	O 0
a	O 0
novel	O 0
splice	O 0
-	O 0
site	O 0
mutation	O 0
in	O 0
COL17A1	O 0
in	O 0
a	O 0
patient	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
,	O 0
and	O 0
applies	O 0
a	O 0
new	O 0
methodology	O 0
to	O 0
define	O 0
and	O 0
characterize	O 0
the	O 0
resulting	O 0
mRNA	O 0
splice	O 0
variants	O 0
.	O 0

Mutational	O 0
analysis	O 0
of	O 0
COL17A1	O 0
identified	O 0
a	O 0
maternally	O 0
inherited	O 0
G	O 0
-	O 0
to	O 0
-	O 0
T	O 0
transversion	O 0
at	O 0
the	O 0
-	O 0
1	O 0
position	O 0
of	O 0
exon	O 0
32	O 0
.	O 0

This	O 0
acceptor	O 0
splice	O 0
-	O 0
site	O 0
mutation	O 0
led	O 0
to	O 0
the	O 0
formation	O 0
of	O 0
aberrant	O 0
transcripts	O 0
present	O 0
at	O 0
extremely	O 0
low	O 0
levels	O 0
.	O 0

Based	O 0
on	O 0
our	O 0
recent	O 0
finding	O 0
that	O 0
cycloheximide	O 0
stabilized	O 0
mutant	O 0
COL17A1	O 0
transcripts	O 0
in	O 0
keratinocytes	O 0
homozygous	O 0
for	O 0
a	O 0
frameshift	O 0
mutation	O 0
,	O 0
the	O 0
effects	O 0
of	O 0
the	O 0
splice	O 0
-	O 0
site	O 0
mutation	O 0
on	O 0
splicing	O 0
of	O 0
COL17A1	O 0
transcripts	O 0
were	O 0
determined	O 0
using	O 0
reverse	O 0
transcriptase	O 0
polymerase	O 0
chain	O 0
reaction	O 0
of	O 0
total	O 0
RNA	O 0
from	O 0
keratinocytes	O 0
incubated	O 0
for	O 0
2	O 0
.	O 0

5	O 0
h	O 0
in	O 0
the	O 0
presence	O 0
or	O 0
absence	O 0
of	O 0
10	O 0
microg	O 0
cycloheximide	O 0
per	O 0
ml	O 0
.	O 0

Using	O 0
this	O 0
approach	O 0
,	O 0
an	O 0
abnormally	O 0
spliced	O 0
transcript	O 0
was	O 0
identified	O 0
that	O 0
contains	O 0
an	O 0
extra	O 0
264	O 0
bases	O 0
upstream	O 0
from	O 0
exon	O 0
32	O 0
,	O 0
resulting	O 0
in	O 0
a	O 0
premature	O 0
termination	O 0
codon	O 0
27	O 0
bp	O 0
downstream	O 0
from	O 0
the	O 0
cryptic	O 0
splice	O 0
site	O 0
.	O 0

Three	O 0
other	O 0
splice	O 0
variants	O 0
,	O 0
including	O 0
one	O 0
derived	O 0
from	O 0
the	O 0
skipping	O 0
of	O 0
exon	O 0
32	O 0
,	O 0
were	O 0
also	O 0
identified	O 0
.	O 0

These	O 0
results	O 0
indicate	O 0
the	O 0
usefulness	O 0
of	O 0
cycloheximide	O 0
treatment	O 0
in	O 0
evaluating	O 0
the	O 0
abnormal	O 0
processing	O 0
of	O 0
mRNA	O 0
due	O 0
to	O 0
splice	O 0
-	O 0
site	O 0
mutations	O 0
,	O 0
because	O 0
(	O 0
i	O 0
)	O 0
aberrant	O 0
splicing	O 0
often	O 0
generates	O 0
a	O 0
premature	O 0
termination	O 0
codon	O 0
,	O 0
(	O 0
ii	O 0
)	O 0
transcripts	O 0
with	O 0
premature	O 0
termination	O 0
codons	O 0
can	O 0
occur	O 0
at	O 0
low	O 0
or	O 0
undetectable	O 0
levels	O 0
due	O 0
to	O 0
nonsense	O 0
-	O 0
mediated	O 0
mRNA	O 0
decay	O 0
,	O 0
and	O 0
(	O 0
iii	O 0
)	O 0
the	O 0
levels	O 0
of	O 0
these	O 0
transcripts	O 0
can	O 0
be	O 0
increased	O 0
by	O 0
cycloheximide	O 0
.	O 0

A	O 0
deletion	O 0
mutation	O 0
in	O 0
COL17A1	O 0
in	O 0
five	O 0
Austrian	O 0
families	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
represents	O 0
propagation	O 0
of	O 0
an	O 0
ancestral	O 0
allele	O 0
.	O 0

Patients	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
,	O 0
a	O 0
usually	O 0
nonlethal	O 0
form	O 0
of	O 0
junctional	B-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
,	O 0
have	O 0
generalized	O 0
blistering	B-Disease 0
,	O 0
nail	B-Disease 0
dystrophy	I-Disease 0
,	O 0
patchy	B-Disease 0
alopecia	I-Disease 0
,	O 0
and	O 0
dental	B-Disease 0
abnormalities	I-Disease 0
.	O 0

Skin	B-Disease 0
fragility	I-Disease 0
in	O 0
most	O 0
cases	O 0
is	O 0
due	O 0
to	O 0
mutations	O 0
in	O 0
the	O 0
gene	O 0
encoding	O 0
type	O 0
XVII	O 0
collagen	O 0
(	O 0
COL17A1	O 0
)	O 0
.	O 0

Recently	O 0
,	O 0
we	O 0
reported	O 0
five	O 0
Austrian	O 0
families	O 0
with	O 0
generalized	O 0
atrophic	B-Disease 0
benign	I-Disease 0
epidermolysis	I-Disease 0
bullosa	I-Disease 0
who	O 0
share	O 0
the	O 0
same	O 0
COL17A1	O 0
mutation	O 0
.	O 0

Affected	O 0
individuals	O 0
in	O 0
three	O 0
families	O 0
are	O 0
homozygous	O 0
for	O 0
4003delTC	O 0
,	O 0
whereas	O 0
those	O 0
in	O 0
two	O 0
others	O 0
are	O 0
compound	O 0
heterozygotes	O 0
.	O 0

To	O 0
determine	O 0
if	O 0
the	O 0
occurrence	O 0
of	O 0
4003delTC	O 0
in	O 0
these	O 0
unrelated	O 0
families	O 0
signifies	O 0
propagation	O 0
of	O 0
an	O 0
ancestral	O 0
allele	O 0
or	O 0
a	O 0
mutational	O 0
hot	O 0
spot	O 0
,	O 0
haplotypes	O 0
were	O 0
determined	O 0
for	O 0
polymorphisms	O 0
both	O 0
within	O 0
and	O 0
flanking	O 0
COL17A1	O 0
.	O 0

Five	O 0
intragenic	O 0
polymorphisms	O 0
were	O 0
chosen	O 0
based	O 0
on	O 0
their	O 0
informativeness	O 0
.	O 0

One	O 0
of	O 0
these	O 0
,	O 0
not	O 0
previously	O 0
reported	O 0
,	O 0
was	O 0
2988	O 0
A	O 0
or	O 0
C	O 0
that	O 0
introduces	O 0
a	O 0
new	O 0
restriction	O 0
site	O 0
for	O 0
Eco0109	O 0
I	O 0
.	O 0

All	O 0
the	O 0
4003delTC	O 0
alleles	O 0
showed	O 0
the	O 0
same	O 0
haplotype	O 0
for	O 0
these	O 0
five	O 0
polymorphic	O 0
markers	O 0
.	O 0

Fourteen	O 0
microsatellite	O 0
polymorphisms	O 0
were	O 0
selected	O 0
based	O 0
on	O 0
their	O 0
high	O 0
heterozygosity	O 0
and	O 0
their	O 0
location	O 0
within	O 0
10q23	O 0
-	O 0
q25	O 0
near	O 0
COL17A1	O 0
.	O 0

Three	O 0
families	O 0
shared	O 0
microsatellite	O 0
polymorphisms	O 0
covering	O 0
at	O 0
most	O 0
19	O 0
cM	O 0
,	O 0
whereas	O 0
the	O 0
others	O 0
shared	O 0
smaller	O 0
regions	O 0
consistent	O 0
with	O 0
cross	O 0
-	O 0
over	O 0
events	O 0
during	O 0
passage	O 0
of	O 0
this	O 0
mutation	O 0
through	O 0
several	O 0
generations	O 0
.	O 0

These	O 0
results	O 0
indicate	O 0
that	O 0
4003delTC	O 0
occurs	O 0
on	O 0
a	O 0
single	O 0
ancestral	O 0
allele	O 0
.	O 0
.	O 0

The	O 0
haptoglobin	O 0
-	O 0
gene	O 0
deletion	O 0
responsible	O 0
for	O 0
anhaptoglobinemia	B-Disease 0
.	O 0

We	O 0
have	O 0
found	O 0
an	O 0
allelic	O 0
deletion	O 0
of	O 0
the	O 0
haptoglobin	O 0
(	O 0
Hp	O 0
)	O 0
gene	O 0
from	O 0
an	O 0
individual	O 0
with	O 0
anhaptoglobinemia	B-Disease 0
.	O 0

The	O 0
Hp	O 0
gene	O 0
cluster	O 0
consists	O 0
of	O 0
coding	O 0
regions	O 0
of	O 0
the	O 0
alpha	O 0
chain	O 0
and	O 0
beta	O 0
chain	O 0
of	O 0
the	O 0
haptoglobin	O 0
gene	O 0
(	O 0
Hp	O 0
)	O 0
and	O 0
of	O 0
the	O 0
alpha	O 0
chain	O 0
and	O 0
beta	O 0
chain	O 0
of	O 0
the	O 0
haptoglobin	O 0
-	O 0
related	O 0
gene	O 0
(	O 0
Hpr	O 0
)	O 0
,	O 0
in	O 0
tandem	O 0
from	O 0
the	O 0
5	O 0
side	O 0
.	O 0

Southern	O 0
blot	O 0
and	O 0
PCR	O 0
analyses	O 0
have	O 0
indicated	O 0
that	O 0
the	O 0
individual	O 0
with	O 0
anhaptoglobinemia	B-Disease 0
was	O 0
homozygous	O 0
for	O 0
the	O 0
gene	O 0
deletion	O 0
and	O 0
that	O 0
the	O 0
gene	O 0
deletion	O 0
was	O 0
included	O 0
at	O 0
least	O 0
from	O 0
the	O 0
promoter	O 0
region	O 0
of	O 0
Hp	O 0
to	O 0
Hpr	O 0
alpha	O 0
but	O 0
not	O 0
to	O 0
Hpr	O 0
beta	O 0
(	O 0
Hpdel	O 0
)	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
we	O 0
found	O 0
seven	O 0
individuals	O 0
with	O 0
hypohaptoglobinemia	B-Disease 0
in	O 0
three	O 0
families	O 0
,	O 0
and	O 0
the	O 0
genotypes	O 0
of	O 0
six	O 0
of	O 0
the	O 0
seven	O 0
individuals	O 0
were	O 0
found	O 0
to	O 0
be	O 0
Hp2	O 0
/	O 0
Hpdel	O 0
.	O 0

The	O 0
phenotypes	O 0
and	O 0
genotypes	O 0
in	O 0
one	O 0
of	O 0
these	O 0
three	O 0
families	O 0
showed	O 0
the	O 0
father	O 0
to	O 0
be	O 0
hypohaptoglobinemic	B-Disease 0
(	O 0
Hp2	O 0
)	O 0
and	O 0
Hp2	O 0
/	O 0
Hpdel	O 0
,	O 0
the	O 0
mother	O 0
to	O 0
be	O 0
Hp2	O 0
-	O 0
1	O 0
and	O 0
Hp1	O 0
/	O 0
Hp2	O 0
,	O 0
one	O 0
of	O 0
the	O 0
two	O 0
children	O 0
to	O 0
be	O 0
hypohaptoglobinemic	B-Disease 0
(	O 0
Hp2	O 0
)	O 0
and	O 0
Hp2	O 0
/	O 0
Hpdel	O 0
,	O 0
and	O 0
the	O 0
other	O 0
child	O 0
to	O 0
be	O 0
Hp1	O 0
and	O 0
Hp1	O 0
/	O 0
Hpdel	O 0
,	O 0
showing	O 0
an	O 0
anomalous	O 0
inheritance	O 0
of	O 0
Hp	O 0
phenotypes	O 0
in	O 0
the	O 0
child	O 0
with	O 0
Hp1	O 0
.	O 0

The	O 0
Hp2	O 0
/	O 0
Hpdel	O 0
individuals	O 0
had	O 0
an	O 0
extremely	O 0
low	O 0
level	O 0
of	O 0
Hp	O 0
(	O 0
mean	O 0
+	O 0
/	O 0
-	O 0
SD	O 0
=	O 0
0	O 0
.	O 0
049	O 0
+	O 0
/	O 0
-	O 0
0	O 0
.	O 0
043	O 0
mg	O 0
/	O 0
ml	O 0
;	O 0
n	O 0
=	O 0
6	O 0
)	O 0
,	O 0
compared	O 0
with	O 0
the	O 0
level	O 0
(	O 0
1	O 0
.	O 0
64	O 0
+	O 0
/	O 0
-	O 0
1	O 0
.	O 0
07	O 0
mg	O 0
/	O 0
ml	O 0
)	O 0
obtained	O 0
from	O 0
52	O 0
healthy	O 0
volunteers	O 0
having	O 0
phenotype	O 0
Hp2	O 0
,	O 0
whereas	O 0
the	O 0
serum	O 0
Hp	O 0
level	O 0
of	O 0
an	O 0
individual	O 0
with	O 0
Hp1	O 0
/	O 0
Hpdel	O 0
was	O 0
0	O 0
.	O 0

50	O 0
mg	O 0
/	O 0
ml	O 0
,	O 0
which	O 0
was	O 0
approximately	O 0
half	O 0
the	O 0
level	O 0
of	O 0
Hp	O 0
in	O 0
control	O 0
sera	O 0
from	O 0
the	O 0
Hp1	O 0
phenotype	O 0
(	O 0
1	O 0
.	O 0
26	O 0
+	O 0
/	O 0
-	O 0
0	O 0
.	O 0
33	O 0
mg	O 0
/	O 0
ml	O 0
;	O 0
n	O 0
=	O 0
9	O 0
)	O 0
,	O 0
showing	O 0
a	O 0
gene	O 0
-	O 0
dosage	O 0
effect	O 0
.	O 0

The	O 0
other	O 0
allele	O 0
(	O 0
Hp2	O 0
)	O 0
of	O 0
individuals	O 0
with	O 0
Hp2	O 0
/	O 0
Hpdel	O 0
was	O 0
found	O 0
to	O 0
have	O 0
,	O 0
in	O 0
all	O 0
exons	O 0
,	O 0
no	O 0
mutation	O 0
,	O 0
by	O 0
DNA	O 0
sequencing	O 0
.	O 0

On	O 0
the	O 0
basis	O 0
of	O 0
the	O 0
present	O 0
study	O 0
,	O 0
the	O 0
mechanism	O 0
of	O 0
anhaptoglobinemia	B-Disease 0
and	O 0
the	O 0
mechanism	O 0
of	O 0
anomalous	O 0
inheritance	O 0
of	O 0
Hp	O 0
phenotypes	O 0
were	O 0
well	O 0
explained	O 0
.	O 0

However	O 0
,	O 0
the	O 0
mechanism	O 0
of	O 0
hypohaptoglobinemia	B-Disease 0
remains	O 0
unknown	O 0

ATM	O 0
mutations	O 0
and	O 0
phenotypes	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
families	O 0
in	O 0
the	O 0
British	O 0
Isles	O 0
:	O 0
expression	O 0
of	O 0
mutant	O 0
ATM	O 0
and	O 0
the	O 0
risk	O 0
of	O 0
leukemia	B-Disease 0
,	O 0
lymphoma	B-Disease 0
,	O 0
and	O 0
breast	B-Disease 0
cancer	I-Disease 0
.	O 0

We	O 0
report	O 0
the	O 0
spectrum	O 0
of	O 0
59	O 0
ATM	O 0
mutations	O 0
observed	O 0
in	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
patients	O 0
in	O 0
the	O 0
British	O 0
Isles	O 0
.	O 0

Of	O 0
51	O 0
ATM	O 0
mutations	O 0
identified	O 0
in	O 0
families	O 0
native	O 0
to	O 0
the	O 0
British	O 0
Isles	O 0
,	O 0
11	O 0
were	O 0
founder	O 0
mutations	O 0
,	O 0
and	O 0
2	O 0
of	O 0
these	O 0
11	O 0
conferred	O 0
a	O 0
milder	O 0
clinical	O 0
phenotype	O 0
with	O 0
respect	O 0
to	O 0
both	O 0
cerebellar	B-Disease 0
degeneration	I-Disease 0
and	O 0
cellular	O 0
features	O 0
.	O 0

We	O 0
report	O 0
,	O 0
in	O 0
two	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
families	O 0
,	O 0
an	O 0
ATM	O 0
mutation	O 0
(	O 0
7271T	O 0
-	O 0
-	O 0
>	O 0
G	O 0
)	O 0
that	O 0
may	O 0
be	O 0
associated	O 0
with	O 0
an	O 0
increased	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
in	O 0
both	O 0
homozygotes	O 0
and	O 0
heterozygotes	O 0
(	O 0
relative	O 0
risk	O 0
12	O 0
.	O 0
7	O 0
;	O 0
P	O 0
=	O 0
.	O 0
0025	O 0
)	O 0
,	O 0
although	O 0
there	O 0
is	O 0
a	O 0
less	O 0
severe	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
phenotype	O 0
in	O 0
terms	O 0
of	O 0
the	O 0
degree	O 0
of	O 0
cerebellar	B-Disease 0
degeneration	I-Disease 0
.	O 0

This	O 0
mutation	O 0
(	O 0
7271T	O 0
-	O 0
-	O 0
>	O 0
G	O 0
)	O 0
also	O 0
allows	O 0
expression	O 0
of	O 0
full	O 0
-	O 0
length	O 0
ATM	O 0
protein	O 0
at	O 0
a	O 0
level	O 0
comparable	O 0
with	O 0
that	O 0
in	O 0
unaffected	O 0
individuals	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
we	O 0
have	O 0
studied	O 0
18	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
,	O 0
in	O 0
15	O 0
families	O 0
,	O 0
who	O 0
developed	O 0
leukemia	B-Disease 0
,	O 0
lymphoma	B-Disease 0
,	O 0
preleukemic	O 0
T	O 0
-	O 0
cell	O 0
proliferation	O 0
,	O 0
or	O 0
Hodgkin	B-Disease 0
lymphoma	I-Disease 0
,	O 0
mostly	O 0
in	O 0
childhood	O 0
.	O 0

A	O 0
wide	O 0
variety	O 0
of	O 0
ATM	O 0
mutation	O 0
types	O 0
,	O 0
including	O 0
missense	O 0
mutations	O 0
and	O 0
in	O 0
-	O 0
frame	O 0
deletions	O 0
,	O 0
were	O 0
seen	O 0
in	O 0
these	O 0
patients	O 0
.	O 0

We	O 0
also	O 0
show	O 0
that	O 0
25	O 0
%	O 0
of	O 0
all	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
carried	O 0
in	O 0
-	O 0
frame	O 0
deletions	O 0
or	O 0
missense	O 0
mutations	O 0
,	O 0
many	O 0
of	O 0
which	O 0
were	O 0
also	O 0
associated	O 0
with	O 0
expression	O 0
of	O 0
mutant	O 0
ATM	O 0
protein	O 0
.	O 0

The	O 0
DMPK	O 0
gene	O 0
of	O 0
severely	O 0
affected	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
patients	O 0
is	O 0
hypermethylated	O 0
proximal	O 0
to	O 0
the	O 0
largely	O 0
expanded	O 0
CTG	O 0
repeat	O 0
.	O 0

Using	O 0
methylation	O 0
-	O 0
sensitive	O 0
restriction	O 0
enzymes	O 0
,	O 0
we	O 0
characterized	O 0
the	O 0
methylation	O 0
pattern	O 0
on	O 0
the	O 0
5	O 0
side	O 0
of	O 0
the	O 0
CTG	O 0
repeat	O 0
in	O 0
the	O 0
DMPK	O 0
gene	O 0
of	O 0
normal	O 0
individuals	O 0
and	O 0
of	O 0
patients	O 0
affected	O 0
with	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
,	O 0
showing	O 0
expansions	O 0
of	O 0
the	O 0
repetitive	O 0
sequence	O 0
.	O 0

The	O 0
gene	O 0
segment	O 0
analyzed	O 0
corresponds	O 0
to	O 0
the	O 0
genomic	O 0
SacI	O 0
-	O 0
HindIII	O 0
fragment	O 0
carrying	O 0
exons	O 0
11	O 0
-	O 0
15	O 0
.	O 0

There	O 0
is	O 0
constitutive	O 0
methylation	O 0
in	O 0
intron	O 0
12	O 0
at	O 0
restriction	O 0
sites	O 0
of	O 0
SacII	O 0
and	O 0
HhaI	O 0
,	O 0
localized	O 0
1	O 0
,	O 0
159	O 0
-	O 0
1	O 0
,	O 0
232	O 0
bp	O 0
upstream	O 0
of	O 0
the	O 0
CTG	O 0
repeat	O 0
,	O 0
whereas	O 0
most	O 0
,	O 0
if	O 0
not	O 0
all	O 0
,	O 0
of	O 0
the	O 0
other	O 0
sites	O 0
of	O 0
SacII	O 0
,	O 0
HhaI	O 0
,	O 0
and	O 0
HpaII	O 0
in	O 0
this	O 0
region	O 0
are	O 0
unmethylated	O 0
,	O 0
in	O 0
normal	O 0
individuals	O 0
and	O 0
most	O 0
of	O 0
the	O 0
patients	O 0
.	O 0

In	O 0
a	O 0
number	O 0
of	O 0
young	O 0
and	O 0
severely	O 0
affected	O 0
patients	O 0
,	O 0
however	O 0
,	O 0
complete	O 0
methylation	O 0
of	O 0
these	O 0
restriction	O 0
sites	O 0
was	O 0
found	O 0
in	O 0
the	O 0
mutated	O 0
allele	O 0
.	O 0

In	O 0
most	O 0
of	O 0
these	O 0
patients	O 0
,	O 0
the	O 0
onset	O 0
of	O 0
the	O 0
disease	O 0
was	O 0
congenital	O 0
.	O 0

Preliminary	O 0
in	O 0
vivo	O 0
footprinting	O 0
data	O 0
gave	O 0
evidence	O 0
for	O 0
protein	O 0
-	O 0
DNA	O 0
contact	O 0
in	O 0
normal	O 0
genes	O 0
at	O 0
an	O 0
Sp1	O 0
consensus	O 0
binding	O 0
site	O 0
upstream	O 0
of	O 0
the	O 0
CTG	O 0
repeat	O 0
and	O 0
for	O 0
a	O 0
significant	O 0
reduction	O 0
of	O 0
this	O 0
interaction	O 0
in	O 0
cells	O 0
with	O 0
a	O 0
hypermethylated	O 0
DMPK	O 0
gene	O 0
.	O 0
.	O 0

The	O 0
hemochromatosis	B-Disease 0
gene	O 0
product	O 0
complexes	O 0
with	O 0
the	O 0
transferrin	O 0
receptor	O 0
and	O 0
lowers	O 0
its	O 0
affinity	O 0
for	O 0
ligand	O 0
binding	O 0
.	O 0

We	O 0
recently	O 0
reported	O 0
the	O 0
positional	O 0
cloning	O 0
of	O 0
a	O 0
candidate	O 0
gene	O 0
for	O 0
hereditary	B-Disease 0
hemochromatosis	I-Disease 0
called	O 0
HFE	O 0
.	O 0

The	O 0
gene	O 0
product	O 0
,	O 0
a	O 0
member	O 0
of	O 0
the	O 0
major	O 0
histocompatibility	O 0
complex	O 0
class	O 0
I	O 0
-	O 0
like	O 0
family	O 0
,	O 0
was	O 0
found	O 0
to	O 0
have	O 0
a	O 0
mutation	O 0
,	O 0
Cys	O 0
-	O 0
282	O 0
-	O 0
-	O 0
>	O 0
Tyr	O 0
(	O 0
C282Y	O 0
)	O 0
,	O 0
in	O 0
85	O 0
%	O 0
of	O 0
patient	O 0
chromosomes	O 0
.	O 0

This	O 0
mutation	O 0
eliminates	O 0
the	O 0
ability	O 0
of	O 0
HFE	O 0
to	O 0
associate	O 0
with	O 0
beta2	O 0
-	O 0
microglobulin	O 0
(	O 0
beta2m	O 0
)	O 0
and	O 0
prevents	O 0
cell	O 0
-	O 0
surface	O 0
expression	O 0
.	O 0

A	O 0
second	O 0
mutation	O 0
that	O 0
has	O 0
no	O 0
effect	O 0
on	O 0
beta2m	O 0
association	O 0
,	O 0
H63D	O 0
,	O 0
was	O 0
found	O 0
in	O 0
eight	O 0
out	O 0
of	O 0
nine	O 0
patients	O 0
heterozygous	O 0
for	O 0
the	O 0
C282Y	O 0
mutant	O 0
.	O 0

In	O 0
this	O 0
report	O 0
,	O 0
we	O 0
demonstrate	O 0
in	O 0
cultured	O 0
293	O 0
cells	O 0
overexpressing	O 0
wild	O 0
-	O 0
type	O 0
or	O 0
mutant	O 0
HFE	O 0
proteins	O 0
that	O 0
both	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
and	O 0
H63D	O 0
HFE	O 0
proteins	O 0
form	O 0
stable	O 0
complexes	O 0
with	O 0
the	O 0
transferrin	O 0
receptor	O 0
(	O 0
TfR	O 0
)	O 0
.	O 0

The	O 0
C282Y	O 0
mutation	O 0
nearly	O 0
completely	O 0
prevents	O 0
the	O 0
association	O 0
of	O 0
the	O 0
mutant	O 0
HFE	O 0
protein	O 0
with	O 0
the	O 0
TfR	O 0
.	O 0

Studies	O 0
on	O 0
cell	O 0
-	O 0
associated	O 0
transferrin	O 0
at	O 0
37	O 0
degrees	O 0
C	O 0
suggest	O 0
that	O 0
the	O 0
overexpressed	O 0
wild	O 0
-	O 0
type	O 0
HFE	O 0
protein	O 0
decreases	O 0
the	O 0
affinity	O 0
of	O 0
the	O 0
TfR	O 0
for	O 0
transferrin	O 0
.	O 0

The	O 0
overexpressed	O 0
H63D	O 0
protein	O 0
does	O 0
not	O 0
have	O 0
this	O 0
effect	O 0
,	O 0
providing	O 0
the	O 0
first	O 0
direct	O 0
evidence	O 0
for	O 0
a	O 0
functional	O 0
consequence	O 0
of	O 0
the	O 0
H63D	O 0
mutation	O 0
.	O 0

Addition	O 0
of	O 0
soluble	O 0
wild	O 0
-	O 0
type	O 0
HFE	O 0
/	O 0
beta2m	O 0
heterodimers	O 0
to	O 0
cultured	O 0
cells	O 0
also	O 0
decreased	O 0
the	O 0
apparent	O 0
affinity	O 0
of	O 0
the	O 0
TfR	O 0
for	O 0
its	O 0
ligand	O 0
under	O 0
steady	O 0
-	O 0
state	O 0
conditions	O 0
,	O 0
both	O 0
in	O 0
293	O 0
cells	O 0
and	O 0
in	O 0
HeLa	O 0
cells	O 0
.	O 0

Furthermore	O 0
,	O 0
at	O 0
4	O 0
degrees	O 0
C	O 0
,	O 0
the	O 0
added	O 0
soluble	O 0
complex	O 0
of	O 0
HFE	O 0
/	O 0
beta2m	O 0
inhibited	O 0
binding	O 0
of	O 0
transferrin	O 0
to	O 0
HeLa	O 0
cell	O 0
TfR	O 0
in	O 0
a	O 0
concentration	O 0
-	O 0
dependent	O 0
manner	O 0
.	O 0

Scatchard	O 0
plots	O 0
of	O 0
these	O 0
data	O 0
indicate	O 0
that	O 0
the	O 0
added	O 0
heterodimer	O 0
substantially	O 0
reduced	O 0
the	O 0
affinity	O 0
of	O 0
TfR	O 0
for	O 0
transferrin	O 0
.	O 0

These	O 0
results	O 0
establish	O 0
a	O 0
molecular	O 0
link	O 0
between	O 0
HFE	O 0
and	O 0
a	O 0
key	O 0
protein	O 0
involved	O 0
in	O 0
iron	O 0
transport	O 0
,	O 0
the	O 0
TfR	O 0
,	O 0
and	O 0
raise	O 0
the	O 0
possibility	O 0
that	O 0
alterations	O 0
in	O 0
this	O 0
regulatory	O 0
mechanism	O 0
may	O 0
play	O 0
a	O 0
role	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
hereditary	B-Disease 0
hemochromatosis	I-Disease 0
.	O 0
.	O 0

Genomic	O 0
organization	O 0
of	O 0
the	O 0
UBE3A	O 0
/	O 0
E6	O 0
-	O 0
AP	O 0
gene	O 0
and	O 0
related	O 0
pseudogenes	O 0
.	O 0

The	O 0
UBE3A	O 0
gene	O 0
encodes	O 0
the	O 0
E6	O 0
-	O 0
AP	O 0
ubiquitin	O 0
-	O 0
protein	O 0
ligase	O 0
and	O 0
has	O 0
recently	O 0
been	O 0
shown	O 0
to	O 0
be	O 0
mutated	O 0
in	O 0
Angelman	B-Disease 0
syndrome	I-Disease 0
patients	O 0
who	O 0
lack	O 0
15q11	O 0
-	O 0
q13	O 0
deletions	O 0
or	O 0
chromosome	O 0
15	O 0
paternal	O 0
uniparental	B-Disease 0
disomy	I-Disease 0
.	O 0

Previous	O 0
UBE3A	O 0
cDNA	O 0
analysis	O 0
has	O 0
shown	O 0
a	O 0
coding	O 0
region	O 0
of	O 0
approximately	O 0
2	O 0
.	O 0

6	O 0
kb	O 0
and	O 0
a	O 0
3	O 0
-	O 0
untranslated	O 0
region	O 0
(	O 0
UTR	O 0
)	O 0
of	O 0
<	O 0
50	O 0
bp	O 0
,	O 0
whereas	O 0
Northern	O 0
analysis	O 0
has	O 0
indicated	O 0
mRNA	O 0
sizes	O 0
of	O 0
5	O 0
-	O 0
8	O 0
kb	O 0
.	O 0

We	O 0
have	O 0
analyzed	O 0
additional	O 0
cDNA	O 0
clones	O 0
and	O 0
provide	O 0
evidence	O 0
for	O 0
an	O 0
additional	O 0
0	O 0
.	O 0

5	O 0
kb	O 0
of	O 0
5	O 0
-	O 0
UTR	O 0
and	O 0
>	O 0
2	O 0
kb	O 0
of	O 0
3	O 0
-	O 0
UTR	O 0
.	O 0

We	O 0
have	O 0
established	O 0
the	O 0
genomic	O 0
organization	O 0
of	O 0
UBE3A	O 0
and	O 0
the	O 0
sequence	O 0
of	O 0
intron	O 0
-	O 0
exon	O 0
borders	O 0
.	O 0

We	O 0
have	O 0
also	O 0
mapped	O 0
two	O 0
highly	O 0
homologous	O 0
processed	O 0
pseudogenes	O 0
,	O 0
UBE3AP1	O 0
and	O 0
UBE3AP2	O 0
,	O 0
to	O 0
chromosomes	O 0
2	O 0
and	O 0
21	O 0
,	O 0
respectively	O 0
,	O 0
and	O 0
determined	O 0
their	O 0
genomic	O 0
organization	O 0
.	O 0

These	O 0
results	O 0
will	O 0
form	O 0
the	O 0
basis	O 0
for	O 0
studies	O 0
of	O 0
mutation	O 0
and	O 0
imprinting	O 0
of	O 0
UBE3A	O 0
.	O 0

Mutation	O 0
spectrum	O 0
and	O 0
genotype	O 0
-	O 0
phenotype	O 0
analyses	O 0
in	O 0
Cowden	B-Disease 0
disease	I-Disease 0
and	O 0
Bannayan	B-Disease 0
-	I-Disease 0
Zonana	I-Disease 0
syndrome	I-Disease 0
,	O 0
two	O 0
hamartoma	B-Disease 0
syndromes	I-Disease 0
with	O 0
germline	O 0
PTEN	O 0
mutation	O 0
.	O 0

The	O 0
tumour	B-Disease 0
suppressor	O 0
gene	O 0
PTEN	O 0
,	O 0
which	O 0
maps	O 0
to	O 0
10q23	O 0
.	O 0

3	O 0
and	O 0
encodes	O 0
a	O 0
403	O 0
amino	O 0
acid	O 0
dual	O 0
specificity	O 0
phosphatase	O 0
(	O 0
protein	O 0
tyrosine	O 0
phosphatase	O 0
;	O 0
PTPase	O 0
)	O 0
,	O 0
was	O 0
shown	O 0
recently	O 0
to	O 0
play	O 0
a	O 0
broad	O 0
role	O 0
in	O 0
human	O 0
malignancy	B-Disease 0
.	O 0

Somatic	O 0
PTEN	O 0
deletions	O 0
and	O 0
mutations	O 0
were	O 0
observed	O 0
in	O 0
sporadic	B-Disease 0
breast	I-Disease 0
,	I-Disease 0
brain	I-Disease 0
,	I-Disease 0
prostate	I-Disease 0
and	I-Disease 0
kidney	I-Disease 0
cancer	I-Disease 0
cell	O 0
lines	O 0
and	O 0
in	O 0
several	O 0
primary	O 0
tumours	B-Disease 0
such	O 0
as	O 0
endometrial	B-Disease 0
carcinomas	I-Disease 0
,	O 0
malignant	B-Disease 0
melanoma	I-Disease 0
and	O 0
thyroid	B-Disease 0
tumours	I-Disease 0
.	O 0

In	O 0
addition	O 0
,	O 0
PTEN	O 0
was	O 0
identified	O 0
as	O 0
the	O 0
susceptibility	O 0
gene	O 0
for	O 0
two	O 0
hamartoma	B-Disease 0
syndromes	I-Disease 0
Cowden	B-Disease 0
disease	I-Disease 0
(	O 0
CD	B-Disease 0
;	O 0
MIM	O 0
158350	O 0
)	O 0
and	O 0
Bannayan	B-Disease 0
-	I-Disease 0
Zonana	I-Disease 0
(	I-Disease 0
BZS	I-Disease 0
)	I-Disease 0
or	I-Disease 0
Ruvalcaba	I-Disease 0
-	I-Disease 0
Riley	I-Disease 0
-	I-Disease 0
Smith	I-Disease 0
syndrome	I-Disease 0
(	O 0
MIM	O 0
153480	O 0
)	O 0
.	O 0

Constitutive	O 0
DNA	O 0
from	O 0
37	O 0
CD	B-Disease 0
families	O 0
and	O 0
seven	O 0
BZS	B-Disease 0
families	O 0
was	O 0
screened	O 0
for	O 0
germline	O 0
PTEN	O 0
mutations	O 0
.	O 0

PTEN	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
30	O 0
of	O 0
37	O 0
(	O 0
81	O 0
%	O 0
)	O 0
CD	B-Disease 0
families	O 0
,	O 0
including	O 0
missense	O 0
and	O 0
nonsense	O 0
point	O 0
mutations	O 0
,	O 0
deletions	O 0
,	O 0
insertions	O 0
,	O 0
a	O 0
deletion	O 0
/	O 0
insertion	O 0
and	O 0
splice	O 0
site	O 0
mutations	O 0
.	O 0

These	O 0
mutations	O 0
were	O 0
scattered	O 0
over	O 0
the	O 0
entire	O 0
length	O 0
of	O 0
PTEN	O 0
,	O 0
with	O 0
the	O 0
exception	O 0
of	O 0
the	O 0
first	O 0
,	O 0
fourth	O 0
and	O 0
last	O 0
exons	O 0
.	O 0

A	O 0
hot	O 0
spot	O 0
for	O 0
PTEN	O 0
mutation	O 0
in	O 0
CD	B-Disease 0
was	O 0
identified	O 0
in	O 0
exon	O 0
5	O 0
that	O 0
contains	O 0
the	O 0
PTPase	O 0
core	O 0
motif	O 0
,	O 0
with	O 0
13	O 0
of	O 0
30	O 0
(	O 0
43	O 0
%	O 0
)	O 0
CD	B-Disease 0
mutations	O 0
identified	O 0
in	O 0
this	O 0
exon	O 0
.	O 0

Seven	O 0
of	O 0
30	O 0
(	O 0
23	O 0
%	O 0
)	O 0
were	O 0
within	O 0
the	O 0
core	O 0
motif	O 0
,	O 0
the	O 0
majority	O 0
(	O 0
five	O 0
of	O 0
seven	O 0
)	O 0
of	O 0
which	O 0
were	O 0
missense	O 0
mutations	O 0
,	O 0
possibly	O 0
pointing	O 0
to	O 0
the	O 0
functional	O 0
significance	O 0
of	O 0
this	O 0
region	O 0
.	O 0

Germline	O 0
PTEN	O 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
four	O 0
of	O 0
seven	O 0
(	O 0
57	O 0
%	O 0
)	O 0
BZS	B-Disease 0
families	O 0
studied	O 0
.	O 0

Interestingly	O 0
,	O 0
none	O 0
of	O 0
these	O 0
mutations	O 0
was	O 0
observed	O 0
in	O 0
the	O 0
PTPase	O 0
core	O 0
motif	O 0
.	O 0

It	O 0
is	O 0
also	O 0
worthy	O 0
of	O 0
note	O 0
that	O 0
a	O 0
single	O 0
nonsense	O 0
point	O 0
mutation	O 0
,	O 0
R233X	O 0
,	O 0
was	O 0
observed	O 0
in	O 0
the	O 0
germline	O 0
DNA	O 0
from	O 0
two	O 0
unrelated	O 0
CD	B-Disease 0
families	O 0
and	O 0
one	O 0
BZS	B-Disease 0
family	O 0
.	O 0

Genotype	O 0
-	O 0
phenotype	O 0
studies	O 0
were	O 0
not	O 0
performed	O 0
on	O 0
this	O 0
small	O 0
group	O 0
of	O 0
BZS	B-Disease 0
families	O 0
.	O 0

However	O 0
,	O 0
genotype	O 0
-	O 0
phenotype	O 0
analysis	O 0
inthe	O 0
group	O 0
of	O 0
CD	B-Disease 0
families	O 0
revealed	O 0
two	O 0
possible	O 0
associations	O 0
worthy	O 0
of	O 0
follow	O 0
-	O 0
up	O 0
in	O 0
independent	O 0
analyses	O 0
.	O 0

The	O 0
first	O 0
was	O 0
an	O 0
association	O 0
noted	O 0
in	O 0
the	O 0
group	O 0
of	O 0
CD	B-Disease 0
families	O 0
with	O 0
breast	B-Disease 0
disease	I-Disease 0
.	O 0

A	O 0
correlation	O 0
was	O 0
observed	O 0
between	O 0
the	O 0
presence	O 0
/	O 0
absence	O 0
of	O 0
a	O 0
PTEN	O 0
mutation	O 0
and	O 0
the	O 0
type	O 0
of	O 0
breast	O 0
involvement	O 0
(	O 0
unaffected	O 0
versus	O 0
benign	O 0
versus	O 0
malignant	O 0
)	O 0
.	O 0

Specifically	O 0
and	O 0
more	O 0
directly	O 0
,	O 0
an	O 0
association	O 0
was	O 0
also	O 0
observed	O 0
between	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
PTEN	O 0
mutation	O 0
and	O 0
malignant	B-Disease 0
breast	I-Disease 0
disease	I-Disease 0
.	O 0

Secondly	O 0
,	O 0
there	O 0
appeared	O 0
to	O 0
be	O 0
an	O 0
interdependent	O 0
association	O 0
between	O 0
mutations	O 0
upstream	O 0
and	O 0
within	O 0
the	O 0
PTPase	O 0
core	O 0
motif	O 0
,	O 0
the	O 0
core	O 0
motif	O 0
containing	O 0
the	O 0
majority	O 0
of	O 0
missense	O 0
mutations	O 0
,	O 0
and	O 0
the	O 0
involvement	O 0
of	O 0
all	O 0
major	O 0
organ	O 0
systems	O 0
(	O 0
central	O 0
nervous	O 0
system	O 0
,	O 0
thyroid	O 0
,	O 0
breast	O 0
,	O 0
skin	O 0
and	O 0
gastrointestinal	O 0
tract	O 0
)	O 0
.	O 0

However	O 0
,	O 0
these	O 0
observations	O 0
would	O 0
need	O 0
to	O 0
be	O 0
confirmed	O 0
by	O 0
studying	O 0
a	O 0
larger	O 0
number	O 0
of	O 0
CD	B-Disease 0
families	O 0
.	O 0

Molecular	O 0
defects	O 0
leading	O 0
to	O 0
human	O 0
complement	B-Disease 0
component	I-Disease 0
C6	I-Disease 0
deficiency	I-Disease 0
in	O 0
an	O 0
African	O 0
-	O 0
American	O 0
family	O 0
.	O 0

Complement	B-Disease 0
component	I-Disease 0
C6	I-Disease 0
deficiency	I-Disease 0
(	O 0
C6D	B-Disease 0
)	O 0
was	O 0
diagnosed	O 0
in	O 0
a	O 0
16	O 0
-	O 0
year	O 0
-	O 0
old	O 0
African	O 0
-	O 0
American	O 0
male	O 0
with	O 0
meningococcal	B-Disease 0
meningitis	I-Disease 0
.	O 0

The	O 0
patients	O 0
father	O 0
and	O 0
two	O 0
brothers	O 0
also	O 0
had	O 0
C6D	B-Disease 0
,	O 0
but	O 0
gave	O 0
no	O 0
history	O 0
of	O 0
meningitis	B-Disease 0
or	O 0
other	O 0
neisserial	B-Disease 0
infection	I-Disease 0
.	O 0

By	O 0
using	O 0
exon	O 0
-	O 0
specific	O 0
polymerase	O 0
chain	O 0
reaction	O 0
(	O 0
PCR	O 0
)	O 0
/	O 0
single	O 0
-	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
as	O 0
a	O 0
screening	O 0
step	O 0
and	O 0
nucleotide	O 0
sequencing	O 0
of	O 0
target	O 0
exons	O 0
,	O 0
we	O 0
determined	O 0
that	O 0
the	O 0
proband	O 0
was	O 0
a	O 0
compound	O 0
heterozygote	O 0
for	O 0
two	O 0
C6	O 0
gene	O 0
mutations	O 0
.	O 0

The	O 0
first	O 0
,	O 0
1195delC	O 0
located	O 0
in	O 0
exon	O 0
7	O 0
,	O 0
is	O 0
a	O 0
novel	O 0
mutation	O 0
,	O 0
while	O 0
the	O 0
second	O 0
,	O 0
1936delG	O 0
in	O 0
exon	O 0
12	O 0
,	O 0
has	O 0
been	O 0
described	O 0
before	O 0
to	O 0
cause	O 0
C6D	B-Disease 0
in	O 0
an	O 0
unrelated	O 0
African	O 0
-	O 0
American	O 0
individual	O 0
.	O 0

Both	O 0
mutations	O 0
result	O 0
in	O 0
premature	O 0
termination	O 0
codons	O 0
and	O 0
C6	O 0
null	O 0
alleles	O 0
.	O 0

Allele	O 0
-	O 0
specific	O 0
PCR	O 0
indicated	O 0
that	O 0
the	O 0
probands	O 0
two	O 0
brothers	O 0
also	O 0
inherited	O 0
the	O 0
1195delC	O 0
mutation	O 0
from	O 0
their	O 0
heterozygous	O 0
mother	O 0
and	O 0
the	O 0
1936delG	O 0
mutation	O 0
from	O 0
their	O 0
homozygous	O 0
father	O 0
.	O 0
.	O 0

PAX6	O 0
mutations	O 0
reviewed	O 0
.	O 0

Mutations	O 0
in	O 0
PAX6	O 0
are	O 0
responsible	O 0
for	O 0
human	O 0
aniridia	B-Disease 0
and	O 0
have	O 0
also	O 0
been	O 0
found	O 0
in	O 0
patients	O 0
with	O 0
Peters	B-Disease 0
anomaly	I-Disease 0
,	O 0
with	O 0
congenital	B-Disease 0
cataracts	I-Disease 0
,	O 0
with	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
keratitis	I-Disease 0
,	O 0
and	O 0
with	O 0
isolated	B-Disease 0
foveal	I-Disease 0
hypoplasia	I-Disease 0
.	O 0

No	O 0
locus	O 0
other	O 0
than	O 0
chromosome	O 0
11p13	O 0
has	O 0
been	O 0
implicated	O 0
in	O 0
aniridia	B-Disease 0
,	O 0
and	O 0
PAX6	O 0
is	O 0
clearly	O 0
the	O 0
major	O 0
,	O 0
if	O 0
not	O 0
only	O 0
,	O 0
gene	O 0
responsible	O 0
.	O 0

Twenty	O 0
-	O 0
eight	O 0
percent	O 0
of	O 0
identified	O 0
PAX6	O 0
mutations	O 0
are	O 0
C	O 0
-	O 0
T	O 0
changes	O 0
at	O 0
CpG	O 0
dinucleotides	O 0
,	O 0
20	O 0
%	O 0
are	O 0
splicing	O 0
errors	O 0
,	O 0
and	O 0
more	O 0
than	O 0
30	O 0
%	O 0
are	O 0
deletion	O 0
or	O 0
insertion	O 0
events	O 0
.	O 0

There	O 0
is	O 0
a	O 0
noticeably	O 0
elevated	O 0
level	O 0
of	O 0
mutation	O 0
in	O 0
the	O 0
paired	O 0
domain	O 0
compared	O 0
with	O 0
the	O 0
rest	O 0
of	O 0
the	O 0
gene	O 0
.	O 0

Increased	O 0
mutation	O 0
in	O 0
the	O 0
homeodomain	O 0
is	O 0
accounted	O 0
for	O 0
by	O 0
the	O 0
hypermutable	O 0
CpG	O 0
dinucleotide	O 0
in	O 0
codon	O 0
240	O 0
.	O 0

Very	O 0
nearly	O 0
all	O 0
mutations	O 0
appear	O 0
to	O 0
cause	O 0
loss	O 0
of	O 0
function	O 0
of	O 0
the	O 0
mutant	O 0
allele	O 0
,	O 0
and	O 0
more	O 0
than	O 0
80	O 0
%	O 0
of	O 0
exonic	O 0
substitutions	O 0
result	O 0
in	O 0
nonsense	O 0
codons	O 0
.	O 0

In	O 0
a	O 0
gene	O 0
with	O 0
such	O 0
extraordinarily	O 0
high	O 0
sequence	O 0
conservation	O 0
throughout	O 0
evolution	O 0
,	O 0
there	O 0
are	O 0
presumed	O 0
undiscovered	O 0
missense	O 0
mutations	O 0
,	O 0
these	O 0
are	O 0
hypothesized	O 0
to	O 0
exist	O 0
in	O 0
as	O 0
-	O 0
yet	O 0
unidentified	O 0
phenotypes	O 0
.	O 0
.	O 0

Genetic	O 0
heterogeneity	O 0
and	O 0
penetrance	O 0
analysis	O 0
of	O 0
the	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
genes	O 0
in	O 0
breast	B-Disease 0
cancer	I-Disease 0
families	O 0
.	O 0

The	O 0
Breast	B-Disease 0
Cancer	I-Disease 0
Linkage	O 0
Consortium	O 0
.	O 0

The	O 0
contribution	O 0
of	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
to	O 0
inherited	B-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
was	O 0
assessed	O 0
by	O 0
linkage	O 0
and	O 0
mutation	O 0
analysis	O 0
in	O 0
237	O 0
families	O 0
,	O 0
each	O 0
with	O 0
at	O 0
least	O 0
four	O 0
cases	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
,	O 0
collected	O 0
by	O 0
the	O 0
Breast	B-Disease 0
Cancer	I-Disease 0
Linkage	O 0
Consortium	O 0
.	O 0

Families	O 0
were	O 0
included	O 0
without	O 0
regard	O 0
to	O 0
the	O 0
occurrence	O 0
of	O 0
ovarian	B-Disease 0
or	I-Disease 0
other	I-Disease 0
cancers	I-Disease 0
.	O 0

Overall	O 0
,	O 0
disease	O 0
was	O 0
linked	O 0
to	O 0
BRCA1	O 0
in	O 0
an	O 0
estimated	O 0
52	O 0
%	O 0
of	O 0
families	O 0
,	O 0
to	O 0
BRCA2	O 0
in	O 0
32	O 0
%	O 0
of	O 0
families	O 0
,	O 0
and	O 0
to	O 0
neither	O 0
gene	O 0
in	O 0
16	O 0
%	O 0
(	O 0
95	O 0
%	O 0
confidence	O 0
interval	O 0
[	O 0
CI	O 0
]	O 0
6	O 0
%	O 0
-	O 0
28	O 0
%	O 0
)	O 0
,	O 0
suggesting	O 0
other	O 0
predisposition	O 0
genes	O 0
.	O 0

The	O 0
majority	O 0
(	O 0
81	O 0
%	O 0
)	O 0
of	O 0
the	O 0
breast	B-Disease 0
-	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
were	O 0
due	O 0
to	O 0
BRCA1	O 0
,	O 0
with	O 0
most	O 0
others	O 0
(	O 0
14	O 0
%	O 0
)	O 0
due	O 0
to	O 0
BRCA2	O 0
.	O 0

Conversely	O 0
,	O 0
the	O 0
majority	O 0
of	O 0
families	O 0
with	O 0
male	B-Disease 0
and	I-Disease 0
female	I-Disease 0
breast	I-Disease 0
cancer	I-Disease 0
were	O 0
due	O 0
to	O 0
BRCA2	O 0
(	O 0
76	O 0
%	O 0
)	O 0
.	O 0

The	O 0
largest	O 0
proportion	O 0
(	O 0
67	O 0
%	O 0
)	O 0
of	O 0
families	O 0
due	O 0
to	O 0
other	O 0
genes	O 0
was	O 0
found	O 0
in	O 0
families	O 0
with	O 0
four	O 0
or	O 0
five	O 0
cases	O 0
of	O 0
female	O 0
breast	B-Disease 0
cancer	I-Disease 0
only	O 0
.	O 0

These	O 0
estimates	O 0
were	O 0
not	O 0
substantially	O 0
affected	O 0
either	O 0
by	O 0
changing	O 0
the	O 0
assumed	O 0
penetrance	O 0
model	O 0
for	O 0
BRCA1	O 0
or	O 0
by	O 0
including	O 0
or	O 0
excluding	O 0
BRCA1	O 0
mutation	O 0
data	O 0
.	O 0

Among	O 0
those	O 0
families	O 0
with	O 0
disease	O 0
due	O 0
to	O 0
BRCA1	O 0
that	O 0
were	O 0
tested	O 0
by	O 0
one	O 0
of	O 0
the	O 0
standard	O 0
screening	O 0
methods	O 0
,	O 0
mutations	O 0
were	O 0
detected	O 0
in	O 0
the	O 0
coding	O 0
sequence	O 0
or	O 0
splice	O 0
sites	O 0
in	O 0
an	O 0
estimated	O 0
63	O 0
%	O 0
(	O 0
95	O 0
%	O 0
CI	O 0
51	O 0
%	O 0
-	O 0
77	O 0
%	O 0
)	O 0
.	O 0

The	O 0
estimated	O 0
sensitivity	O 0
was	O 0
identical	O 0
for	O 0
direct	O 0
sequencing	O 0
and	O 0
other	O 0
techniques	O 0
.	O 0

The	O 0
penetrance	O 0
of	O 0
BRCA2	O 0
was	O 0
estimated	O 0
by	O 0
maximizing	O 0
the	O 0
LOD	O 0
score	O 0
in	O 0
BRCA2	O 0
-	O 0
mutation	O 0
families	O 0
,	O 0
over	O 0
all	O 0
possible	O 0
penetrance	O 0
functions	O 0
.	O 0

The	O 0
estimated	O 0
cumulative	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
reached	O 0
28	O 0
%	O 0
(	O 0
95	O 0
%	O 0
CI	O 0
9	O 0
%	O 0
-	O 0
44	O 0
%	O 0
)	O 0
by	O 0
age	O 0
50	O 0
years	O 0
and	O 0
84	O 0
%	O 0
(	O 0
95	O 0
%	O 0
CI	O 0
43	O 0
%	O 0
-	O 0
95	O 0
%	O 0
)	O 0
by	O 0
age	O 0
70	O 0
years	O 0
.	O 0

The	O 0
corresponding	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
risks	O 0
were	O 0
0	O 0
.	O 0

4	O 0
%	O 0
(	O 0
95	O 0
%	O 0
CI	O 0
0	O 0
%	O 0
-	O 0
1	O 0
%	O 0
)	O 0
by	O 0
age	O 0
50	O 0
years	O 0
and	O 0
27	O 0
%	O 0
(	O 0
95	O 0
%	O 0
CI	O 0
0	O 0
%	O 0
-	O 0
47	O 0
%	O 0
)	O 0
by	O 0
age	O 0
70	O 0
years	O 0
.	O 0

The	O 0
lifetime	O 0
risk	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
appears	O 0
similar	O 0
to	O 0
the	O 0
risk	O 0
in	O 0
BRCA1	O 0
carriers	O 0
,	O 0
but	O 0
there	O 0
was	O 0
some	O 0
suggestion	O 0
of	O 0
a	O 0
lower	O 0
risk	O 0
in	O 0
BRCA2	O 0
carriers	O 0
<	O 0
50	O 0
years	O 0
of	O 0
age	O 0
.	O 0

Eye	B-Disease 0
movement	I-Disease 0
abnormalities	I-Disease 0
correlate	O 0
with	O 0
genotype	O 0
in	O 0
autosomal	O 0
dominant	O 0
cerebellar	B-Disease 0
ataxia	I-Disease 0
type	I-Disease 0
I	I-Disease 0
.	O 0

We	O 0
compared	O 0
horizontal	O 0
eye	O 0
movements	O 0
(	O 0
visually	O 0
guided	O 0
saccades	O 0
,	O 0
antisaccades	O 0
,	O 0
and	O 0
smooth	O 0
pursuit	O 0
)	O 0
in	O 0
control	O 0
subjects	O 0
(	O 0
n	O 0
=	O 0
14	O 0
)	O 0
and	O 0
patients	O 0
with	O 0
three	O 0
forms	O 0
of	O 0
autosomal	O 0
dominant	O 0
cerebellar	B-Disease 0
ataxias	I-Disease 0
type	I-Disease 0
I	I-Disease 0
spinocerebellar	B-Disease 0
ataxias	I-Disease 0
1	I-Disease 0
and	I-Disease 0
2	I-Disease 0
(	O 0
SCA1	B-Disease 0
,	O 0
n	O 0
=	O 0
11	O 0
;	O 0
SCA2	B-Disease 0
,	O 0
n	O 0
=	O 0
10	O 0
)	O 0
and	O 0
SCA3	B-Disease 0
/	O 0
Machado	B-Disease 0
-	I-Disease 0
Joseph	I-Disease 0
disease	I-Disease 0
(	O 0
MJD	B-Disease 0
)	O 0
(	O 0
n	O 0
=	O 0
16	O 0
)	O 0
.	O 0

In	O 0
SCA1	B-Disease 0
,	O 0
saccade	O 0
amplitude	O 0
was	O 0
significantly	O 0
increased	O 0
,	O 0
resulting	O 0
in	O 0
hypermetria	B-Disease 0
.	O 0

The	O 0
smooth	O 0
pursuit	O 0
gain	O 0
was	O 0
decreased	O 0
.	O 0

In	O 0
SCA2	B-Disease 0
,	O 0
saccade	O 0
velocity	O 0
was	O 0
markedly	O 0
decreased	O 0
.	O 0

The	O 0
percentage	O 0
of	O 0
errors	O 0
in	O 0
antisaccades	O 0
was	O 0
greatly	O 0
increased	O 0
and	O 0
was	O 0
significantly	O 0
correlated	O 0
with	O 0
age	O 0
at	O 0
disease	O 0
onset	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
a	O 0
correlation	O 0
between	O 0
smooth	O 0
pursuit	O 0
gain	O 0
and	O 0
the	O 0
number	O 0
of	O 0
trinucleotide	O 0
repeats	O 0
was	O 0
found	O 0
.	O 0

In	O 0
SCA3	B-Disease 0
,	O 0
gaze	B-Disease 0
-	I-Disease 0
evoked	I-Disease 0
nystagmus	I-Disease 0
was	O 0
often	O 0
present	O 0
as	O 0
was	O 0
saccade	O 0
hypometria	O 0
and	O 0
smooth	O 0
pursuit	O 0
gain	O 0
was	O 0
markedly	O 0
decreased	O 0
.	O 0

Three	O 0
major	O 0
criteria	O 0
,	O 0
saccade	O 0
amplitude	O 0
,	O 0
saccade	O 0
velocity	O 0
,	O 0
and	O 0
presence	O 0
of	O 0
gaze	B-Disease 0
-	I-Disease 0
evoked	I-Disease 0
nystagmus	I-Disease 0
,	O 0
permitted	O 0
the	O 0
correct	O 0
assignment	O 0
of	O 0
90	O 0
%	O 0
of	O 0
the	O 0
SCA1	B-Disease 0
,	O 0
90	O 0
%	O 0
of	O 0
the	O 0
SCA2	B-Disease 0
,	O 0
and	O 0
93	O 0
%	O 0
of	O 0
the	O 0
patients	O 0
with	O 0
SCA3	B-Disease 0
to	O 0
their	O 0
genetically	O 0
confirmed	O 0
patient	O 0
group	O 0
and	O 0
,	O 0
therefore	O 0
,	O 0
may	O 0
help	O 0
orient	O 0
diagnoses	O 0
of	O 0
SCA1	B-Disease 0
,	O 0
SCA2	B-Disease 0
,	O 0
and	O 0
SCA3	B-Disease 0
at	O 0
early	O 0
clinical	O 0
stages	O 0
of	O 0
the	O 0
diseases	O 0
.	O 0
.	O 0

Genetic	O 0
basis	O 0
and	O 0
molecular	O 0
mechanism	O 0
for	O 0
idiopathic	B-Disease 0
ventricular	I-Disease 0
fibrillation	I-Disease 0
.	O 0

Ventricular	B-Disease 0
fibrillation	I-Disease 0
causes	O 0
more	O 0
than	O 0
300	O 0
,	O 0
000	O 0
sudden	O 0
deaths	O 0
each	O 0
year	O 0
in	O 0
the	O 0
USA	O 0
alone	O 0
.	O 0

In	O 0
approximately	O 0
5	O 0
-	O 0
12	O 0
%	O 0
of	O 0
these	O 0
cases	O 0
,	O 0
there	O 0
are	O 0
no	O 0
demonstrable	O 0
cardiac	O 0
or	O 0
non	O 0
-	O 0
cardiac	O 0
causes	O 0
to	O 0
account	O 0
for	O 0
the	O 0
episode	O 0
,	O 0
which	O 0
is	O 0
therefore	O 0
classified	O 0
as	O 0
idiopathic	B-Disease 0
ventricular	I-Disease 0
fibrillation	I-Disease 0
(	O 0
IVF	B-Disease 0
)	O 0
.	O 0

A	O 0
distinct	O 0
group	O 0
of	O 0
IVF	B-Disease 0
patients	O 0
has	O 0
been	O 0
found	O 0
to	O 0
present	O 0
with	O 0
a	O 0
characteristic	O 0
electrocardiographic	O 0
pattern	O 0
.	O 0

Because	O 0
of	O 0
the	O 0
small	O 0
size	O 0
of	O 0
most	O 0
pedigrees	O 0
and	O 0
the	O 0
high	O 0
incidence	O 0
of	O 0
sudden	B-Disease 0
death	I-Disease 0
,	O 0
however	O 0
,	O 0
molecular	O 0
genetic	O 0
studies	O 0
of	O 0
IVF	B-Disease 0
have	O 0
not	O 0
yet	O 0
been	O 0
done	O 0
.	O 0

Because	O 0
IVF	B-Disease 0
causes	O 0
cardiac	O 0
rhythm	O 0
disturbance	O 0
,	O 0
we	O 0
investigated	O 0
whether	O 0
malfunction	O 0
of	O 0
ion	O 0
channels	O 0
could	O 0
cause	O 0
the	O 0
disorder	O 0
by	O 0
studying	O 0
mutations	O 0
in	O 0
the	O 0
cardiac	O 0
sodium	O 0
channel	O 0
gene	O 0
SCN5A	O 0
.	O 0

We	O 0
have	O 0
now	O 0
identified	O 0
a	O 0
missense	O 0
mutation	O 0
,	O 0
a	O 0
splice	O 0
-	O 0
donor	O 0
mutation	O 0
,	O 0
and	O 0
a	O 0
frameshift	O 0
mutation	O 0
in	O 0
the	O 0
coding	O 0
region	O 0
of	O 0
SCN5A	O 0
in	O 0
three	O 0
IVF	B-Disease 0
families	O 0
.	O 0

We	O 0
show	O 0
that	O 0
sodium	O 0
channels	O 0
with	O 0
the	O 0
missense	O 0
mutation	O 0
recover	O 0
from	O 0
inactivation	O 0
more	O 0
rapidly	O 0
than	O 0
normal	O 0
and	O 0
that	O 0
the	O 0
frameshift	O 0
mutation	O 0
causes	O 0
the	O 0
sodium	O 0
channel	O 0
to	O 0
be	O 0
non	O 0
-	O 0
functional	O 0
.	O 0

Our	O 0
results	O 0
indicate	O 0
that	O 0
mutations	O 0
in	O 0
cardiac	O 0
ion	O 0
-	O 0
channel	O 0
genes	O 0
contribute	O 0
to	O 0
the	O 0
risk	O 0
of	O 0
developing	O 0
IVF	B-Disease 0
.	O 0
.	O 0

Molecular	O 0
heterogeneity	O 0
in	O 0
mucopolysaccharidosis	B-Disease 0
IVA	I-Disease 0
in	O 0
Australia	O 0
and	O 0
Northern	O 0
Ireland	O 0
:	O 0
nine	O 0
novel	O 0
mutations	O 0
including	O 0
T312S	O 0
,	O 0
a	O 0
common	O 0
allele	O 0
that	O 0
confers	O 0
a	O 0
mild	O 0
phenotype	O 0
.	O 0

Mucopolysaccharidosis	B-Disease 0
IVA	I-Disease 0
(	O 0
MPS	B-Disease 0
IVA	I-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
lysosomal	I-Disease 0
storage	I-Disease 0
disorder	I-Disease 0
caused	O 0
by	O 0
a	O 0
genetic	B-Disease 0
defect	I-Disease 0
in	O 0
N	O 0
-	O 0
acetylgalactosamine	O 0
-	O 0
6	O 0
-	O 0
sulfate	O 0
sulfatase	O 0
(	O 0
GALNS	O 0
)	O 0
.	O 0

Previous	O 0
studies	O 0
of	O 0
patients	O 0
from	O 0
a	O 0
British	O 0
-	O 0
Irish	O 0
population	O 0
showed	O 0
that	O 0
the	O 0
I113F	O 0
mutation	O 0
is	O 0
the	O 0
most	O 0
common	O 0
single	O 0
mutation	O 0
among	O 0
MPS	B-Disease 0
IVA	I-Disease 0
patients	O 0
and	O 0
produces	O 0
a	O 0
severe	O 0
clinical	O 0
phenotype	O 0
.	O 0

We	O 0
studied	O 0
mutations	O 0
in	O 0
the	O 0
GALNS	O 0
gene	O 0
from	O 0
23	O 0
additional	O 0
MPS	B-Disease 0
IVA	I-Disease 0
patients	O 0
(	O 0
15	O 0
from	O 0
Australia	O 0
,	O 0
8	O 0
from	O 0
Northern	O 0
Ireland	O 0
)	O 0
,	O 0
with	O 0
various	O 0
clinical	O 0
phenotypes	O 0
(	O 0
severe	O 0
,	O 0
16	O 0
cases	O 0
;	O 0
intermediate	O 0
,	O 0
4	O 0
cases	O 0
;	O 0
mild	O 0
,	O 0
3	O 0
cases	O 0
)	O 0
.	O 0

We	O 0
found	O 0
two	O 0
common	O 0
mutations	O 0
that	O 0
together	O 0
accounted	O 0
for	O 0
32	O 0
%	O 0
of	O 0
the	O 0
44	O 0
unrelated	O 0
alleles	O 0
in	O 0
these	O 0
patients	O 0
.	O 0

One	O 0
is	O 0
the	O 0
T312S	O 0
mutation	O 0
,	O 0
a	O 0
novel	O 0
mutation	O 0
found	O 0
exclusively	O 0
in	O 0
milder	O 0
patients	O 0
.	O 0

The	O 0
other	O 0
is	O 0
the	O 0
previously	O 0
described	O 0
I113F	O 0
that	O 0
produces	O 0
a	O 0
severe	O 0
phenotype	O 0
.	O 0

The	O 0
I113F	O 0
and	O 0
T312S	O 0
mutations	O 0
accounted	O 0
for	O 0
8	O 0
(	O 0
18	O 0
%	O 0
)	O 0
and	O 0
6	O 0
(	O 0
14	O 0
%	O 0
)	O 0
of	O 0
44	O 0
unrelated	O 0
alleles	O 0
,	O 0
respectively	O 0
.	O 0

The	O 0
relatively	O 0
high	O 0
residual	O 0
GALNS	O 0
activity	O 0
seen	O 0
when	O 0
the	O 0
T312S	O 0
mutant	O 0
cDNA	O 0
is	O 0
overexpressed	O 0
in	O 0
mutant	O 0
cells	O 0
provides	O 0
an	O 0
explanation	O 0
for	O 0
the	O 0
mild	O 0
phenotype	O 0
in	O 0
patients	O 0
with	O 0
this	O 0
mutation	O 0
.	O 0

The	O 0
distribution	O 0
and	O 0
relative	O 0
frequencies	O 0
of	O 0
the	O 0
I113F	O 0
and	O 0
T312S	O 0
mutations	O 0
in	O 0
Australia	O 0
corresponded	O 0
to	O 0
those	O 0
observed	O 0
in	O 0
Northern	O 0
Ireland	O 0
and	O 0
are	O 0
unique	O 0
to	O 0
these	O 0
two	O 0
populations	O 0
,	O 0
suggesting	O 0
that	O 0
both	O 0
mutations	O 0
were	O 0
probably	O 0
introduced	O 0
to	O 0
Australia	O 0
by	O 0
Irish	O 0
migrants	O 0
during	O 0
the	O 0
19th	O 0
century	O 0
.	O 0

Haplotype	O 0
analysis	O 0
using	O 0
6	O 0
RFLPs	O 0
provides	O 0
additional	O 0
data	O 0
that	O 0
the	O 0
I113F	O 0
mutation	O 0
originated	O 0
from	O 0
a	O 0
common	O 0
ancestor	O 0
.	O 0

The	O 0
other	O 0
9	O 0
novel	O 0
mutations	O 0
identified	O 0
in	O 0
these	O 0
23	O 0
patients	O 0
were	O 0
each	O 0
limited	O 0
to	O 0
a	O 0
single	O 0
family	O 0
.	O 0

These	O 0
data	O 0
provide	O 0
further	O 0
evidence	O 0
for	O 0
extensive	O 0
allelic	O 0
heterogeneity	O 0
in	O 0
MPS	B-Disease 0
IVA	I-Disease 0
in	O 0
British	O 0
-	O 0
Irish	O 0
patients	O 0
and	O 0
provide	O 0
evidence	O 0
for	O 0
their	O 0
transmission	O 0
to	O 0
Australia	O 0
by	O 0
British	O 0
-	O 0
Irish	O 0
migrants	O 0
.	O 0
.	O 0

Identification	O 0
of	O 0
constitutional	O 0
WT1	O 0
mutations	O 0
,	O 0
in	O 0
patients	O 0
with	O 0
isolated	O 0
diffuse	B-Disease 0
mesangial	I-Disease 0
sclerosis	I-Disease 0
,	O 0
and	O 0
analysis	O 0
of	O 0
genotype	O 0
/	O 0
phenotype	O 0
correlations	O 0
by	O 0
use	O 0
of	O 0
a	O 0
computerized	O 0
mutation	O 0
database	O 0
.	O 0

Constitutional	O 0
mutations	O 0
of	O 0
the	O 0
WT1	O 0
gene	O 0
,	O 0
encoding	O 0
a	O 0
zinc	O 0
-	O 0
finger	O 0
transcription	O 0
factor	O 0
involved	O 0
in	O 0
renal	O 0
and	O 0
gonadal	O 0
development	O 0
,	O 0
are	O 0
found	O 0
in	O 0
most	O 0
patients	O 0
with	O 0
Denys	B-Disease 0
-	I-Disease 0
Drash	I-Disease 0
syndrome	I-Disease 0
(	O 0
DDS	B-Disease 0
)	O 0
,	O 0
or	O 0
diffuse	B-Disease 0
mesangial	I-Disease 0
sclerosis	I-Disease 0
(	O 0
DMS	B-Disease 0
)	O 0
associated	O 0
with	O 0
pseudohermaphroditism	B-Disease 0
and	O 0
/	O 0
or	O 0
Wilms	B-Disease 0
tumor	I-Disease 0
(	O 0
WT	B-Disease 0
)	O 0
.	O 0

Most	O 0
mutations	O 0
in	O 0
DDS	B-Disease 0
patients	O 0
lie	O 0
in	O 0
exon	O 0
8	O 0
or	O 0
exon	O 0
9	O 0
,	O 0
encoding	O 0
zinc	O 0
finger	O 0
2	O 0
or	O 0
zinc	O 0
finger	O 0
3	O 0
,	O 0
respectively	O 0
,	O 0
with	O 0
a	O 0
hot	O 0
spot	O 0
(	O 0
R394W	O 0
)	O 0
in	O 0
exon	O 0
9	O 0
.	O 0

We	O 0
analyzed	O 0
a	O 0
series	O 0
of	O 0
24	O 0
patients	O 0
,	O 0
10	O 0
with	O 0
isolated	B-Disease 0
DMS	I-Disease 0
(	O 0
IDMS	B-Disease 0
)	O 0
,	O 0
10	O 0
with	O 0
DDS	B-Disease 0
,	O 0
and	O 0
4	O 0
with	O 0
urogenital	B-Disease 0
abnormalities	I-Disease 0
and	O 0
/	O 0
or	O 0
WT	B-Disease 0
.	O 0

We	O 0
report	O 0
WT1	O 0
heterozygous	O 0
mutations	O 0
in	O 0
16	O 0
patients	O 0
,	O 0
4	O 0
of	O 0
whom	O 0
presented	O 0
with	O 0
IDMS	B-Disease 0
.	O 0

One	O 0
male	O 0
and	O 0
two	O 0
female	O 0
IDMS	B-Disease 0
patients	O 0
with	O 0
WT1	O 0
mutations	O 0
underwent	O 0
normal	O 0
puberty	O 0
.	O 0

Two	O 0
mutations	O 0
associated	O 0
with	O 0
IDMS	B-Disease 0
are	O 0
different	O 0
from	O 0
those	O 0
described	O 0
in	O 0
DDS	B-Disease 0
patients	O 0
.	O 0

No	O 0
WT1	O 0
mutations	O 0
were	O 0
detected	O 0
in	O 0
the	O 0
six	O 0
other	O 0
IDMS	B-Disease 0
patients	O 0
,	O 0
suggesting	O 0
genetic	O 0
heterogeneity	O 0
of	O 0
this	O 0
disease	O 0
.	O 0

We	O 0
analyzed	O 0
genotype	O 0
/	O 0
phenotype	O 0
correlations	O 0
,	O 0
on	O 0
the	O 0
basis	O 0
of	O 0
the	O 0
constitution	O 0
of	O 0
a	O 0
WT1	O 0
mutation	O 0
database	O 0
of	O 0
84	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
,	O 0
to	O 0
compare	O 0
the	O 0
distribution	O 0
and	O 0
type	O 0
of	O 0
mutations	O 0
,	O 0
according	O 0
to	O 0
the	O 0
different	O 0
symptoms	O 0
.	O 0

This	O 0
demonstrated	O 0
(	O 0
1	O 0
)	O 0
the	O 0
association	O 0
between	O 0
mutations	O 0
in	O 0
exons	O 0
8	O 0
and	O 0
9	O 0
and	O 0
DMS	B-Disease 0
;	O 0
(	O 0
2	O 0
)	O 0
among	O 0
patients	O 0
with	O 0
DMS	B-Disease 0
,	O 0
a	O 0
higher	O 0
frequency	O 0
of	O 0
exon	O 0
8	O 0
mutations	O 0
among	O 0
46	O 0
,	O 0
XY	O 0
patients	O 0
with	O 0
female	O 0
phenotype	O 0
than	O 0
among	O 0
46	O 0
,	O 0
XY	O 0
patients	O 0
with	O 0
sexual	O 0
ambiguity	O 0
or	O 0
male	O 0
phenotype	O 0
;	O 0
and	O 0
(	O 0
3	O 0
)	O 0
statistically	O 0
significant	O 0
evidence	O 0
that	O 0
mutations	O 0
in	O 0
exons	O 0
8	O 0
and	O 0
9	O 0
preferentially	O 0
affect	O 0
amino	O 0
acids	O 0
with	O 0
different	O 0
functions	O 0
.	O 0
.	O 0

The	O 0
185delAG	O 0
BRCA1	O 0
mutation	O 0
originated	O 0
before	O 0
the	O 0
dispersion	O 0
of	O 0
Jews	O 0
in	O 0
the	O 0
diaspora	O 0
and	O 0
is	O 0
not	O 0
limited	O 0
to	O 0
Ashkenazim	O 0
.	O 0

The	O 0
185delAG	O 0
mutation	O 0
in	O 0
BRCA1	O 0
is	O 0
detected	O 0
in	O 0
Ashkenazi	O 0
Jews	O 0
both	O 0
in	O 0
familial	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
and	O 0
in	O 0
the	O 0
general	O 0
population	O 0
.	O 0

All	O 0
tested	O 0
Ashkenazi	O 0
mutation	O 0
carriers	O 0
share	O 0
the	O 0
same	O 0
allelic	O 0
pattern	O 0
at	O 0
the	O 0
BRCA1	O 0
locus	O 0
.	O 0

Our	O 0
previous	O 0
study	O 0
showed	O 0
that	O 0
this	O 0
Ashkenazi	O 0
mutation	O 0
also	O 0
occurs	O 0
in	O 0
Iraqi	O 0
Jews	O 0
with	O 0
a	O 0
similar	O 0
allelic	O 0
pattern	O 0
.	O 0

We	O 0
extended	O 0
our	O 0
analysis	O 0
to	O 0
other	O 0
non	O 0
-	O 0
Ashkenazi	O 0
subsets	O 0
354	O 0
of	O 0
Moroccan	O 0
origin	O 0
,	O 0
200	O 0
Yemenites	O 0
and	O 0
150	O 0
Iranian	O 0
Jews	O 0
.	O 0

Heteroduplex	O 0
analysis	O 0
complemented	O 0
by	O 0
direct	O 0
DNA	O 0
sequencing	O 0
of	O 0
abnormally	O 0
migrating	O 0
bands	O 0
were	O 0
employed	O 0
.	O 0

Four	O 0
of	O 0
Moroccan	O 0
origin	O 0
(	O 0
1	O 0
.	O 0
1	O 0
%	O 0
)	O 0
and	O 0
none	O 0
of	O 0
the	O 0
Yemenites	O 0
or	O 0
Iranians	O 0
was	O 0
a	O 0
carrier	O 0
of	O 0
the	O 0
185delAG	O 0
mutation	O 0
.	O 0

BRCA1	O 0
allelic	O 0
patterns	O 0
were	O 0
determined	O 0
for	O 0
four	O 0
of	O 0
these	O 0
individuals	O 0
and	O 0
for	O 0
12	O 0
additional	O 0
non	O 0
-	O 0
Ashkenazi	O 0
185delAG	O 0
mutation	O 0
carriers	O 0
who	O 0
had	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

Six	O 0
non	O 0
-	O 0
Ashkenazi	O 0
individuals	O 0
shared	O 0
the	O 0
common	O 0
Ashkenazi	O 0
haplotype	O 0
,	O 0
four	O 0
had	O 0
a	O 0
closely	O 0
related	O 0
pattern	O 0
,	O 0
and	O 0
the	O 0
rest	O 0
(	O 0
n	O 0
=	O 0
6	O 0
)	O 0
displayed	O 0
a	O 0
distinct	O 0
BRCA1	O 0
allelic	O 0
pattern	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
the	O 0
185delAG	O 0
BRCA1	O 0
mutation	O 0
occurs	O 0
in	O 0
some	O 0
non	O 0
-	O 0
Ashkenazi	O 0
populations	O 0
at	O 0
rates	O 0
comparable	O 0
with	O 0
that	O 0
of	O 0
Ashkenazim	O 0
.	O 0

The	O 0
majority	O 0
of	O 0
Jewish	O 0
185delAG	O 0
mutation	O 0
carriers	O 0
have	O 0
a	O 0
common	O 0
allelic	O 0
pattern	O 0
,	O 0
supporting	O 0
the	O 0
founder	O 0
effect	O 0
notion	O 0
,	O 0
but	O 0
dating	O 0
the	O 0
mutations	O 0
origin	O 0
to	O 0
an	O 0
earlier	O 0
date	O 0
than	O 0
currently	O 0
estimated	O 0
.	O 0

However	O 0
,	O 0
the	O 0
different	O 0
allelic	O 0
pattern	O 0
at	O 0
the	O 0
BRCA1	O 0
locus	O 0
even	O 0
in	O 0
some	O 0
Jewish	O 0
mutation	O 0
carriers	O 0
,	O 0
might	O 0
suggest	O 0
that	O 0
the	O 0
mutation	O 0
arose	O 0
independently	O 0
.	O 0
.	O 0

Crystal	O 0
structure	O 0
of	O 0
the	O 0
hemochromatosis	B-Disease 0
protein	O 0
HFE	O 0
and	O 0
characterization	O 0
of	O 0
its	O 0
interaction	O 0
with	O 0
transferrin	O 0
receptor	O 0
.	O 0

HFE	O 0
is	O 0
an	O 0
MHC	O 0
-	O 0
related	O 0
protein	O 0
that	O 0
is	O 0
mutated	O 0
in	O 0
the	O 0
iron	B-Disease 0
-	I-Disease 0
overload	I-Disease 0
disease	I-Disease 0
hereditary	B-Disease 0
hemochromatosis	I-Disease 0
.	O 0

HFE	O 0
binds	O 0
to	O 0
transferrin	O 0
receptor	O 0
(	O 0
TfR	O 0
)	O 0
and	O 0
reduces	O 0
its	O 0
affinity	O 0
for	O 0
iron	O 0
-	O 0
loaded	O 0
transferrin	O 0
,	O 0
implicating	O 0
HFE	O 0
in	O 0
iron	O 0
metabolism	O 0
.	O 0

The	O 0
2	O 0
.	O 0

6	O 0
A	O 0
crystal	O 0
structure	O 0
of	O 0
HFE	O 0
reveals	O 0
the	O 0
locations	O 0
of	O 0
hemochromatosis	B-Disease 0
mutations	O 0
and	O 0
a	O 0
patch	O 0
of	O 0
histidines	O 0
that	O 0
could	O 0
be	O 0
involved	O 0
in	O 0
pH	O 0
-	O 0
dependent	O 0
interactions	O 0
.	O 0

We	O 0
also	O 0
demonstrate	O 0
that	O 0
soluble	O 0
TfR	O 0
and	O 0
HFE	O 0
bind	O 0
tightly	O 0
at	O 0
the	O 0
basic	O 0
pH	O 0
of	O 0
the	O 0
cell	O 0
surface	O 0
,	O 0
but	O 0
not	O 0
at	O 0
the	O 0
acidic	O 0
pH	O 0
of	O 0
intracellular	O 0
vesicles	O 0
.	O 0

TfR	O 0
HFE	O 0
stoichiometry	O 0
(	O 0
2	O 0
1	O 0
)	O 0
differs	O 0
from	O 0
TfR	O 0
transferrin	O 0
stoichiometry	O 0
(	O 0
2	O 0
2	O 0
)	O 0
,	O 0
implying	O 0
a	O 0
different	O 0
mode	O 0
of	O 0
binding	O 0
for	O 0
HFE	O 0
and	O 0
transferrin	O 0
to	O 0
TfR	O 0
,	O 0
consistent	O 0
with	O 0
our	O 0
demonstration	O 0
that	O 0
HFE	O 0
,	O 0
transferrin	O 0
,	O 0
and	O 0
TfR	O 0
form	O 0
a	O 0
ternary	O 0
complex	O 0
.	O 0

Identification	O 0
of	O 0
three	O 0
novel	O 0
mutations	O 0
and	O 0
a	O 0
high	O 0
frequency	O 0
of	O 0
the	O 0
Arg778Leu	O 0
mutation	O 0
in	O 0
Korean	O 0
patients	O 0
with	O 0
Wilson	B-Disease 0
disease	I-Disease 0
.	O 0

Four	O 0
mutations	O 0
-	O 0
-	O 0
R778L	O 0
,	O 0
A874V	O 0
,	O 0
L1083F	O 0
,	O 0
and	O 0
2304delC	O 0
-	O 0
-	O 0
in	O 0
the	O 0
copper	O 0
-	O 0
transporting	O 0
enzyme	O 0
,	O 0
P	O 0
-	O 0
type	O 0
ATPase	O 0
(	O 0
ATP7B	O 0
)	O 0
,	O 0
were	O 0
identified	O 0
in	O 0
Korean	O 0
Patients	O 0
with	O 0
Wilson	B-Disease 0
disease	I-Disease 0
.	O 0

Arg778Leu	O 0
,	O 0
the	O 0
most	O 0
frequently	O 0
reported	O 0
mutation	O 0
of	O 0
this	O 0
enzyme	O 0
,	O 0
was	O 0
found	O 0
in	O 0
six	O 0
of	O 0
eight	O 0
unrelated	O 0
patients	O 0
studied	O 0
,	O 0
an	O 0
allele	O 0
frequency	O 0
of	O 0
37	O 0
.	O 0

5	O 0
%	O 0
,	O 0
which	O 0
is	O 0
considerably	O 0
higher	O 0
than	O 0
those	O 0
in	O 0
other	O 0
Asian	O 0
populations	O 0
.	O 0

The	O 0
novel	O 0
single	O 0
nucleotide	O 0
deletion	O 0
,	O 0
2304delC	O 0
,	O 0
was	O 0
found	O 0
in	O 0
one	O 0
patient	O 0
.	O 0

Since	O 0
a	O 0
mutation	O 0
at	O 0
cDNA	O 0
nucleotide	O 0
2302	O 0
(	O 0
2302insC	O 0
)	O 0
had	O 0
been	O 0
previously	O 0
described	O 0
,	O 0
this	O 0
region	O 0
of	O 0
the	O 0
ATP7B	O 0
gene	O 0
may	O 0
be	O 0
susceptible	O 0
to	O 0
gene	O 0
rearrangements	O 0
causing	O 0
Wilson	B-Disease 0
disease	I-Disease 0
.	O 0

Disruption	O 0
of	O 0
splicing	O 0
regulated	O 0
by	O 0
a	O 0
CUG	O 0
-	O 0
binding	O 0
protein	O 0
in	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
caused	O 0
by	O 0
a	O 0
CTG	O 0
expansion	O 0
in	O 0
the	O 0
3	O 0
untranslated	O 0
region	O 0
of	O 0
the	O 0
DM	B-Disease 0
gene	O 0
.	O 0

One	O 0
model	O 0
of	O 0
DM	B-Disease 0
pathogenesis	O 0
suggests	O 0
that	O 0
RNAs	O 0
from	O 0
the	O 0
expanded	O 0
allele	O 0
create	O 0
a	O 0
gain	O 0
-	O 0
of	O 0
-	O 0
function	O 0
mutation	O 0
by	O 0
the	O 0
inappropriate	O 0
binding	O 0
of	O 0
proteins	O 0
to	O 0
the	O 0
CUG	O 0
repeats	O 0
.	O 0

Data	O 0
presented	O 0
here	O 0
indicate	O 0
that	O 0
the	O 0
conserved	O 0
heterogeneous	O 0
nuclear	O 0
ribonucleoprotein	O 0
,	O 0
CUG	O 0
-	O 0
binding	O 0
protein	O 0
(	O 0
CUG	O 0
-	O 0
BP	O 0
)	O 0
,	O 0
may	O 0
mediate	O 0
the	O 0
trans	O 0
-	O 0
dominant	O 0
effect	O 0
of	O 0
the	O 0
RNA	O 0
.	O 0

CUG	O 0
-	O 0
BP	O 0
was	O 0
found	O 0
to	O 0
bind	O 0
to	O 0
the	O 0
human	O 0
cardiac	O 0
troponin	O 0
T	O 0
(	O 0
cTNT	O 0
)	O 0
pre	O 0
-	O 0
messenger	O 0
RNA	O 0
and	O 0
regulate	O 0
its	O 0
alternative	O 0
splicing	O 0
.	O 0

Splicing	O 0
of	O 0
cTNT	O 0
was	O 0
disrupted	O 0
in	O 0
DM	B-Disease 0
striated	O 0
muscle	O 0
and	O 0
in	O 0
normal	O 0
cells	O 0
expressing	O 0
transcripts	O 0
that	O 0
contain	O 0
CUG	O 0
repeats	O 0
.	O 0

Altered	O 0
expression	O 0
of	O 0
genes	O 0
regulated	O 0
posttranscriptionally	O 0
by	O 0
CUG	O 0
-	O 0
BP	O 0
therefore	O 0
may	O 0
contribute	O 0
to	O 0
DM	B-Disease 0
pathogenesis	O 0
.	O 0
.	O 0

Identification	O 0
of	O 0
a	O 0
novel	O 0
nonsense	O 0
mutation	O 0
and	O 0
a	O 0
missense	O 0
substitution	O 0
in	O 0
the	O 0
vasopressin	O 0
-	O 0
neurophysin	O 0
II	O 0
gene	O 0
in	O 0
two	O 0
Spanish	O 0
kindreds	O 0
with	O 0
familial	B-Disease 0
neurohypophyseal	I-Disease 0
diabetes	I-Disease 0
insipidus	I-Disease 0
.	O 0

Familial	B-Disease 0
neurohypophyseal	I-Disease 0
diabetes	I-Disease 0
insipidus	I-Disease 0
(	O 0
FNDI	B-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disease	I-Disease 0
caused	O 0
by	O 0
deficiency	O 0
in	O 0
the	O 0
antidiuretic	O 0
hormone	O 0
arginine	O 0
vasopressin	O 0
(	O 0
AVP	O 0
)	O 0
encoded	O 0
by	O 0
the	O 0
AVP	O 0
-	O 0
neurophysin	O 0
II	O 0
(	O 0
AVP	O 0
-	O 0
NPII	O 0
)	O 0
gene	O 0
on	O 0
chromosome	O 0
20p13	O 0
.	O 0

In	O 0
this	O 0
study	O 0
,	O 0
we	O 0
analyzed	O 0
two	O 0
families	O 0
with	O 0
FNDI	B-Disease 0
using	O 0
direct	O 0
automated	O 0
fluorescent	O 0
,	O 0
solid	O 0
phase	O 0
,	O 0
single	O 0
-	O 0
stranded	O 0
DNA	O 0
sequencing	O 0
of	O 0
PCR	O 0
-	O 0
amplified	O 0
AVP	O 0
-	O 0
NPII	O 0
DNA	O 0
.	O 0

In	O 0
one	O 0
of	O 0
the	O 0
families	O 0
,	O 0
affected	O 0
individuals	O 0
presented	O 0
a	O 0
novel	O 0
nonsense	O 0
mutation	O 0
in	O 0
exon	O 0
3	O 0
of	O 0
the	O 0
gene	O 0
,	O 0
consisting	O 0
in	O 0
a	O 0
G	O 0
to	O 0
T	O 0
transition	O 0
at	O 0
nucleotide	O 0
2101	O 0
,	O 0
which	O 0
produces	O 0
a	O 0
stop	O 0
signal	O 0
in	O 0
codon	O 0
82	O 0
(	O 0
Glu	O 0
)	O 0
of	O 0
NPII	O 0
.	O 0

The	O 0
premature	O 0
termination	O 0
eliminates	O 0
part	O 0
of	O 0
the	O 0
C	O 0
-	O 0
terminal	O 0
domain	O 0
of	O 0
NPII	O 0
,	O 0
including	O 0
a	O 0
cysteine	O 0
residue	O 0
in	O 0
position	O 0
85	O 0
,	O 0
which	O 0
could	O 0
be	O 0
involved	O 0
in	O 0
the	O 0
correct	O 0
folding	O 0
of	O 0
the	O 0
prohormone	O 0
.	O 0

In	O 0
the	O 0
second	O 0
family	O 0
,	O 0
a	O 0
G279A	O 0
substitution	O 0
at	O 0
position	O 0
-	O 0
1	O 0
of	O 0
the	O 0
signal	O 0
peptide	O 0
was	O 0
observed	O 0
in	O 0
all	O 0
affected	O 0
individuals	O 0
.	O 0

This	O 0
missense	O 0
mutation	O 0
,	O 0
which	O 0
replaces	O 0
Ala	O 0
with	O 0
Thr	O 0
,	O 0
is	O 0
frequent	O 0
among	O 0
FNDI	B-Disease 0
patients	O 0
and	O 0
is	O 0
thought	O 0
to	O 0
reduce	O 0
the	O 0
efficiency	O 0
of	O 0
cleavage	O 0
by	O 0
signal	O 0
peptidases	O 0
.	O 0
.	O 0

Genetic	O 0
heterogeneity	O 0
of	O 0
Saethre	B-Disease 0
-	I-Disease 0
Chotzen	I-Disease 0
syndrome	I-Disease 0
,	O 0
due	O 0
to	O 0
TWIST	O 0
and	O 0
FGFR	O 0
mutations	O 0
.	O 0

Thirty	O 0
-	O 0
two	O 0
unrelated	O 0
patients	O 0
with	O 0
features	O 0
of	O 0
Saethre	B-Disease 0
-	I-Disease 0
Chotzen	I-Disease 0
syndrome	I-Disease 0
,	O 0
a	O 0
common	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
condition	I-Disease 0
of	O 0
craniosynostosis	B-Disease 0
and	O 0
limb	B-Disease 0
anomalies	I-Disease 0
,	O 0
were	O 0
screened	O 0
for	O 0
mutations	O 0
in	O 0
TWIST	O 0
,	O 0
FGFR2	O 0
,	O 0
and	O 0
FGFR3	O 0
.	O 0

Nine	O 0
novel	O 0
and	O 0
three	O 0
recurrent	O 0
TWIST	O 0
mutations	O 0
were	O 0
found	O 0
in	O 0
12	O 0
families	O 0
.	O 0

Seven	O 0
families	O 0
were	O 0
found	O 0
to	O 0
have	O 0
the	O 0
FGFR3	O 0
P250R	O 0
mutation	O 0
,	O 0
and	O 0
one	O 0
individual	O 0
was	O 0
found	O 0
to	O 0
have	O 0
an	O 0
FGFR2	O 0
VV269	O 0
-	O 0
270	O 0
deletion	O 0
.	O 0

To	O 0
date	O 0
,	O 0
our	O 0
detection	O 0
rate	O 0
for	O 0
TWIST	O 0
or	O 0
FGFR	O 0
mutations	O 0
is	O 0
68	O 0
%	O 0
in	O 0
our	O 0
Saethre	B-Disease 0
-	I-Disease 0
Chotzen	I-Disease 0
syndrome	I-Disease 0
patients	O 0
,	O 0
including	O 0
our	O 0
five	O 0
patients	O 0
elsewhere	O 0
reported	O 0
with	O 0
TWIST	O 0
mutations	O 0
.	O 0

More	O 0
than	O 0
35	O 0
different	O 0
TWIST	O 0
mutations	O 0
are	O 0
now	O 0
known	O 0
in	O 0
the	O 0
literature	O 0
.	O 0

The	O 0
most	O 0
common	O 0
phenotypic	O 0
features	O 0
,	O 0
present	O 0
in	O 0
more	O 0
than	O 0
a	O 0
third	O 0
of	O 0
our	O 0
patients	O 0
with	O 0
TWIST	O 0
mutations	O 0
,	O 0
are	O 0
coronal	B-Disease 0
synostosis	I-Disease 0
,	O 0
brachycephaly	B-Disease 0
,	O 0
low	B-Disease 0
frontal	I-Disease 0
hairline	I-Disease 0
,	O 0
facial	B-Disease 0
asymmetry	I-Disease 0
,	O 0
ptosis	B-Disease 0
,	O 0
hypertelorism	B-Disease 0
,	O 0
broad	B-Disease 0
great	I-Disease 0
toes	I-Disease 0
,	O 0
and	O 0
clinodactyly	B-Disease 0
.	O 0

Significant	O 0
intra	O 0
-	O 0
and	O 0
interfamilial	O 0
phenotypic	O 0
variability	O 0
is	O 0
present	O 0
for	O 0
either	O 0
TWIST	O 0
mutations	O 0
or	O 0
FGFR	O 0
mutations	O 0
.	O 0

The	O 0
overlap	O 0
in	O 0
clinical	O 0
features	O 0
and	O 0
the	O 0
presence	O 0
,	O 0
in	O 0
the	O 0
same	O 0
genes	O 0
,	O 0
of	O 0
mutations	O 0
for	O 0
more	O 0
than	O 0
one	O 0
craniosynostotic	B-Disease 0
condition	I-Disease 0
-	O 0
such	O 0
as	O 0
Saethre	B-Disease 0
-	I-Disease 0
Chotzen	I-Disease 0
,	I-Disease 0
Crouzon	I-Disease 0
,	I-Disease 0
and	I-Disease 0
Pfeiffer	I-Disease 0
syndromes	I-Disease 0
-	O 0
support	O 0
the	O 0
hypothesis	O 0
that	O 0
TWIST	O 0
and	O 0
FGFRs	O 0
are	O 0
components	O 0
of	O 0
the	O 0
same	O 0
molecular	O 0
pathway	O 0
involved	O 0
in	O 0
the	O 0
modulation	O 0
of	O 0
craniofacial	O 0
and	O 0
limb	O 0
development	O 0
in	O 0
humans	O 0
.	O 0
.	O 0

Mutation	O 0
analysis	O 0
of	O 0
UBE3A	O 0
in	O 0
Angelman	B-Disease 0
syndrome	I-Disease 0
patients	O 0
.	O 0

Angelman	B-Disease 0
syndrome	I-Disease 0
(	O 0
AS	B-Disease 0
)	O 0
is	O 0
caused	O 0
by	O 0
chromosome	O 0
15q11	O 0
-	O 0
q13	O 0
deletions	O 0
of	O 0
maternal	O 0
origin	O 0
,	O 0
by	O 0
paternal	O 0
uniparental	B-Disease 0
disomy	I-Disease 0
(	O 0
UPD	B-Disease 0
)	O 0
15	O 0
,	O 0
by	O 0
imprinting	O 0
defects	O 0
,	O 0
and	O 0
by	O 0
mutations	O 0
in	O 0
the	O 0
UBE3A	O 0
gene	O 0
.	O 0

UBE3A	O 0
encodes	O 0
a	O 0
ubiquitin	O 0
-	O 0
protein	O 0
ligase	O 0
and	O 0
shows	O 0
brain	O 0
-	O 0
specific	O 0
imprinting	O 0
.	O 0

Here	O 0
we	O 0
describe	O 0
UBE3A	O 0
coding	O 0
-	O 0
region	O 0
mutations	O 0
detected	O 0
by	O 0
SSCP	O 0
analysis	O 0
in	O 0
13	O 0
AS	B-Disease 0
individuals	O 0
or	O 0
families	O 0
.	O 0

Two	O 0
identical	O 0
de	O 0
novo	O 0
5	O 0
-	O 0
bp	O 0
duplications	O 0
in	O 0
exon	O 0
16	O 0
were	O 0
found	O 0
.	O 0

Among	O 0
the	O 0
other	O 0
11	O 0
unique	O 0
mutations	O 0
,	O 0
8	O 0
were	O 0
small	O 0
deletions	O 0
or	O 0
insertions	O 0
predicted	O 0
to	O 0
cause	O 0
frameshifts	O 0
,	O 0
1	O 0
was	O 0
a	O 0
mutation	O 0
to	O 0
a	O 0
stop	O 0
codon	O 0
,	O 0
1	O 0
was	O 0
a	O 0
missense	O 0
mutation	O 0
,	O 0
and	O 0
1	O 0
was	O 0
predicted	O 0
to	O 0
cause	O 0
insertion	O 0
of	O 0
an	O 0
isoleucine	O 0
in	O 0
the	O 0
hect	O 0
domain	O 0
of	O 0
the	O 0
UBE3A	O 0
protein	O 0
,	O 0
which	O 0
functions	O 0
in	O 0
E2	O 0
binding	O 0
and	O 0
ubiquitin	O 0
transfer	O 0
.	O 0

Eight	O 0
of	O 0
the	O 0
cases	O 0
were	O 0
familial	O 0
,	O 0
and	O 0
five	O 0
were	O 0
sporadic	O 0
.	O 0

In	O 0
two	O 0
familial	O 0
cases	O 0
and	O 0
one	O 0
sporadic	O 0
case	O 0
,	O 0
mosaicism	O 0
for	O 0
UBE3A	O 0
mutations	O 0
was	O 0
detected	O 0
in	O 0
the	O 0
mother	O 0
of	O 0
three	O 0
AS	B-Disease 0
sons	O 0
,	O 0
in	O 0
the	O 0
maternal	O 0
grandfather	O 0
of	O 0
two	O 0
AS	B-Disease 0
first	O 0
cousins	O 0
,	O 0
and	O 0
in	O 0
the	O 0
mother	O 0
of	O 0
an	O 0
AS	B-Disease 0
daughter	O 0
.	O 0

The	O 0
frequencies	O 0
with	O 0
which	O 0
we	O 0
detected	O 0
mutations	O 0
were	O 0
5	O 0
(	O 0
14	O 0
%	O 0
)	O 0
of	O 0
35	O 0
in	O 0
sporadic	O 0
cases	O 0
and	O 0
8	O 0
(	O 0
80	O 0
%	O 0
)	O 0
of	O 0
10	O 0
in	O 0
familial	O 0
cases	O 0
.	O 0
.	O 0

The	O 0
hemochromatosis	B-Disease 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
and	O 0
187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
mutations	O 0
:	O 0
prevalence	O 0
in	O 0
non	O 0
-	O 0
Caucasian	O 0
populations	O 0
.	O 0

Hemochromatosis	B-Disease 0
,	O 0
the	O 0
inherited	B-Disease 0
disorder	I-Disease 0
of	I-Disease 0
iron	I-Disease 0
metabolism	I-Disease 0
,	O 0
leads	O 0
,	O 0
if	O 0
untreated	O 0
,	O 0
to	O 0
progressive	O 0
iron	B-Disease 0
overload	I-Disease 0
and	O 0
premature	B-Disease 0
death	I-Disease 0
.	O 0

The	O 0
hemochromatosis	B-Disease 0
gene	O 0
,	O 0
HFE	O 0
,	O 0
recently	O 0
has	O 0
been	O 0
identified	O 0
,	O 0
and	O 0
characterization	O 0
of	O 0
this	O 0
gene	O 0
has	O 0
shown	O 0
that	O 0
it	O 0
contains	O 0
two	O 0
mutations	O 0
that	O 0
result	O 0
in	O 0
amino	O 0
acid	O 0
substitutions	O 0
-	O 0
cDNA	O 0
nucleotides	O 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
(	O 0
C282Y	O 0
)	O 0
and	O 0
187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
(	O 0
H63D	O 0
)	O 0
.	O 0

Although	O 0
hemochromatosis	B-Disease 0
is	O 0
common	O 0
in	O 0
Caucasians	O 0
,	O 0
affecting	O 0
>	O 0
=	O 0
1	O 0
/	O 0
300	O 0
individuals	O 0
of	O 0
northern	O 0
European	O 0
origin	O 0
,	O 0
it	O 0
has	O 0
not	O 0
been	O 0
recognized	O 0
in	O 0
other	O 0
populations	O 0
.	O 0

The	O 0
present	O 0
study	O 0
used	O 0
PCR	O 0
and	O 0
restriction	O 0
-	O 0
enzyme	O 0
digestion	O 0
to	O 0
analyze	O 0
the	O 0
frequency	O 0
of	O 0
the	O 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
and	O 0
187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
mutations	O 0
in	O 0
HLA	O 0
-	O 0
typed	O 0
samples	O 0
from	O 0
non	O 0
-	O 0
Caucasian	O 0
populations	O 0
,	O 0
comprising	O 0
Australian	O 0
Aboriginal	O 0
,	O 0
Chinese	O 0
,	O 0
and	O 0
Pacific	O 0
Islanders	O 0
.	O 0

Results	O 0
showed	O 0
that	O 0
the	O 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
mutation	O 0
was	O 0
present	O 0
in	O 0
these	O 0
populations	O 0
(	O 0
allele	O 0
frequency	O 0
0	O 0
.	O 0
32	O 0
%	O 0
)	O 0
,	O 0
and	O 0
,	O 0
furthermore	O 0
,	O 0
it	O 0
was	O 0
always	O 0
seen	O 0
in	O 0
conjunction	O 0
with	O 0
HLA	O 0
haplotypes	O 0
common	O 0
in	O 0
Caucasians	O 0
,	O 0
suggesting	O 0
that	O 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
may	O 0
have	O 0
been	O 0
introduced	O 0
into	O 0
these	O 0
populations	O 0
by	O 0
Caucasian	O 0
admixture	O 0
.	O 0

187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
was	O 0
present	O 0
at	O 0
an	O 0
allele	O 0
frequency	O 0
of	O 0
2	O 0
.	O 0

68	O 0
%	O 0
in	O 0
the	O 0
two	O 0
populations	O 0
analyzed	O 0
(	O 0
Australian	O 0
Aboriginal	O 0
and	O 0
Chinese	O 0
)	O 0
.	O 0

In	O 0
the	O 0
Australian	O 0
Aboriginal	O 0
samples	O 0
,	O 0
187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
was	O 0
found	O 0
to	O 0
be	O 0
associated	O 0
with	O 0
HLA	O 0
haplotypes	O 0
common	O 0
in	O 0
Caucasians	O 0
,	O 0
suggesting	O 0
that	O 0
it	O 0
was	O 0
introduced	O 0
by	O 0
recent	O 0
admixture	O 0
.	O 0

In	O 0
the	O 0
Chinese	O 0
samples	O 0
analyzed	O 0
,	O 0
187	O 0
C	O 0
-	O 0
-	O 0
>	O 0
G	O 0
was	O 0
present	O 0
in	O 0
association	O 0
with	O 0
a	O 0
wide	O 0
variety	O 0
of	O 0
HLA	O 0
haplotypes	O 0
,	O 0
showing	O 0
this	O 0
mutation	O 0
to	O 0
be	O 0
widespread	O 0
and	O 0
likely	O 0
to	O 0
predate	O 0
the	O 0
more	O 0
genetically	O 0
restricted	O 0
845	O 0
G	O 0
-	O 0
-	O 0
>	O 0
A	O 0
mutation	O 0
.	O 0

Genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
in	O 0
attenuated	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
.	O 0

Germ	O 0
-	O 0
line	O 0
mutations	O 0
of	O 0
the	O 0
tumor	B-Disease 0
suppressor	O 0
APC	O 0
are	O 0
implicated	O 0
in	O 0
attenuated	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
(	O 0
AAPC	B-Disease 0
)	O 0
,	O 0
a	O 0
variant	O 0
of	O 0
familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
(	O 0
FAP	B-Disease 0
)	O 0
.	O 0

AAPC	B-Disease 0
is	O 0
recognized	O 0
by	O 0
the	O 0
occurrence	O 0
of	O 0
<	O 0
100	O 0
colonic	B-Disease 0
adenomas	I-Disease 0
and	O 0
a	O 0
later	O 0
onset	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
(	O 0
age	O 0
>	O 0
40	O 0
years	O 0
)	O 0
.	O 0

The	O 0
aim	O 0
of	O 0
this	O 0
study	O 0
was	O 0
to	O 0
assess	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
in	O 0
AAPC	B-Disease 0
families	O 0
.	O 0

By	O 0
protein	O 0
-	O 0
truncation	O 0
test	O 0
(	O 0
PTT	O 0
)	O 0
assay	O 0
,	O 0
the	O 0
entire	O 0
coding	O 0
region	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
was	O 0
screened	O 0
in	O 0
affected	O 0
individuals	O 0
from	O 0
11	O 0
AAPC	B-Disease 0
kindreds	O 0
,	O 0
and	O 0
their	O 0
phenotypic	O 0
differences	O 0
were	O 0
examined	O 0
.	O 0

Five	O 0
novel	O 0
germ	O 0
-	O 0
line	O 0
APC	B-Disease 0
mutations	O 0
were	O 0
identified	O 0
in	O 0
seven	O 0
kindreds	O 0
.	O 0

Mutations	O 0
were	O 0
located	O 0
in	O 0
three	O 0
different	O 0
regions	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
(	O 0
1	O 0
)	O 0
at	O 0
the	O 0
5	O 0
end	O 0
spanning	O 0
exons	O 0
4	O 0
and	O 0
5	O 0
,	O 0
(	O 0
2	O 0
)	O 0
within	O 0
exon	O 0
9	O 0
,	O 0
and	O 0
(	O 0
3	O 0
)	O 0
at	O 0
the	O 0
3	O 0
distal	O 0
end	O 0
of	O 0
the	O 0
gene	O 0
.	O 0

Variability	O 0
in	O 0
the	O 0
number	O 0
of	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
was	O 0
most	O 0
apparent	O 0
in	O 0
individuals	O 0
with	O 0
mutations	O 0
in	O 0
region	O 0
1	O 0
,	O 0
and	O 0
upper	O 0
-	O 0
gastrointestinal	O 0
manifestations	O 0
were	O 0
more	O 0
severe	O 0
in	O 0
them	O 0
.	O 0

In	O 0
individuals	O 0
with	O 0
mutations	O 0
in	O 0
either	O 0
region	O 0
2	O 0
or	O 0
region	O 0
3	O 0
,	O 0
the	O 0
average	O 0
number	O 0
of	O 0
adenomas	B-Disease 0
tended	O 0
to	O 0
be	O 0
lower	O 0
than	O 0
those	O 0
in	O 0
individuals	O 0
with	O 0
mutations	O 0
in	O 0
region	O 0
1	O 0
,	O 0
although	O 0
age	O 0
at	O 0
diagnosis	O 0
was	O 0
similar	O 0
.	O 0

In	O 0
all	O 0
AAPC	B-Disease 0
kindreds	O 0
,	O 0
a	O 0
predominance	O 0
of	O 0
right	O 0
-	O 0
sided	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
and	O 0
rectal	B-Disease 0
polyp	I-Disease 0
sparing	O 0
was	O 0
observed	O 0
.	O 0

No	O 0
desmoid	B-Disease 0
tumors	I-Disease 0
were	O 0
found	O 0
in	O 0
these	O 0
kindreds	O 0
.	O 0

Our	O 0
data	O 0
suggest	O 0
that	O 0
,	O 0
in	O 0
AAPC	B-Disease 0
families	O 0
,	O 0
the	O 0
location	O 0
of	O 0
the	O 0
APC	B-Disease 0
mutation	O 0
may	O 0
partially	O 0
predict	O 0
specific	O 0
phenotypic	O 0
expression	O 0
.	O 0

This	O 0
should	O 0
help	O 0
in	O 0
the	O 0
design	O 0
of	O 0
tailored	O 0
clinical	O 0
-	O 0
management	O 0
protocols	O 0
in	O 0
this	O 0
subset	O 0
of	O 0
FAP	B-Disease 0
patients	O 0
.	O 0
.	O 0

Wilms	B-Disease 0
'	I-Disease 0
tumor	I-Disease 0
1	O 0
and	O 0
Dax	O 0
-	O 0
1	O 0
modulate	O 0
the	O 0
orphan	O 0
nuclear	O 0
receptor	O 0
SF	O 0
-	O 0
1	O 0
in	O 0
sex	O 0
-	O 0
specific	O 0
gene	O 0
expression	O 0
.	O 0

Products	O 0
of	O 0
steroidogenic	O 0
factor	O 0
1	O 0
(	O 0
SF	O 0
-	O 0
1	O 0
)	O 0
and	O 0
Wilms	B-Disease 0
tumor	I-Disease 0
1	O 0
(	O 0
WT1	O 0
)	O 0
genes	O 0
are	O 0
essential	O 0
for	O 0
mammalian	O 0
gonadogenesis	O 0
prior	O 0
to	O 0
sexual	O 0
differentiation	O 0
.	O 0

In	O 0
males	O 0
,	O 0
SF	O 0
-	O 0
1	O 0
participates	O 0
in	O 0
sexual	O 0
development	O 0
by	O 0
regulating	O 0
expression	O 0
of	O 0
the	O 0
polypeptide	O 0
hormone	O 0
Mullerian	O 0
inhibiting	O 0
substance	O 0
(	O 0
MIS	O 0
)	O 0
.	O 0

Here	O 0
,	O 0
we	O 0
show	O 0
that	O 0
WT1	O 0
-	O 0
KTS	O 0
isoforms	O 0
associate	O 0
and	O 0
synergize	O 0
with	O 0
SF	O 0
-	O 0
1	O 0
to	O 0
promote	O 0
MIS	O 0
expression	O 0
.	O 0

In	O 0
contrast	O 0
,	O 0
WT1	O 0
missense	O 0
mutations	O 0
,	O 0
associated	O 0
with	O 0
male	B-Disease 0
pseudohermaphroditism	I-Disease 0
in	O 0
Denys	B-Disease 0
-	I-Disease 0
Drash	I-Disease 0
syndrome	I-Disease 0
,	O 0
fail	O 0
to	O 0
synergize	O 0
with	O 0
SF	O 0
-	O 0
1	O 0
.	O 0

Additionally	O 0
,	O 0
the	O 0
X	O 0
-	O 0
linked	O 0
,	O 0
candidate	O 0
dosage	O 0
-	O 0
sensitive	O 0
sex	O 0
-	O 0
reversal	O 0
gene	O 0
,	O 0
Dax	O 0
-	O 0
1	O 0
,	O 0
antagonizes	O 0
synergy	O 0
between	O 0
SF	O 0
-	O 0
1	O 0
and	O 0
WT1	O 0
,	O 0
most	O 0
likely	O 0
through	O 0
a	O 0
direct	O 0
interaction	O 0
with	O 0
SF	O 0
-	O 0
1	O 0
.	O 0

We	O 0
propose	O 0
that	O 0
WT1	O 0
and	O 0
Dax	O 0
-	O 0
1	O 0
functionally	O 0
oppose	O 0
each	O 0
other	O 0
in	O 0
testis	O 0
development	O 0
by	O 0
modulating	O 0
SF	O 0
-	O 0
1	O 0
-	O 0
mediated	O 0
transactivation	O 0
.	O 0
.	O 0

A	O 0
mouse	O 0
model	O 0
for	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
imprinting	O 0
-	O 0
centre	O 0
mutations	O 0
.	O 0

Imprinting	O 0
in	O 0
the	O 0
15q11	O 0
-	O 0
q13	O 0
region	O 0
involves	O 0
an	O 0
imprinting	O 0
centre	O 0
(	O 0
IC	O 0
)	O 0
,	O 0
mapping	O 0
in	O 0
part	O 0
to	O 0
the	O 0
promoter	O 0
and	O 0
first	O 0
exon	O 0
of	O 0
SNRPN	O 0
.	O 0

Deletion	O 0
of	O 0
this	O 0
IC	O 0
abolishes	O 0
local	O 0
paternally	O 0
derived	O 0
gene	O 0
expression	O 0
and	O 0
results	O 0
in	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
(	O 0
PWS	B-Disease 0
)	O 0
.	O 0

We	O 0
have	O 0
created	O 0
two	O 0
deletion	O 0
mutations	O 0
in	O 0
mice	O 0
to	O 0
understand	O 0
PWS	B-Disease 0
and	O 0
the	O 0
mechanism	O 0
of	O 0
this	O 0
IC	O 0
.	O 0

Mice	O 0
harbouring	O 0
an	O 0
intragenic	O 0
deletion	O 0
in	O 0
Snrpn	O 0
are	O 0
phenotypically	O 0
normal	O 0
,	O 0
suggesting	O 0
that	O 0
mutations	O 0
of	O 0
SNRPN	O 0
are	O 0
not	O 0
sufficient	O 0
to	O 0
induce	O 0
PWS	B-Disease 0
.	O 0

Mice	O 0
with	O 0
a	O 0
larger	O 0
deletion	O 0
involving	O 0
both	O 0
Snrpn	O 0
and	O 0
the	O 0
putative	O 0
PWS	O 0
-	O 0
IC	O 0
lack	O 0
expression	O 0
of	O 0
the	O 0
imprinted	O 0
genes	O 0
Zfp127	O 0
(	O 0
mouse	O 0
homologue	O 0
of	O 0
ZNF127	O 0
)	O 0
,	O 0
Ndn	O 0
and	O 0
Ipw	O 0
,	O 0
and	O 0
manifest	O 0
several	O 0
phenotypes	O 0
common	O 0
to	O 0
PWS	B-Disease 0
infants	O 0
.	O 0

These	O 0
data	O 0
demonstrate	O 0
that	O 0
both	O 0
the	O 0
position	O 0
of	O 0
the	O 0
IC	O 0
and	O 0
its	O 0
role	O 0
in	O 0
the	O 0
coordinate	O 0
expression	O 0
of	O 0
genes	O 0
is	O 0
conserved	O 0
between	O 0
mouse	O 0
and	O 0
human	O 0
,	O 0
and	O 0
indicate	O 0
that	O 0
the	O 0
mouse	O 0
is	O 0
a	O 0
suitable	O 0
model	O 0
system	O 0
in	O 0
which	O 0
to	O 0
investigate	O 0
the	O 0
molecular	O 0
mechanisms	O 0
of	O 0
imprinting	O 0
in	O 0
this	O 0
region	O 0
of	O 0
the	O 0
genome	O 0
.	O 0
.	O 0

Mutations	O 0
of	O 0
the	O 0
ATM	O 0
gene	O 0
detected	O 0
in	O 0
Japanese	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
patients	O 0
:	O 0
possible	O 0
preponderance	O 0
of	O 0
the	O 0
two	O 0
founder	O 0
mutations	O 0
4612del165	O 0
and	O 0
7883del5	O 0
.	O 0

The	O 0
ATM	O 0
(	O 0
A	O 0
-	O 0
T	O 0
,	O 0
mutated	O 0
)	O 0
gene	O 0
on	O 0
human	O 0
chromosome	O 0
11q22	O 0
.	O 0

3	O 0
has	O 0
recently	O 0
been	O 0
identified	O 0
as	O 0
the	O 0
gene	O 0
responsible	O 0
for	O 0
the	O 0
human	O 0
recessive	B-Disease 0
disease	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
.	O 0

In	O 0
order	O 0
to	O 0
define	O 0
the	O 0
types	O 0
of	O 0
disease	O 0
-	O 0
causing	O 0
ATM	O 0
mutations	O 0
in	O 0
Japanese	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
as	O 0
well	O 0
as	O 0
to	O 0
look	O 0
for	O 0
possible	O 0
mutational	O 0
hotspots	O 0
,	O 0
reverse	O 0
-	O 0
transcribed	O 0
RNA	O 0
derived	O 0
from	O 0
ten	O 0
patients	O 0
belonging	O 0
to	O 0
eight	O 0
unrelated	O 0
Japanese	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
families	O 0
was	O 0
analyzed	O 0
for	O 0
mutations	O 0
by	O 0
the	O 0
restriction	O 0
endonuclease	O 0
fingerprinting	O 0
method	O 0
.	O 0

As	O 0
has	O 0
been	O 0
reported	O 0
by	O 0
others	O 0
,	O 0
mutations	O 0
that	O 0
lead	O 0
to	O 0
exon	O 0
skipping	O 0
or	O 0
premature	O 0
protein	O 0
truncation	O 0
were	O 0
also	O 0
predominant	O 0
in	O 0
our	O 0
mutants	O 0
.	O 0

Six	O 0
different	O 0
mutations	O 0
were	O 0
identified	O 0
on	O 0
12	O 0
of	O 0
the	O 0
16	O 0
alleles	O 0
examined	O 0
.	O 0

Four	O 0
were	O 0
deletions	O 0
involving	O 0
a	O 0
loss	O 0
of	O 0
a	O 0
single	O 0
exon	O 0
exon	O 0
7	O 0
,	O 0
exon	O 0
16	O 0
,	O 0
exon	O 0
33	O 0
or	O 0
exon	O 0
35	O 0
.	O 0

The	O 0
others	O 0
were	O 0
minute	O 0
deletions	O 0
,	O 0
4649delA	O 0
in	O 0
exon	O 0
33	O 0
and	O 0
7883del5	O 0
in	O 0
exon	O 0
55	O 0
.	O 0

The	O 0
mutations	O 0
4612del165	O 0
and	O 0
7883del5	O 0
were	O 0
found	O 0
in	O 0
more	O 0
than	O 0
two	O 0
unrelated	O 0
families	O 0
;	O 0
44	O 0
%	O 0
(	O 0
7	O 0
of	O 0
16	O 0
)	O 0
of	O 0
the	O 0
mutant	O 0
alleles	O 0
had	O 0
one	O 0
of	O 0
the	O 0
two	O 0
mutations	O 0
.	O 0

The	O 0
4612del165	O 0
mutations	O 0
in	O 0
three	O 0
different	O 0
families	O 0
were	O 0
all	O 0
ascribed	O 0
to	O 0
the	O 0
same	O 0
T	O 0
-	O 0
-	O 0
>	O 0
A	O 0
substitution	O 0
at	O 0
the	O 0
splice	O 0
donor	O 0
site	O 0
in	O 0
intron	O 0
33	O 0
.	O 0

Microsatellite	O 0
genotyping	O 0
around	O 0
the	O 0
ATM	O 0
locus	O 0
also	O 0
indicated	O 0
that	O 0
a	O 0
common	O 0
haplotype	O 0
was	O 0
shared	O 0
by	O 0
the	O 0
mutant	O 0
alleles	O 0
in	O 0
both	O 0
mutations	O 0
.	O 0

This	O 0
suggests	O 0
that	O 0
these	O 0
two	O 0
founder	O 0
mutations	O 0
may	O 0
be	O 0
predominant	O 0
among	O 0
Japanese	O 0
ATM	O 0
mutant	O 0
alleles	O 0
.	O 0

W474C	O 0
amino	O 0
acid	O 0
substitution	O 0
affects	O 0
early	O 0
processing	O 0
of	O 0
the	O 0
alpha	O 0
-	O 0
subunit	O 0
of	O 0
beta	O 0
-	O 0
hexosaminidase	O 0
A	O 0
and	O 0
is	O 0
associated	O 0
with	O 0
subacute	O 0
G	B-Disease 0
(	I-Disease 0
M2	I-Disease 0
)	I-Disease 0
gangliosidosis	I-Disease 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
HEXA	O 0
gene	O 0
,	O 0
encoding	O 0
the	O 0
alpha	O 0
-	O 0
subunit	O 0
of	O 0
beta	O 0
-	O 0
hexosaminidase	O 0
A	O 0
(	O 0
Hex	O 0
A	O 0
)	O 0
,	O 0
that	O 0
abolish	O 0
Hex	O 0
A	O 0
enzyme	O 0
activity	O 0
cause	O 0
Tay	B-Disease 0
-	I-Disease 0
Sachs	I-Disease 0
disease	I-Disease 0
(	O 0
TSD	B-Disease 0
)	O 0
,	O 0
the	O 0
fatal	O 0
infantile	B-Disease 0
form	I-Disease 0
of	I-Disease 0
G	I-Disease 0
(	I-Disease 0
M2	I-Disease 0
)	I-Disease 0
gangliosidosis	I-Disease 0
,	I-Disease 0
Type	I-Disease 0
1	I-Disease 0
.	O 0

Less	O 0
severe	O 0
,	O 0
subacute	O 0
(	O 0
juvenile	O 0
-	O 0
onset	O 0
)	O 0
and	O 0
chronic	O 0
(	O 0
adult	O 0
-	O 0
onset	O 0
)	O 0
variants	O 0
are	O 0
characterized	O 0
by	O 0
a	O 0
broad	O 0
spectrum	O 0
of	O 0
clinical	O 0
manifestations	O 0
and	O 0
are	O 0
associated	O 0
with	O 0
residual	O 0
levels	O 0
of	O 0
Hex	O 0
A	O 0
enzyme	O 0
activity	O 0
.	O 0

We	O 0
identified	O 0
a	O 0
1422	O 0
G	O 0
-	O 0
-	O 0
>	O 0
C	O 0
(	O 0
amino	O 0
acid	O 0
W474C	O 0
)	O 0
substitution	O 0
in	O 0
the	O 0
first	O 0
position	O 0
of	O 0
exon	O 0
13	O 0
of	O 0
HEXA	O 0
of	O 0
a	O 0
non	O 0
-	O 0
Jewish	O 0
proband	O 0
who	O 0
manifested	O 0
a	O 0
subacute	O 0
variant	O 0
of	O 0
G	B-Disease 0
(	I-Disease 0
M2	I-Disease 0
)	I-Disease 0
gangliosidosis	I-Disease 0
.	O 0

On	O 0
the	O 0
second	O 0
maternally	O 0
inherited	O 0
allele	O 0
,	O 0
we	O 0
identified	O 0
the	O 0
common	O 0
infantile	O 0
disease	O 0
-	O 0
causing	O 0
4	O 0
-	O 0
bp	O 0
insertion	O 0
,	O 0
+	O 0
TATC	O 0
1278	O 0
,	O 0
in	O 0
exon	O 0
11	O 0
.	O 0

Pulse	O 0
-	O 0
chase	O 0
analysis	O 0
using	O 0
proband	O 0
fibroblasts	O 0
revealed	O 0
that	O 0
the	O 0
W474C	O 0
-	O 0
containing	O 0
alpha	O 0
-	O 0
subunit	O 0
precursor	O 0
was	O 0
normally	O 0
synthesized	O 0
,	O 0
but	O 0
not	O 0
phosphorylated	O 0
or	O 0
secreted	O 0
,	O 0
and	O 0
the	O 0
mature	O 0
lysosomal	O 0
alpha	O 0
-	O 0
subunit	O 0
was	O 0
not	O 0
detected	O 0
.	O 0

When	O 0
the	O 0
W474C	O 0
-	O 0
containing	O 0
alpha	O 0
-	O 0
subunit	O 0
was	O 0
transiently	O 0
co	O 0
-	O 0
expressed	O 0
with	O 0
the	O 0
beta	O 0
-	O 0
subunit	O 0
to	O 0
produce	O 0
Hex	O 0
A	O 0
(	O 0
alphabeta	O 0
)	O 0
in	O 0
COS	O 0
-	O 0
7	O 0
cells	O 0
,	O 0
the	O 0
mature	O 0
alpha	O 0
-	O 0
subunit	O 0
was	O 0
present	O 0
,	O 0
but	O 0
its	O 0
level	O 0
was	O 0
much	O 0
lower	O 0
than	O 0
that	O 0
from	O 0
normal	O 0
alpha	O 0
-	O 0
subunit	O 0
transfections	O 0
,	O 0
although	O 0
higher	O 0
than	O 0
in	O 0
those	O 0
cells	O 0
transfected	O 0
with	O 0
an	O 0
alpha	O 0
-	O 0
subunit	O 0
associated	O 0
with	O 0
infantile	O 0
TSD	B-Disease 0
.	O 0

Furthermore	O 0
,	O 0
the	O 0
precursor	O 0
level	O 0
of	O 0
the	O 0
W474C	O 0
alpha	O 0
-	O 0
subunit	O 0
was	O 0
found	O 0
to	O 0
accumulate	O 0
in	O 0
comparison	O 0
to	O 0
the	O 0
normal	O 0
alpha	O 0
-	O 0
subunit	O 0
precursor	O 0
levels	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
the	O 0
1422	O 0
G	O 0
-	O 0
-	O 0
>	O 0
C	O 0
mutation	O 0
is	O 0
the	O 0
cause	O 0
of	O 0
Hex	B-Disease 0
A	I-Disease 0
enzyme	I-Disease 0
deficiency	I-Disease 0
in	O 0
the	O 0
proband	O 0
.	O 0

The	O 0
resulting	O 0
W474C	O 0
substitution	O 0
clearly	O 0
interferes	O 0
with	O 0
alpha	O 0
-	O 0
subunit	O 0
processing	O 0
,	O 0
but	O 0
because	O 0
the	O 0
base	O 0
substitution	O 0
falls	O 0
at	O 0
the	O 0
first	O 0
position	O 0
of	O 0
exon	O 0
13	O 0
,	O 0
aberrant	O 0
splicing	O 0
may	O 0
also	O 0
contribute	O 0
to	O 0
Hex	B-Disease 0
A	I-Disease 0
deficiency	I-Disease 0
in	O 0
this	O 0
proband	O 0
.	O 0
.	O 0

Two	O 0
frequent	O 0
missense	O 0
mutations	O 0
in	O 0
Pendred	B-Disease 0
syndrome	I-Disease 0
.	O 0

Pendred	B-Disease 0
syndrome	I-Disease 0
is	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
disorder	I-Disease 0
characterized	O 0
by	O 0
early	O 0
childhood	O 0
deafness	B-Disease 0
and	O 0
goiter	B-Disease 0
.	O 0

A	O 0
century	O 0
after	O 0
its	O 0
recognition	O 0
as	O 0
a	O 0
syndrome	O 0
by	O 0
Vaughan	O 0
Pendred	O 0
,	O 0
the	O 0
disease	O 0
gene	O 0
(	O 0
PDS	O 0
)	O 0
was	O 0
mapped	O 0
to	O 0
chromosome	O 0
7q22	O 0
-	O 0
q31	O 0
.	O 0

1	O 0
and	O 0
,	O 0
recently	O 0
,	O 0
found	O 0
to	O 0
encode	O 0
a	O 0
putative	O 0
sulfate	O 0
transporter	O 0
.	O 0

We	O 0
performed	O 0
mutation	O 0
analysis	O 0
of	O 0
the	O 0
PDS	B-Disease 0
gene	O 0
in	O 0
patients	O 0
from	O 0
14	O 0
Pendred	B-Disease 0
families	O 0
originating	O 0
from	O 0
seven	O 0
countries	O 0
and	O 0
identified	O 0
all	O 0
mutations	O 0
.	O 0

The	O 0
mutations	O 0
include	O 0
three	O 0
single	O 0
base	O 0
deletions	O 0
,	O 0
one	O 0
splice	O 0
site	O 0
mutation	O 0
and	O 0
10	O 0
missense	O 0
mutations	O 0
.	O 0

One	O 0
missense	O 0
mutation	O 0
(	O 0
L236P	O 0
)	O 0
was	O 0
found	O 0
in	O 0
a	O 0
homozygous	O 0
state	O 0
in	O 0
two	O 0
consanguineous	O 0
families	O 0
and	O 0
in	O 0
a	O 0
heterozygous	O 0
state	O 0
in	O 0
five	O 0
additional	O 0
non	O 0
-	O 0
consanguineous	O 0
families	O 0
.	O 0

Another	O 0
missense	O 0
mutation	O 0
(	O 0
T416P	O 0
)	O 0
was	O 0
found	O 0
in	O 0
a	O 0
homozygous	O 0
state	O 0
in	O 0
one	O 0
family	O 0
and	O 0
in	O 0
a	O 0
heterozygous	O 0
state	O 0
in	O 0
four	O 0
families	O 0
.	O 0

Pendred	B-Disease 0
patients	O 0
in	O 0
three	O 0
non	O 0
-	O 0
consanguineous	O 0
families	O 0
were	O 0
shown	O 0
to	O 0
be	O 0
compound	O 0
heterozygotes	O 0
for	O 0
L236P	O 0
and	O 0
T416P	O 0
.	O 0

In	O 0
total	O 0
,	O 0
one	O 0
or	O 0
both	O 0
of	O 0
these	O 0
mutations	O 0
were	O 0
found	O 0
in	O 0
nine	O 0
of	O 0
the	O 0
14	O 0
families	O 0
analyzed	O 0
.	O 0

The	O 0
identification	O 0
of	O 0
two	O 0
frequent	O 0
PDS	B-Disease 0
mutations	O 0
will	O 0
facilitate	O 0
the	O 0
molecular	O 0
diagnosis	O 0
of	O 0
Pendred	B-Disease 0
syndrome	I-Disease 0
.	O 0

Insertional	O 0
mutation	O 0
by	O 0
transposable	O 0
element	O 0
,	O 0
L1	O 0
,	O 0
in	O 0
the	O 0
DMD	B-Disease 0
gene	O 0
results	O 0
in	O 0
X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
dilated	I-Disease 0
cardiomyopathy	I-Disease 0
.	O 0

X	B-Disease 0
-	I-Disease 0
linked	I-Disease 0
dilated	I-Disease 0
cardiomyopathy	I-Disease 0
(	O 0
XLDCM	B-Disease 0
)	O 0
is	O 0
a	O 0
clinical	O 0
phenotype	O 0
of	O 0
dystrophinopathy	B-Disease 0
which	O 0
is	O 0
characterized	O 0
by	O 0
preferential	O 0
myocardial	B-Disease 0
involvement	I-Disease 0
without	O 0
any	O 0
overt	O 0
clinical	O 0
signs	O 0
of	O 0
skeletal	B-Disease 0
myopathy	I-Disease 0
.	O 0

To	O 0
date	O 0
,	O 0
several	O 0
mutations	O 0
in	O 0
the	O 0
Duchenne	B-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
gene	O 0
,	O 0
DMD	O 0
,	O 0
have	O 0
been	O 0
identified	O 0
in	O 0
patients	O 0
with	O 0
XLDCM	B-Disease 0
,	O 0
but	O 0
a	O 0
pathogenic	O 0
correlation	O 0
of	O 0
these	O 0
cardiospecific	O 0
mutations	O 0
in	O 0
DMD	O 0
with	O 0
the	O 0
XLDCM	B-Disease 0
phenotype	O 0
has	O 0
remained	O 0
to	O 0
be	O 0
elucidated	O 0
.	O 0

We	O 0
report	O 0
here	O 0
the	O 0
identification	O 0
of	O 0
a	O 0
unique	O 0
de	O 0
novo	O 0
L1	O 0
insertion	O 0
in	O 0
the	O 0
muscle	O 0
exon	O 0
1	O 0
in	O 0
DMD	O 0
in	O 0
three	O 0
XLDCM	B-Disease 0
patients	O 0
from	O 0
two	O 0
unrelated	O 0
Japanese	O 0
families	O 0
.	O 0

The	O 0
insertion	O 0
was	O 0
a	O 0
5	O 0
-	O 0
truncated	O 0
form	O 0
of	O 0
human	O 0
L1	O 0
inversely	O 0
integrated	O 0
in	O 0
the	O 0
5	O 0
-	O 0
untranslated	O 0
region	O 0
in	O 0
the	O 0
muscle	O 0
exon	O 0
1	O 0
,	O 0
which	O 0
affected	O 0
the	O 0
transcription	O 0
or	O 0
the	O 0
stability	O 0
of	O 0
the	O 0
muscle	O 0
form	O 0
of	O 0
dystrophin	O 0
transcripts	O 0
but	O 0
not	O 0
that	O 0
of	O 0
the	O 0
brain	O 0
or	O 0
Purkinje	O 0
cell	O 0
form	O 0
,	O 0
probably	O 0
due	O 0
to	O 0
its	O 0
unique	O 0
site	O 0
of	O 0
integration	O 0
.	O 0

We	O 0
speculate	O 0
that	O 0
this	O 0
insertion	O 0
of	O 0
an	O 0
L1	O 0
sequence	O 0
in	O 0
DMD	O 0
is	O 0
responsible	O 0
for	O 0
some	O 0
of	O 0
the	O 0
population	O 0
of	O 0
Japanese	O 0
patients	O 0
with	O 0
XLDCM	B-Disease 0
.	O 0
.	O 0

Severe	O 0
early	O 0
-	O 0
onset	O 0
obesity	B-Disease 0
,	O 0
adrenal	B-Disease 0
insufficiency	I-Disease 0
and	O 0
red	O 0
hair	O 0
pigmentation	O 0
caused	O 0
by	O 0
POMC	O 0
mutations	O 0
in	O 0
humans	O 0
.	O 0

Sequential	O 0
cleavage	O 0
of	O 0
the	O 0
precursor	O 0
protein	O 0
pre	O 0
-	O 0
pro	O 0
-	O 0
opiomelanocortin	O 0
(	O 0
POMC	O 0
)	O 0
generates	O 0
the	O 0
melanocortin	O 0
peptides	O 0
adrenocorticotrophin	O 0
(	O 0
ACTH	O 0
)	O 0
,	O 0
melanocyte	O 0
-	O 0
stimulating	O 0
hormones	O 0
(	O 0
MSH	O 0
)	O 0
alpha	O 0
,	O 0
beta	O 0
and	O 0
gamma	O 0
as	O 0
well	O 0
as	O 0
the	O 0
opioid	O 0
-	O 0
receptor	O 0
ligand	O 0
beta	O 0
-	O 0
endorphin	O 0
.	O 0

While	O 0
a	O 0
few	O 0
cases	O 0
of	O 0
isolated	O 0
ACTH	B-Disease 0
deficiency	I-Disease 0
have	O 0
been	O 0
reported	O 0
(	O 0
OMIM	O 0
201400	O 0
)	O 0
,	O 0
an	O 0
inherited	O 0
POMC	O 0
defect	O 0
has	O 0
not	O 0
been	O 0
described	O 0
so	O 0
far	O 0
.	O 0

Recent	O 0
studies	O 0
in	O 0
animal	O 0
models	O 0
elucidated	O 0
a	O 0
central	O 0
role	O 0
of	O 0
alpha	O 0
-	O 0
MSH	O 0
in	O 0
the	O 0
regulation	O 0
of	O 0
food	O 0
intake	O 0
by	O 0
activation	O 0
of	O 0
the	O 0
brain	O 0
melanocortin	O 0
-	O 0
4	O 0
-	O 0
receptor	O 0
(	O 0
MC4	O 0
-	O 0
R	O 0
;	O 0
refs	O 0
3	O 0
-	O 0
5	O 0
)	O 0
and	O 0
the	O 0
linkage	O 0
of	O 0
human	O 0
obesity	B-Disease 0
to	O 0
chromosome	O 0
2	O 0
in	O 0
close	O 0
proximity	O 0
to	O 0
the	O 0
POMC	O 0
locus	O 0
,	O 0
led	O 0
to	O 0
the	O 0
proposal	O 0
of	O 0
an	O 0
association	O 0
of	O 0
POMC	O 0
with	O 0
human	O 0
obesity	B-Disease 0
.	O 0

The	O 0
dual	O 0
role	O 0
of	O 0
alpha	O 0
-	O 0
MSH	O 0
in	O 0
regulating	O 0
food	O 0
intake	O 0
and	O 0
influencing	O 0
hair	O 0
pigmentation	O 0
predicts	O 0
that	O 0
the	O 0
phenotype	O 0
associated	O 0
with	O 0
a	O 0
defect	O 0
in	O 0
POMC	O 0
function	O 0
would	O 0
include	O 0
obesity	B-Disease 0
,	O 0
alteration	O 0
in	O 0
pigmentation	O 0
and	O 0
ACTH	B-Disease 0
deficiency	I-Disease 0
.	O 0

The	O 0
observation	O 0
of	O 0
these	O 0
symptoms	O 0
in	O 0
two	O 0
probands	O 0
prompted	O 0
us	O 0
to	O 0
search	O 0
for	O 0
mutations	O 0
within	O 0
their	O 0
POMC	O 0
genes	O 0
.	O 0

Patient	O 0
1	O 0
was	O 0
found	O 0
to	O 0
be	O 0
a	O 0
compound	O 0
heterozygote	O 0
for	O 0
two	O 0
mutations	O 0
in	O 0
exon	O 0
3	O 0
(	O 0
G7013T	O 0
,	O 0
C7133delta	O 0
)	O 0
which	O 0
interfere	O 0
with	O 0
appropriate	O 0
synthesis	O 0
of	O 0
ACTH	O 0
and	O 0
alpha	O 0
-	O 0
MSH	O 0
.	O 0

Patient	O 0
2	O 0
was	O 0
homozygous	O 0
for	O 0
a	O 0
mutation	O 0
in	O 0
exon	O 0
2	O 0
(	O 0
C3804A	O 0
)	O 0
which	O 0
abolishes	O 0
POMC	O 0
translation	O 0
.	O 0

These	O 0
findings	O 0
represent	O 0
the	O 0
first	O 0
examples	O 0
of	O 0
a	O 0
genetic	B-Disease 0
defect	I-Disease 0
within	O 0
the	O 0
POMC	O 0
gene	O 0
and	O 0
define	O 0
a	O 0
new	O 0
monogenic	B-Disease 0
endocrine	I-Disease 0
disorder	I-Disease 0
resulting	O 0
in	O 0
early	O 0
-	O 0
onset	O 0
obesity	B-Disease 0
,	O 0
adrenal	B-Disease 0
insufficiency	I-Disease 0
and	O 0
red	O 0
hair	O 0
pigmentation	O 0
.	O 0
.	O 0

A	O 0
European	O 0
multicenter	O 0
study	O 0
of	O 0
phenylalanine	B-Disease 0
hydroxylase	I-Disease 0
deficiency	I-Disease 0
:	O 0
classification	O 0
of	O 0
105	O 0
mutations	O 0
and	O 0
a	O 0
general	O 0
system	O 0
for	O 0
genotype	O 0
-	O 0
based	O 0
prediction	O 0
of	O 0
metabolic	O 0
phenotype	O 0
.	O 0

Phenylketonuria	B-Disease 0
(	O 0
PKU	B-Disease 0
)	O 0
and	O 0
mild	B-Disease 0
hyperphenylalaninemia	I-Disease 0
(	O 0
MHP	B-Disease 0
)	O 0
are	O 0
allelic	B-Disease 0
disorders	I-Disease 0
caused	O 0
by	O 0
mutations	O 0
in	O 0
the	O 0
gene	O 0
encoding	O 0
phenylalanine	O 0
hydroxylase	O 0
(	O 0
PAH	O 0
)	O 0
.	O 0

Previous	O 0
studies	O 0
have	O 0
suggested	O 0
that	O 0
the	O 0
highly	O 0
variable	O 0
metabolic	O 0
phenotypes	O 0
of	O 0
PAH	B-Disease 0
deficiency	I-Disease 0
correlate	O 0
with	O 0
PAH	O 0
genotypes	O 0
.	O 0

We	O 0
identified	O 0
both	O 0
causative	O 0
mutations	O 0
in	O 0
686	O 0
patients	O 0
from	O 0
seven	O 0
European	O 0
centers	O 0
.	O 0

On	O 0
the	O 0
basis	O 0
of	O 0
the	O 0
phenotypic	O 0
characteristics	O 0
of	O 0
297	O 0
functionally	O 0
hemizygous	O 0
patients	O 0
,	O 0
105	O 0
of	O 0
the	O 0
mutations	O 0
were	O 0
assigned	O 0
to	O 0
one	O 0
of	O 0
four	O 0
arbitrary	O 0
phenotype	O 0
categories	O 0
.	O 0

We	O 0
proposed	O 0
and	O 0
tested	O 0
a	O 0
simple	O 0
model	O 0
for	O 0
correlation	O 0
between	O 0
genotype	O 0
and	O 0
phenotypic	O 0
outcome	O 0
.	O 0

The	O 0
observed	O 0
phenotype	O 0
matched	O 0
the	O 0
predicted	O 0
phenotype	O 0
in	O 0
79	O 0
%	O 0
of	O 0
the	O 0
cases	O 0
,	O 0
and	O 0
in	O 0
only	O 0
5	O 0
of	O 0
184	O 0
patients	O 0
was	O 0
the	O 0
observed	O 0
phenotype	O 0
more	O 0
than	O 0
one	O 0
category	O 0
away	O 0
from	O 0
that	O 0
expected	O 0
.	O 0

Among	O 0
the	O 0
seven	O 0
contributing	O 0
centers	O 0
,	O 0
the	O 0
proportion	O 0
of	O 0
patients	O 0
for	O 0
whom	O 0
the	O 0
observed	O 0
phenotype	O 0
did	O 0
not	O 0
match	O 0
the	O 0
predicted	O 0
phenotype	O 0
was	O 0
4	O 0
%	O 0
-	O 0
23	O 0
%	O 0
(	O 0
P	O 0
<	O 0
.	O 0
0001	O 0
)	O 0
,	O 0
suggesting	O 0
that	O 0
differences	O 0
in	O 0
methods	O 0
used	O 0
for	O 0
mutation	O 0
detection	O 0
or	O 0
phenotype	O 0
classification	O 0
may	O 0
account	O 0
for	O 0
a	O 0
considerable	O 0
proportion	O 0
of	O 0
genotype	O 0
-	O 0
phenotype	O 0
inconsistencies	O 0
.	O 0

Our	O 0
data	O 0
indicate	O 0
that	O 0
the	O 0
PAH	O 0
-	O 0
mutation	O 0
genotype	O 0
is	O 0
the	O 0
main	O 0
determinant	O 0
of	O 0
metabolic	O 0
phenotype	O 0
in	O 0
most	O 0
patients	O 0
with	O 0
PAH	B-Disease 0
deficiency	I-Disease 0
.	O 0

In	O 0
the	O 0
present	O 0
study	O 0
,	O 0
the	O 0
classification	O 0
of	O 0
105	O 0
PAH	O 0
mutations	O 0
may	O 0
allow	O 0
the	O 0
prediction	O 0
of	O 0
the	O 0
biochemical	O 0
phenotype	O 0
in	O 0
>	O 0
10	O 0
,	O 0
000	O 0
genotypes	O 0
,	O 0
which	O 0
may	O 0
be	O 0
useful	O 0
for	O 0
the	O 0
management	O 0
of	O 0
hyperphenylalaninemia	B-Disease 0
in	O 0
newborns	O 0
.	O 0

Somatic	O 0
instability	O 0
of	O 0
the	O 0
CTG	O 0
repeat	O 0
in	O 0
mice	O 0
transgenic	O 0
for	O 0
the	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
region	O 0
is	O 0
age	O 0
dependent	O 0
but	O 0
not	O 0
correlated	O 0
to	O 0
the	O 0
relative	O 0
intertissue	O 0
transcription	O 0
levels	O 0
and	O 0
proliferative	O 0
capacities	O 0
.	O 0

A	O 0
(	O 0
CTG	O 0
)	O 0
nexpansion	O 0
in	O 0
the	O 0
3	O 0
-	O 0
untranslated	O 0
region	O 0
(	O 0
UTR	O 0
)	O 0
of	O 0
the	O 0
DM	O 0
protein	O 0
kinase	O 0
gene	O 0
(	O 0
DMPK	O 0
)	O 0
is	O 0
responsible	O 0
for	O 0
causing	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
.	O 0

Major	O 0
instability	O 0
,	O 0
with	O 0
very	O 0
large	O 0
expansions	O 0
between	O 0
generations	O 0
and	O 0
high	O 0
levels	O 0
of	O 0
somatic	O 0
mosaicism	O 0
,	O 0
is	O 0
observed	O 0
in	O 0
patients	O 0
.	O 0

There	O 0
is	O 0
a	O 0
good	O 0
correlation	O 0
between	O 0
repeat	O 0
size	O 0
(	O 0
at	O 0
least	O 0
in	O 0
leucocytes	O 0
)	O 0
,	O 0
clinical	O 0
severity	O 0
and	O 0
age	O 0
of	O 0
onset	O 0
.	O 0

The	O 0
trinucleotide	O 0
repeat	O 0
instability	O 0
mechanisms	O 0
involved	O 0
in	O 0
DM	B-Disease 0
and	O 0
other	O 0
human	O 0
genetic	B-Disease 0
diseases	I-Disease 0
are	O 0
unknown	O 0
.	O 0

We	O 0
studied	O 0
somatic	O 0
instability	O 0
by	O 0
measuring	O 0
the	O 0
CTG	O 0
repeat	O 0
length	O 0
at	O 0
several	O 0
ages	O 0
in	O 0
various	O 0
tissues	O 0
of	O 0
transgenic	O 0
mice	O 0
carrying	O 0
a	O 0
(	O 0
CTG	O 0
)	O 0
55expansion	O 0
surrounded	O 0
by	O 0
45	O 0
kb	O 0
of	O 0
the	O 0
human	O 0
DM	B-Disease 0
region	O 0
,	O 0
using	O 0
small	O 0
-	O 0
pool	O 0
PCR	O 0
.	O 0

These	O 0
mice	O 0
have	O 0
been	O 0
shown	O 0
to	O 0
reproduce	O 0
the	O 0
intergenerational	O 0
and	O 0
somatic	O 0
instability	O 0
of	O 0
the	O 0
55	O 0
CTG	O 0
repeat	O 0
suggesting	O 0
that	O 0
surrounding	O 0
sequences	O 0
and	O 0
the	O 0
chromatin	O 0
environment	O 0
are	O 0
involved	O 0
in	O 0
instability	O 0
mechanisms	O 0
.	O 0

As	O 0
observed	O 0
in	O 0
some	O 0
of	O 0
the	O 0
tissues	O 0
of	O 0
DM	B-Disease 0
patients	O 0
,	O 0
there	O 0
is	O 0
a	O 0
tendency	O 0
for	O 0
repeat	O 0
length	O 0
and	O 0
somatic	O 0
mosaicism	O 0
to	O 0
increase	O 0
with	O 0
the	O 0
age	O 0
of	O 0
the	O 0
mouse	O 0
.	O 0

Furthermore	O 0
,	O 0
we	O 0
observed	O 0
no	O 0
correlation	O 0
between	O 0
the	O 0
somatic	O 0
mutation	O 0
rate	O 0
and	O 0
tissue	O 0
proliferation	O 0
capacity	O 0
.	O 0

The	O 0
somatic	O 0
mutation	O 0
rates	O 0
in	O 0
different	O 0
tissues	O 0
were	O 0
also	O 0
not	O 0
correlated	O 0
to	O 0
the	O 0
relative	O 0
inter	O 0
-	O 0
tissue	O 0
difference	O 0
in	O 0
transcriptional	O 0
levels	O 0
of	O 0
the	O 0
three	O 0
genes	O 0
(	O 0
DMAHP	O 0
,	O 0
DMPK	O 0
and	O 0
59	O 0
)	O 0
surrounding	O 0
the	O 0
repeat	O 0
.	O 0
.	O 0

A	O 0
novel	O 0
missense	O 0
mutation	O 0
in	O 0
patients	O 0
from	O 0
a	O 0
retinoblastoma	B-Disease 0
pedigree	O 0
showing	O 0
only	O 0
mild	O 0
expression	O 0
of	O 0
the	O 0
tumor	B-Disease 0
phenotype	O 0
.	O 0

We	O 0
have	O 0
used	O 0
single	O 0
strand	O 0
conformation	O 0
polymorphism	O 0
analysis	O 0
to	O 0
study	O 0
the	O 0
27	O 0
exons	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
in	O 0
individuals	O 0
from	O 0
a	O 0
family	O 0
showing	O 0
mild	O 0
expression	O 0
of	O 0
the	O 0
retinoblastoma	B-Disease 0
phenotype	O 0
.	O 0

In	O 0
this	O 0
family	O 0
affected	O 0
individuals	O 0
developed	O 0
unilateral	B-Disease 0
tumors	I-Disease 0
and	O 0
,	O 0
as	O 0
a	O 0
result	O 0
of	O 0
linkage	O 0
analysis	O 0
,	O 0
unaffected	O 0
mutation	O 0
carriers	O 0
were	O 0
also	O 0
identified	O 0
within	O 0
the	O 0
pedigree	O 0
.	O 0

A	O 0
single	O 0
band	O 0
shift	O 0
using	O 0
SSCP	O 0
was	O 0
identified	O 0
in	O 0
exon	O 0
21	O 0
which	O 0
resulted	O 0
in	O 0
a	O 0
missense	O 0
mutation	O 0
converting	O 0
a	O 0
cys	O 0
-	O 0
-	O 0
>	O 0
arg	O 0
at	O 0
nucleotide	O 0
position	O 0
28	O 0
in	O 0
the	O 0
exon	O 0
.	O 0

The	O 0
mutation	O 0
destroyed	O 0
an	O 0
NdeI	O 0
restriction	O 0
enzyme	O 0
site	O 0
.	O 0

Analysis	O 0
of	O 0
all	O 0
family	O 0
members	O 0
demonstrated	O 0
that	O 0
the	O 0
missense	O 0
mutation	O 0
co	O 0
-	O 0
segregated	O 0
with	O 0
patients	O 0
with	O 0
tumors	B-Disease 0
or	O 0
who	O 0
,	O 0
as	O 0
a	O 0
result	O 0
of	O 0
linkage	O 0
analysis	O 0
had	O 0
been	O 0
predicted	O 0
to	O 0
carry	O 0
the	O 0
predisposing	O 0
mutation	O 0
.	O 0

These	O 0
observations	O 0
point	O 0
to	O 0
another	O 0
region	O 0
of	O 0
the	O 0
RB1	O 0
gene	O 0
where	O 0
mutations	O 0
only	O 0
modify	O 0
the	O 0
function	O 0
of	O 0
the	O 0
gene	O 0
and	O 0
raise	O 0
important	O 0
questions	O 0
for	O 0
genetic	O 0
counseling	O 0
in	O 0
families	O 0
with	O 0
these	O 0
distinctive	O 0
phenotypes	O 0
.	O 0
.	O 0

Maternal	B-Disease 0
disomy	I-Disease 0
and	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
consistent	O 0
with	O 0
gamete	O 0
complementation	O 0
in	O 0
a	O 0
case	O 0
of	O 0
familial	O 0
translocation	O 0
(	O 0
3	O 0
;	O 0
15	O 0
)	O 0
(	O 0
p25	O 0
;	O 0
q11	O 0
.	O 0
2	O 0
)	O 0
.	O 0

Maternal	B-Disease 0
uniparental	I-Disease 0
disomy	I-Disease 0
(	I-Disease 0
UPD	I-Disease 0
)	I-Disease 0
for	I-Disease 0
chromosome	I-Disease 0
15	I-Disease 0
is	O 0
responsible	O 0
for	O 0
an	O 0
estimated	O 0
30	O 0
%	O 0
of	O 0
cases	O 0
of	O 0
Prader	B-Disease 0
-	I-Disease 0
Willi	I-Disease 0
syndrome	I-Disease 0
(	O 0
PWS	B-Disease 0
)	O 0
.	O 0

We	O 0
report	O 0
on	O 0
an	O 0
unusual	O 0
case	O 0
of	O 0
maternal	B-Disease 0
disomy	I-Disease 0
15	I-Disease 0
in	O 0
PWS	B-Disease 0
that	O 0
is	O 0
most	O 0
consistent	O 0
with	O 0
adjacent	O 0
-	O 0
1	O 0
segregation	O 0
of	O 0
a	O 0
paternal	O 0
t	O 0
(	O 0
3	O 0
;	O 0
15	O 0
)	O 0
(	O 0
p25	O 0
;	O 0
q11	O 0
.	O 0
2	O 0
)	O 0
with	O 0
simultaneous	O 0
maternal	O 0
meiotic	O 0
nondisjunction	O 0
for	O 0
chromosome	O 0
15	O 0
.	O 0

The	O 0
patient	O 0
(	O 0
J	O 0
.	O 0
B	O 0
.	O 0
)	O 0
,	O 0
a	O 0
17	O 0
-	O 0
year	O 0
-	O 0
old	O 0
white	O 0
male	O 0
with	O 0
PWS	B-Disease 0
,	O 0
was	O 0
found	O 0
to	O 0
have	O 0
47	O 0
chromosomes	O 0
with	O 0
a	O 0
supernumerary	O 0
,	O 0
paternal	O 0
der	O 0
(	O 0
15	O 0
)	O 0
consisting	O 0
of	O 0
the	O 0
short	O 0
arm	O 0
and	O 0
the	O 0
proximal	O 0
long	O 0
arm	O 0
of	O 0
chromosome	O 0
15	O 0
,	O 0
and	O 0
distal	O 0
chromosome	O 0
arm	O 0
3p	O 0
.	O 0

The	O 0
t	O 0
(	O 0
3	O 0
;	O 0
15	O 0
)	O 0
was	O 0
present	O 0
in	O 0
the	O 0
balanced	O 0
state	O 0
in	O 0
the	O 0
patients	O 0
father	O 0
and	O 0
a	O 0
sister	O 0
.	O 0

Fluorescent	O 0
in	O 0
situ	O 0
hybridization	O 0
analysis	O 0
demonstrated	O 0
that	O 0
the	O 0
PWS	B-Disease 0
critical	O 0
region	O 0
resided	O 0
on	O 0
the	O 0
derivative	O 0
chromosome	O 0
3	O 0
and	O 0
that	O 0
there	O 0
was	O 0
no	O 0
deletion	O 0
of	O 0
the	O 0
PWS	B-Disease 0
region	O 0
on	O 0
the	O 0
normal	O 0
pair	O 0
of	O 0
15s	O 0
present	O 0
in	O 0
J	O 0
.	O 0

B	O 0
.	O 0

Methylation	O 0
analysis	O 0
at	O 0
exon	O 0
alpha	O 0
of	O 0
the	O 0
small	O 0
nuclear	O 0
ribonucleoprotein	O 0
-	O 0
associated	O 0
polypeptide	O 0
N	O 0
(	O 0
SNRPN	O 0
)	O 0
gene	O 0
showed	O 0
a	O 0
pattern	O 0
characteristic	O 0
of	O 0
only	O 0
the	O 0
maternal	O 0
chromosome	O 0
15	O 0
in	O 0
J	O 0
.	O 0

B	O 0
.	O 0

Maternal	B-Disease 0
disomy	I-Disease 0
was	O 0
confirmed	O 0
by	O 0
polymerase	O 0
chain	O 0
reaction	O 0
analysis	O 0
of	O 0
microsatellite	O 0
repeats	O 0
at	O 0
the	O 0
gamma	O 0
-	O 0
aminobutyric	O 0
acid	O 0
receptor	O 0
beta3	O 0
subunit	O 0
(	O 0
GABRB3	O 0
)	O 0
locus	O 0
.	O 0

A	O 0
niece	O 0
(	O 0
B	O 0
.	O 0
B	O 0
.	O 0
)	O 0
with	O 0
45	O 0
chromosomes	O 0
and	O 0
the	O 0
derivative	O 0
3	O 0
but	O 0
without	O 0
the	O 0
der	O 0
(	O 0
15	O 0
)	O 0
demonstrated	O 0
a	O 0
phenotype	O 0
consistent	O 0
with	O 0
that	O 0
reported	O 0
for	O 0
haploinsufficiency	O 0
of	O 0
distal	O 0
3	O 0
p	O 0
.	O 0

Uniparental	B-Disease 0
disomy	I-Disease 0
associated	O 0
with	O 0
unbalanced	O 0
segregation	O 0
of	O 0
non	O 0
-	O 0
Robertsonian	O 0
translocations	O 0
has	O 0
been	O 0
reported	O 0
previously	O 0
but	O 0
has	O 0
not	O 0
,	O 0
to	O 0
our	O 0
knowledge	O 0
,	O 0
been	O 0
observed	O 0
in	O 0
a	O 0
case	O 0
of	O 0
PWS	B-Disease 0
.	O 0

Furthermore	O 0
,	O 0
our	O 0
findings	O 0
are	O 0
best	O 0
interpreted	O 0
as	O 0
true	O 0
gamete	O 0
complementation	O 0
resulting	O 0
in	O 0
maternal	B-Disease 0
UPD	I-Disease 0
15	I-Disease 0
and	O 0
PWS	B-Disease 0

Schwartz	B-Disease 0
-	I-Disease 0
Jampel	I-Disease 0
syndrome	I-Disease 0
type	I-Disease 0
2	I-Disease 0
and	O 0
Stuve	B-Disease 0
-	I-Disease 0
Wiedemann	I-Disease 0
syndrome	I-Disease 0
:	O 0
a	O 0
case	O 0
for	O 0
"	O 0
lumping	O 0
"	O 0
.	O 0

Recent	O 0
studies	O 0
demonstrated	O 0
the	O 0
existence	O 0
of	O 0
a	O 0
genetically	O 0
distinct	O 0
,	O 0
usually	O 0
lethal	O 0
form	O 0
of	O 0
the	O 0
Schwartz	B-Disease 0
-	I-Disease 0
Jampel	I-Disease 0
syndrome	I-Disease 0
(	O 0
SJS	B-Disease 0
)	O 0
of	O 0
myotonia	B-Disease 0
and	O 0
skeletal	B-Disease 0
dysplasia	I-Disease 0
,	O 0
which	O 0
we	O 0
called	O 0
SJS	B-Disease 0
type	I-Disease 0
2	I-Disease 0
.	O 0

This	O 0
disorder	O 0
is	O 0
reminiscent	O 0
of	O 0
another	O 0
rare	O 0
condition	O 0
,	O 0
the	O 0
Stuve	B-Disease 0
-	I-Disease 0
Wiedemann	I-Disease 0
syndrome	I-Disease 0
(	O 0
SWS	B-Disease 0
)	O 0
,	O 0
which	O 0
comprises	O 0
campomelia	B-Disease 0
at	O 0
birth	O 0
with	O 0
skeletal	B-Disease 0
dysplasia	I-Disease 0
,	O 0
contractures	B-Disease 0
,	O 0
and	O 0
early	B-Disease 0
death	I-Disease 0
.	O 0

To	O 0
test	O 0
for	O 0
possible	O 0
nosologic	O 0
identity	O 0
between	O 0
these	O 0
disorders	O 0
,	O 0
we	O 0
reviewed	O 0
the	O 0
literature	O 0
and	O 0
obtained	O 0
a	O 0
follow	O 0
-	O 0
up	O 0
of	O 0
the	O 0
only	O 0
two	O 0
surviving	O 0
patients	O 0
,	O 0
one	O 0
with	O 0
SJS	B-Disease 0
type	I-Disease 0
2	I-Disease 0
at	O 0
age	O 0
10	O 0
years	O 0
and	O 0
another	O 0
with	O 0
SWS	B-Disease 0
at	O 0
age	O 0
7	O 0
years	O 0
.	O 0

Patients	O 0
reported	O 0
as	O 0
having	O 0
either	O 0
neonatal	O 0
SJS	B-Disease 0
or	O 0
SWS	B-Disease 0
presented	O 0
a	O 0
combination	O 0
of	O 0
a	O 0
severe	O 0
,	O 0
prenatal	O 0
-	O 0
onset	O 0
neuromuscular	B-Disease 0
disorder	I-Disease 0
(	O 0
with	O 0
congenital	B-Disease 0
joint	I-Disease 0
contractures	I-Disease 0
,	O 0
respiratory	O 0
and	O 0
feeding	O 0
difficulties	O 0
,	O 0
tendency	O 0
to	O 0
hyperthermia	B-Disease 0
,	O 0
and	O 0
frequent	O 0
death	O 0
in	O 0
infancy	O 0
)	O 0
with	O 0
a	O 0
distinct	O 0
campomelic	B-Disease 0
-	I-Disease 0
metaphyseal	I-Disease 0
skeletal	I-Disease 0
dysplasia	I-Disease 0
.	O 0

The	O 0
similarity	O 0
of	O 0
the	O 0
clinical	O 0
and	O 0
radiographic	O 0
findings	O 0
is	O 0
so	O 0
extensive	O 0
that	O 0
these	O 0
disorders	O 0
appear	O 0
to	O 0
be	O 0
a	O 0
single	O 0
entity	O 0
.	O 0

The	O 0
follow	O 0
-	O 0
up	O 0
observation	O 0
of	O 0
an	O 0
identical	O 0
and	O 0
unique	O 0
pattern	O 0
of	O 0
progressive	O 0
bone	B-Disease 0
dysplasia	I-Disease 0
in	O 0
the	O 0
two	O 0
patients	O 0
(	O 0
one	O 0
with	O 0
SJS	B-Disease 0
type	I-Disease 0
2	I-Disease 0
,	O 0
one	O 0
with	O 0
SWS	B-Disease 0
)	O 0
surviving	O 0
beyond	O 0
infancy	O 0
adds	O 0
to	O 0
the	O 0
evidence	O 0
in	O 0
favor	O 0
of	O 0
identity	O 0
.	O 0

The	O 0
hypothesis	O 0
that	O 0
SWS	B-Disease 0
and	O 0
SJS	B-Disease 0
type	I-Disease 0
2	I-Disease 0
are	O 0
the	O 0
same	O 0
disorder	O 0
should	O 0
be	O 0
testable	O 0
by	O 0
molecular	O 0
methods	O 0
.	O 0
.	O 0

A	O 0
mouse	O 0
model	O 0
of	O 0
severe	O 0
von	B-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
:	O 0
defects	O 0
in	O 0
hemostasis	O 0
and	O 0
thrombosis	B-Disease 0
.	O 0

von	B-Disease 0
Willebrand	I-Disease 0
factor	I-Disease 0
(	I-Disease 0
vWf	I-Disease 0
)	I-Disease 0
deficiency	I-Disease 0
causes	O 0
severe	O 0
von	B-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
in	O 0
humans	O 0
.	O 0

We	O 0
generated	O 0
a	O 0
mouse	O 0
model	O 0
for	O 0
this	O 0
disease	O 0
by	O 0
using	O 0
gene	O 0
targeting	O 0
.	O 0

vWf	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
mice	O 0
appeared	O 0
normal	O 0
at	O 0
birth	O 0
;	O 0
they	O 0
were	O 0
viable	O 0
and	O 0
fertile	O 0
.	O 0

Neither	O 0
vWf	O 0
nor	O 0
vWf	O 0
propolypeptide	O 0
(	O 0
von	B-Disease 0
Willebrand	I-Disease 0
antigen	O 0
II	O 0
)	O 0
were	O 0
detectable	O 0
in	O 0
plasma	O 0
,	O 0
platelets	O 0
,	O 0
or	O 0
endothelial	O 0
cells	O 0
of	O 0
the	O 0
homozygous	O 0
mutant	O 0
mice	O 0
.	O 0

The	O 0
mutant	O 0
mice	O 0
exhibited	O 0
defects	O 0
in	O 0
hemostasis	O 0
with	O 0
a	O 0
highly	O 0
prolonged	O 0
bleeding	O 0
time	O 0
and	O 0
spontaneous	O 0
bleeding	O 0
events	O 0
in	O 0
approximately	O 0
10	O 0
%	O 0
of	O 0
neonates	O 0
.	O 0

As	O 0
in	O 0
the	O 0
human	O 0
disease	O 0
,	O 0
the	O 0
factor	O 0
VIII	O 0
level	O 0
in	O 0
these	O 0
mice	O 0
was	O 0
reduced	O 0
strongly	O 0
as	O 0
a	O 0
result	O 0
of	O 0
the	O 0
lack	O 0
of	O 0
protection	O 0
provided	O 0
by	O 0
vWf	O 0
.	O 0

Defective	O 0
thrombosis	B-Disease 0
in	O 0
mutant	O 0
mice	O 0
was	O 0
also	O 0
evident	O 0
in	O 0
an	O 0
in	O 0
vivo	O 0
model	O 0
of	O 0
vascular	B-Disease 0
injury	I-Disease 0
.	O 0

In	O 0
this	O 0
model	O 0
,	O 0
the	O 0
exteriorized	O 0
mesentery	O 0
was	O 0
superfused	O 0
with	O 0
ferric	O 0
chloride	O 0
and	O 0
the	O 0
accumulation	O 0
of	O 0
fluorescently	O 0
labeled	O 0
platelets	O 0
was	O 0
observed	O 0
by	O 0
intravital	O 0
microscopy	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
these	O 0
mice	O 0
very	O 0
closely	O 0
mimic	O 0
severe	O 0
human	O 0
von	B-Disease 0
Willebrand	I-Disease 0
disease	I-Disease 0
and	O 0
will	O 0
be	O 0
very	O 0
useful	O 0
for	O 0
investigating	O 0
the	O 0
role	O 0
of	O 0
vWf	O 0
in	O 0
normal	O 0
physiology	O 0
and	O 0
in	O 0
disease	O 0
models	O 0
.	O 0
.	O 0

Oral	O 0
contraceptives	O 0
and	O 0
the	O 0
risk	O 0
of	O 0
hereditary	B-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

Hereditary	B-Disease 0
Ovarian	I-Disease 0
Cancer	I-Disease 0
Clinical	O 0
Study	O 0
Group	O 0
.	O 0

BACKGROUND	O 0
Women	O 0
with	O 0
mutations	O 0
in	O 0
either	O 0
the	O 0
BRCA1	O 0
or	O 0
the	O 0
BRCA2	O 0
gene	O 0
have	O 0
a	O 0
high	O 0
lifetime	O 0
risk	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
.	O 0

Oral	O 0
contraceptives	O 0
protect	O 0
against	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
in	O 0
general	O 0
,	O 0
but	O 0
it	O 0
is	O 0
not	O 0
known	O 0
whether	O 0
they	O 0
also	O 0
protect	O 0
against	O 0
hereditary	B-Disease 0
forms	I-Disease 0
of	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0

METHODS	O 0
We	O 0
enrolled	O 0
207	O 0
women	O 0
with	O 0
hereditary	B-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
and	O 0
161	O 0
of	O 0
their	O 0
sisters	O 0
as	O 0
controls	O 0
in	O 0
a	O 0
case	O 0
-	O 0
control	O 0
study	O 0
.	O 0

All	O 0
the	O 0
patients	O 0
carried	O 0
a	O 0
pathogenic	O 0
mutation	O 0
in	O 0
either	O 0
BRCA1	O 0
(	O 0
179	O 0
women	O 0
)	O 0
or	O 0
BRCA2	O 0
(	O 0
28	O 0
women	O 0
)	O 0
.	O 0

The	O 0
control	O 0
women	O 0
were	O 0
enrolled	O 0
regardless	O 0
of	O 0
whether	O 0
or	O 0
not	O 0
they	O 0
had	O 0
either	O 0
mutation	O 0
.	O 0

Lifetime	O 0
histories	O 0
of	O 0
oral	O 0
-	O 0
contraceptive	O 0
use	O 0
were	O 0
obtained	O 0
by	O 0
interview	O 0
or	O 0
by	O 0
written	O 0
questionnaire	O 0
and	O 0
were	O 0
compared	O 0
between	O 0
patients	O 0
and	O 0
control	O 0
women	O 0
,	O 0
after	O 0
adjustment	O 0
for	O 0
year	O 0
of	O 0
birth	O 0
and	O 0
parity	O 0
.	O 0

RESULTS	O 0
The	O 0
adjusted	O 0
odds	O 0
ratio	O 0
for	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
associated	O 0
with	O 0
any	O 0
past	O 0
use	O 0
of	O 0
oral	O 0
contraceptives	O 0
was	O 0
0	O 0
.	O 0

5	O 0
(	O 0
95	O 0
percent	O 0
confidence	O 0
interval	O 0
,	O 0
0	O 0
.	O 0
3	O 0
to	O 0
0	O 0
.	O 0
8	O 0
)	O 0
.	O 0

The	O 0
risk	O 0
decreased	O 0
with	O 0
increasing	O 0
duration	O 0
of	O 0
use	O 0
(	O 0
P	O 0
for	O 0
trend	O 0
,	O 0
<	O 0
0	O 0
.	O 0
001	O 0
)	O 0
;	O 0
use	O 0
for	O 0
six	O 0
or	O 0
more	O 0
years	O 0
was	O 0
associated	O 0
with	O 0
a	O 0
60	O 0
percent	O 0
reduction	O 0
in	O 0
risk	O 0
.	O 0

Oral	O 0
-	O 0
contraceptive	O 0
use	O 0
protected	O 0
against	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
both	O 0
for	O 0
carriers	O 0
of	O 0
the	O 0
BRCA1	O 0
mutation	O 0
(	O 0
odds	O 0
ratio	O 0
,	O 0
0	O 0
.	O 0
5	O 0
;	O 0
95	O 0
percent	O 0
confidence	O 0
interval	O 0
,	O 0
0	O 0
.	O 0
3	O 0
to	O 0
0	O 0
.	O 0
9	O 0
)	O 0
and	O 0
for	O 0
carriers	O 0
of	O 0
the	O 0
BRCA2	O 0
mutation	O 0
(	O 0
odds	O 0
ratio	O 0
,	O 0
0	O 0
.	O 0
4	O 0
;	O 0
95	O 0
percent	O 0
confidence	O 0
interval	O 0
,	O 0
0	O 0
.	O 0
2	O 0
to	O 0
1	O 0
.	O 0
1	O 0
)	O 0
.	O 0

CONCLUSIONS	O 0
Oral	O 0
-	O 0
contraceptive	O 0
use	O 0
may	O 0
reduce	O 0
the	O 0
risk	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
in	O 0
women	O 0
with	O 0
pathogenic	O 0
mutations	O 0
in	O 0
the	O 0
BRCA1	O 0
or	O 0
BRCA2	O 0
gene	O 0

A	O 0
Japanese	O 0
family	O 0
with	O 0
adrenoleukodystrophy	B-Disease 0
with	O 0
a	O 0
codon	O 0
291	O 0
deletion	O 0
:	O 0
a	O 0
clinical	O 0
,	O 0
biochemical	O 0
,	O 0
pathological	O 0
,	O 0
and	O 0
genetic	O 0
report	O 0
.	O 0

We	O 0
report	O 0
a	O 0
Japanese	O 0
family	O 0
with	O 0
adrenoleukodystrophy	B-Disease 0
(	O 0
ALD	B-Disease 0
)	O 0
with	O 0
a	O 0
three	O 0
base	O 0
pair	O 0
deletion	O 0
(	O 0
delGAG	O 0
291	O 0
)	O 0
in	O 0
the	O 0
ALD	B-Disease 0
gene	O 0
.	O 0

A	O 0
variety	O 0
of	O 0
phenotypes	O 0
were	O 0
observed	O 0
within	O 0
this	O 0
family	O 0
.	O 0

While	O 0
the	O 0
proband	O 0
(	O 0
patient	O 0
1	O 0
)	O 0
was	O 0
classified	O 0
as	O 0
having	O 0
a	O 0
rare	O 0
intermediate	O 0
type	O 0
of	O 0
adult	O 0
cerebral	O 0
and	O 0
cerebello	O 0
-	O 0
brain	O 0
stem	O 0
forms	O 0
,	O 0
his	O 0
younger	O 0
brother	O 0
(	O 0
patient	O 0
2	O 0
)	O 0
and	O 0
nephew	O 0
(	O 0
patient	O 0
3	O 0
)	O 0
had	O 0
a	O 0
childhood	O 0
ALD	B-Disease 0
type	O 0
.	O 0

Another	O 0
nephew	O 0
(	O 0
patient	O 0
4	O 0
)	O 0
of	O 0
patient	O 0
1	O 0
was	O 0
classified	O 0
as	O 0
having	O 0
an	O 0
adolescent	O 0
form	O 0
.	O 0

The	O 0
tau	O 0
level	O 0
in	O 0
the	O 0
cerebrospinal	O 0
fluid	O 0
(	O 0
CSF	O 0
)	O 0
in	O 0
patient	O 0
1	O 0
was	O 0
as	O 0
high	O 0
as	O 0
that	O 0
of	O 0
patients	O 0
with	O 0
Alzheimers	B-Disease 0
disease	I-Disease 0
(	O 0
AD	B-Disease 0
)	O 0
.	O 0

His	O 0
brain	O 0
magnetic	O 0
resonance	O 0
image	O 0
(	O 0
MRI	O 0
)	O 0
showed	O 0
abnormalities	B-Disease 0
in	I-Disease 0
the	I-Disease 0
bilateral	I-Disease 0
cerebellar	I-Disease 0
hemispheres	I-Disease 0
and	O 0
brain	O 0
stem	O 0
,	O 0
but	O 0
not	O 0
in	O 0
the	O 0
cerebral	O 0
white	O 0
matter	O 0
,	O 0
where	O 0
marked	O 0
reductions	O 0
of	O 0
the	O 0
cerebral	O 0
blood	O 0
flow	O 0
and	O 0
oxygen	O 0
metabolism	O 0
were	O 0
clearly	O 0
demonstrated	O 0
by	O 0
positron	O 0
emission	O 0
tomography	O 0
(	O 0
PET	O 0
)	O 0
.	O 0

In	O 0
patients	O 0
2	O 0
and	O 0
3	O 0
,	O 0
the	O 0
autopsy	O 0
findings	O 0
showed	O 0
massive	O 0
demyelination	B-Disease 0
of	I-Disease 0
the	I-Disease 0
cerebral	I-Disease 0
white	I-Disease 0
matter	I-Disease 0
with	O 0
sparing	O 0
of	O 0
the	O 0
U	O 0
-	O 0
fibers	O 0
,	O 0
compatible	O 0
with	O 0
the	O 0
findings	O 0
of	O 0
childhood	O 0
ALD	B-Disease 0
.	O 0

Oleic	O 0
and	O 0
erucic	O 0
acids	O 0
(	O 0
Lorenzos	O 0
Oil	O 0
)	O 0
were	O 0
administered	O 0
to	O 0
patients	O 0
1	O 0
and	O 0
4	O 0
,	O 0
but	O 0
sufficient	O 0
effectiveness	O 0
was	O 0
not	O 0
obtained	O 0
.	O 0

The	O 0
findings	O 0
in	O 0
this	O 0
family	O 0
suggest	O 0
that	O 0
delGAG291	O 0
is	O 0
part	O 0
of	O 0
the	O 0
cause	O 0
of	O 0
Japanese	O 0
ALD	B-Disease 0
with	O 0
phenotypic	O 0
variations	O 0
.	O 0

Moreover	O 0
,	O 0
although	O 0
the	O 0
scale	O 0
of	O 0
the	O 0
study	O 0
is	O 0
limited	O 0
,	O 0
there	O 0
is	O 0
a	O 0
possibility	O 0
that	O 0
PET	O 0
can	O 0
detect	O 0
an	O 0
insidious	B-Disease 0
lesion	I-Disease 0
which	O 0
is	O 0
undetectable	O 0
by	O 0
computed	O 0
tomogram	O 0
(	O 0
CT	O 0
)	O 0
or	O 0
MRI	O 0
analysis	O 0
,	O 0
and	O 0
that	O 0
the	O 0
higher	O 0
level	O 0
of	O 0
tau	O 0
reflects	O 0
the	O 0
process	O 0
of	O 0
neuronal	B-Disease 0
degeneration	I-Disease 0
in	O 0
ALD	B-Disease 0
.	O 0

Lorenzos	O 0
Oil	O 0
should	O 0
be	O 0
given	O 0
in	O 0
the	O 0
early	O 0
stage	O 0
.	O 0
.	O 0

Nonsense	O 0
mutation	O 0
in	O 0
exon	O 0
4	O 0
of	O 0
human	O 0
complement	O 0
C9	O 0
gene	O 0
is	O 0
the	O 0
major	O 0
cause	O 0
of	O 0
Japanese	O 0
complement	B-Disease 0
C9	I-Disease 0
deficiency	I-Disease 0
.	O 0

Deficiency	B-Disease 0
of	I-Disease 0
the	I-Disease 0
ninth	I-Disease 0
component	I-Disease 0
of	I-Disease 0
human	I-Disease 0
complement	I-Disease 0
(	O 0
C9	O 0
)	O 0
is	O 0
the	O 0
most	O 0
common	O 0
complement	B-Disease 0
deficiency	I-Disease 0
in	O 0
Japan	O 0
but	O 0
is	O 0
rare	O 0
in	O 0
other	O 0
countries	O 0
.	O 0

We	O 0
studied	O 0
the	O 0
molecular	O 0
basis	O 0
of	O 0
C9	B-Disease 0
deficiency	I-Disease 0
in	O 0
four	O 0
Japanese	O 0
C9	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
patients	O 0
who	O 0
had	O 0
suffered	O 0
from	O 0
meningococcal	B-Disease 0
meningitis	I-Disease 0
.	O 0

Direct	O 0
sequencing	O 0
of	O 0
amplified	O 0
C9	O 0
cDNA	O 0
and	O 0
DNA	O 0
revealed	O 0
a	O 0
nonsense	O 0
substitution	O 0
(	O 0
CGA	O 0
-	O 0
-	O 0
>	O 0
TGA	O 0
)	O 0
at	O 0
codon	O 0
95	O 0
in	O 0
exon	O 0
4	O 0
in	O 0
the	O 0
four	O 0
C9	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
individuals	O 0
.	O 0

An	O 0
allele	O 0
-	O 0
specific	O 0
polymerase	O 0
chain	O 0
reaction	O 0
system	O 0
designed	O 0
to	O 0
detect	O 0
exclusively	O 0
only	O 0
one	O 0
of	O 0
the	O 0
normal	O 0
and	O 0
mutant	O 0
alleles	O 0
indicated	O 0
that	O 0
all	O 0
the	O 0
four	O 0
patients	O 0
were	O 0
homozygous	O 0
for	O 0
the	O 0
mutation	O 0
in	O 0
exon	O 0
4	O 0
and	O 0
that	O 0
the	O 0
parents	O 0
of	O 0
patient	O 0
2	O 0
were	O 0
heterozygous	O 0
.	O 0

The	O 0
common	O 0
mutation	O 0
at	O 0
codon	O 0
95	O 0
in	O 0
exon	O 0
4	O 0
might	O 0
be	O 0
responsible	O 0
for	O 0
most	O 0
Japanese	O 0
C9	B-Disease 0
deficiency	I-Disease 0
.	O 0
.	O 0

BRCA1	O 0
required	O 0
for	O 0
transcription	O 0
-	O 0
coupled	O 0
repair	O 0
of	O 0
oxidative	O 0
DNA	O 0
damage	O 0
.	O 0

The	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
susceptibility	O 0
gene	O 0
BRCA1	O 0
encodes	O 0
a	O 0
zinc	O 0
finger	O 0
protein	O 0
of	O 0
unknown	O 0
function	O 0
.	O 0

Association	O 0
of	O 0
the	O 0
BRCA1	O 0
protein	O 0
with	O 0
the	O 0
DNA	O 0
repair	O 0
protein	O 0
Rad51	O 0
and	O 0
changes	O 0
in	O 0
the	O 0
phosphorylation	O 0
and	O 0
cellular	O 0
localization	O 0
of	O 0
the	O 0
protein	O 0
after	O 0
exposure	O 0
to	O 0
DNA	O 0
-	O 0
damaging	O 0
agents	O 0
are	O 0
consistent	O 0
with	O 0
a	O 0
role	O 0
for	O 0
BRCA1	O 0
in	O 0
DNA	O 0
repair	O 0
.	O 0

Here	O 0
,	O 0
it	O 0
is	O 0
shown	O 0
that	O 0
mouse	O 0
embryonic	O 0
stem	O 0
cells	O 0
deficient	B-Disease 0
in	I-Disease 0
BRCA1	I-Disease 0
are	O 0
defective	O 0
in	O 0
the	O 0
ability	O 0
to	O 0
carry	O 0
out	O 0
transcription	O 0
-	O 0
coupled	O 0
repair	O 0
of	O 0
oxidative	O 0
DNA	O 0
damage	O 0
,	O 0
and	O 0
are	O 0
hypersensitive	O 0
to	O 0
ionizing	O 0
radiation	O 0
and	O 0
hydrogen	O 0
peroxide	O 0
.	O 0

These	O 0
results	O 0
suggest	O 0
that	O 0
BRCA1	O 0
participates	O 0
,	O 0
directly	O 0
or	O 0
indirectly	O 0
,	O 0
in	O 0
transcription	O 0
-	O 0
coupled	O 0
repair	O 0
of	O 0
oxidative	O 0
DNA	O 0
damage	O 0
.	O 0
.	O 0

Truncation	O 0
mutations	O 0
in	O 0
the	O 0
transactivation	O 0
region	O 0
of	O 0
PAX6	O 0
result	O 0
in	O 0
dominant	O 0
-	O 0
negative	O 0
mutants	O 0
.	O 0

PAX6	O 0
is	O 0
a	O 0
transcription	O 0
factor	O 0
with	O 0
two	O 0
DNA	O 0
-	O 0
binding	O 0
domains	O 0
(	O 0
paired	O 0
box	O 0
and	O 0
homeobox	O 0
)	O 0
and	O 0
a	O 0
proline	O 0
-	O 0
serine	O 0
-	O 0
threonine	O 0
(	O 0
PST	O 0
)	O 0
-	O 0
rich	O 0
transactivation	O 0
domain	O 0
.	O 0

PAX6	O 0
regulates	O 0
eye	O 0
development	O 0
in	O 0
animals	O 0
ranging	O 0
from	O 0
jellyfish	O 0
to	O 0
Drosophila	O 0
to	O 0
humans	O 0
.	O 0

Heterozygous	O 0
mutations	O 0
in	O 0
the	O 0
human	O 0
PAX6	O 0
gene	O 0
result	O 0
in	O 0
various	O 0
phenotypes	O 0
,	O 0
including	O 0
aniridia	B-Disease 0
,	O 0
Peters	B-Disease 0
anomaly	I-Disease 0
,	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
keratitis	I-Disease 0
,	O 0
and	O 0
familial	B-Disease 0
foveal	I-Disease 0
dysplasia	I-Disease 0
.	O 0

It	O 0
is	O 0
believed	O 0
that	O 0
the	O 0
mutated	O 0
allele	O 0
of	O 0
PAX6	O 0
produces	O 0
an	O 0
inactive	O 0
protein	O 0
and	O 0
aniridia	B-Disease 0
is	O 0
caused	O 0
due	O 0
to	O 0
genetic	O 0
haploinsufficiency	O 0
.	O 0

However	O 0
,	O 0
several	O 0
truncation	O 0
mutations	O 0
have	O 0
been	O 0
found	O 0
to	O 0
occur	O 0
in	O 0
the	O 0
C	O 0
-	O 0
terminal	O 0
half	O 0
of	O 0
PAX6	O 0
in	O 0
patients	O 0
with	O 0
Aniridia	B-Disease 0
resulting	O 0
in	O 0
mutant	O 0
proteins	O 0
that	O 0
retain	O 0
the	O 0
DNA	O 0
-	O 0
binding	O 0
domains	O 0
but	O 0
have	O 0
lost	O 0
most	O 0
of	O 0
the	O 0
transactivation	O 0
domain	O 0
.	O 0

It	O 0
is	O 0
not	O 0
clear	O 0
whether	O 0
such	O 0
mutants	O 0
really	O 0
behave	O 0
as	O 0
loss	O 0
-	O 0
of	O 0
-	O 0
function	O 0
mutants	O 0
as	O 0
predicted	O 0
by	O 0
haploinsufficiency	O 0
.	O 0

Contrary	O 0
to	O 0
this	O 0
theory	O 0
,	O 0
our	O 0
data	O 0
showed	O 0
that	O 0
these	O 0
mutants	O 0
are	O 0
dominant	O 0
-	O 0
negative	O 0
in	O 0
transient	O 0
transfection	O 0
assays	O 0
when	O 0
they	O 0
are	O 0
coexpressed	O 0
with	O 0
wild	O 0
-	O 0
type	O 0
PAX6	O 0
.	O 0

We	O 0
found	O 0
that	O 0
the	O 0
dominant	O 0
-	O 0
negative	O 0
effects	O 0
result	O 0
from	O 0
the	O 0
enhanced	O 0
DNA	O 0
binding	O 0
ability	O 0
of	O 0
these	O 0
mutants	O 0
.	O 0

Kinetic	O 0
studies	O 0
of	O 0
binding	O 0
and	O 0
dissociation	O 0
revealed	O 0
that	O 0
various	O 0
truncation	O 0
mutants	O 0
have	O 0
3	O 0
-	O 0
5	O 0
-	O 0
fold	O 0
higher	O 0
affinity	O 0
to	O 0
various	O 0
DNA	O 0
-	O 0
binding	O 0
sites	O 0
when	O 0
compared	O 0
with	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
PAX6	O 0
.	O 0

These	O 0
results	O 0
provide	O 0
a	O 0
new	O 0
insight	O 0
into	O 0
the	O 0
role	O 0
of	O 0
mutant	O 0
PAX6	O 0
in	O 0
causing	O 0
aniridia	B-Disease 0
.	O 0
.	O 0

Reversal	O 0
of	O 0
severe	O 0
hypertrophic	B-Disease 0
cardiomyopathy	I-Disease 0
and	O 0
excellent	O 0
neuropsychologic	O 0
outcome	O 0
in	O 0
very	B-Disease 0
-	I-Disease 0
long	I-Disease 0
-	I-Disease 0
chain	I-Disease 0
acyl	I-Disease 0
-	I-Disease 0
coenzyme	I-Disease 0
A	I-Disease 0
dehydrogenase	I-Disease 0
deficiency	I-Disease 0
.	O 0

Very	B-Disease 0
-	I-Disease 0
long	I-Disease 0
-	I-Disease 0
chain	I-Disease 0
acyl	I-Disease 0
-	I-Disease 0
coenzyme	I-Disease 0
A	I-Disease 0
dehydrogenase	I-Disease 0
(	I-Disease 0
VLCAD	I-Disease 0
)	I-Disease 0
deficiency	I-Disease 0
is	O 0
a	O 0
disorder	O 0
of	O 0
fatty	O 0
acid	O 0
beta	O 0
oxidation	O 0
that	O 0
reportedly	O 0
has	O 0
high	O 0
rates	O 0
of	O 0
morbidity	O 0
and	O 0
mortality	O 0
.	O 0

We	O 0
describe	O 0
the	O 0
outcome	O 0
of	O 0
a	O 0
5	O 0
-	O 0
year	O 0
-	O 0
old	O 0
girl	O 0
with	O 0
VLCAD	B-Disease 0
deficiency	I-Disease 0
who	O 0
was	O 0
first	O 0
seen	O 0
at	O 0
5	O 0
months	O 0
of	O 0
age	O 0
with	O 0
severe	O 0
hypertrophic	B-Disease 0
cardiomyopathy	I-Disease 0
,	O 0
hepatomegaly	B-Disease 0
,	O 0
encephalopathy	B-Disease 0
,	O 0
and	O 0
hypotonia	B-Disease 0
.	O 0

Biochemical	O 0
studies	O 0
indicated	O 0
VLCAD	B-Disease 0
deficiency	I-Disease 0
caused	O 0
by	O 0
a	O 0
stable	O 0
yet	O 0
inactive	O 0
enzyme	O 0
.	O 0

Molecular	O 0
genetic	O 0
analysis	O 0
of	O 0
her	O 0
VLCAD	O 0
gene	O 0
revealed	O 0
a	O 0
T1372C	O 0
(	O 0
F458L	O 0
)	O 0
missense	O 0
mutation	O 0
and	O 0
a	O 0
1668	O 0
ACAG	O 0
1669	O 0
splice	O 0
site	O 0
mutation	O 0
.	O 0

After	O 0
initial	O 0
treatment	O 0
with	O 0
intravenous	O 0
glucose	O 0
and	O 0
carnitine	O 0
,	O 0
the	O 0
patient	O 0
has	O 0
thrived	O 0
on	O 0
a	O 0
low	O 0
-	O 0
fat	O 0
diet	O 0
supplemented	O 0
with	O 0
medium	O 0
-	O 0
chain	O 0
triglyceride	O 0
oil	O 0
and	O 0
carnitine	O 0
and	O 0
avoidance	O 0
of	O 0
fasting	O 0
.	O 0

Her	O 0
ventricular	O 0
hypertrophy	O 0
resolved	O 0
significantly	O 0
over	O 0
1	O 0
year	O 0
,	O 0
and	O 0
cognitively	O 0
,	O 0
she	O 0
is	O 0
in	O 0
the	O 0
superior	O 0
range	O 0
for	O 0
age	O 0
.	O 0

Clinical	O 0
recognition	O 0
of	O 0
VLCAD	B-Disease 0
deficiency	I-Disease 0
is	O 0
important	O 0
because	O 0
it	O 0
is	O 0
one	O 0
of	O 0
the	O 0
few	O 0
directly	O 0
treatable	O 0
causes	O 0
of	O 0
cardiomyopathy	B-Disease 0
in	O 0
children	O 0
.	O 0
.	O 0

Cloning	O 0
of	O 0
a	O 0
novel	O 0
member	O 0
of	O 0
the	O 0
low	O 0
-	O 0
density	O 0
lipoprotein	O 0
receptor	O 0
family	O 0
.	O 0

A	O 0
gene	O 0
encoding	O 0
a	O 0
novel	O 0
transmembrane	O 0
protein	O 0
was	O 0
identified	O 0
by	O 0
DNA	O 0
sequence	O 0
analysis	O 0
within	O 0
the	O 0
insulin	B-Disease 0
-	I-Disease 0
dependent	I-Disease 0
diabetes	I-Disease 0
mellitus	I-Disease 0
(	O 0
IDDM	B-Disease 0
)	O 0
locus	O 0
IDDM4	O 0
on	O 0
chromosome	O 0
11q13	O 0
.	O 0

Based	O 0
on	O 0
its	O 0
chromosomal	O 0
position	O 0
,	O 0
this	O 0
gene	O 0
is	O 0
a	O 0
candidate	O 0
for	O 0
conferring	O 0
susceptibility	O 0
to	O 0
diabetes	B-Disease 0
.	O 0

The	O 0
gene	O 0
,	O 0
termed	O 0
low	O 0
-	O 0
density	O 0
lipoprotein	O 0
receptor	O 0
related	O 0
protein	O 0
5	O 0
(	O 0
LRP5	O 0
)	O 0
,	O 0
encodes	O 0
a	O 0
protein	O 0
of	O 0
1615	O 0
amino	O 0
acids	O 0
that	O 0
contains	O 0
conserved	O 0
modules	O 0
which	O 0
are	O 0
characteristic	O 0
of	O 0
the	O 0
low	O 0
-	O 0
density	O 0
lipoprotein	O 0
(	O 0
LDL	O 0
)	O 0
receptor	O 0
family	O 0
.	O 0

These	O 0
modules	O 0
include	O 0
a	O 0
putative	O 0
signal	O 0
peptide	O 0
for	O 0
protein	O 0
export	O 0
,	O 0
four	O 0
epidermal	O 0
growth	O 0
factor	O 0
(	O 0
EGF	O 0
)	O 0
repeats	O 0
with	O 0
associated	O 0
spacer	O 0
domains	O 0
,	O 0
three	O 0
LDL	O 0
-	O 0
receptor	O 0
(	O 0
LDLR	O 0
)	O 0
repeats	O 0
,	O 0
a	O 0
single	O 0
transmembrane	O 0
spanning	O 0
domain	O 0
,	O 0
and	O 0
a	O 0
cytoplasmic	O 0
domain	O 0
.	O 0

The	O 0
encoded	O 0
protein	O 0
has	O 0
a	O 0
unique	O 0
organization	O 0
of	O 0
EGF	O 0
and	O 0
LDLR	O 0
repeats	O 0
;	O 0
therefore	O 0
,	O 0
LRP5	O 0
likely	O 0
represents	O 0
a	O 0
new	O 0
category	O 0
of	O 0
the	O 0
LDLR	O 0
family	O 0
.	O 0

Both	O 0
human	O 0
and	O 0
mouse	O 0
LRP5	O 0
cDNAs	O 0
have	O 0
been	O 0
isolated	O 0
and	O 0
the	O 0
encoded	O 0
mature	O 0
proteins	O 0
are	O 0
95	O 0
%	O 0
identical	O 0
,	O 0
indicating	O 0
a	O 0
high	O 0
degree	O 0
of	O 0
evolutionary	O 0
conservation	O 0
.	O 0
.	O 0

The	O 0
APC	B-Disease 0
variants	O 0
I1307K	O 0
and	O 0
E1317Q	O 0
are	O 0
associated	O 0
with	O 0
colorectal	B-Disease 0
tumors	I-Disease 0
,	O 0
but	O 0
not	O 0
always	O 0
with	O 0
a	O 0
family	O 0
history	O 0
.	O 0

Classical	O 0
familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
(	O 0
FAP	B-Disease 0
)	O 0
is	O 0
a	O 0
high	O 0
-	O 0
penetrance	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disease	I-Disease 0
that	O 0
predisposes	O 0
to	O 0
hundreds	O 0
or	O 0
thousands	O 0
of	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
and	I-Disease 0
carcinoma	I-Disease 0
and	O 0
that	O 0
results	O 0
from	O 0
truncating	O 0
mutations	O 0
in	O 0
the	O 0
APC	B-Disease 0
gene	O 0
.	O 0

A	O 0
variant	O 0
of	O 0
FAP	B-Disease 0
is	O 0
attenuated	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
,	O 0
which	O 0
results	O 0
from	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
in	O 0
the	O 0
5	O 0
and	O 0
3	O 0
regions	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
.	O 0

Attenuated	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
patients	O 0
have	O 0
"	O 0
multiple	O 0
"	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
(	O 0
typically	O 0
fewer	O 0
than	O 0
100	O 0
)	O 0
without	O 0
the	O 0
florid	O 0
phenotype	O 0
of	O 0
classical	O 0
FAP	B-Disease 0
.	O 0

Another	O 0
group	O 0
of	O 0
patients	O 0
with	O 0
multiple	O 0
adenomas	B-Disease 0
has	O 0
no	O 0
mutations	O 0
in	O 0
the	O 0
APC	B-Disease 0
gene	O 0
,	O 0
and	O 0
their	O 0
phenotype	O 0
probably	O 0
results	O 0
from	O 0
variation	O 0
at	O 0
a	O 0
locus	O 0
,	O 0
or	O 0
loci	O 0
,	O 0
elsewhere	O 0
in	O 0
the	O 0
genome	O 0
.	O 0

Recently	O 0
,	O 0
however	O 0
,	O 0
a	O 0
missense	O 0
variant	O 0
of	O 0
APC	B-Disease 0
(	O 0
I1307K	O 0
)	O 0
was	O 0
described	O 0
that	O 0
confers	O 0
an	O 0
increased	O 0
risk	O 0
of	O 0
colorectal	B-Disease 0
tumors	I-Disease 0
,	O 0
including	O 0
multiple	O 0
adenomas	B-Disease 0
,	O 0
in	O 0
Ashkenazim	O 0
.	O 0

We	O 0
have	O 0
studied	O 0
a	O 0
set	O 0
of	O 0
164	O 0
patients	O 0
with	O 0
multiple	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
carcinoma	I-Disease 0
and	O 0
analyzed	O 0
codons	O 0
1263	O 0
-	O 0
1377	O 0
(	O 0
exon	O 0
15G	O 0
)	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
for	O 0
germ	O 0
-	O 0
line	O 0
variants	O 0
.	O 0

Three	O 0
patients	O 0
with	O 0
the	O 0
I1307K	O 0
allele	O 0
were	O 0
detected	O 0
,	O 0
each	O 0
of	O 0
Ashkenazi	O 0
descent	O 0
.	O 0

Four	O 0
patients	O 0
had	O 0
a	O 0
germ	O 0
-	O 0
line	O 0
E1317Q	O 0
missense	O 0
variant	O 0
of	O 0
APC	O 0
that	O 0
was	O 0
not	O 0
present	O 0
in	O 0
controls	O 0
;	O 0
one	O 0
of	O 0
these	O 0
individuals	O 0
had	O 0
an	O 0
unusually	O 0
large	O 0
number	O 0
of	O 0
metaplastic	B-Disease 0
polyps	I-Disease 0
of	I-Disease 0
the	I-Disease 0
colorectum	I-Disease 0
.	O 0

There	O 0
is	O 0
increasing	O 0
evidence	O 0
that	O 0
there	O 0
exist	O 0
germ	O 0
-	O 0
line	O 0
variants	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
that	O 0
predispose	O 0
to	O 0
the	O 0
development	O 0
of	O 0
multiple	O 0
colorectal	B-Disease 0
adenomas	I-Disease 0
and	I-Disease 0
carcinoma	I-Disease 0
,	O 0
but	O 0
without	O 0
the	O 0
florid	O 0
phenotype	O 0
of	O 0
classical	O 0
FAP	B-Disease 0
,	O 0
and	O 0
possibly	O 0
with	O 0
importance	O 0
for	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
risk	O 0
in	O 0
the	O 0
general	O 0
population	O 0
.	O 0
.	O 0

Genomic	O 0
structure	O 0
of	O 0
the	O 0
human	O 0
congenital	B-Disease 0
chloride	I-Disease 0
diarrhea	I-Disease 0
(	O 0
CLD	B-Disease 0
)	O 0
gene	O 0
.	O 0

Congenital	B-Disease 0
chloride	I-Disease 0
diarrhea	I-Disease 0
(	O 0
CLD	B-Disease 0
)	O 0
is	O 0
caused	O 0
by	O 0
mutations	O 0
in	O 0
a	O 0
gene	O 0
which	O 0
encodes	O 0
an	O 0
intestinal	O 0
anion	O 0
transporter	O 0
.	O 0

We	O 0
report	O 0
here	O 0
the	O 0
complete	O 0
genomic	O 0
organization	O 0
of	O 0
the	O 0
human	O 0
CLD	B-Disease 0
gene	O 0
which	O 0
spans	O 0
approximately	O 0
39kb	O 0
,	O 0
and	O 0
comprises	O 0
21	O 0
exons	O 0
.	O 0

All	O 0
exon	O 0
/	O 0
intron	O 0
boundaries	O 0
conform	O 0
to	O 0
the	O 0
GT	O 0
/	O 0
AG	O 0
rule	O 0
.	O 0

An	O 0
analysis	O 0
of	O 0
the	O 0
putative	O 0
promoter	O 0
region	O 0
sequence	O 0
shows	O 0
a	O 0
putative	O 0
TATA	O 0
box	O 0
and	O 0
predicts	O 0
multiple	O 0
transcription	O 0
factor	O 0
binding	O 0
sites	O 0
.	O 0

The	O 0
genomic	O 0
structure	O 0
was	O 0
determined	O 0
using	O 0
DNA	O 0
from	O 0
several	O 0
sources	O 0
including	O 0
multiple	O 0
large	O 0
-	O 0
insert	O 0
libaries	O 0
and	O 0
genomic	O 0
DNA	O 0
from	O 0
Finnish	O 0
CLD	B-Disease 0
patients	O 0
and	O 0
controls	O 0
.	O 0

Exon	O 0
-	O 0
specific	O 0
primers	O 0
developed	O 0
in	O 0
this	O 0
study	O 0
will	O 0
facilitate	O 0
mutation	O 0
screening	O 0
studies	O 0
of	O 0
patients	O 0
with	O 0
the	O 0
disease	O 0
.	O 0

Genomic	O 0
sequencing	O 0
of	O 0
a	O 0
BAC	O 0
clone	O 0
H	O 0
_	O 0
RG364P16	O 0
revealed	O 0
the	O 0
presence	O 0
of	O 0
another	O 0
,	O 0
highly	O 0
homologous	O 0
gene	O 0
3	O 0
of	O 0
the	O 0
CLD	B-Disease 0
gene	O 0
,	O 0
with	O 0
a	O 0
similar	O 0
genomic	O 0
structure	O 0
,	O 0
recently	O 0
identified	O 0
as	O 0
the	O 0
Pendred	B-Disease 0
syndrome	I-Disease 0
gene	O 0
(	O 0
PDS	B-Disease 0
)	O 0
.	O 0
.	O 0

The	O 0
APCI1307K	O 0
allele	O 0
and	O 0
cancer	B-Disease 0
risk	O 0
in	O 0
a	O 0
community	O 0
-	O 0
based	O 0
study	O 0
of	O 0
Ashkenazi	O 0
Jews	O 0
.	O 0

Mutations	O 0
in	O 0
APC	O 0
are	O 0
classically	O 0
associated	O 0
with	O 0
familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
(	O 0
FAP	B-Disease 0
)	O 0
,	O 0
a	O 0
highly	O 0
penetrant	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disorder	I-Disease 0
characterized	O 0
by	O 0
multiple	O 0
intestinal	O 0
polyps	B-Disease 0
and	O 0
,	O 0
without	O 0
surgical	O 0
intervention	O 0
,	O 0
the	O 0
development	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
(	O 0
CRC	B-Disease 0
)	O 0
.	O 0

APC	B-Disease 0
is	O 0
a	O 0
tumour	O 0
-	O 0
suppressor	O 0
gene	O 0
,	O 0
and	O 0
somatic	O 0
loss	O 0
occurs	O 0
in	O 0
tumours	B-Disease 0
.	O 0

The	O 0
germline	O 0
T	O 0
-	O 0
to	O 0
-	O 0
A	O 0
transversion	O 0
responsible	O 0
for	O 0
the	O 0
APC	O 0
I1307K	O 0
allele	O 0
converts	O 0
the	O 0
wild	O 0
-	O 0
type	O 0
sequence	O 0
to	O 0
a	O 0
homopolymer	O 0
tract	O 0
(	O 0
A8	O 0
)	O 0
that	O 0
is	O 0
genetically	O 0
unstable	O 0
and	O 0
prone	O 0
to	O 0
somatic	O 0
mutation	O 0
.	O 0

The	O 0
I1307K	O 0
allele	O 0
was	O 0
found	O 0
in	O 0
6	O 0
.	O 0

1	O 0
%	O 0
of	O 0
unselected	O 0
Ashkenazi	O 0
Jews	O 0
and	O 0
higher	O 0
proportions	O 0
of	O 0
Ashkenazim	O 0
with	O 0
family	O 0
or	O 0
personal	O 0
histories	O 0
of	O 0
CRC	B-Disease 0
(	O 0
ref	O 0
.	O 0
2	O 0
)	O 0
.	O 0

To	O 0
evaluate	O 0
the	O 0
role	O 0
of	O 0
I1307K	O 0
in	O 0
cancer	B-Disease 0
,	O 0
we	O 0
genotyped	O 0
5	O 0
,	O 0
081	O 0
Ashkenazi	O 0
volunteers	O 0
in	O 0
a	O 0
community	O 0
survey	O 0
.	O 0

Risk	O 0
of	O 0
developing	O 0
colorectal	B-Disease 0
,	I-Disease 0
breast	I-Disease 0
and	I-Disease 0
other	I-Disease 0
cancers	I-Disease 0
were	O 0
compared	O 0
between	O 0
genotyped	O 0
I1307K	O 0
carriers	O 0
and	O 0
non	O 0
-	O 0
carriers	O 0
and	O 0
their	O 0
first	O 0
-	O 0
degree	O 0
relatives	O 0
.	O 0

Sperm	O 0
DNA	O 0
analysis	O 0
in	O 0
a	O 0
Friedreich	B-Disease 0
ataxia	I-Disease 0
premutation	O 0
carrier	O 0
suggests	O 0
both	O 0
meiotic	O 0
and	O 0
mitotic	O 0
expansion	O 0
in	O 0
the	O 0
FRDA	B-Disease 0
gene	O 0
.	O 0

Friedreich	B-Disease 0
ataxia	I-Disease 0
is	O 0
usually	O 0
caused	O 0
by	O 0
an	O 0
expansion	O 0
of	O 0
a	O 0
GAA	O 0
trinucleotide	O 0
repeat	O 0
in	O 0
intron	O 0
1	O 0
of	O 0
the	O 0
FRDA	B-Disease 0
gene	O 0
.	O 0

Occasionally	O 0
,	O 0
a	O 0
fully	O 0
expanded	O 0
allele	O 0
has	O 0
been	O 0
found	O 0
to	O 0
arise	O 0
from	O 0
a	O 0
premutation	O 0
of	O 0
100	O 0
or	O 0
less	O 0
triplet	O 0
repeats	O 0
.	O 0

We	O 0
have	O 0
examined	O 0
the	O 0
sperm	O 0
DNA	O 0
of	O 0
a	O 0
premutation	O 0
carrier	O 0
.	O 0

This	O 0
mans	O 0
leucocyte	O 0
DNA	O 0
showed	O 0
one	O 0
normal	O 0
allele	O 0
and	O 0
one	O 0
allele	O 0
of	O 0
approximately	O 0
100	O 0
repeats	O 0
.	O 0

His	O 0
sperm	O 0
showed	O 0
an	O 0
expanded	O 0
allele	O 0
in	O 0
a	O 0
tight	O 0
range	O 0
centering	O 0
on	O 0
a	O 0
size	O 0
of	O 0
approximately	O 0
320	O 0
trinucleotide	O 0
repeats	O 0
.	O 0

His	O 0
affected	O 0
son	O 0
has	O 0
repeat	O 0
sizes	O 0
of	O 0
1040	O 0
and	O 0
540	O 0
.	O 0

These	O 0
data	O 0
suggest	O 0
that	O 0
expansion	O 0
occurs	O 0
in	O 0
two	O 0
stages	O 0
,	O 0
the	O 0
first	O 0
during	O 0
meiosis	O 0
followed	O 0
by	O 0
a	O 0
second	O 0
mitotic	O 0
expansion	O 0
.	O 0

We	O 0
also	O 0
show	O 0
that	O 0
in	O 0
all	O 0
informative	O 0
carrier	O 0
father	O 0
to	O 0
affected	O 0
child	O 0
transmissions	O 0
,	O 0
with	O 0
the	O 0
notable	O 0
exception	O 0
of	O 0
the	O 0
premutation	O 0
carrier	O 0
,	O 0
the	O 0
expansion	O 0
size	O 0
decreases	O 0
.	O 0
.	O 0

The	O 0
R496H	O 0
mutation	O 0
of	O 0
arylsulfatase	O 0
A	O 0
does	O 0
not	O 0
cause	O 0
metachromatic	B-Disease 0
leukodystrophy	I-Disease 0
.	O 0

Deficiency	B-Disease 0
of	I-Disease 0
arylsulfatase	I-Disease 0
A	I-Disease 0
(	O 0
ARSA	O 0
)	O 0
enzyme	O 0
activity	O 0
causes	O 0
metachromatic	B-Disease 0
leukodystrophy	I-Disease 0
(	O 0
MLD	B-Disease 0
)	O 0
.	O 0

A	O 0
number	O 0
of	O 0
ARSA	O 0
gene	O 0
mutations	O 0
responsible	O 0
for	O 0
MLD	B-Disease 0
have	O 0
been	O 0
identified	O 0
.	O 0

Recently	O 0
,	O 0
the	O 0
R496H	O 0
mutation	O 0
of	O 0
ARSA	O 0
was	O 0
proposed	O 0
to	O 0
be	O 0
a	O 0
cause	O 0
of	O 0
MLD	B-Disease 0
(	O 0
Draghia	O 0
et	O 0
al	O 0
.	O 0
,	O 0
1997	O 0
)	O 0
.	O 0

We	O 0
have	O 0
investigated	O 0
the	O 0
R496H	O 0
mutation	O 0
and	O 0
found	O 0
this	O 0
mutation	O 0
at	O 0
a	O 0
relatively	O 0
high	O 0
frequency	O 0
in	O 0
an	O 0
African	O 0
American	O 0
population	O 0
(	O 0
f	O 0
=	O 0
0	O 0
.	O 0
09	O 0
,	O 0
n	O 0
=	O 0
61	O 0
subjects	O 0
)	O 0
.	O 0

The	O 0
ARSA	O 0
enzyme	O 0
activity	O 0
in	O 0
subjects	O 0
with	O 0
and	O 0
without	O 0
the	O 0
R496H	O 0
mutation	O 0
was	O 0
determined	O 0
and	O 0
found	O 0
to	O 0
be	O 0
normal	O 0
.	O 0

It	O 0
is	O 0
therefore	O 0
concluded	O 0
that	O 0
the	O 0
R496H	O 0
mutation	O 0
of	O 0
ARSA	O 0
does	O 0
not	O 0
negatively	O 0
influence	O 0
the	O 0
activity	O 0
of	O 0
ARSA	O 0
and	O 0
is	O 0
not	O 0
a	O 0
cause	O 0
of	O 0
MLD	B-Disease 0

Down	O 0
-	O 0
regulation	O 0
of	O 0
transmembrane	O 0
carbonic	O 0
anhydrases	O 0
in	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
cell	O 0
lines	O 0
by	O 0
wild	O 0
-	O 0
type	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
transgenes	O 0
.	O 0

To	O 0
discover	O 0
genes	O 0
involved	O 0
in	O 0
von	B-Disease 0
Hippel	I-Disease 0
-	I-Disease 0
Lindau	I-Disease 0
(	O 0
VHL	B-Disease 0
)	O 0
-	O 0
mediated	O 0
carcinogenesis	O 0
,	O 0
we	O 0
used	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
cell	O 0
lines	O 0
stably	O 0
transfected	O 0
with	O 0
wild	O 0
-	O 0
type	O 0
VHL	O 0
-	O 0
expressing	O 0
transgenes	O 0
.	O 0

Large	O 0
-	O 0
scale	O 0
RNA	O 0
differential	O 0
display	O 0
technology	O 0
applied	O 0
to	O 0
these	O 0
cell	O 0
lines	O 0
identified	O 0
several	O 0
differentially	O 0
expressed	O 0
genes	O 0
,	O 0
including	O 0
an	O 0
alpha	O 0
carbonic	O 0
anhydrase	O 0
gene	O 0
,	O 0
termed	O 0
CA12	O 0
.	O 0

The	O 0
deduced	O 0
protein	O 0
sequence	O 0
was	O 0
classified	O 0
as	O 0
a	O 0
one	O 0
-	O 0
pass	O 0
transmembrane	O 0
CA	O 0
possessing	O 0
an	O 0
apparently	O 0
intact	O 0
catalytic	O 0
domain	O 0
in	O 0
the	O 0
extracellular	O 0
CA	O 0
module	O 0
.	O 0

Reintroduced	O 0
wild	O 0
-	O 0
type	O 0
VHL	B-Disease 0
strongly	O 0
inhibited	O 0
the	O 0
overexpression	O 0
of	O 0
the	O 0
CA12	O 0
gene	O 0
in	O 0
the	O 0
parental	O 0
renal	B-Disease 0
cell	I-Disease 0
carcinoma	I-Disease 0
cell	O 0
lines	O 0
.	O 0

Similar	O 0
results	O 0
were	O 0
obtained	O 0
with	O 0
CA9	O 0
,	O 0
encoding	O 0
another	O 0
transmembrane	O 0
CA	O 0
with	O 0
an	O 0
intact	O 0
catalytic	O 0
domain	O 0
.	O 0

Although	O 0
both	O 0
domains	O 0
of	O 0
the	O 0
VHL	B-Disease 0
protein	O 0
contribute	O 0
to	O 0
regulation	O 0
of	O 0
CA12	O 0
expression	O 0
,	O 0
the	O 0
elongin	O 0
binding	O 0
domain	O 0
alone	O 0
could	O 0
effectively	O 0
regulate	O 0
CA9	O 0
expression	O 0
.	O 0

We	O 0
mapped	O 0
CA12	O 0
and	O 0
CA9	O 0
loci	O 0
to	O 0
chromosome	O 0
bands	O 0
15q22	O 0
and	O 0
17q21	O 0
.	O 0

2	O 0
respectively	O 0
,	O 0
regions	O 0
prone	O 0
to	O 0
amplification	O 0
in	O 0
some	O 0
human	O 0
cancers	B-Disease 0
.	O 0

Additional	O 0
experiments	O 0
are	O 0
needed	O 0
to	O 0
define	O 0
the	O 0
role	O 0
of	O 0
CA	O 0
IX	O 0
and	O 0
CA	O 0
XII	O 0
enzymes	O 0
in	O 0
the	O 0
regulation	O 0
of	O 0
pH	O 0
in	O 0
the	O 0
extracellular	O 0
microenvironment	O 0
and	O 0
its	O 0
potential	O 0
impact	O 0
on	O 0
cancer	B-Disease 0
cell	O 0
growth	O 0
.	O 0

A	O 0
gene	O 0
encoding	O 0
a	O 0
transmembrane	O 0
protein	O 0
is	O 0
mutated	O 0
in	O 0
patients	O 0
with	O 0
diabetes	B-Disease 0
mellitus	I-Disease 0
and	O 0
optic	B-Disease 0
atrophy	I-Disease 0
(	O 0
Wolfram	B-Disease 0
syndrome	I-Disease 0
)	O 0
.	O 0

Wolfram	B-Disease 0
syndrome	I-Disease 0
(	O 0
WFS	B-Disease 0
;	O 0
OMIM	O 0
222300	O 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
neurodegenerative	I-Disease 0
disorder	I-Disease 0
defined	O 0
by	O 0
young	O 0
-	O 0
onset	O 0
non	O 0
-	O 0
immune	O 0
insulin	B-Disease 0
-	I-Disease 0
dependent	I-Disease 0
diabetes	I-Disease 0
mellitus	I-Disease 0
and	O 0
progressive	O 0
optic	B-Disease 0
atrophy	I-Disease 0
.	O 0

Linkage	O 0
to	O 0
markers	O 0
on	O 0
chromosome	O 0
4p	O 0
was	O 0
confirmed	O 0
in	O 0
five	O 0
families	O 0
.	O 0

On	O 0
the	O 0
basis	O 0
of	O 0
meiotic	O 0
recombinants	O 0
and	O 0
disease	O 0
-	O 0
associated	O 0
haplotypes	O 0
,	O 0
the	O 0
WFS	B-Disease 0
gene	O 0
was	O 0
localized	O 0
to	O 0
a	O 0
BAC	O 0
/	O 0
P1	O 0
contig	O 0
of	O 0
less	O 0
than	O 0
250	O 0
kb	O 0
.	O 0

Mutations	O 0
in	O 0
a	O 0
novel	O 0
gene	O 0
(	O 0
WFS1	O 0
)	O 0
encoding	O 0
a	O 0
putative	O 0
transmembrane	O 0
protein	O 0
were	O 0
found	O 0
in	O 0
all	O 0
affected	O 0
individuals	O 0
in	O 0
six	O 0
WFS	B-Disease 0
families	O 0
,	O 0
and	O 0
these	O 0
mutations	O 0
were	O 0
associated	O 0
with	O 0
the	O 0
disease	O 0
phenotype	O 0
.	O 0

WFS1	O 0
appears	O 0
to	O 0
function	O 0
in	O 0
survival	O 0
of	O 0
islet	O 0
beta	O 0
-	O 0
cells	O 0
and	O 0
neurons	O 0
.	O 0
.	O 0

Stable	O 0
interaction	O 0
between	O 0
the	O 0
products	O 0
of	O 0
the	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
tumor	B-Disease 0
suppressor	O 0
genes	O 0
in	O 0
mitotic	O 0
and	O 0
meiotic	O 0
cells	O 0
.	O 0

BRCA1	O 0
and	O 0
BRCA2	O 0
account	O 0
for	O 0
most	O 0
cases	O 0
of	O 0
familial	O 0
,	O 0
early	O 0
onset	O 0
breast	B-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
and	O 0
encode	O 0
products	O 0
that	O 0
each	O 0
interact	O 0
with	O 0
hRAD51	O 0
.	O 0

Results	O 0
presented	O 0
here	O 0
show	O 0
that	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
coexist	O 0
in	O 0
a	O 0
biochemical	O 0
complex	O 0
and	O 0
colocalize	O 0
in	O 0
subnuclear	O 0
foci	O 0
in	O 0
somatic	O 0
cells	O 0
and	O 0
on	O 0
the	O 0
axial	O 0
elements	O 0
of	O 0
developing	O 0
synaptonemal	O 0
complexes	O 0
.	O 0

Like	O 0
BRCA1	O 0
and	O 0
RAD51	O 0
,	O 0
BRCA2	O 0
relocates	O 0
to	O 0
PCNA	O 0
+	O 0
replication	O 0
sites	O 0
following	O 0
exposure	O 0
of	O 0
S	O 0
phase	O 0
cells	O 0
to	O 0
hydroxyurea	O 0
or	O 0
UV	O 0
irradiation	O 0
.	O 0

Thus	O 0
,	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
participate	O 0
,	O 0
together	O 0
,	O 0
in	O 0
a	O 0
pathway	O 0
(	O 0
s	O 0
)	O 0
associated	O 0
with	O 0
the	O 0
activation	O 0
of	O 0
double	O 0
-	O 0
strand	O 0
break	O 0
repair	O 0
and	O 0
/	O 0
or	O 0
homologous	O 0
recombination	O 0
.	O 0

Dysfunction	O 0
of	O 0
this	O 0
pathway	O 0
may	O 0
be	O 0
a	O 0
general	O 0
phenomenon	O 0
in	O 0
the	O 0
majority	O 0
of	O 0
cases	O 0
of	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
/	I-Disease 0
or	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
.	O 0
.	O 0

A	O 0
novel	O 0
Arg362Ser	O 0
mutation	O 0
in	O 0
the	O 0
sterol	O 0
27	O 0
-	O 0
hydroxylase	O 0
gene	O 0
(	O 0
CYP27	O 0
)	O 0
:	O 0
its	O 0
effects	O 0
on	O 0
pre	O 0
-	O 0
mRNA	O 0
splicing	O 0
and	O 0
enzyme	O 0
activity	O 0
.	O 0

A	O 0
novel	O 0
C	O 0
to	O 0
A	O 0
mutation	O 0
in	O 0
the	O 0
sterol	O 0
27	O 0
-	O 0
hydroxylase	O 0
gene	O 0
(	O 0
CYP27	O 0
)	O 0
was	O 0
identified	O 0
by	O 0
sequencing	O 0
amplified	O 0
CYP27	O 0
gene	O 0
products	O 0
from	O 0
a	O 0
patient	O 0
with	O 0
cerebrotendinous	B-Disease 0
xanthomatosis	I-Disease 0
(	O 0
CTX	B-Disease 0
)	O 0
.	O 0

The	O 0
mutation	O 0
changed	O 0
the	O 0
adrenodoxin	O 0
cofactor	O 0
binding	O 0
residue	O 0
362Arg	O 0
to	O 0
362Ser	O 0
(	O 0
CGT	O 0
362Arg	O 0
to	O 0
AGT	O 0
362Ser	O 0
)	O 0
,	O 0
and	O 0
was	O 0
responsible	O 0
for	O 0
deficiency	O 0
in	O 0
the	O 0
sterol	O 0
27	O 0
-	O 0
hydroxylase	O 0
activity	O 0
,	O 0
as	O 0
confirmed	O 0
by	O 0
expression	O 0
of	O 0
mutant	O 0
cDNA	O 0
into	O 0
COS	O 0
-	O 0
1	O 0
cells	O 0
.	O 0

Quantitative	O 0
analysis	O 0
showed	O 0
that	O 0
the	O 0
expression	O 0
of	O 0
CYP27	O 0
gene	O 0
mRNA	O 0
in	O 0
the	O 0
patient	O 0
represented	O 0
52	O 0
.	O 0

5	O 0
%	O 0
of	O 0
the	O 0
normal	O 0
level	O 0
.	O 0

As	O 0
the	O 0
mutation	O 0
occurred	O 0
at	O 0
the	O 0
penultimate	O 0
nucleotide	O 0
of	O 0
exon	O 0
6	O 0
(	O 0
-	O 0
2	O 0
position	O 0
of	O 0
exon	O 0
6	O 0
-	O 0
intron	O 0
6	O 0
splice	O 0
site	O 0
)	O 0
of	O 0
the	O 0
gene	O 0
,	O 0
we	O 0
hypothesized	O 0
that	O 0
the	O 0
mutation	O 0
may	O 0
partially	O 0
affect	O 0
the	O 0
normal	O 0
splicing	O 0
efficiency	O 0
in	O 0
exon	O 0
6	O 0
and	O 0
cause	O 0
alternative	O 0
splicing	O 0
elsewhere	O 0
,	O 0
which	O 0
resulted	O 0
in	O 0
decreased	O 0
transcript	O 0
in	O 0
the	O 0
patient	O 0
.	O 0

Transfection	O 0
of	O 0
constructed	O 0
minigenes	O 0
,	O 0
with	O 0
or	O 0
without	O 0
the	O 0
mutation	O 0
,	O 0
into	O 0
COS	O 0
-	O 0
1	O 0
cells	O 0
confirmed	O 0
that	O 0
the	O 0
mutant	O 0
minigene	O 0
was	O 0
responsible	O 0
for	O 0
a	O 0
mRNA	O 0
species	O 0
alternatively	O 0
spliced	O 0
at	O 0
an	O 0
activated	O 0
cryptic	O 0
5	O 0
splice	O 0
site	O 0
88	O 0
bp	O 0
upstream	O 0
from	O 0
the	O 0
3	O 0
end	O 0
of	O 0
exon	O 0
6	O 0
.	O 0

Our	O 0
data	O 0
suggest	O 0
that	O 0
the	O 0
C	O 0
to	O 0
A	O 0
mutation	O 0
at	O 0
the	O 0
penultimate	O 0
nucleotide	O 0
of	O 0
exon	O 0
6	O 0
of	O 0
the	O 0
CYP27	O 0
gene	O 0
not	O 0
only	O 0
causes	O 0
the	O 0
deficiency	B-Disease 0
in	I-Disease 0
the	I-Disease 0
sterol	I-Disease 0
27	I-Disease 0
-	I-Disease 0
hydroxylase	I-Disease 0
activity	I-Disease 0
,	O 0
but	O 0
also	O 0
partially	O 0
leads	O 0
to	O 0
alternative	O 0
pre	O 0
-	O 0
mRNA	O 0
splicing	O 0
of	O 0
the	O 0
gene	O 0
.	O 0

To	O 0
our	O 0
knowledge	O 0
,	O 0
this	O 0
is	O 0
the	O 0
first	O 0
report	O 0
regarding	O 0
effects	O 0
on	O 0
pre	O 0
-	O 0
mRNA	O 0
splicing	O 0
of	O 0
a	O 0
mutation	O 0
at	O 0
the	O 0
-	O 0
2	O 0
position	O 0
of	O 0
a	O 0
5	O 0
splice	O 0
site	O 0
.	O 0

ATM	O 0
germline	O 0
mutations	O 0
in	O 0
classical	O 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
patients	O 0
in	O 0
the	O 0
Dutch	O 0
population	O 0
.	O 0

Germline	O 0
mutations	O 0
in	O 0
the	O 0
ATM	O 0
gene	O 0
are	O 0
responsible	O 0
for	O 0
the	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
disorder	I-Disease 0
ataxia	B-Disease 0
-	I-Disease 0
telangiectasia	I-Disease 0
(	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
)	O 0
.	O 0

In	O 0
our	O 0
study	O 0
,	O 0
we	O 0
have	O 0
determined	O 0
the	O 0
ATM	O 0
mutation	O 0
spectrum	O 0
in	O 0
19	O 0
classical	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
patients	O 0
,	O 0
including	O 0
some	O 0
immigrant	O 0
populations	O 0
,	O 0
as	O 0
well	O 0
as	O 0
12	O 0
of	O 0
Dutch	O 0
ethnic	O 0
origin	O 0
.	O 0

Both	O 0
the	O 0
protein	O 0
truncation	O 0
test	O 0
(	O 0
PTT	O 0
)	O 0
and	O 0
the	O 0
restriction	O 0
endonuclease	O 0
fingerprinting	O 0
(	O 0
REF	O 0
)	O 0
method	O 0
were	O 0
used	O 0
and	O 0
compared	O 0
for	O 0
their	O 0
detection	O 0
efficiency	O 0
,	O 0
identifying	O 0
76	O 0
%	O 0
and	O 0
60	O 0
%	O 0
of	O 0
the	O 0
mutations	O 0
,	O 0
respectively	O 0
.	O 0

Most	O 0
patients	O 0
were	O 0
found	O 0
to	O 0
be	O 0
compound	O 0
heterozygote	O 0
.	O 0

Seventeen	O 0
mutations	O 0
were	O 0
distinct	O 0
,	O 0
of	O 0
which	O 0
10	O 0
were	O 0
not	O 0
reported	O 0
previously	O 0
.	O 0

Mutations	O 0
are	O 0
small	O 0
deletions	O 0
or	O 0
point	O 0
mutations	O 0
frequently	O 0
affecting	O 0
splice	O 0
sites	O 0
.	O 0

Moreover	O 0
,	O 0
a	O 0
16	O 0
.	O 0

7	O 0
-	O 0
kb	O 0
genomic	O 0
deletion	O 0
of	O 0
the	O 0
3	O 0
end	O 0
of	O 0
the	O 0
gene	O 0
,	O 0
most	O 0
likely	O 0
a	O 0
result	O 0
of	O 0
recombination	O 0
between	O 0
two	O 0
LINE	O 0
elements	O 0
,	O 0
was	O 0
identified	O 0
.	O 0

The	O 0
most	O 0
frequently	O 0
found	O 0
mutation	O 0
,	O 0
identified	O 0
in	O 0
three	O 0
unrelated	O 0
Turkish	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
individuals	O 0
,	O 0
was	O 0
previously	O 0
described	O 0
to	O 0
be	O 0
a	O 0
Turkish	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
founder	O 0
mutation	O 0
.	O 0

The	O 0
presence	O 0
of	O 0
a	O 0
founder	O 0
mutation	O 0
among	O 0
relatively	O 0
small	O 0
ethnic	O 0
population	O 0
groups	O 0
in	O 0
Western	O 0
Europe	O 0
could	O 0
indicate	O 0
a	O 0
high	O 0
carrier	O 0
frequency	O 0
in	O 0
such	O 0
communities	O 0
.	O 0

In	O 0
patients	O 0
of	O 0
Dutch	O 0
ethnic	O 0
origin	O 0
,	O 0
however	O 0
,	O 0
no	O 0
significant	O 0
founder	O 0
effect	O 0
could	O 0
be	O 0
identified	O 0
.	O 0

The	O 0
observed	O 0
genetic	O 0
heterogeneity	O 0
including	O 0
the	O 0
relative	O 0
high	O 0
percentage	O 0
of	O 0
splice	O 0
-	O 0
site	O 0
mutations	O 0
had	O 0
no	O 0
reflection	O 0
on	O 0
the	O 0
phenotype	O 0
.	O 0

All	O 0
patients	O 0
manifested	O 0
classical	O 0
A	B-Disease 0
-	I-Disease 0
T	I-Disease 0
and	O 0
increased	O 0
cellular	O 0
radioresistant	O 0
DNA	O 0
synthesis	O 0
.	O 0

Determination	O 0
of	O 0
the	O 0
genomic	O 0
structure	O 0
of	O 0
the	O 0
COL4A4	O 0
gene	O 0
and	O 0
of	O 0
novel	O 0
mutations	O 0
causing	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
Alport	I-Disease 0
syndrome	I-Disease 0
.	O 0

Autosomal	B-Disease 0
recessive	I-Disease 0
Alport	I-Disease 0
syndrome	I-Disease 0
is	O 0
a	O 0
progressive	O 0
hematuric	B-Disease 0
glomerulonephritis	I-Disease 0
characterized	O 0
by	O 0
glomerular	B-Disease 0
basement	I-Disease 0
membrane	I-Disease 0
abnormalities	I-Disease 0
and	O 0
associated	O 0
with	O 0
mutations	O 0
in	O 0
either	O 0
the	O 0
COL4A3	O 0
or	O 0
the	O 0
COL4A4	O 0
gene	O 0
,	O 0
which	O 0
encode	O 0
the	O 0
alpha3	O 0
and	O 0
alpha4	O 0
type	O 0
IV	O 0
collagen	O 0
chains	O 0
,	O 0
respectively	O 0
.	O 0

To	O 0
date	O 0
,	O 0
mutation	O 0
screening	O 0
in	O 0
the	O 0
two	O 0
genes	O 0
has	O 0
been	O 0
hampered	O 0
by	O 0
the	O 0
lack	O 0
of	O 0
genomic	O 0
structure	O 0
information	O 0
.	O 0

We	O 0
report	O 0
here	O 0
the	O 0
complete	O 0
characterization	O 0
of	O 0
the	O 0
48	O 0
exons	O 0
of	O 0
the	O 0
COL4A4	O 0
gene	O 0
,	O 0
a	O 0
comprehensive	O 0
gene	O 0
screen	O 0
,	O 0
and	O 0
the	O 0
subsequent	O 0
detection	O 0
of	O 0
10	O 0
novel	O 0
mutations	O 0
in	O 0
eight	O 0
patients	O 0
diagnosed	O 0
with	O 0
autosomal	B-Disease 0
recessive	I-Disease 0
Alport	I-Disease 0
syndrome	I-Disease 0
.	O 0

Furthermore	O 0
,	O 0
we	O 0
identified	O 0
a	O 0
glycine	O 0
to	O 0
alanine	O 0
substitution	O 0
in	O 0
the	O 0
collagenous	O 0
domain	O 0
that	O 0
is	O 0
apparently	O 0
silent	O 0
in	O 0
the	O 0
heterozygous	O 0
carriers	O 0
,	O 0
in	O 0
11	O 0
.	O 0

5	O 0
%	O 0
of	O 0
all	O 0
control	O 0
individuals	O 0
,	O 0
and	O 0
in	O 0
one	O 0
control	O 0
individual	O 0
homozygous	O 0
for	O 0
this	O 0
glycine	O 0
substitution	O 0
.	O 0

There	O 0
has	O 0
been	O 0
no	O 0
previous	O 0
finding	O 0
of	O 0
a	O 0
glycine	O 0
substitution	O 0
that	O 0
is	O 0
not	O 0
associated	O 0
with	O 0
any	O 0
obvious	O 0
phenotype	O 0
in	O 0
homozygous	O 0
individuals	O 0
.	O 0

Founder	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
mutations	O 0
in	O 0
French	O 0
Canadian	O 0
breast	B-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
.	O 0

We	O 0
have	O 0
identified	O 0
four	O 0
mutations	O 0
in	O 0
each	O 0
of	O 0
the	O 0
breast	B-Disease 0
cancer	I-Disease 0
-	O 0
susceptibility	O 0
genes	O 0
,	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
,	O 0
in	O 0
French	O 0
Canadian	O 0
breast	B-Disease 0
cancer	I-Disease 0
and	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
from	O 0
Quebec	O 0
.	O 0

To	O 0
identify	O 0
founder	O 0
effects	O 0
,	O 0
we	O 0
examined	O 0
independently	O 0
ascertained	O 0
French	O 0
Canadian	O 0
cancer	B-Disease 0
families	O 0
for	O 0
the	O 0
distribution	O 0
of	O 0
these	O 0
eight	O 0
mutations	O 0
.	O 0

Mutations	O 0
were	O 0
found	O 0
in	O 0
41	O 0
of	O 0
97	O 0
families	O 0
.	O 0

Six	O 0
of	O 0
eight	O 0
mutations	O 0
were	O 0
observed	O 0
at	O 0
least	O 0
twice	O 0
.	O 0

The	O 0
BRCA1	O 0
C4446T	O 0
mutation	O 0
was	O 0
the	O 0
most	O 0
common	O 0
mutation	O 0
found	O 0
,	O 0
followed	O 0
by	O 0
the	O 0
BRCA2	O 0
8765delAG	O 0
mutation	O 0
.	O 0

Together	O 0
,	O 0
these	O 0
mutations	O 0
were	O 0
found	O 0
in	O 0
28	O 0
of	O 0
41	O 0
families	O 0
identified	O 0
to	O 0
have	O 0
a	O 0
mutation	O 0
.	O 0

The	O 0
odds	O 0
of	O 0
detection	O 0
of	O 0
any	O 0
of	O 0
the	O 0
four	O 0
BRCA1	O 0
mutations	O 0
was	O 0
18	O 0
.	O 0

7x	O 0
greater	O 0
if	O 0
one	O 0
or	O 0
more	O 0
cases	O 0
of	O 0
ovarian	B-Disease 0
cancer	I-Disease 0
were	O 0
also	O 0
present	O 0
in	O 0
the	O 0
family	O 0
.	O 0

The	O 0
odds	O 0
of	O 0
detection	O 0
of	O 0
any	O 0
of	O 0
the	O 0
four	O 0
BRCA2	O 0
mutations	O 0
was	O 0
5	O 0
.	O 0

3x	O 0
greater	O 0
if	O 0
there	O 0
were	O 0
at	O 0
least	O 0
five	O 0
cases	O 0
of	O 0
breast	B-Disease 0
cancer	I-Disease 0
in	O 0
the	O 0
family	O 0
.	O 0

Interestingly	O 0
,	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
breast	B-Disease 0
cancer	I-Disease 0
case	O 0
<	O 0
36	O 0
years	O 0
of	O 0
age	O 0
was	O 0
strongly	O 0
predictive	O 0
of	O 0
the	O 0
presence	O 0
of	O 0
any	O 0
of	O 0
the	O 0
eight	O 0
mutations	O 0
screened	O 0
.	O 0

Carriers	O 0
of	O 0
the	O 0
same	O 0
mutation	O 0
,	O 0
from	O 0
different	O 0
families	O 0
,	O 0
shared	O 0
similar	O 0
haplotypes	O 0
,	O 0
indicating	O 0
that	O 0
the	O 0
mutant	O 0
alleles	O 0
were	O 0
likely	O 0
to	O 0
be	O 0
identical	O 0
by	O 0
descent	O 0
for	O 0
a	O 0
mutation	O 0
in	O 0
the	O 0
founder	O 0
population	O 0
.	O 0

The	O 0
identification	O 0
of	O 0
common	O 0
BRCA1	O 0
and	O 0
BRCA2	O 0
mutations	O 0
will	O 0
facilitate	O 0
carrier	O 0
detection	O 0
in	O 0
French	O 0
Canadian	O 0
breast	B-Disease 0
cancer	I-Disease 0
and	O 0
breast	B-Disease 0
/	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
families	O 0
.	O 0

Are	O 0
Dp71	O 0
and	O 0
Dp140	O 0
brain	O 0
dystrophin	O 0
isoforms	O 0
related	O 0
to	O 0
cognitive	B-Disease 0
impairment	I-Disease 0
in	O 0
Duchenne	B-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
?	O 0

Molecular	O 0
study	O 0
and	O 0
neuropsychological	O 0
analysis	O 0
were	O 0
performed	O 0
concurrently	O 0
on	O 0
49	O 0
patients	O 0
with	O 0
Duchenne	B-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
(	O 0
DMD	B-Disease 0
)	O 0
in	O 0
order	O 0
to	O 0
find	O 0
a	O 0
molecular	O 0
explanation	O 0
for	O 0
the	O 0
cognitive	B-Disease 0
impairment	I-Disease 0
observed	O 0
in	O 0
most	O 0
DMD	B-Disease 0
patients	O 0
.	O 0

Complete	O 0
analysis	O 0
of	O 0
the	O 0
dystrophin	O 0
gene	O 0
was	O 0
performed	O 0
to	O 0
define	O 0
the	O 0
localization	O 0
of	O 0
deletions	O 0
and	O 0
duplications	O 0
in	O 0
relation	O 0
to	O 0
the	O 0
different	O 0
DMD	B-Disease 0
promoters	O 0
.	O 0

Qualitative	O 0
analysis	O 0
of	O 0
the	O 0
Dp71	O 0
transcript	O 0
and	O 0
testing	O 0
for	O 0
the	O 0
specific	O 0
first	O 0
exon	O 0
of	O 0
Dp140	O 0
were	O 0
also	O 0
carried	O 0
out	O 0
.	O 0

Neuropsychological	O 0
analysis	O 0
assessed	O 0
verbal	O 0
and	O 0
visuospatial	O 0
intelligence	O 0
,	O 0
verbal	O 0
memory	O 0
,	O 0
and	O 0
reading	O 0
skills	O 0
.	O 0

Comparison	O 0
of	O 0
molecular	O 0
and	O 0
psychometric	O 0
findings	O 0
demonstrated	O 0
that	O 0
deletions	O 0
and	O 0
duplications	O 0
that	O 0
were	O 0
localized	O 0
in	O 0
the	O 0
distal	O 0
part	O 0
of	O 0
the	O 0
gene	O 0
seemed	O 0
to	O 0
be	O 0
preferentially	O 0
associated	O 0
with	O 0
cognitive	B-Disease 0
impairment	I-Disease 0
.	O 0

Two	O 0
altered	O 0
Dp71	O 0
transcripts	O 0
and	O 0
two	O 0
deleted	O 0
Dp140	O 0
DNA	O 0
sequences	O 0
were	O 0
found	O 0
in	O 0
four	O 0
patients	O 0
with	O 0
severe	O 0
cerebral	B-Disease 0
dysfunction	I-Disease 0
.	O 0

These	O 0
findings	O 0
suggest	O 0
that	O 0
some	O 0
sequences	O 0
located	O 0
in	O 0
the	O 0
distal	O 0
part	O 0
of	O 0
the	O 0
gene	O 0
and	O 0
,	O 0
in	O 0
particular	O 0
,	O 0
some	O 0
DMD	B-Disease 0
isoforms	O 0
expressed	O 0
in	O 0
the	O 0
brain	O 0
may	O 0
be	O 0
related	O 0
to	O 0
the	O 0
cognitive	B-Disease 0
impairment	I-Disease 0
associated	O 0
with	O 0
DMD	B-Disease 0
.	O 0
.	O 0

I1307K	O 0
APC	O 0
and	O 0
hMLH1	O 0
mutations	O 0
in	O 0
a	O 0
non	O 0
-	O 0
Jewish	O 0
family	O 0
with	O 0
hereditary	B-Disease 0
non	I-Disease 0
-	I-Disease 0
polyposis	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
.	O 0

We	O 0
describe	O 0
a	O 0
French	O 0
Canadian	O 0
hereditary	B-Disease 0
non	I-Disease 0
-	I-Disease 0
polyposis	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
(	O 0
HNPCC	B-Disease 0
)	O 0
kindred	O 0
which	O 0
carries	O 0
a	O 0
novel	O 0
truncating	O 0
mutation	O 0
in	O 0
hMLH1	O 0
.	O 0

Interestingly	O 0
,	O 0
the	O 0
I1307K	O 0
APC	O 0
polymorphism	O 0
,	O 0
associated	O 0
with	O 0
an	O 0
increased	O 0
risk	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
,	O 0
is	O 0
also	O 0
present	O 0
in	O 0
this	O 0
family	O 0
.	O 0

The	O 0
I1307K	O 0
polymorphism	O 0
has	O 0
previously	O 0
only	O 0
been	O 0
identified	O 0
in	O 0
individuals	O 0
of	O 0
self	O 0
-	O 0
reported	O 0
Ashkenazi	O 0
Jewish	O 0
origins	O 0
.	O 0

In	O 0
addition	O 0
,	O 0
in	O 0
this	O 0
family	O 0
,	O 0
there	O 0
appears	O 0
to	O 0
be	O 0
no	O 0
relationship	O 0
between	O 0
the	O 0
I1307K	O 0
polymorphism	O 0
and	O 0
the	O 0
presence	O 0
or	O 0
absence	O 0
of	O 0
cancer	B-Disease 0
.	O 0
.	O 0

Identification	O 0
of	O 0
a	O 0
novel	O 0
mutation	O 0
of	O 0
the	O 0
CPO	O 0
gene	O 0
in	O 0
a	O 0
Japanese	O 0
hereditary	B-Disease 0
coproporphyria	I-Disease 0
family	O 0
.	O 0

Hereditary	B-Disease 0
coproporphyria	I-Disease 0
(	O 0
HCP	B-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disease	I-Disease 0
characterized	O 0
by	O 0
a	O 0
deficiency	B-Disease 0
of	I-Disease 0
coproporphyrinogen	I-Disease 0
oxidase	I-Disease 0
(	O 0
CPO	O 0
)	O 0
caused	O 0
by	O 0
a	O 0
mutation	O 0
in	O 0
the	O 0
CPO	O 0
gene	O 0
.	O 0

Only	O 0
11	O 0
mutations	O 0
of	O 0
the	O 0
gene	O 0
have	O 0
been	O 0
reported	O 0
in	O 0
HCP	B-Disease 0
patients	O 0
.	O 0

We	O 0
report	O 0
another	O 0
mutation	O 0
in	O 0
a	O 0
Japanese	O 0
family	O 0
.	O 0

Polymerase	O 0
chain	O 0
reaction	O 0
-	O 0
single	O 0
strand	O 0
conformational	O 0
polymorphism	O 0
and	O 0
direct	O 0
sequence	O 0
analyses	O 0
demonstrated	O 0
a	O 0
C	O 0
to	O 0
T	O 0
substitution	O 0
in	O 0
exon	O 0
1	O 0
of	O 0
the	O 0
CPO	O 0
gene	O 0
at	O 0
nucleotide	O 0
position	O 0
85	O 0
,	O 0
which	O 0
lies	O 0
in	O 0
the	O 0
putative	O 0
presequence	O 0
for	O 0
targeting	O 0
to	O 0
mitochondria	O 0
.	O 0

This	O 0
mutation	O 0
changes	O 0
the	O 0
codon	O 0
for	O 0
glutamine	O 0
to	O 0
a	O 0
termination	O 0
codon	O 0
at	O 0
amino	O 0
acid	O 0
position	O 0
29	O 0
.	O 0

MaeI	O 0
restriction	O 0
analysis	O 0
showed	O 0
two	O 0
other	O 0
carriers	O 0
in	O 0
the	O 0
family	O 0
.	O 0

The	O 0
C	O 0
-	O 0
T	O 0
mutation	O 0
is	O 0
located	O 0
within	O 0
a	O 0
recently	O 0
proposed	O 0
putative	O 0
alternative	O 0
translation	O 0
initiation	O 0
codon	O 0
(	O 0
TIC	O 0
-	O 0
1	O 0
)	O 0
,	O 0
supporting	O 0
that	O 0
TIC	O 0
-	O 0
1	O 0
is	O 0
the	O 0
real	O 0
TIC	O 0
rather	O 0
than	O 0
TIC	O 0
-	O 0
2	O 0
.	O 0
.	O 0

Human	B-Disease 0
complement	I-Disease 0
factor	I-Disease 0
H	I-Disease 0
deficiency	I-Disease 0
associated	O 0
with	O 0
hemolytic	B-Disease 0
uremic	I-Disease 0
syndrome	I-Disease 0
.	O 0

This	O 0
study	O 0
reports	O 0
on	O 0
six	O 0
cases	O 0
of	O 0
deficiency	B-Disease 0
in	I-Disease 0
the	I-Disease 0
human	I-Disease 0
complement	I-Disease 0
regulatory	I-Disease 0
protein	I-Disease 0
Factor	I-Disease 0
H	I-Disease 0
(	O 0
FH	O 0
)	O 0
in	O 0
the	O 0
context	O 0
of	O 0
an	O 0
acute	B-Disease 0
renal	I-Disease 0
disease	I-Disease 0
.	O 0

Five	O 0
of	O 0
the	O 0
cases	O 0
were	O 0
observed	O 0
in	O 0
children	O 0
presenting	O 0
with	O 0
idiopathic	O 0
hemolytic	B-Disease 0
uremic	I-Disease 0
syndrome	I-Disease 0
(	O 0
HUS	B-Disease 0
)	O 0
.	O 0

Two	O 0
of	O 0
the	O 0
children	O 0
exhibited	O 0
a	O 0
homozygous	O 0
deficiency	O 0
characterized	O 0
by	O 0
the	O 0
absence	O 0
of	O 0
the	O 0
150	O 0
-	O 0
kD	O 0
form	O 0
of	O 0
Factor	O 0
H	O 0
and	O 0
the	O 0
presence	O 0
,	O 0
upon	O 0
immunoblotting	O 0
,	O 0
of	O 0
the	O 0
42	O 0
-	O 0
kD	O 0
Factor	O 0
H	O 0
-	O 0
like	O 0
protein	O 0
1	O 0
(	O 0
FHL	O 0
-	O 0
1	O 0
)	O 0
and	O 0
other	O 0
FH	O 0
-	O 0
related	O 0
protein	O 0
(	O 0
FHR	O 0
)	O 0
bands	O 0
.	O 0

Southern	O 0
blot	O 0
and	O 0
PCR	O 0
analysis	O 0
of	O 0
DNA	O 0
of	O 0
one	O 0
patient	O 0
with	O 0
homozygous	O 0
deficiency	O 0
ruled	O 0
out	O 0
the	O 0
presence	O 0
of	O 0
a	O 0
large	O 0
deletion	O 0
of	O 0
the	O 0
FH	O 0
gene	O 0
as	O 0
the	O 0
underlying	O 0
defect	O 0
for	O 0
the	O 0
deficiency	O 0
.	O 0

The	O 0
other	O 0
four	O 0
children	O 0
presented	O 0
with	O 0
heterozygous	O 0
deficiency	O 0
and	O 0
exhibited	O 0
a	O 0
normal	O 0
immunoblotting	O 0
pattern	O 0
of	O 0
proteins	O 0
of	O 0
the	O 0
FH	O 0
family	O 0
.	O 0

Factor	B-Disease 0
H	I-Disease 0
deficiency	I-Disease 0
is	O 0
the	O 0
only	O 0
complement	B-Disease 0
deficiency	I-Disease 0
associated	O 0
with	O 0
HUS	B-Disease 0
.	O 0

These	O 0
observations	O 0
suggest	O 0
a	O 0
role	O 0
for	O 0
FH	O 0
and	O 0
/	O 0
or	O 0
FH	O 0
receptors	O 0
in	O 0
the	O 0
pathogenesis	O 0
of	O 0
idiopathic	O 0
HUS	B-Disease 0
.	O 0
.	O 0

Further	O 0
evidence	O 0
for	O 0
a	O 0
major	O 0
ancient	O 0
mutation	O 0
underlying	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
from	O 0
linkage	O 0
disequilibrium	O 0
studies	O 0
in	O 0
the	O 0
Japanese	O 0
population	O 0
.	O 0

The	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
mutation	O 0
is	O 0
an	O 0
unstable	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
,	O 0
present	O 0
at	O 0
a	O 0
copy	O 0
number	O 0
of	O 0
5	O 0
-	O 0
37	O 0
repeats	O 0
on	O 0
normal	O 0
chromosomes	O 0
but	O 0
amplified	O 0
to	O 0
50	O 0
-	O 0
3000	O 0
copies	O 0
on	O 0
DM	B-Disease 0
chromosomes	O 0
.	O 0

Previous	O 0
findings	O 0
in	O 0
Caucasian	O 0
populations	O 0
of	O 0
a	O 0
DM	B-Disease 0
founder	O 0
chromosome	O 0
raise	O 0
a	O 0
question	O 0
about	O 0
the	O 0
molecular	O 0
events	O 0
involved	O 0
in	O 0
the	O 0
expansion	O 0
mutation	O 0
.	O 0

To	O 0
investigate	O 0
whether	O 0
a	O 0
founder	O 0
chromosome	O 0
for	O 0
the	O 0
DM	B-Disease 0
mutation	O 0
exists	O 0
in	O 0
the	O 0
Japanese	O 0
population	O 0
,	O 0
we	O 0
genotyped	O 0
families	O 0
using	O 0
polymorphic	O 0
markers	O 0
near	O 0
the	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
region	O 0
and	O 0
constructed	O 0
haplotypes	O 0
.	O 0

Six	O 0
different	O 0
haplotypes	O 0
were	O 0
found	O 0
and	O 0
DM	B-Disease 0
alleles	O 0
were	O 0
always	O 0
haplotype	O 0
A	O 0
.	O 0

To	O 0
find	O 0
an	O 0
origin	O 0
of	O 0
the	O 0
(	O 0
CTG	O 0
)	O 0
n	O 0
repeat	O 0
mutation	O 0
and	O 0
to	O 0
investigate	O 0
the	O 0
mechanism	O 0
of	O 0
the	O 0
expansion	O 0
mutation	O 0
in	O 0
the	O 0
Japanese	O 0
population	O 0
we	O 0
have	O 0
studied	O 0
90	O 0
Japanese	O 0
DM	B-Disease 0
families	O 0
comprising	O 0
190	O 0
affected	O 0
and	O 0
130	O 0
unaffected	O 0
members	O 0
.	O 0

The	O 0
results	O 0
suggest	O 0
that	O 0
a	O 0
few	O 0
common	O 0
ancestral	O 0
mutations	O 0
in	O 0
both	O 0
Caucasian	O 0
and	O 0
Japanese	O 0
populations	O 0
have	O 0
originated	O 0
by	O 0
expansion	O 0
of	O 0
an	O 0
ancestral	O 0
n	O 0
=	O 0
5	O 0
repeat	O 0
to	O 0
n	O 0
=	O 0
19	O 0
-	O 0
37	O 0
copies	O 0
.	O 0

These	O 0
data	O 0
support	O 0
multistep	O 0
models	O 0
of	O 0
triplet	O 0
repeat	O 0
expansion	O 0
that	O 0
have	O 0
been	O 0
proposed	O 0
for	O 0
both	O 0
DM	B-Disease 0
and	O 0
Friedreichs	B-Disease 0
ataxia	I-Disease 0
.	O 0
.	O 0

The	O 0
molecular	O 0
basis	O 0
of	O 0
C6	B-Disease 0
deficiency	I-Disease 0
in	O 0
the	O 0
western	O 0
Cape	O 0
,	O 0
South	O 0
Africa	O 0
.	O 0

Deficiency	B-Disease 0
of	I-Disease 0
the	I-Disease 0
sixth	I-Disease 0
component	I-Disease 0
of	I-Disease 0
human	I-Disease 0
complement	I-Disease 0
(	O 0
C6	O 0
)	O 0
has	O 0
been	O 0
reported	O 0
in	O 0
a	O 0
number	O 0
of	O 0
families	O 0
from	O 0
the	O 0
western	O 0
Cape	O 0
,	O 0
South	O 0
Africa	O 0
.	O 0

Meningococcal	B-Disease 0
disease	I-Disease 0
is	O 0
endemic	O 0
in	O 0
the	O 0
Cape	O 0
and	O 0
almost	O 0
all	O 0
pedigrees	O 0
of	O 0
total	O 0
C6	B-Disease 0
deficiency	I-Disease 0
(	O 0
C6Q0	O 0
)	O 0
have	O 0
been	O 0
ascertained	O 0
because	O 0
of	O 0
recurrent	O 0
disease	O 0
.	O 0

We	O 0
have	O 0
sequenced	O 0
the	O 0
expressed	O 0
exons	O 0
of	O 0
the	O 0
C6	O 0
gene	O 0
from	O 0
selected	O 0
cases	O 0
and	O 0
have	O 0
found	O 0
three	O 0
molecular	O 0
defects	O 0
leading	O 0
to	O 0
total	O 0
deficiency	O 0
879delG	O 0
,	O 0
which	O 0
is	O 0
the	O 0
common	O 0
defect	O 0
in	O 0
the	O 0
Cape	O 0
and	O 0
hitherto	O 0
unreported	O 0
,	O 0
and	O 0
1195delC	O 0
and	O 0
1936delG	O 0
,	O 0
which	O 0
have	O 0
been	O 0
previously	O 0
reported	O 0
in	O 0
African	O 0
-	O 0
Americans	O 0
.	O 0

We	O 0
also	O 0
show	O 0
that	O 0
the	O 0
879delG	O 0
and	O 0
1195delC	O 0
defects	O 0
are	O 0
associated	O 0
with	O 0
characteristic	O 0
C6	O 0
/	O 0
C7	O 0
region	O 0
DNA	O 0
marker	O 0
haplotypes	O 0
,	O 0
although	O 0
small	O 0
variations	O 0
were	O 0
observed	O 0
.	O 0

The	O 0
1936delG	O 0
defect	O 0
was	O 0
observed	O 0
only	O 0
once	O 0
in	O 0
the	O 0
Cape	O 0
,	O 0
but	O 0
its	O 0
associated	O 0
haplotype	O 0
could	O 0
be	O 0
deduced	O 0
.	O 0

The	O 0
data	O 0
from	O 0
the	O 0
haplotypes	O 0
indicate	O 0
that	O 0
these	O 0
three	O 0
molecular	O 0
defects	O 0
account	O 0
for	O 0
the	O 0
defects	O 0
in	O 0
all	O 0
the	O 0
38	O 0
unrelated	O 0
C6Q0	O 0
individuals	O 0
we	O 0
have	O 0
studied	O 0
from	O 0
the	O 0
Cape	O 0
.	O 0

We	O 0
have	O 0
also	O 0
observed	O 0
the	O 0
879delG	O 0
defect	O 0
in	O 0
two	O 0
Dutch	O 0
C6	B-Disease 0
-	I-Disease 0
deficient	I-Disease 0
kindreds	O 0
,	O 0
but	O 0
the	O 0
879delG	O 0
defect	O 0
in	O 0
the	O 0
Cape	O 0
probably	O 0
did	O 0
not	O 0
come	O 0
from	O 0
The	O 0
Netherlands	O 0
.	O 0
.	O 0

Complement	B-Disease 0
C7	I-Disease 0
deficiency	I-Disease 0
:	O 0
seven	O 0
further	O 0
molecular	O 0
defects	O 0
and	O 0
their	O 0
associated	O 0
marker	O 0
haplotypes	O 0
.	O 0

Seven	O 0
further	O 0
molecular	O 0
bases	O 0
of	O 0
C7	B-Disease 0
deficiency	I-Disease 0
are	O 0
described	O 0
.	O 0

All	O 0
these	O 0
new	O 0
molecular	O 0
defects	O 0
involve	O 0
single	O 0
-	O 0
nucleotide	O 0
events	O 0
,	O 0
deletions	O 0
and	O 0
substitutions	O 0
,	O 0
some	O 0
of	O 0
which	O 0
alter	O 0
splice	O 0
sites	O 0
,	O 0
and	O 0
others	O 0
codons	O 0
.	O 0

They	O 0
are	O 0
distributed	O 0
along	O 0
the	O 0
C7	O 0
gene	O 0
,	O 0
but	O 0
predominantly	O 0
towards	O 0
the	O 0
3	O 0
end	O 0
.	O 0

All	O 0
were	O 0
found	O 0
in	O 0
compound	O 0
heterozygous	O 0
individuals	O 0
.	O 0

The	O 0
C6	O 0
/	O 0
C7	O 0
marker	O 0
haplotypes	O 0
associated	O 0
with	O 0
most	O 0
C7	B-Disease 0
defects	I-Disease 0
are	O 0
tabulated	O 0
.	O 0
.	O 0

A	O 0
genome	O 0
-	O 0
wide	O 0
search	O 0
for	O 0
chromosomal	O 0
loci	O 0
linked	O 0
to	O 0
mental	O 0
health	O 0
wellness	O 0
in	O 0
relatives	O 0
at	O 0
high	O 0
risk	O 0
for	O 0
bipolar	B-Disease 0
affective	I-Disease 0
disorder	I-Disease 0
among	O 0
the	O 0
Old	O 0
Order	O 0
Amish	O 0
.	O 0

Bipolar	B-Disease 0
affective	I-Disease 0
disorder	I-Disease 0
(	O 0
BPAD	B-Disease 0
;	O 0
manic	B-Disease 0
-	I-Disease 0
depressive	I-Disease 0
illness	I-Disease 0
)	O 0
is	O 0
characterized	O 0
by	O 0
episodes	O 0
of	O 0
mania	B-Disease 0
and	O 0
/	O 0
or	O 0
hypomania	B-Disease 0
interspersed	O 0
with	O 0
periods	O 0
of	O 0
depression	B-Disease 0
.	O 0

Compelling	O 0
evidence	O 0
supports	O 0
a	O 0
significant	O 0
genetic	O 0
component	O 0
in	O 0
the	O 0
susceptibility	O 0
to	O 0
develop	O 0
BPAD	B-Disease 0
.	O 0

To	O 0
date	O 0
,	O 0
however	O 0
,	O 0
linkage	O 0
studies	O 0
have	O 0
attempted	O 0
only	O 0
to	O 0
identify	O 0
chromosomal	O 0
loci	O 0
that	O 0
cause	O 0
or	O 0
increase	O 0
the	O 0
risk	O 0
of	O 0
developing	O 0
BPAD	B-Disease 0
.	O 0

To	O 0
determine	O 0
whether	O 0
there	O 0
could	O 0
be	O 0
protective	O 0
alleles	O 0
that	O 0
prevent	O 0
or	O 0
reduce	O 0
the	O 0
risk	O 0
of	O 0
developing	O 0
BPAD	B-Disease 0
,	O 0
similar	O 0
to	O 0
what	O 0
is	O 0
observed	O 0
in	O 0
other	O 0
genetic	B-Disease 0
disorders	I-Disease 0
,	O 0
we	O 0
used	O 0
mental	O 0
health	O 0
wellness	O 0
(	O 0
absence	O 0
of	O 0
any	O 0
psychiatric	B-Disease 0
disorder	I-Disease 0
)	O 0
as	O 0
the	O 0
phenotype	O 0
in	O 0
our	O 0
genome	O 0
-	O 0
wide	O 0
linkage	O 0
scan	O 0
of	O 0
several	O 0
large	O 0
multigeneration	O 0
Old	O 0
Order	O 0
Amish	O 0
pedigrees	O 0
exhibiting	O 0
an	O 0
extremely	O 0
high	O 0
incidence	O 0
of	O 0
BPAD	B-Disease 0
.	O 0

We	O 0
have	O 0
found	O 0
strong	O 0
evidence	O 0
for	O 0
a	O 0
locus	O 0
on	O 0
chromosome	O 0
4p	O 0
at	O 0
D4S2949	O 0
(	O 0
maximum	O 0
GENEHUNTER	O 0
-	O 0
PLUS	O 0
nonparametric	O 0
linkage	O 0
score	O 0
=	O 0
4	O 0
.	O 0
05	O 0
,	O 0
P	O 0
=	O 0
5	O 0
.	O 0
22	O 0
x	O 0
10	O 0
(	O 0
-	O 0
4	O 0
)	O 0
;	O 0
SIBPAL	O 0
Pempirical	O 0
value	O 0
<	O 0
3	O 0
x	O 0
10	O 0
(	O 0
-	O 0
5	O 0
)	O 0
)	O 0
and	O 0
suggestive	O 0
evidence	O 0
for	O 0
a	O 0
locus	O 0
on	O 0
chromosome	O 0
4q	O 0
at	O 0
D4S397	O 0
(	O 0
maximum	O 0
GENEHUNTER	O 0
-	O 0
PLUS	O 0
nonparametric	O 0
linkage	O 0
score	O 0
=	O 0
3	O 0
.	O 0
29	O 0
,	O 0
P	O 0
=	O 0
2	O 0
.	O 0
57	O 0
x	O 0
10	O 0
(	O 0
-	O 0
3	O 0
)	O 0
;	O 0
SIBPAL	O 0
Pempirical	O 0
value	O 0
<	O 0
1	O 0
x	O 0
10	O 0
(	O 0
-	O 0
3	O 0
)	O 0
)	O 0
that	O 0
are	O 0
linked	O 0
to	O 0
mental	O 0
health	O 0
wellness	O 0
.	O 0

These	O 0
findings	O 0
are	O 0
consistent	O 0
with	O 0
the	O 0
hypothesis	O 0
that	O 0
certain	O 0
alleles	O 0
could	O 0
prevent	O 0
or	O 0
modify	O 0
the	O 0
clinical	O 0
manifestations	O 0
of	O 0
BPAD	B-Disease 0
and	O 0
perhaps	O 0
other	O 0
related	O 0
affective	B-Disease 0
disorders	I-Disease 0
.	O 0

Segregation	O 0
distortion	O 0
in	O 0
myotonic	B-Disease 0
dystrophy	I-Disease 0
.	O 0

Myotonic	B-Disease 0
dystrophy	I-Disease 0
(	O 0
DM	B-Disease 0
)	O 0
is	O 0
an	O 0
autosomal	B-Disease 0
dominant	I-Disease 0
disease	I-Disease 0
which	O 0
,	O 0
in	O 0
the	O 0
typical	O 0
pedigree	O 0
,	O 0
shows	O 0
a	O 0
three	O 0
generation	O 0
anticipation	O 0
cascade	O 0
.	O 0

This	O 0
results	O 0
in	O 0
infertility	B-Disease 0
and	O 0
congenital	B-Disease 0
myotonic	I-Disease 0
dystrophy	I-Disease 0
(	O 0
CDM	B-Disease 0
)	O 0
with	O 0
the	O 0
disappearance	O 0
of	O 0
DM	B-Disease 0
in	O 0
that	O 0
pedigree	O 0
.	O 0

The	O 0
concept	O 0
of	O 0
segregation	O 0
distortion	O 0
,	O 0
where	O 0
there	O 0
is	O 0
preferential	O 0
transmission	O 0
of	O 0
the	O 0
larger	O 0
allele	O 0
at	O 0
the	O 0
DM	B-Disease 0
locus	O 0
,	O 0
has	O 0
been	O 0
put	O 0
forward	O 0
to	O 0
explain	O 0
partially	O 0
the	O 0
maintenance	O 0
of	O 0
DM	B-Disease 0
in	O 0
the	O 0
population	O 0
.	O 0

In	O 0
a	O 0
survey	O 0
of	O 0
DM	B-Disease 0
in	O 0
Northern	O 0
Ireland	O 0
,	O 0
59	O 0
pedigrees	O 0
were	O 0
ascertained	O 0
.	O 0

Sibships	O 0
where	O 0
the	O 0
status	O 0
of	O 0
all	O 0
the	O 0
members	O 0
had	O 0
been	O 0
identified	O 0
were	O 0
examined	O 0
to	O 0
determine	O 0
the	O 0
transmission	O 0
of	O 0
the	O 0
DM	B-Disease 0
expansion	O 0
from	O 0
affected	O 0
parents	O 0
to	O 0
their	O 0
offspring	O 0
.	O 0

Where	O 0
the	O 0
transmitting	O 0
parent	O 0
was	O 0
male	O 0
,	O 0
58	O 0
.	O 0

3	O 0
%	O 0
of	O 0
the	O 0
offspring	O 0
were	O 0
affected	O 0
,	O 0
and	O 0
in	O 0
the	O 0
case	O 0
of	O 0
a	O 0
female	O 0
transmitting	O 0
parent	O 0
,	O 0
68	O 0
.	O 0

7	O 0
%	O 0
were	O 0
affected	O 0
.	O 0

Studies	O 0
on	O 0
meiotic	O 0
drive	O 0
in	O 0
DM	B-Disease 0
have	O 0
shown	O 0
increased	O 0
transmission	O 0
of	O 0
the	O 0
larger	O 0
allele	O 0
at	O 0
the	O 0
DM	B-Disease 0
locus	O 0
in	O 0
non	O 0
-	O 0
DM	O 0
heterozygotes	O 0
for	O 0
CTGn	O 0
.	O 0

This	O 0
study	O 0
provides	O 0
further	O 0
evidence	O 0
that	O 0
the	O 0
DM	B-Disease 0
expansion	O 0
tends	O 0
to	O 0
be	O 0
transmitted	O 0
preferentially	O 0
.	O 0

Diagnosis	O 0
of	O 0
hemochromatosis	B-Disease 0
.	O 0

If	O 0
untreated	O 0
,	O 0
hemochromatosis	B-Disease 0
can	O 0
cause	O 0
serious	O 0
illness	O 0
and	O 0
early	B-Disease 0
death	I-Disease 0
,	O 0
but	O 0
the	O 0
disease	O 0
is	O 0
still	O 0
substantially	O 0
under	O 0
-	O 0
diagnosed	O 0
.	O 0

The	O 0
cornerstone	O 0
of	O 0
screening	O 0
and	O 0
case	O 0
detection	O 0
is	O 0
the	O 0
measurement	O 0
of	O 0
serum	O 0
transferrin	O 0
saturation	O 0
and	O 0
the	O 0
serum	O 0
ferritin	O 0
level	O 0
.	O 0

Once	O 0
the	O 0
diagnosis	O 0
is	O 0
suspected	O 0
,	O 0
physicians	O 0
must	O 0
use	O 0
serum	O 0
ferritin	O 0
levels	O 0
and	O 0
hepatic	O 0
iron	O 0
stores	O 0
on	O 0
liver	O 0
biopsy	O 0
specimens	O 0
to	O 0
assess	O 0
patients	O 0
for	O 0
the	O 0
presence	O 0
of	O 0
iron	B-Disease 0
overload	I-Disease 0
.	O 0

Liver	O 0
biopsy	O 0
is	O 0
also	O 0
used	O 0
to	O 0
establish	O 0
the	O 0
presence	O 0
or	O 0
absence	O 0
of	O 0
cirrhosis	B-Disease 0
,	O 0
which	O 0
can	O 0
affect	O 0
prognosis	O 0
and	O 0
management	O 0
.	O 0

A	O 0
DNA	O 0
-	O 0
based	O 0
test	O 0
for	O 0
the	O 0
HFE	O 0
gene	O 0
is	O 0
commercially	O 0
available	O 0
,	O 0
but	O 0
its	O 0
place	O 0
in	O 0
the	O 0
diagnosis	O 0
of	O 0
hemochromatosis	B-Disease 0
is	O 0
still	O 0
being	O 0
evaluated	O 0
.	O 0

Currently	O 0
,	O 0
the	O 0
most	O 0
useful	O 0
role	O 0
for	O 0
this	O 0
test	O 0
is	O 0
in	O 0
the	O 0
detection	O 0
of	O 0
hemochromatosis	B-Disease 0
in	O 0
the	O 0
family	O 0
members	O 0
of	O 0
patients	O 0
with	O 0
a	O 0
proven	O 0
case	O 0
of	O 0
the	O 0
disease	O 0
.	O 0

It	O 0
is	O 0
crucial	O 0
to	O 0
diagnose	O 0
hemochromatosis	B-Disease 0
before	O 0
hepatic	B-Disease 0
cirrhosis	I-Disease 0
develops	O 0
because	O 0
phlebotomy	O 0
therapy	O 0
can	O 0
avert	O 0
serious	O 0
chronic	O 0
disease	O 0
and	O 0
can	O 0
even	O 0
lead	O 0
to	O 0
normal	O 0
life	O 0
expectancy	O 0
.	O 0
.	O 0

Prevalence	O 0
of	O 0
the	O 0
I1307K	O 0
APC	B-Disease 0
gene	O 0
variant	O 0
in	O 0
Israeli	O 0
Jews	O 0
of	O 0
differing	O 0
ethnic	O 0
origin	O 0
and	O 0
risk	O 0
for	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
.	O 0

BACKGROUND	O 0
&	O 0
AIMS	O 0
Israeli	O 0
Jews	O 0
of	O 0
European	O 0
birth	O 0
,	O 0
i	O 0
.	O 0
e	O 0
.	O 0
,	O 0
Ashkenazim	O 0
,	O 0
have	O 0
the	O 0
highest	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
incidence	O 0
of	O 0
any	O 0
Israeli	O 0
ethnic	O 0
group	O 0
.	O 0

The	O 0
I1307K	O 0
APC	B-Disease 0
gene	O 0
variant	O 0
was	O 0
found	O 0
in	O 0
6	O 0
.	O 0

1	O 0
%	O 0
of	O 0
American	O 0
Jews	O 0
,	O 0
28	O 0
%	O 0
of	O 0
their	O 0
familial	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
cases	O 0
,	O 0
but	O 0
not	O 0
in	O 0
non	O 0
-	O 0
Jews	O 0
.	O 0

We	O 0
assessed	O 0
the	O 0
I1307K	O 0
prevalence	O 0
in	O 0
Israeli	O 0
Jews	O 0
of	O 0
differing	O 0
ethnic	O 0
origin	O 0
and	O 0
risk	O 0
for	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
.	O 0

METHODS	O 0
DNA	O 0
samples	O 0
from	O 0
500	O 0
unrelated	O 0
Jews	O 0
of	O 0
European	O 0
or	O 0
non	O 0
-	O 0
European	O 0
origin	O 0
,	O 0
with	O 0
or	O 0
without	O 0
a	O 0
personal	O 0
and	O 0
/	O 0
or	O 0
family	O 0
history	O 0
of	O 0
neoplasia	B-Disease 0
,	O 0
were	O 0
examined	O 0
for	O 0
the	O 0
I1307K	O 0
variant	O 0
by	O 0
the	O 0
allele	O 0
-	O 0
specific	O 0
oligonucleotide	O 0
(	O 0
ASO	O 0
)	O 0
method	O 0
.	O 0

RESULTS	O 0
In	O 0
persons	O 0
at	O 0
average	O 0
risk	O 0
for	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
,	O 0
I1307K	O 0
was	O 0
found	O 0
in	O 0
5	O 0
.	O 0

0	O 0
%	O 0
of	O 0
120	O 0
European	O 0
and	O 0
1	O 0
.	O 0

6	O 0
%	O 0
of	O 0
188	O 0
non	O 0
-	O 0
European	O 0
Jews	O 0
(	O 0
P	O 0
=	O 0
0	O 0
.	O 0
08	O 0
)	O 0
.	O 0

It	O 0
occurred	O 0
in	O 0
15	O 0
.	O 0

4	O 0
%	O 0
of	O 0
52	O 0
Ashkenazi	O 0
Israelis	O 0
with	O 0
familial	O 0
cancer	B-Disease 0
(	O 0
P	O 0
=	O 0
0	O 0
.	O 0
02	O 0
)	O 0
and	O 0
was	O 0
not	O 0
detected	O 0
in	O 0
51	O 0
non	O 0
-	O 0
European	O 0
Jews	O 0
at	O 0
increased	O 0
cancer	B-Disease 0
risk	O 0
.	O 0

Colorectal	B-Disease 0
neoplasia	I-Disease 0
occurred	O 0
personally	O 0
or	O 0
in	O 0
the	O 0
families	O 0
of	O 0
13	O 0
of	O 0
20	O 0
Ashkenazi	O 0
I1307K	O 0
carriers	O 0
,	O 0
8	O 0
of	O 0
whom	O 0
also	O 0
had	O 0
a	O 0
personal	O 0
or	O 0
family	O 0
history	O 0
of	O 0
noncolonic	O 0
neoplasia	B-Disease 0
.	O 0

CONCLUSIONS	O 0
The	O 0
I1307K	O 0
APC	O 0
variant	O 0
may	O 0
represent	O 0
a	O 0
susceptibility	O 0
gene	O 0
for	O 0
colorectal	B-Disease 0
,	I-Disease 0
or	I-Disease 0
other	I-Disease 0
,	I-Disease 0
cancers	I-Disease 0
in	O 0
Ashkenazi	O 0
Jews	O 0
,	O 0
and	O 0
partially	O 0
explains	O 0
the	O 0
higher	O 0
incidence	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
in	O 0
European	O 0
Israelis	O 0
.	O 0

Systematic	O 0
analysis	O 0
of	O 0
coproporphyrinogen	O 0
oxidase	O 0
gene	O 0
defects	O 0
in	O 0
hereditary	B-Disease 0
coproporphyria	I-Disease 0
and	O 0
mutation	O 0
update	O 0
.	O 0

Hereditary	B-Disease 0
coproporphyria	I-Disease 0
(	O 0
HC	B-Disease 0
)	O 0
is	O 0
an	O 0
acute	O 0
hepatic	B-Disease 0
porphyria	I-Disease 0
with	O 0
autosomal	O 0
dominant	O 0
inheritance	O 0
caused	O 0
by	O 0
deficient	B-Disease 0
activity	I-Disease 0
of	I-Disease 0
coproporphyrinogen	I-Disease 0
III	I-Disease 0
oxidase	I-Disease 0
(	O 0
CPO	O 0
)	O 0
.	O 0

Clinical	O 0
manifestations	O 0
of	O 0
the	O 0
disease	O 0
are	O 0
characterized	O 0
by	O 0
acute	O 0
attacks	O 0
of	O 0
neurological	B-Disease 0
dysfunction	I-Disease 0
often	O 0
precipitated	O 0
by	O 0
drugs	O 0
,	O 0
fasting	O 0
,	O 0
cyclical	O 0
hormonal	O 0
changes	O 0
,	O 0
or	O 0
infectious	B-Disease 0
diseases	I-Disease 0
.	O 0

Skin	O 0
photosensitivity	O 0
may	O 0
also	O 0
be	O 0
present	O 0
.	O 0

The	O 0
seven	O 0
exons	O 0
,	O 0
the	O 0
exon	O 0
/	O 0
intron	O 0
boundaries	O 0
and	O 0
part	O 0
of	O 0
3	O 0
noncoding	O 0
sequence	O 0
of	O 0
the	O 0
CPO	O 0
gene	O 0
were	O 0
systematically	O 0
analyzed	O 0
by	O 0
an	O 0
exon	O 0
-	O 0
by	O 0
-	O 0
exon	O 0
denaturing	O 0
gradient	O 0
gel	O 0
electrophoresis	O 0
(	O 0
DGGE	O 0
)	O 0
strategy	O 0
followed	O 0
by	O 0
direct	O 0
sequencing	O 0
in	O 0
seven	O 0
unrelated	O 0
heterozygous	O 0
HC	B-Disease 0
patients	O 0
from	O 0
France	O 0
,	O 0
Holland	O 0
,	O 0
and	O 0
Czech	O 0
Republic	O 0
.	O 0

Seven	O 0
novel	O 0
mutations	O 0
and	O 0
two	O 0
new	O 0
polymorphisms	O 0
were	O 0
detected	O 0
.	O 0

Among	O 0
these	O 0
mutations	O 0
two	O 0
are	O 0
missense	O 0
(	O 0
G197W	O 0
,	O 0
W427R	O 0
)	O 0
,	O 0
two	O 0
are	O 0
nonsense	O 0
(	O 0
Q306X	O 0
,	O 0
Q385X	O 0
)	O 0
,	O 0
two	O 0
are	O 0
small	O 0
deletions	O 0
(	O 0
662de14bp	O 0
;	O 0
1168del3bp	O 0
removing	O 0
a	O 0
glycine	O 0
at	O 0
position	O 0
390	O 0
)	O 0
,	O 0
and	O 0
one	O 0
is	O 0
a	O 0
splicing	O 0
mutation	O 0
(	O 0
IVS1	O 0
-	O 0
15c	O 0
-	O 0
-	O 0
>	O 0
g	O 0
)	O 0
which	O 0
creates	O 0
a	O 0
new	O 0
acceptor	O 0
splice	O 0
site	O 0
.	O 0

The	O 0
pathological	O 0
significance	O 0
of	O 0
the	O 0
point	O 0
mutations	O 0
G197W	O 0
,	O 0
W427R	O 0
,	O 0
and	O 0
the	O 0
in	O 0
-	O 0
frame	O 0
deletion	O 0
390delGly	O 0
were	O 0
assessed	O 0
by	O 0
their	O 0
respective	O 0
expression	O 0
in	O 0
a	O 0
prokaryotic	O 0
system	O 0
using	O 0
site	O 0
-	O 0
directed	O 0
mutagenesis	O 0
.	O 0

These	O 0
mutations	O 0
resulted	O 0
in	O 0
the	O 0
absence	O 0
or	O 0
a	O 0
dramatic	O 0
decrease	O 0
of	O 0
CPO	O 0
activity	O 0
.	O 0

The	O 0
two	O 0
polymorphisms	O 0
were	O 0
localized	O 0
in	O 0
noncoding	O 0
part	O 0
of	O 0
the	O 0
gene	O 0
1	O 0
)	O 0
a	O 0
C	O 0
/	O 0
G	O 0
polymorphism	O 0
in	O 0
the	O 0
promotor	O 0
region	O 0
,	O 0
142	O 0
bp	O 0
upstream	O 0
from	O 0
the	O 0
transcriptional	O 0
initiation	O 0
site	O 0
(	O 0
-	O 0
142C	O 0
/	O 0
G	O 0
)	O 0
,	O 0
and	O 0
2	O 0
)	O 0
a	O 0
6	O 0
bp	O 0
deletion	O 0
polymorphism	O 0
in	O 0
the	O 0
3	O 0
noncoding	O 0
part	O 0
of	O 0
the	O 0
CPO	O 0
gene	O 0
,	O 0
574	O 0
bp	O 0
downstream	O 0
of	O 0
the	O 0
last	O 0
base	O 0
of	O 0
the	O 0
normal	O 0
termination	O 0
codon	O 0
(	O 0
+	O 0
574	O 0
delATTCTT	O 0
)	O 0
.	O 0

Five	O 0
intragenic	O 0
dimorphisms	O 0
are	O 0
now	O 0
well	O 0
characterized	O 0
and	O 0
the	O 0
high	O 0
degree	O 0
of	O 0
allelic	O 0
heterogeneity	O 0
in	O 0
HC	B-Disease 0
is	O 0
demonstrated	O 0
with	O 0
seven	O 0
new	O 0
different	O 0
mutations	O 0
making	O 0
a	O 0
total	O 0
of	O 0
nineteen	O 0
CPO	O 0
gene	B-Disease 0
defects	I-Disease 0
reported	O 0
so	O 0
far	O 0
.	O 0
.	O 0

Coincidence	O 0
of	O 0
two	O 0
novel	O 0
arylsulfatase	O 0
A	O 0
alleles	O 0
and	O 0
mutation	O 0
459	O 0
+	O 0
1G	O 0
>	O 0
A	O 0
within	O 0
a	O 0
family	O 0
with	O 0
metachromatic	B-Disease 0
leukodystrophy	I-Disease 0
:	O 0
molecular	O 0
basis	O 0
of	O 0
phenotypic	O 0
heterogeneity	O 0
.	O 0

In	O 0
a	O 0
family	O 0
with	O 0
three	O 0
siblings	O 0
,	O 0
one	O 0
developed	O 0
classical	O 0
late	O 0
infantile	O 0
metachromatic	B-Disease 0
leukodystrophy	I-Disease 0
(	O 0
MLD	B-Disease 0
)	O 0
,	O 0
fatal	O 0
at	O 0
age	O 0
5	O 0
years	O 0
,	O 0
with	O 0
deficient	O 0
arylsulfatase	O 0
A	O 0
(	O 0
ARSA	O 0
)	O 0
activity	O 0
and	O 0
increased	O 0
galactosylsulfatide	O 0
(	O 0
GS	O 0
)	O 0
excretion	O 0
.	O 0

The	O 0
two	O 0
other	O 0
siblings	O 0
,	O 0
apparently	O 0
healthy	O 0
at	O 0
12	O 0
(	O 0
1	O 0
/	O 0
2	O 0
)	O 0
and	O 0
15	O 0
years	O 0
,	O 0
respectively	O 0
,	O 0
and	O 0
their	O 0
father	O 0
,	O 0
apparently	O 0
healthy	O 0
as	O 0
well	O 0
,	O 0
presented	O 0
ARSA	O 0
and	O 0
GS	O 0
values	O 0
within	O 0
the	O 0
range	O 0
of	O 0
MLD	B-Disease 0
patients	O 0
.	O 0

Mutation	O 0
screening	O 0
and	O 0
sequence	O 0
analysis	O 0
disclosed	O 0
the	O 0
involvement	O 0
of	O 0
three	O 0
different	O 0
ARSA	O 0
mutations	O 0
being	O 0
the	O 0
molecular	O 0
basis	O 0
of	O 0
intrafamilial	O 0
phenotypic	O 0
heterogeneity	O 0
.	O 0

The	O 0
late	O 0
infantile	O 0
patient	O 0
inherited	O 0
from	O 0
his	O 0
mother	O 0
the	O 0
frequent	O 0
0	O 0
-	O 0
type	O 0
mutation	O 0
459	O 0
+	O 0
1G	O 0
>	O 0
A	O 0
,	O 0
and	O 0
from	O 0
his	O 0
father	O 0
a	O 0
novel	O 0
,	O 0
single	O 0
basepair	O 0
microdeletion	O 0
of	O 0
guanine	O 0
at	O 0
nucleotide	O 0
7	O 0
in	O 0
exon	O 0
1	O 0
(	O 0
7delG	O 0
)	O 0
.	O 0

The	O 0
two	O 0
clinically	O 0
unaffected	O 0
siblings	O 0
carried	O 0
the	O 0
maternal	O 0
mutation	O 0
459	O 0
+	O 0
1G	O 0
>	O 0
A	O 0
and	O 0
,	O 0
on	O 0
their	O 0
paternal	O 0
allele	O 0
,	O 0
a	O 0
novel	O 0
cytosine	O 0
to	O 0
thymidine	O 0
transition	O 0
at	O 0
nucleotide	O 0
2435	O 0
in	O 0
exon	O 0
8	O 0
,	O 0
resulting	O 0
in	O 0
substitution	O 0
of	O 0
alanine	O 0
464	O 0
by	O 0
valine	O 0
(	O 0
A464V	O 0
)	O 0
.	O 0

The	O 0
fathers	O 0
genotype	O 0
thus	O 0
was	O 0
7delG	O 0
/	O 0
A464V	O 0
.	O 0

Mutation	O 0
A464V	O 0
was	O 0
not	O 0
found	O 0
in	O 0
18	O 0
unrelated	O 0
MLD	B-Disease 0
patients	O 0
and	O 0
50	O 0
controls	O 0
.	O 0

A464V	O 0
,	O 0
although	O 0
clearly	O 0
modifying	O 0
ARSA	O 0
and	O 0
GS	O 0
levels	O 0
,	O 0
apparently	O 0
bears	O 0
little	O 0
significance	O 0
for	O 0
clinical	O 0
manifestation	O 0
of	O 0
MLD	B-Disease 0
,	O 0
mimicking	O 0
the	O 0
frequent	O 0
ARSA	O 0
pseudodeficiency	O 0
allele	O 0
.	O 0

Our	O 0
results	O 0
demonstrate	O 0
that	O 0
in	O 0
certain	O 0
genetic	O 0
conditions	O 0
MLD	B-Disease 0
-	O 0
like	O 0
ARSA	O 0
and	O 0
GS	O 0
values	O 0
need	O 0
not	O 0
be	O 0
paralleled	O 0
by	O 0
clinical	O 0
disease	O 0
,	O 0
a	O 0
finding	O 0
with	O 0
serious	O 0
diagnostic	O 0
and	O 0
prognostic	O 0
implications	O 0
.	O 0

Moreover	O 0
,	O 0
further	O 0
ARSA	O 0
alleles	O 0
functionally	O 0
similar	O 0
to	O 0
A464V	O 0
might	O 0
exist	O 0
which	O 0
,	O 0
together	O 0
with	O 0
0	O 0
-	O 0
type	O 0
mutations	O 0
,	O 0
may	O 0
cause	O 0
pathological	O 0
ARSA	O 0
and	O 0
GS	O 0
levels	O 0
,	O 0
but	O 0
not	O 0
clinical	O 0
outbreak	O 0
of	O 0
the	O 0
disease	O 0
.	O 0
.	O 0

Human	O 0
MLH1	O 0
deficiency	O 0
predisposes	O 0
to	O 0
hematological	B-Disease 0
malignancy	I-Disease 0
and	O 0
neurofibromatosis	B-Disease 0
type	I-Disease 0
1	I-Disease 0
.	O 0

Heterozygous	O 0
germ	O 0
-	O 0
line	O 0
mutations	O 0
in	O 0
the	O 0
DNA	O 0
mismatch	O 0
repair	O 0
genes	O 0
lead	O 0
to	O 0
hereditary	B-Disease 0
nonpolyposis	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
.	O 0

The	O 0
disease	O 0
susceptibility	O 0
of	O 0
individuals	O 0
who	O 0
constitutionally	O 0
lack	O 0
both	O 0
wild	O 0
-	O 0
type	O 0
alleles	O 0
is	O 0
unknown	O 0
.	O 0

We	O 0
have	O 0
identified	O 0
three	O 0
offspring	O 0
in	O 0
a	O 0
hereditary	B-Disease 0
nonpolyposis	I-Disease 0
colorectal	I-Disease 0
cancer	I-Disease 0
family	O 0
who	O 0
developed	O 0
hematological	B-Disease 0
malignancy	I-Disease 0
at	O 0
a	O 0
very	O 0
early	O 0
age	O 0
,	O 0
and	O 0
at	O 0
least	O 0
two	O 0
of	O 0
them	O 0
displayed	O 0
signs	O 0
of	O 0
neurofibromatosis	B-Disease 0
type	I-Disease 0
1	I-Disease 0
(	O 0
NF1	B-Disease 0
)	O 0
.	O 0

DNA	O 0
sequence	O 0
analysis	O 0
and	O 0
allele	O 0
-	O 0
specific	O 0
amplification	O 0
in	O 0
two	O 0
siblings	O 0
revealed	O 0
a	O 0
homozygous	O 0
MLH1	O 0
mutation	O 0
(	O 0
C676T	O 0
-	O 0
-	O 0
>	O 0
Arg226Stop	O 0
)	O 0
.	O 0

Thus	O 0
,	O 0
a	O 0
homozygous	O 0
germ	O 0
-	O 0
line	O 0
MLH1	O 0
mutation	O 0
and	O 0
consequent	O 0
mismatch	O 0
repair	O 0
deficiency	O 0
results	O 0
in	O 0
a	O 0
mutator	O 0
phenotype	O 0
characterized	O 0
by	O 0
leukemia	B-Disease 0
and	O 0
/	O 0
or	O 0
lymphoma	B-Disease 0
associated	O 0
with	O 0
neurofibromatosis	B-Disease 0
type	I-Disease 0
1	I-Disease 0
.	O 0
.	O 0

Missense	O 0
mutations	O 0
in	O 0
the	O 0
most	O 0
ancient	O 0
residues	O 0
of	O 0
the	O 0
PAX6	O 0
paired	O 0
domain	O 0
underlie	O 0
a	O 0
spectrum	O 0
of	O 0
human	O 0
congenital	B-Disease 0
eye	I-Disease 0
malformations	I-Disease 0
.	O 0

Mutations	O 0
of	O 0
the	O 0
human	O 0
PAX6	O 0
gene	O 0
underlie	O 0
aniridia	B-Disease 0
(	O 0
congenital	B-Disease 0
absence	I-Disease 0
of	I-Disease 0
the	I-Disease 0
iris	I-Disease 0
)	O 0
,	O 0
a	O 0
rare	O 0
dominant	O 0
malformation	B-Disease 0
of	I-Disease 0
the	I-Disease 0
eye	I-Disease 0
.	O 0

The	O 0
spectrum	O 0
of	O 0
PAX6	O 0
mutations	O 0
in	O 0
aniridia	B-Disease 0
patients	O 0
is	O 0
highly	O 0
biased	O 0
,	O 0
with	O 0
92	O 0
%	O 0
of	O 0
all	O 0
reported	O 0
mutations	O 0
leading	O 0
to	O 0
premature	O 0
truncation	O 0
of	O 0
the	O 0
protein	O 0
(	O 0
nonsense	O 0
,	O 0
splicing	O 0
,	O 0
insertions	O 0
and	O 0
deletions	O 0
)	O 0
and	O 0
just	O 0
2	O 0
%	O 0
leading	O 0
to	O 0
substitution	O 0
of	O 0
one	O 0
amino	O 0
acid	O 0
by	O 0
another	O 0
(	O 0
missense	O 0
)	O 0
.	O 0

The	O 0
extraordinary	O 0
conservation	O 0
of	O 0
the	O 0
PAX6	O 0
protein	O 0
at	O 0
the	O 0
amino	O 0
acid	O 0
level	O 0
amongst	O 0
vertebrates	O 0
predicts	O 0
that	O 0
pathological	O 0
missense	O 0
mutations	O 0
should	O 0
in	O 0
fact	O 0
be	O 0
common	O 0
even	O 0
though	O 0
they	O 0
are	O 0
hardly	O 0
ever	O 0
seen	O 0
in	O 0
aniridia	B-Disease 0
patients	O 0
.	O 0

This	O 0
indicates	O 0
that	O 0
there	O 0
is	O 0
a	O 0
heavy	O 0
ascertainment	O 0
bias	O 0
in	O 0
the	O 0
selection	O 0
of	O 0
patients	O 0
for	O 0
PAX6	O 0
mutation	O 0
analysis	O 0
and	O 0
that	O 0
the	O 0
missing	O 0
PAX6	O 0
missense	O 0
mutations	O 0
frequently	O 0
may	O 0
underlie	O 0
phenotypes	O 0
distinct	O 0
from	O 0
textbook	O 0
aniridia	B-Disease 0
.	O 0

Here	O 0
we	O 0
present	O 0
four	O 0
novel	O 0
PAX6	O 0
missense	O 0
mutations	O 0
,	O 0
two	O 0
in	O 0
association	O 0
with	O 0
atypical	O 0
phenotypes	O 0
ectopia	B-Disease 0
pupillae	I-Disease 0
(	O 0
displaced	B-Disease 0
pupils	I-Disease 0
)	O 0
and	O 0
congenital	B-Disease 0
nystagmus	I-Disease 0
(	O 0
searching	B-Disease 0
gaze	I-Disease 0
)	O 0
,	O 0
and	O 0
two	O 0
in	O 0
association	O 0
with	O 0
more	O 0
recognizable	O 0
aniridia	B-Disease 0
phenotypes	O 0
.	O 0

Strikingly	O 0
,	O 0
all	O 0
four	O 0
mutations	O 0
are	O 0
located	O 0
within	O 0
the	O 0
PAX6	O 0
paired	O 0
domain	O 0
and	O 0
affect	O 0
amino	O 0
acids	O 0
which	O 0
are	O 0
highly	O 0
conserved	O 0
in	O 0
all	O 0
known	O 0
paired	O 0
domain	O 0
proteins	O 0
.	O 0

Our	O 0
results	O 0
support	O 0
the	O 0
hypothesis	O 0
that	O 0
the	O 0
under	O 0
-	O 0
representation	O 0
of	O 0
missense	O 0
mutations	O 0
is	O 0
caused	O 0
by	O 0
ascertainment	O 0
bias	O 0
and	O 0
suggest	O 0
that	O 0
a	O 0
substantial	O 0
burden	O 0
of	O 0
PAX6	B-Disease 0
-	I-Disease 0
related	I-Disease 0
disease	I-Disease 0
remains	O 0
to	O 0
be	O 0
uncovered	O 0
.	O 0
.	O 0

The	O 0
chromosomal	O 0
order	O 0
of	O 0
genes	O 0
controlling	O 0
the	O 0
major	O 0
histocompatibility	O 0
complex	O 0
,	O 0
properdin	O 0
factor	O 0
B	O 0
,	O 0
and	O 0
deficiency	B-Disease 0
of	I-Disease 0
the	I-Disease 0
second	I-Disease 0
component	I-Disease 0
of	I-Disease 0
complement	I-Disease 0
.	O 0

The	O 0
relationship	O 0
of	O 0
the	O 0
genes	O 0
coding	O 0
for	O 0
HLA	O 0
to	O 0
those	O 0
coding	O 0
for	O 0
properdin	O 0
Factor	O 0
B	O 0
allotypes	O 0
and	O 0
for	O 0
deficiency	B-Disease 0
of	I-Disease 0
the	I-Disease 0
second	I-Disease 0
component	I-Disease 0
of	I-Disease 0
complement	I-Disease 0
(	O 0
C2	O 0
)	O 0
was	O 0
studied	O 0
in	O 0
families	O 0
of	O 0
patients	O 0
with	O 0
connective	O 0
tissue	O 0
disorders	O 0
.	O 0

Patients	O 0
were	O 0
selected	O 0
because	O 0
they	O 0
were	O 0
heterozygous	O 0
or	O 0
homozygous	O 0
for	O 0
C2	B-Disease 0
deficiency	I-Disease 0
.	O 0

12	O 0
families	O 0
with	O 0
15	O 0
matings	O 0
informative	O 0
for	O 0
C2	B-Disease 0
deficiency	I-Disease 0
were	O 0
found	O 0
.	O 0

Of	O 0
57	O 0
informative	O 0
meioses	O 0
,	O 0
two	O 0
crossovers	O 0
were	O 0
noted	O 0
between	O 0
the	O 0
C2	B-Disease 0
deficiency	I-Disease 0
gene	O 0
and	O 0
the	O 0
HLA	O 0
-	O 0
B	O 0
gene	O 0
,	O 0
with	O 0
a	O 0
recombinant	O 0
fraction	O 0
of	O 0
0	O 0
.	O 0

035	O 0
.	O 0

A	O 0
lod	O 0
score	O 0
of	O 0
13	O 0
was	O 0
calculated	O 0
for	O 0
linkage	O 0
between	O 0
C2	B-Disease 0
deficiency	I-Disease 0
and	O 0
HLA	O 0
-	O 0
B	O 0
at	O 0
a	O 0
maximum	O 0
likelihood	O 0
value	O 0
of	O 0
the	O 0
recombinant	O 0
fraction	O 0
of	O 0
0	O 0
.	O 0

04	O 0
.	O 0

18	O 0
families	O 0
with	O 0
21	O 0
informative	O 0
matings	O 0
for	O 0
both	O 0
properdin	O 0
Factor	O 0
B	O 0
allotype	O 0
and	O 0
HLA	O 0
-	O 0
B	O 0
were	O 0
found	O 0
.	O 0

Of	O 0
72	O 0
informative	O 0
meioses	O 0
,	O 0
three	O 0
recombinants	O 0
were	O 0
found	O 0
,	O 0
giving	O 0
a	O 0
recombinant	O 0
fraction	O 0
of	O 0
0	O 0
.	O 0

042	O 0
.	O 0

A	O 0
lod	O 0
score	O 0
of	O 0
16	O 0
between	O 0
HLA	O 0
-	O 0
B	O 0
and	O 0
Factor	O 0
B	O 0
allotypes	O 0
was	O 0
calculated	O 0
at	O 0
a	O 0
maximum	O 0
likelihood	O 0
value	O 0
of	O 0
the	O 0
recombinant	O 0
fraction	O 0
of	O 0
0	O 0
.	O 0

04	O 0
.	O 0

A	O 0
crossover	O 0
was	O 0
shown	O 0
to	O 0
have	O 0
occurred	O 0
between	O 0
genes	O 0
for	O 0
Factor	O 0
B	O 0
and	O 0
HLA	O 0
-	O 0
D	O 0
,	O 0
in	O 0
which	O 0
HLA	O 0
-	O 0
D	O 0
segregared	O 0
with	O 0
HLA	O 0
-	O 0
A	O 0
and	O 0
B	O 0
.	O 0

These	O 0
studies	O 0
suggest	O 0
that	O 0
the	O 0
genes	O 0
for	O 0
Factor	O 0
B	O 0
and	O 0
C2	B-Disease 0
deficiency	I-Disease 0
are	O 0
located	O 0
outside	O 0
those	O 0
for	O 0
HLA	O 0
,	O 0
that	O 0
the	O 0
order	O 0
of	O 0
genese	O 0
is	O 0
HLA	O 0
-	O 0
A	O 0
,	O 0
-	O 0
B	O 0
,	O 0
-	O 0
D	O 0
,	O 0
Factor	O 0
B	O 0
allotype	O 0
,	O 0
C2	B-Disease 0
deficiency	I-Disease 0
,	O 0
that	O 0
the	O 0
genes	O 0
coding	O 0
for	O 0
C2	B-Disease 0
deficiency	I-Disease 0
and	O 0
Factor	O 0
B	O 0
allotypes	O 0
are	O 0
approximately	O 0
3	O 0
-	O 0
-	O 0
5	O 0
centimorgans	O 0
from	O 0
the	O 0
HLA	O 0
-	O 0
A	O 0
and	O 0
HLA	O 0
-	O 0
B	O 0
loci	O 0
,	O 0
and	O 0
that	O 0
the	O 0
apparent	O 0
lack	O 0
of	O 0
recombinants	O 0
between	O 0
the	O 0
Factor	O 0
B	O 0
gene	O 0
and	O 0
C2	B-Disease 0
deficiency	I-Disease 0
gene	O 0
suggests	O 0
that	O 0
these	O 0
two	O 0
genes	O 0
lie	O 0
in	O 0
close	O 0
proximity	O 0
to	O 0
one	O 0
another	O 0
.	O 0

Distribution	O 0
of	O 0
emerin	O 0
and	O 0
lamins	O 0
in	O 0
the	O 0
heart	O 0
and	O 0
implications	O 0
for	O 0
Emery	B-Disease 0
-	I-Disease 0
Dreifuss	I-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
.	O 0

Emerin	O 0
is	O 0
a	O 0
nuclear	O 0
membrane	O 0
protein	O 0
which	O 0
is	O 0
missing	O 0
or	O 0
defective	O 0
in	O 0
Emery	B-Disease 0
-	I-Disease 0
Dreifuss	I-Disease 0
muscular	I-Disease 0
dystrophy	I-Disease 0
(	O 0
EDMD	B-Disease 0
)	O 0
.	O 0

It	O 0
is	O 0
one	O 0
member	O 0
of	O 0
a	O 0
family	O 0
of	O 0
lamina	O 0
-	O 0
associated	O 0
proteins	O 0
which	O 0
includes	O 0
LAP1	O 0
,	O 0
LAP2	O 0
and	O 0
lamin	O 0
B	O 0
receptor	O 0
(	O 0
LBR	O 0
)	O 0
.	O 0

A	O 0
panel	O 0
of	O 0
16	O 0
monoclonal	O 0
antibodies	O 0
(	O 0
mAbs	O 0
)	O 0
has	O 0
been	O 0
mapped	O 0
to	O 0
six	O 0
specific	O 0
sites	O 0
throughout	O 0
the	O 0
emerin	O 0
molecule	O 0
using	O 0
phage	O 0
-	O 0
displayed	O 0
peptide	O 0
libraries	O 0
and	O 0
has	O 0
been	O 0
used	O 0
to	O 0
localize	O 0
emerin	O 0
in	O 0
human	O 0
and	O 0
rabbit	O 0
heart	O 0
.	O 0

Several	O 0
mAbs	O 0
against	O 0
different	O 0
emerin	O 0
epitopes	O 0
did	O 0
not	O 0
recognize	O 0
intercalated	O 0
discs	O 0
in	O 0
the	O 0
heart	O 0
,	O 0
though	O 0
they	O 0
recognized	O 0
cardiomyocyte	O 0
nuclei	O 0
strongly	O 0
,	O 0
both	O 0
at	O 0
the	O 0
rim	O 0
and	O 0
in	O 0
intranuclear	O 0
spots	O 0
or	O 0
channels	O 0
.	O 0

A	O 0
polyclonal	O 0
rabbit	O 0
antiserum	O 0
against	O 0
emerin	O 0
did	O 0
recognize	O 0
both	O 0
nuclear	O 0
membrane	O 0
and	O 0
intercalated	O 0
discs	O 0
but	O 0
,	O 0
after	O 0
affinity	O 0
purification	O 0
against	O 0
a	O 0
pure	O 0
-	O 0
emerin	O 0
band	O 0
on	O 0
a	O 0
western	O 0
blot	O 0
,	O 0
it	O 0
stained	O 0
only	O 0
the	O 0
nuclear	O 0
membrane	O 0
.	O 0

These	O 0
results	O 0
would	O 0
not	O 0
be	O 0
expected	O 0
if	O 0
immunostaining	O 0
at	O 0
intercalated	O 0
discs	O 0
were	O 0
due	O 0
to	O 0
a	O 0
product	O 0
of	O 0
the	O 0
emerin	O 0
gene	O 0
and	O 0
,	O 0
therefore	O 0
,	O 0
cast	O 0
some	O 0
doubt	O 0
upon	O 0
the	O 0
hypothesis	O 0
that	O 0
cardiac	B-Disease 0
defects	I-Disease 0
in	O 0
EDMD	B-Disease 0
are	O 0
caused	O 0
by	O 0
absence	O 0
of	O 0
emerin	O 0
from	O 0
intercalated	O 0
discs	O 0
.	O 0

Although	O 0
emerin	O 0
was	O 0
abundant	O 0
in	O 0
the	O 0
membranes	O 0
of	O 0
cardiomyocyte	O 0
nuclei	O 0
,	O 0
it	O 0
was	O 0
absent	O 0
from	O 0
many	O 0
non	O 0
-	O 0
myocyte	O 0
cells	O 0
in	O 0
the	O 0
heart	O 0
.	O 0

This	O 0
distribution	O 0
of	O 0
emerin	O 0
was	O 0
similar	O 0
to	O 0
that	O 0
of	O 0
lamin	O 0
A	O 0
,	O 0
a	O 0
candidate	O 0
gene	O 0
for	O 0
an	O 0
autosomal	O 0
form	O 0
of	O 0
EDMD	B-Disease 0
.	O 0

In	O 0
contrast	O 0
,	O 0
lamin	O 0
B1	O 0
was	O 0
absent	O 0
from	O 0
cardiomyocyte	O 0
nuclei	O 0
,	O 0
showing	O 0
that	O 0
lamin	O 0
B1	O 0
is	O 0
not	O 0
essential	O 0
for	O 0
localization	O 0
of	O 0
emerin	O 0
to	O 0
the	O 0
nuclear	O 0
lamina	O 0
.	O 0

Lamin	O 0
B1	O 0
is	O 0
also	O 0
almost	O 0
completely	O 0
absent	O 0
from	O 0
skeletal	O 0
muscle	O 0
nuclei	O 0
.	O 0

In	O 0
EDMD	B-Disease 0
,	O 0
the	O 0
additional	O 0
absence	O 0
of	O 0
lamin	O 0
B1	O 0
from	O 0
heart	O 0
and	O 0
skeletal	O 0
muscle	O 0
nuclei	O 0
which	O 0
already	O 0
lack	O 0
emerin	O 0
may	O 0
offer	O 0
an	O 0
alternative	O 0
explanation	O 0
of	O 0
why	O 0
these	O 0
tissues	O 0
are	O 0
particularly	O 0
affected	O 0
.	O 0
.	O 0

Genetic	O 0
mapping	O 0
of	O 0
the	O 0
copper	B-Disease 0
toxicosis	I-Disease 0
locus	O 0
in	O 0
Bedlington	O 0
terriers	O 0
to	O 0
dog	O 0
chromosome	O 0
10	O 0
,	O 0
in	O 0
a	O 0
region	O 0
syntenic	O 0
to	O 0
human	O 0
chromosome	O 0
region	O 0
2p13	O 0
-	O 0
p16	O 0
.	O 0

Abnormal	O 0
hepatic	B-Disease 0
copper	I-Disease 0
accumulation	I-Disease 0
is	O 0
recognized	O 0
as	O 0
an	O 0
inherited	B-Disease 0
disorder	I-Disease 0
in	O 0
man	O 0
,	O 0
mouse	O 0
,	O 0
rat	O 0
and	O 0
dog	O 0
.	O 0

The	O 0
major	O 0
cause	O 0
of	O 0
hepatic	B-Disease 0
copper	I-Disease 0
accumulation	I-Disease 0
in	O 0
man	O 0
is	O 0
a	O 0
dysfunctional	O 0
ATP7B	O 0
gene	O 0
,	O 0
causing	O 0
Wilson	B-Disease 0
disease	I-Disease 0
(	O 0
WD	B-Disease 0
)	O 0
.	O 0

Mutations	O 0
in	O 0
the	O 0
ATP7B	O 0
genes	O 0
have	O 0
also	O 0
been	O 0
demonstrated	O 0
in	O 0
mouse	O 0
and	O 0
rat	O 0
.	O 0

The	O 0
ATP7B	O 0
gene	O 0
has	O 0
been	O 0
excluded	O 0
in	O 0
the	O 0
much	O 0
rarer	O 0
human	O 0
copper	B-Disease 0
overload	I-Disease 0
disease	O 0
non	B-Disease 0
-	I-Disease 0
Indian	I-Disease 0
childhood	I-Disease 0
cirrhosis	I-Disease 0
,	O 0
indicating	O 0
genetic	O 0
heterogeneity	O 0
.	O 0

By	O 0
investigating	O 0
the	O 0
common	O 0
autosomal	O 0
recessive	O 0
copper	B-Disease 0
toxicosis	I-Disease 0
(	O 0
CT	B-Disease 0
)	O 0
in	O 0
Bedlington	O 0
terriers	O 0
,	O 0
we	O 0
have	O 0
identified	O 0
a	O 0
new	O 0
locus	O 0
involved	O 0
in	O 0
progressive	O 0
liver	B-Disease 0
disease	I-Disease 0
.	O 0

We	O 0
examined	O 0
whether	O 0
the	O 0
WD	B-Disease 0
gene	O 0
ATP7B	O 0
was	O 0
also	O 0
causative	O 0
for	O 0
CT	B-Disease 0
by	O 0
investigating	O 0
the	O 0
chromosomal	O 0
co	O 0
-	O 0
localization	O 0
of	O 0
ATP7B	O 0
and	O 0
C04107	O 0
,	O 0
using	O 0
fluorescence	O 0
in	O 0
situ	O 0
hybridization	O 0
(	O 0
FISH	O 0
)	O 0
.	O 0

C04107	O 0
is	O 0
an	O 0
anonymous	O 0
microsatellite	O 0
marker	O 0
closely	O 0
linked	O 0
to	O 0
CT	B-Disease 0
.	O 0

However	O 0
,	O 0
BAC	O 0
clones	O 0
containing	O 0
ATP7B	O 0
and	O 0
C04107	O 0
mapped	O 0
to	O 0
the	O 0
canine	O 0
chromosome	O 0
regions	O 0
CFA22q11	O 0
and	O 0
CFA10q26	O 0
,	O 0
respectively	O 0
,	O 0
demonstrating	O 0
that	O 0
WD	B-Disease 0
cannot	O 0
be	O 0
homologous	O 0
to	O 0
CT	B-Disease 0
.	O 0

The	O 0
copper	O 0
transport	O 0
genes	O 0
CTR1	O 0
and	O 0
CTR2	O 0
were	O 0
also	O 0
excluded	O 0
as	O 0
candidate	O 0
genes	O 0
for	O 0
CT	B-Disease 0
since	O 0
they	O 0
both	O 0
mapped	O 0
to	O 0
canine	O 0
chromosome	O 0
region	O 0
CFA11q22	O 0
.	O 0

2	O 0
-	O 0
22	O 0
.	O 0

5	O 0
.	O 0

A	O 0
transcribed	O 0
sequence	O 0
identified	O 0
from	O 0
the	O 0
C04107	O 0
-	O 0
containing	O 0
BAC	O 0
was	O 0
found	O 0
to	O 0
be	O 0
homologous	O 0
to	O 0
a	O 0
gene	O 0
expressed	O 0
from	O 0
human	O 0
chromosome	O 0
2p13	O 0
-	O 0
p16	O 0
,	O 0
a	O 0
region	O 0
devoid	O 0
of	O 0
any	O 0
positional	O 0
candidate	O 0
genes	O 0
.	O 0

Molecular	O 0
analysis	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
in	O 0
205	O 0
families	O 0
:	O 0
extended	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
in	O 0
FAP	B-Disease 0
and	O 0
evidence	O 0
for	O 0
the	O 0
role	O 0
of	O 0
APC	B-Disease 0
amino	O 0
acid	O 0
changes	O 0
in	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
predisposition	O 0
.	O 0

BACKGROUND	O 0
/	O 0
AIMS	O 0
The	O 0
development	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
and	O 0
a	O 0
variable	O 0
range	O 0
of	O 0
extracolonic	O 0
manifestations	O 0
in	O 0
familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
(	O 0
FAP	B-Disease 0
)	O 0
is	O 0
the	O 0
result	O 0
of	O 0
the	O 0
dominant	O 0
inheritance	O 0
of	O 0
adenomatous	B-Disease 0
polyposis	I-Disease 0
coli	I-Disease 0
(	O 0
APC	B-Disease 0
)	O 0
gene	O 0
mutations	O 0
.	O 0

In	O 0
this	O 0
study	O 0
,	O 0
direct	O 0
mutation	O 0
analysis	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
was	O 0
performed	O 0
to	O 0
determine	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
for	O 0
nine	O 0
extracolonic	O 0
manifestations	O 0
and	O 0
to	O 0
investigate	O 0
the	O 0
incidence	O 0
of	O 0
APC	B-Disease 0
mutations	O 0
in	O 0
non	O 0
-	O 0
FAP	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
.	O 0

METHODS	O 0
The	O 0
APC	B-Disease 0
gene	O 0
was	O 0
analysed	O 0
in	O 0
190	O 0
unrelated	O 0
FAP	B-Disease 0
and	O 0
15	O 0
non	O 0
-	O 0
FAP	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
patients	O 0
using	O 0
denaturing	O 0
gradient	O 0
gel	O 0
electrophoresis	O 0
,	O 0
the	O 0
protein	O 0
truncation	O 0
test	O 0
,	O 0
and	O 0
direct	O 0
sequencing	O 0
.	O 0

RESULTS	O 0
Chain	O 0
terminating	O 0
signals	O 0
were	O 0
only	O 0
identified	O 0
in	O 0
patients	O 0
belonging	O 0
to	O 0
the	O 0
FAP	B-Disease 0
group	O 0
(	O 0
105	O 0
patients	O 0
)	O 0
.	O 0

Amino	O 0
acid	O 0
changes	O 0
were	O 0
identified	O 0
in	O 0
four	O 0
patients	O 0
,	O 0
three	O 0
of	O 0
whom	O 0
belonged	O 0
to	O 0
the	O 0
non	O 0
-	O 0
FAP	O 0
group	O 0
of	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
patients	O 0
.	O 0

Genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
identified	O 0
significant	O 0
differences	O 0
in	O 0
the	O 0
nature	O 0
of	O 0
certain	O 0
extracolonic	O 0
manifestations	O 0
in	O 0
FAP	B-Disease 0
patients	O 0
belonging	O 0
to	O 0
three	O 0
mutation	O 0
subgroups	O 0
.	O 0

CONCLUSIONS	O 0
Extended	O 0
genotype	O 0
-	O 0
phenotype	O 0
correlations	O 0
made	O 0
in	O 0
this	O 0
study	O 0
may	O 0
have	O 0
the	O 0
potential	O 0
to	O 0
determine	O 0
the	O 0
most	O 0
appropriate	O 0
surveillance	O 0
and	O 0
prophylactic	O 0
treatment	O 0
regimens	O 0
for	O 0
those	O 0
patients	O 0
with	O 0
mutations	O 0
associated	O 0
with	O 0
life	O 0
threatening	O 0
conditions	O 0
.	O 0

This	O 0
study	O 0
also	O 0
provided	O 0
evidence	O 0
for	O 0
the	O 0
pathological	O 0
nature	O 0
of	O 0
amino	O 0
acid	O 0
changes	O 0
in	O 0
APC	O 0
associated	O 0
with	O 0
both	O 0
FAP	B-Disease 0
and	O 0
non	O 0
-	O 0
FAP	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
patients	O 0
.	O 0
.	O 0

Inherited	B-Disease 0
colorectal	I-Disease 0
polyposis	I-Disease 0
and	O 0
cancer	B-Disease 0
risk	O 0
of	O 0
the	O 0
APC	O 0
I1307K	O 0
polymorphism	O 0
.	O 0

Germ	O 0
-	O 0
line	O 0
and	O 0
somatic	O 0
truncating	O 0
mutations	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
are	O 0
thought	O 0
to	O 0
initiate	O 0
colorectal	B-Disease 0
tumor	I-Disease 0
formation	O 0
in	O 0
familial	B-Disease 0
adenomatous	I-Disease 0
polyposis	I-Disease 0
syndrome	I-Disease 0
and	O 0
sporadic	O 0
colorectal	O 0
carcinogenesis	O 0
,	O 0
respectively	O 0
.	O 0

Recently	O 0
,	O 0
an	O 0
isoleucine	O 0
-	O 0
-	O 0
>	O 0
lysine	O 0
polymorphism	O 0
at	O 0
codon	O 0
1307	O 0
(	O 0
I1307K	O 0
)	O 0
of	O 0
the	O 0
APC	B-Disease 0
gene	O 0
has	O 0
been	O 0
identified	O 0
in	O 0
6	O 0
%	O 0
-	O 0
7	O 0
%	O 0
of	O 0
the	O 0
Ashkenazi	O 0
Jewish	O 0
population	O 0
.	O 0

To	O 0
assess	O 0
the	O 0
risk	O 0
of	O 0
this	O 0
common	O 0
APC	B-Disease 0
allelic	O 0
variant	O 0
in	O 0
colorectal	O 0
carcinogenesis	O 0
,	O 0
we	O 0
have	O 0
analyzed	O 0
a	O 0
large	O 0
cohort	O 0
of	O 0
unselected	O 0
Ashkenazi	O 0
Jewish	O 0
subjects	O 0
with	O 0
adenomatous	B-Disease 0
polyps	I-Disease 0
and	O 0
.	O 0
or	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
,	I-Disease 0
for	O 0
the	O 0
APC	O 0
I1307K	O 0
polymorphism	O 0
.	O 0

The	O 0
APC	O 0
I1307K	O 0
allele	O 0
was	O 0
identified	O 0
in	O 0
48	O 0
(	O 0
10	O 0
.	O 0
1	O 0
%	O 0
)	O 0
of	O 0
476	O 0
patients	O 0
.	O 0

Compared	O 0
with	O 0
the	O 0
frequency	O 0
in	O 0
two	O 0
separate	O 0
population	O 0
control	O 0
groups	O 0
,	O 0
the	O 0
APC	O 0
I1307K	O 0
allele	O 0
is	O 0
associated	O 0
with	O 0
an	O 0
estimated	O 0
relative	O 0
risk	O 0
of	O 0
1	O 0
.	O 0

5	O 0
-	O 0
1	O 0
.	O 0

7	O 0
for	O 0
colorectal	B-Disease 0
neoplasia	I-Disease 0
(	O 0
both	O 0
P	O 0
=	O 0
.	O 0
01	O 0
)	O 0
.	O 0

Furthermore	O 0
,	O 0
compared	O 0
with	O 0
noncarriers	O 0
,	O 0
APC	O 0
I1307K	O 0
carriers	O 0
had	O 0
increased	O 0
numbers	O 0
of	O 0
adenomas	B-Disease 0
and	O 0
colorectal	B-Disease 0
cancers	I-Disease 0
per	O 0
patient	O 0
(	O 0
P	O 0
=	O 0
.	O 0
03	O 0
)	O 0
,	O 0
as	O 0
well	O 0
as	O 0
a	O 0
younger	O 0
age	O 0
at	O 0
diagnosis	O 0
.	O 0

We	O 0
conclude	O 0
that	O 0
the	O 0
APC	O 0
I1307K	O 0
variant	O 0
leads	O 0
to	O 0
increased	O 0
adenoma	B-Disease 0
formation	O 0
and	O 0
directly	O 0
contributes	O 0
to	O 0
3	O 0
%	O 0
-	O 0
4	O 0
%	O 0
of	O 0
all	O 0
Ashkenazi	O 0
Jewish	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
.	O 0

The	O 0
estimated	O 0
relative	O 0
risk	O 0
for	O 0
carriers	O 0
may	O 0
justify	O 0
specific	O 0
clinical	O 0
screening	O 0
for	O 0
the	O 0
360	O 0
,	O 0
000	O 0
Americans	O 0
expected	O 0
to	O 0
harbor	O 0
this	O 0
allele	O 0
,	O 0
and	O 0
genetic	O 0
testing	O 0
in	O 0
the	O 0
setting	O 0
of	O 0
long	O 0
-	O 0
term	O 0
-	O 0
outcome	O 0
studies	O 0
may	O 0
impact	O 0
significantly	O 0
on	O 0
colorectal	B-Disease 0
cancer	I-Disease 0
prevention	O 0
in	O 0
this	O 0
population	O 0
.	O 0

Localization	O 0
of	O 0
human	O 0
BRCA1	O 0
and	O 0
its	O 0
loss	O 0
in	O 0
high	O 0
-	O 0
grade	O 0
,	O 0
non	B-Disease 0
-	I-Disease 0
inherited	I-Disease 0
breast	I-Disease 0
carcinomas	I-Disease 0
.	O 0

Although	O 0
the	O 0
link	O 0
between	O 0
the	O 0
BRCA1	O 0
tumour	B-Disease 0
-	O 0
suppressor	O 0
gene	O 0
and	O 0
hereditary	B-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancer	I-Disease 0
is	O 0
established	O 0
,	O 0
the	O 0
role	O 0
,	O 0
if	O 0
any	O 0
,	O 0
of	O 0
BRCA1	O 0
in	O 0
non	B-Disease 0
-	I-Disease 0
familial	I-Disease 0
cancers	I-Disease 0
is	O 0
unclear	O 0
.	O 0

BRCA1	O 0
mutations	O 0
are	O 0
rare	O 0
in	O 0
sporadic	B-Disease 0
cancers	I-Disease 0
,	O 0
but	O 0
loss	O 0
of	O 0
BRCA1	O 0
resulting	O 0
from	O 0
reduced	O 0
expression	O 0
or	O 0
incorrect	O 0
subcellular	O 0
localization	O 0
is	O 0
postulated	O 0
to	O 0
be	O 0
important	O 0
in	O 0
non	B-Disease 0
-	I-Disease 0
familial	I-Disease 0
breast	I-Disease 0
and	I-Disease 0
ovarian	I-Disease 0
cancers	I-Disease 0
.	O 0

Epigenetic	O 0
loss	O 0
,	O 0
however	O 0
,	O 0
has	O 0
not	O 0
received	O 0
general	O 0
acceptance	O 0
due	O 0
to	O 0
controversy	O 0
regarding	O 0
the	O 0
subcellular	O 0
localization	O 0
of	O 0
BRCA1	O 0
proteins	O 0
,	O 0
reports	O 0
of	O 0
which	O 0
have	O 0
ranged	O 0
from	O 0
exclusively	O 0
nuclear	O 0
,	O 0
to	O 0
conditionally	O 0
nuclear	O 0
,	O 0
to	O 0
the	O 0
ER	O 0
/	O 0
golgi	O 0
,	O 0
to	O 0
cytoplasmic	O 0
invaginations	O 0
into	O 0
the	O 0
nucleus	O 0
.	O 0

In	O 0
an	O 0
attempt	O 0
to	O 0
resolve	O 0
this	O 0
issue	O 0
,	O 0
we	O 0
have	O 0
comprehensively	O 0
characterized	O 0
19	O 0
anti	O 0
-	O 0
BRCA1	O 0
antibodies	O 0
.	O 0

These	O 0
reagents	O 0
detect	O 0
a	O 0
220	O 0
-	O 0
kD	O 0
protein	O 0
localized	O 0
in	O 0
discrete	O 0
nuclear	O 0
foci	O 0
in	O 0
all	O 0
epithelial	O 0
cell	O 0
lines	O 0
,	O 0
including	O 0
those	O 0
derived	O 0
from	O 0
breast	B-Disease 0
malignancies	I-Disease 0
.	O 0

Immunohistochemical	O 0
staining	O 0
of	O 0
human	O 0
breast	O 0
specimens	O 0
also	O 0
revealed	O 0
BRCA1	O 0
nuclear	O 0
foci	O 0
in	O 0
benign	O 0
breast	O 0
,	O 0
invasive	B-Disease 0
lobular	I-Disease 0
cancers	I-Disease 0
and	O 0
low	B-Disease 0
-	I-Disease 0
grade	I-Disease 0
ductal	I-Disease 0
carcinomas	I-Disease 0
.	O 0

Conversely	O 0
,	O 0
BRCA1	O 0
expression	O 0
was	O 0
reduced	O 0
or	O 0
undetectable	O 0
in	O 0
the	O 0
majority	O 0
of	O 0
high	O 0
-	O 0
grade	O 0
,	O 0
ductal	B-Disease 0
carcinomas	I-Disease 0
,	O 0
suggesting	O 0
that	O 0
absence	O 0
of	O 0
BRCA1	O 0
may	O 0
contribute	O 0
to	O 0
the	O 0
pathogenesis	O 0
of	O 0
a	O 0
significant	O 0
percentage	O 0
of	O 0
sporadic	B-Disease 0
breast	I-Disease 0
cancers	I-Disease 0
.	O 0
.	O 0

